US20140114156A1 - Advanced analyte sensor calibration and error detection - Google Patents

Advanced analyte sensor calibration and error detection Download PDF

Info

Publication number
US20140114156A1
US20140114156A1 US14/144,343 US201314144343A US2014114156A1 US 20140114156 A1 US20140114156 A1 US 20140114156A1 US 201314144343 A US201314144343 A US 201314144343A US 2014114156 A1 US2014114156 A1 US 2014114156A1
Authority
US
United States
Prior art keywords
sensor
sensitivity
analyte
impedance
data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/144,343
Inventor
Sebastian Bohm
Daiting Rong
Peter C. Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexcom Inc
Original Assignee
Dexcom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47006011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140114156(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dexcom Inc filed Critical Dexcom Inc
Priority to US14/144,343 priority Critical patent/US20140114156A1/en
Publication of US20140114156A1 publication Critical patent/US20140114156A1/en
Assigned to DEXCOM, INC. reassignment DEXCOM, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RONG, DAITING, SIMPSON, PETER C., BOHM, SEBASTIAN
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495Calibrating or testing of in-vivo probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0031Implanted circuitry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14503Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/14517Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for sweat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14539Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • A61B5/14735Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter comprising an immobilised reagent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • A61B5/15003Source of blood for venous or arterial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150992Blood sampling from a fluid line external to a patient, such as a catheter line, combined with an infusion line; blood sampling from indwelling needle sets, e.g. sealable ports, luer couplings, valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/155Devices specially adapted for continuous or multiple sampling, e.g. at predetermined intervals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/157Devices characterised by integrated means for measuring characteristics of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/41Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/412Detecting or monitoring sepsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4836Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6848Needles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6848Needles
    • A61B5/6849Needles in combination with a needle set
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6866Extracorporeal blood circuits, e.g. dialysis circuits
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7253Details of waveform analysis characterised by using transforms
    • A61B5/7257Details of waveform analysis characterised by using transforms using Fourier transforms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7264Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A61B5/7267Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/005Enzyme electrodes involving specific analytes or enzymes
    • C12Q1/006Enzyme electrodes involving specific analytes or enzymes for glucose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01DMEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D18/00Testing or calibrating apparatus or arrangements provided for in groups G01D1/00 - G01D15/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/02Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
    • G01N27/026Dielectric impedance spectroscopy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3274Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05KPRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05KPRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H05K999/99PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0223Operational features of calibration, e.g. protocols for calibrating sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0266Operational features for monitoring or limiting apparatus function
    • A61B2560/0276Determining malfunction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/04Constructional details of apparatus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/08Sensors provided with means for identification, e.g. barcodes or memory chips
    • A61B2562/085Sensors provided with means for identification, e.g. barcodes or memory chips combined with means for recording calibration data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14535Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring haematocrit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7275Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/74Details of notification to user or communication with user or patient ; user input means
    • A61B5/742Details of notification to user or communication with user or patient ; user input means using visual displays
    • A61B5/743Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M2005/14288Infusion or injection simulation
    • A61M2005/14296Pharmacokinetic models
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/201Glucose concentration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/16804Flow controllers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/40ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • Diabetes mellitus is a chronic disease, which occurs when the pancreas does not produce enough insulin (Type I), or when the body cannot effectively use the insulin it produces (Type II).
  • This condition typically leads to an increased concentration of glucose in the blood (hyperglycemia), which can cause an array of physiological derangements (e.g., kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels.
  • a hypoglycemic reaction low blood sugar
  • SMBG self-monitoring blood glucose
  • the diabetic may not know whether his or her blood glucose value is increasing or decreasing, based on the SMBG alone.
  • a method for calibrating sensor data generated by a continuous analyte sensor comprising: generating sensor data using a continuous analyte sensor; iteratively determining, with an electronic device, a sensitivity value of the continuous analyte sensor as a function of time by applying a priori information comprising sensor sensitivity information; and calibrating the sensor data based at least in part on the determined sensitivity value.
  • calibrating the sensor data is performed iteratively throughout a substantially entire sensor session.
  • iteratively determining a sensitivity value is performed at regular intervals or performed at irregular intervals, as determined by the a priori information.
  • iteratively determining a sensitivity value is performed throughout a substantially entire sensor session.
  • determining a sensitivity value is performed in substantially real time.
  • the a priori information is associated with at least one predetermined sensitivity value that is associated with a predetermined time after start of a sensor session.
  • At least one predetermined sensitivity value is associated with a correlation between a sensitivity determined from in vitro analyte concentration measurements and a sensitivity determined from in vivo analyte concentration measurements at the predetermined time.
  • the a priori information is associated with a predetermined sensitivity function that uses time as input.
  • time corresponds to time after start of a sensor session.
  • time corresponds to at least one of time of manufacture or time since manufacture.
  • the sensitivity value of the continuous analyte sensor is also a function of at least one other parameter.
  • the at least one other parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • calibrating the sensor data is performed without using reference blood glucose data.
  • the electronic device is configured to provide a level of accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days, and wherein reference measurements associated with calculation of the mean absolute relative difference are determined by analysis of blood.
  • the sensor session is at least about 4 days.
  • the sensor session is at least about 5 days.
  • the sensor session is at least about 6 days.
  • the sensor session is at least about 7 days.
  • the sensor session is at least about 10 days.
  • the mean absolute relative difference is no more than about 7% over the sensor session.
  • the mean absolute relative difference is no more than about 5% over the sensor session.
  • the mean absolute relative difference is no more than about 3% over the sensor session.
  • the a priori information is associated with a calibration code.
  • the a priori sensitivity information is stored in the sensor electronics prior to use of the sensor.
  • a system for implementing the method of the first aspect or any embodiments thereof.
  • a method for calibrating sensor data generated by a continuous analyte sensor comprising: generating sensor data using a continuous analyte sensor; determining, with an electronic device, a plurality of different sensitivity values of the continuous analyte sensor as a function of time and of sensitivity information associated with a priori information; and calibrating the sensor data based at least in part on at least one of the plurality of different sensitivity values.
  • calibrating the continuous analyte sensor is performed iteratively throughout a substantially entire sensor session.
  • the plurality of different sensitivity values are stored in a lookup table in computer memory.
  • determining a plurality of different sensitivity values is performed once throughout a substantially entire sensor session.
  • the a priori information is associated with at least one predetermined sensitivity value that is associated with a predetermined time after start of a sensor session.
  • the at least one predetermined sensitivity value is associated with a correlation between a sensitivity determined from in vitro analyte concentration measurements and a sensitivity determined from in vivo analyte concentration measurements at the predetermined time.
  • the a priori information is associated with a predetermined sensitivity function that uses time as input.
  • time corresponds to time after start of a sensor session.
  • time corresponds to time of manufacture or time since manufacture.
  • the plurality of sensitivity values are also a function of at least one parameter other than time.
  • the at least one other parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • calibrating the continuous analyte sensor is performed without using reference blood glucose data.
  • the electronic device is configured to provide a level of accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days; and wherein reference measurements associated with calculation of the mean absolute relative difference are determined by analysis of blood.
  • the sensor session is at least about 4 days.
  • the sensor session is at least about 5 days.
  • the sensor session is at least about 6 days.
  • the sensor session is at least about 7 days.
  • the sensor session is at least about 10 days.
  • the mean absolute relative difference is no more than about 7% over the sensor session.
  • the mean absolute relative difference is no more than about 5% over the sensor session.
  • the mean absolute relative difference is no more than about 3% over the sensor session.
  • the a priori information is associated with a calibration code.
  • a system for implementing the method of the third aspect or any embodiments thereof.
  • a method for processing data from a continuous analyte sensor comprising: receiving, with an electronic device, sensor data from a continuous analyte sensor, the sensor data comprising at least one sensor data point; iteratively determining a sensitivity value of the continuous analyte sensor as a function of time and of an at least one predetermined sensitivity value associated with a predetermined time after start of a sensor session; forming a conversion function based at least in part on the sensitivity value; and determining an analyte output value by applying the conversion function to the at least one sensor data point.
  • the iteratively determining a sensitivity of the continuous analyte sensor is performed continuously.
  • iteratively determining a sensitivity is performed in substantially real time.
  • the method further comprises determining a baseline of the continuous analyte sensor, and wherein the conversion function is based at least in part on the baseline.
  • determining a baseline of the continuous analyte sensor is performed continuously.
  • determining a sensitivity of the continuous analyte sensor and determining a baseline of the analyte sensor are performed at substantially the same time.
  • the at least one predetermined sensitivity value is set at a manufacturing facility for the continuous analyte sensor.
  • the method further comprises receiving at least one calibration code; and applying the at least one calibration code to the electronic device at a predetermined time after start of the sensor session.
  • iteratively determining a sensitivity is performed at regular intervals or performed at irregular intervals, as determined by the at least one calibration code.
  • the at least one calibration code is associated with the at least one predetermined sensitivity.
  • the at least one calibration code is associated with a predetermined sensitivity function that uses time of the function of time as input.
  • time corresponds to time after start of the sensor session.
  • time corresponds to time of manufacture or time since manufacture.
  • the sensitivity value of the continuous analyte sensor is also a function of at least one other parameter.
  • the at least one other parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • a system for implementing the method of the fifth aspect or any embodiments thereof.
  • a method for calibrating a continuous analyte sensor comprising: receiving sensor data from a continuous analyte sensor; forming or receiving a predetermined sensitivity profile corresponding to a change in sensor sensitivity to an analyte over a substantially entire sensor session, wherein the predetermined sensitivity profile is a function of at least one predetermined sensitivity value associated with a predetermined time after start of the sensor session; and applying, with an electronic device, the sensitivity profile in real-time calibrations.
  • the at least one predetermined sensitivity value, the predetermined sensitivity profile, or both are set at a manufacturing facility for the continuous analyte sensor.
  • the method further comprises receiving at least one calibration code; and applying the at least one calibration code to the electronic device at a predetermined time after start of the sensor session.
  • the at least one calibration code is associated with the at least one predetermined sensitivity.
  • the at least one calibration code is associated with a predetermined sensitivity function that uses time as input.
  • the sensitivity profile is a function of time.
  • time corresponds to time after start of the sensor session.
  • time corresponds to time of manufacture or time since manufacture.
  • the sensitivity value is a function of time, the predetermined sensitivity value, and at least one parameter selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • a system for implementing the method of the seventh aspect or any embodiments thereof.
  • a method for processing data from a continuous analyte sensor comprising: receiving, with an electronic device, sensor data from a continuous analyte sensor, the sensor data comprising at least one sensor data point; receiving or forming a sensitivity profile corresponding to a change in sensor sensitivity over a substantially entire sensor session; forming a conversion function based at least in part on the sensitivity profile; and determining an analyte output value by applying the conversion function to the at least one sensor data point.
  • the sensitivity profile is set at a manufacturing facility for the continuous analyte sensor.
  • the method comprises receiving at least one calibration code; and applying the at least one calibration code to the electronic device at a predetermined time after start of the sensor session.
  • the at least one calibration code is associated with the at least one predetermined sensitivity.
  • the at least one calibration code is associated with the sensitivity profile.
  • the sensitivity profile is a function of time.
  • time corresponds to time after start of the sensor session.
  • time corresponds to time of manufacture or time since manufacture.
  • the sensitivity is a function of time and at least one parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • a system for implementing the method of the ninth aspect or any embodiments thereof.
  • a system for monitoring analyte concentration in a host, the system comprising: a continuous analyte sensor configured to measure analyte concentration in a host and to provide factory-calibrated sensor data, the factory-calibrated sensor data being calibrated without reference blood glucose data; wherein the system is configured to provide a level of accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days, wherein reference measurements associated with calculation of the mean absolute relative difference are determined by analysis of blood.
  • the sensor session is at least about 4 days.
  • the sensor session is at least about 5 days.
  • the sensor session is at least about 6 days.
  • the sensor session is at least about 7 days.
  • the sensor session is at least about 10 days.
  • the mean absolute relative difference is no more than about 7% over the sensor session.
  • the mean absolute relative difference is no more than about 5% over the sensor session.
  • the mean absolute relative difference is no more than about 3% over the sensor session.
  • a method for determining a property of a continuous analyte sensor comprising: applying a bias voltage to an analyte sensor; applying a voltage step above the bias voltage to the analyte sensor; measuring, using sensor electronics, a signal response of the voltage step; determining, using the sensor electronics, a peak current of the signal response; determining, using the sensor electronics, a property of the sensor by correlating the peak current to a predetermined relationship.
  • correlating the peak current to the predetermined relationship comprises calculating an impedance of the sensor based on the peak current and correlating the sensor impedance to the predetermined relationship.
  • the property of the sensor is a sensitivity of the sensor or a temperature of the sensor.
  • the peak current is a difference between a magnitude of the response prior to the voltage step and a magnitude of the largest measured response resulting from the voltage step.
  • the predetermined relationship is an impedance-to-sensor sensitivity relationship, and wherein the property of the sensor is a sensitivity of the sensor.
  • the method further comprises compensating sensor data using the determined property of the sensor.
  • the compensating comprises correlating a predetermined relationship of the peak current to sensor sensitivity or change in sensor sensitivity and modifying a value or values of the sensor data responsive to the correlated sensor sensitivity or change in sensor sensitivity.
  • predetermined relationship is a linear relationship over time of use of the analyte sensor.
  • the predetermined relationship is a non-linear relationship over time of use of the analyte sensor.
  • the predetermined relationship is determined by prior testing of sensors similar to the analyte sensor.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processor of the sensor system, cause the sensor system to implement the method of the twelfth aspect or any embodiment thereof.
  • a method for calibrating an analyte sensor comprising: applying a time-varying signal to the analyte sensor; measuring a signal response to the applied signal; determining, using sensor electronics, a sensitivity of the analyte sensor, the determining comprising correlating at least one property of the signal response to a predetermined sensor sensitivity profile; and generating, using sensor electronics, estimated analyte concentration values using the determined sensitivity and sensor data generated by the analyte sensor.
  • the sensitivity profile comprises varying sensitivity values over time since implantation of the sensor.
  • the predetermined sensitivity profile comprises a plurality of sensitivity values.
  • the predetermined sensitivity profile is based on sensor sensitivity data generated from studying sensitivity changes of analyte sensors similar to the analyte sensor.
  • the method further comprises applying a bias voltage to the sensor, wherein the time-varying signal comprises a step voltage above the bias voltage or a sine wave overlaying a voltage bias voltage.
  • the determining further comprises calculating an impedance value based on the measured signal response and correlating the impedance value to a sensitivity value of the predetermined sensitivity profile.
  • the method further comprises applying a DC bias voltage to the sensor to generate sensor data, wherein the estimating analyte concentration values includes generating corrected sensor data using the determined sensitivity.
  • the method further comprises applying a conversion function to the corrected sensor data to generate the estimated analyte concentration values.
  • the method further comprises forming a conversion function based at least in part of the determined sensitivity, and wherein the conversion function is applied to the sensor data to generate the estimated analyte concentration values.
  • the property is a peak current value of the signal response.
  • the determining further comprises using at least one of performing a Fast Fourier Transform on the signal response data, integrating at least a portion of a curve of the signal response, and determining a peak current of the signal response.
  • the determining further comprises selecting the predetermined sensitivity profile based on the determined sensor property from a plurality of different predetermined sensitivity profiles.
  • the selecting includes performing a data association analysis to determine a correlation between the determined sensor property and each of the plurality of different predetermined sensitivity profiles and wherein the selected predetermined sensitivity profile has the highest correlation.
  • the method further comprises generating estimated analyte concentration values using the selected sensitivity profile.
  • the method further comprises determining a second sensitivity value using the selected sensitivity profile, wherein a first set of estimated analyte concentration values is generated using the determined sensitivity value and sensor data associated with a first time period, and wherein a second set of concentration values is generated using the second sensitivity value and sensor data associated with a second time period.
  • a sensor system for implementing the method of the fourteenth aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the fourteenth aspect or any embodiment thereof.
  • a method for determining whether an analyte sensor system is functioning properly, the method comprising: applying a stimulus signal to the analyte sensor; measuring a response to the stimulus signal; estimating a value of a sensor property based on the signal response; correlating the sensor property value with a predetermined relationship of the sensor property and a predetermined sensor sensitivity profile; and initiating an error routine if the correlation does not exceed a predetermined correlation threshold.
  • correlating includes performing a data association analysis.
  • the error routine comprises displaying a message to a user indicating that the analyte sensor is not functioning properly.
  • the sensor property is an impedance of the sensor membrane.
  • a sensor system configured to implement the method of the sixteenth aspect or any embodiment thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the sixteenth aspect or any embodiment thereof.
  • a method for determining a temperature associated with an analyte sensor comprising: applying a stimulus signal to the analyte sensor; measuring a signal response of the signal; and determining a temperature associated with of the analyte sensor, the determining comprising correlating at least one property of the signal response to a predetermined relationship of the sensor property to temperature.
  • the method further comprises generating estimated analyte concentration values using the determined temperature and sensor data generated from the analyst sensor.
  • the generating includes compensating the sensor data using the determined temperature and converting the compensated sensor data to the generated estimated analyte values using a conversion function.
  • the generating includes forming or modifying a conversion function using the determined temperature and converting the sensor data to the generated estimated analyte values using the formed or modified conversion function.
  • the method further comprises measuring a temperature using a second sensor, wherein the determining further comprises using the measured temperature to determine the temperature associated with the analyte sensor.
  • the second sensor is a thermistor.
  • a sensor system configured to implement the methods of the eighteenth aspect or any embodiment thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the eighteenth aspect or any embodiment thereof.
  • a method for determining moisture ingress in an electronic sensor system comprising: applying a stimulus signal having a particular frequency or a signal comprising a spectrum of frequencies to an analyte sensor; measuring a response to the stimulus signal; calculating, using sensor electronics, an impedance based on the measured signal response; determining, using sensor electronics, whether the impedance falls within a predefined level corresponding to moisture ingress; initiating, using sensor electronics, an error routine if the impedance exceeds one or both of the respective predefined levels
  • the method further comprises the error routine includes one or more of triggering an audible alarm and a visual alarm on a display screen to alert a user that the sensor system may not be functioning properly.
  • the stimulus signal has a predetermined frequency.
  • the stimulus signal comprises a spectrum of frequencies.
  • the calculated impedance comprises a magnitude value and a phase value
  • the determination comprises comparing the impedance magnitude value to a predefined impedance magnitude threshold and the phase value to a predefined phase threshold.
  • the calculated impedance is a complex impedance value.
  • a sensor system configured to implement the methods of the twentieth aspect or any embodiment thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twentieth aspect or any embodiment thereof.
  • a method for determining membrane damage of an analyte sensor using a sensor system comprising: applying a stimulus signal to an analyte sensor; measuring a response to the stimulus signal; calculating, using sensor electronics, an impedance based on the signal response; determining, using the sensor electronics, whether the impedance falls within a predefined level corresponding to membrane damage; and initiating, using the sensor electronics, an error routine if the impedance exceeds the predefined level.
  • the error routine includes triggering one or more of an audible alarm and a visual alarm on a display screen.
  • the stimulus signal has a predetermined frequency.
  • the stimulus signal comprises a spectrum of frequencies.
  • the calculated impedance comprises a magnitude value and a phase value
  • the determination comprises comparing the impedance magnitude value to a predefined impedance magnitude threshold and the phase value to a predefined phase threshold.
  • the calculated impedance is a complex impedance value.
  • a sensor system configured to implement the methods of the twenty-second aspect or any embodiment thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-second aspect or any embodiment thereof.
  • a method for determining reuse of an analyte sensor comprising, applying a stimulus signal to an analyte sensor; measuring a response of the stimulus signal; calculating an impedance response based on the response; comparing the calculated impedance to a predetermined threshold; initiating a sensor reuse routine if it is determined that the impedance exceeds the threshold.
  • the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
  • the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
  • a sensor system configured to implement the methods of the twenty-fourth aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-fourth aspect or any embodiments thereof.
  • a system for determining reuse of an analyte sensor, comprising, applying a stimulus signal to an analyte sensor; measuring a response of the stimulus signal; calculating an impedance based on the response; using a data association function to determine a correlation of the calculated impedance to one or more recorded impedance values; and initiating a sensor reuse routine if it is determined that the correlation is above a predetermined threshold.
  • the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
  • the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-fifth aspect.
  • a method for applying an overpotential to an analyte sensor comprising, applying a stimulus signal to an analyte sensor; measuring a response of the stimulus signal; determining a sensor sensitivity or change in sensor sensitivity based on the response; and applying an over potential to the sensor based on the determined sensitivity or sensitivity change.
  • the determining further comprises calculating an impedance based on the response and determining the sensitivity or sensitivity change based on the impedance.
  • the determining the sensitivity or sensitivity change further comprises correlating the impedance to a predetermined impedance to sensitivity relationship.
  • the applying comprises determining or modifying a length of time the over potential is applied to the sensor.
  • the applying comprises determining or modifying a magnitude of the over potential applied to the sensor.
  • a sensor system configured to implement the methods of the twenty-seventh aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-seventh aspect or any embodiment thereof.
  • a method for determining a property of a continuous analyte sensor comprising: applying a stimulus signal to a first analyte sensor having a first working electrode and a first reference electrode; measuring a signal response of the stimulus signal using a second analyte sensor having a second working electrode and a second reference electrode; and determining a property of the first sensor by correlating the response to a predetermined relationship.
  • the method further comprises generating sensor data by applying a bias voltage to the first working electrode and measuring a response to the bias voltage.
  • the method further comprises calibrating the sensor data using the determined property.
  • the determined property is one of an impedance and a temperature.
  • the method further comprises determining sensor membrane damage using the determined property.
  • the method further comprises determining moisture ingress in a sensor system encompassing the first and second analyte sensors using the determined property.
  • a sensor system configured to implement the methods of one of the twenty-ninth aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-ninth aspect or any embodiments thereof.
  • a method for determining a scaling used in a continuous analyte sensor system comprising: applying a first stimulus signal to a first working electrode of an analyte sensor; measuring a response to the first stimulus signal; applying a second stimulus signal to a second working electrode of the analyte sensor; measuring a response to the first stimulus signal; determining, using sensor electronics, a scaling factor based on the measured responses to the first and second stimulus signals; and using the scaling factor to generate estimated analyte values based on sensor data generated by the analyte sensor.
  • the method further comprises the method is performed periodically.
  • the determining comprises calculating a first impedance using the response to the first stimulus signal and calculating a second impedance using the response to the second stimulus signal, and wherein the scaling factor is a ratio of the first impedance and the second impedance.
  • the first working electrode has a membrane comprising an enzyme configured to react with the analyte and the second working electrode has a membrane does not have the enzyme.
  • determining the scaling factor comprises updating a previous scaling factor based on the measured responses to the first and second stimulus signals.
  • scaling factor is an acetaminophen scaling factor
  • the method further comprises updating a further scaling factor based on the acetaminophen scaling factor, and wherein the further scaling factor applied to the sensor data to generate the estimated analyte values.
  • a sensor system configured to implement the methods of the thirty-first aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the thirty-first aspect or any embodiment thereof.
  • a method for calibrating an analyte sensor comprising: applying a predetermined signal to an analyte sensor; measuring a response to the applied signal; determining, using sensor electronics, a change in impedance associated with a membrane of the analyte sensor based on the measured response; calculating a sensitivity change of the analyte sensor based on the determined impedance; calculating a corrected sensitivity based on the calculated sensitivity change and a previously used sensitivity of the analyte sensor; and generating estimated analyte values using the corrected sensitivity.
  • calculating the sensitivity change comprises applying a non-linear compensation function.
  • a and b are determined by prior testing of similar analyte sensors.
  • a sensor system configured to implement the methods of the thirty-third aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the thirty-third aspect or any embodiments thereof.
  • a method for calibrating an analyte sensor comprising: generating sensor data using a subcutaneous analyte sensor; forming or modifying a conversion function, wherein pre-implant information, internal diagnostic information, and/or external reference information are used as inputs to form or modify the conversion function; and calibrating the sensor data using the conversion function.
  • the pre-implant information comprises information selected from the group consisting of: a predetermined sensitivity profile associated with the analyte sensor, a previously determined relationship between a measured sensor property and sensor sensitivity, one or more previously determined relationships between a measured sensor property and sensor temperature; sensor data obtained from previously used analyte sensors, a calibration code associated with the analyte sensor, patient specific relationships between the analyte sensor and one or more of sensitivity, baseline, drift and impedance, information indicative of a site of sensor implantation; time since manufacture of the analyte sensor, and information indicative of the analyte being exposed to temperature or humidity.
  • the internal diagnostic information comprises information selected from the group consisting of: stimulus signal output; sensor data indicative of an analyte concentration measured by the sensor; temperature measurements using the sensor or a separate sensor; sensor data generated by a redundant sensor, where the redundant sensor is designed to be substantially the same as analyte sensor; sensor data generated by an auxiliary sensors, where the auxiliary sensor is having a different modality as the analyte sensor; a time since the sensor was implanted or connected to sensor electronics coupled to the sensor; data representative of a pressure on the sensor or sensor system generated by a pressure sensor; data generated by an accelerometer; a measure of moisture ingress; and a measure of noise in an analyte concentration signal.
  • the reference information comprises information selected from the group consisting of: real-time and/or prior analyte concentration information obtained from a reference monitor, information relating to a type/brand of reference monitor used to provide reference data; information relating to an amount of carbohydrate consumed by a user; information received from a medicament delivery device, glucagon sensitivity information, and information gathered from population based data.
  • a sensor system configured to implement the methods of the thirty-fifth aspect or any embodiments thereof.
  • the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the thirty-fifth aspect or any embodiment thereof.
  • FIG. 1A illustrates a schematic diagram of sensor sensitivity as a function of time during a sensor session, in accordance with one embodiment
  • FIG. 1B illustrates schematic diagrams of conversion functions at different time periods of a sensor session, in accordance with the embodiment of FIG. 1A .
  • FIGS. 2A-2B and FIGS. 2C-2D collectively illustrate different embodiments of processes for generating a sensor sensitivity profile.
  • FIG. 3A is a Bland-Altman plot illustrating differences between YSI reference measurements and certain in vivo continuous analyte sensors that were factory calibrated, in accordance with one embodiment
  • FIG. 3B is a Clarke error grid associated with data from the continuous analyte sensors associated with FIG. 3A .
  • FIG. 4 illustrates data from one study that examined the accuracy level of continuous analyte sensors that accepted one reference measurement about one hour after insertion into patients, in accordance with one embodiment.
  • FIG. 5 illustrates a diagram showing different types of information that can be input into the sensor system to define the sensor sensitivity profile over time
  • FIG. 6 illustrates a schematic diagram of sensor sensitivity as a function of time between completion of sensor fabrication and the start of the sensor session, in accordance with one embodiment.
  • FIG. 7A is a schematic diagram depicting distribution curves of sensor sensitivity corresponding to the Bayesian learning process, in accordance with one embodiment
  • FIG. 7B is a schematic diagram depicting confidence levels, associated with the sensor sensitivity profile, that correspond with the distribution curves shown in FIG. 7A .
  • FIG. 8 illustrates a graph that provides a comparison between an estimated glucose equivalent baseline and detected glucose equivalent baseline, in accordance with one study.
  • FIG. 9 is a schematic of a model sensor circuit in accordance with one embodiment.
  • FIG. 10 is a Bode plot of an analyte sensor in accordance with one embodiment.
  • FIG. 11 is a flowchart describing a process for determining an impedance of a sensor in accordance with one embodiment.
  • FIG. 12 is a flowchart describing a process for determining an impedance of a sensor based on a derivative response in accordance with one embodiment.
  • FIG. 13 is a flowchart describing a process for determining an impedance of a sensor based on a peak current response in accordance with one embodiment.
  • FIG. 14A illustrates a step voltage applied to a sensor and FIG. 14B illustrates a response to the step voltage in accordance with one embodiment.
  • FIG. 15 is a flowchart describing a process for estimating analyte concentration values using a corrected signal based on an impedance measurement in accordance with one embodiment.
  • FIG. 16 is a flowchart describing a process for estimating analyte concentration values using a predetermined sensitivity profile selected based on an impedance measurement in accordance with one embodiment.
  • FIG. 17 is a flowchart describing a process for determining an error based whether a sensitivity determined using an impedance measurement sufficiently corresponds to a predetermined sensitivity in accordance with one embodiment.
  • FIG. 18 is a flowchart describing a process for determining a temperature associated with a sensor by correlating an impedance measurement to a predetermined temperature-to-impedance relationship in accordance with one embodiment.
  • FIG. 19 is a flowchart describing a process for determining moisture egress in sensor electronics associates with an analyte sensor accordance with one embodiment.
  • FIG. 20 is a flowchart describing a process for determining membrane damage associated with an analyte sensor in accordance with one embodiment.
  • FIG. 21 is a flowchart describing a first process for determining sensor reuse associated in accordance with one embodiment.
  • FIG. 22 is a flowchart describing a second process for determining sensor reuse associated in accordance with one embodiment.
  • FIG. 23 is a schematic of a dual-electrode configuration used to determine sensor properties in accordance with one embodiment.
  • FIG. 24 is a diagram of a calibration process that uses various inputs to form a conversion function in accordance with one embodiment.
  • FIGS. 25-49 collectively illustrate results of studies using stimulus signals to determine sensor properties.
  • FIG. 50 is a flowchart describing a process for generating estimated analyte values using a compensation algorithm based on a measured change in impedance in accordance with one embodiment.
  • FIGS. 51-53 are graphs of studies comparing use of compensation algorithms based on measured changes in impedance.
  • analyte is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is are not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes may include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensor heads, devices, and methods disclosed herein is glucose.
  • analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1- ⁇ hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase
  • Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids may also constitute analytes in certain embodiments.
  • the analyte may be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like.
  • the analyte may be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, p
  • Analytes such as neurochemicals and other chemicals generated within the body may also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
  • continuous analyte sensor and “continuous glucose sensor,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a device that continuously or continually measures a concentration of an analyte/glucose and/or calibrates the device (e.g., by continuously or continually adjusting or determining the sensor's sensitivity and background), for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.
  • biological sample is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to sample derived from the body or tissue of a host, such as, for example, blood, interstitial fluid, spinal fluid, saliva, urine, tears, sweat, or other like fluids.
  • host is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to animals, including humans.
  • membrane system is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a permeable or semi-permeable membrane that can be comprised of two or more domains and is typically constructed of materials of a few microns thickness or more, which may be permeable to oxygen and are optionally permeable to glucose.
  • the membrane system comprises an immobilized glucose oxidase enzyme, which enables an electrochemical reaction to occur to measure a concentration of glucose.
  • domain is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to regions of a membrane that can be layers, uniform or non-uniform gradients (for example, anisotropic), functional aspects of a material, or provided as portions of the membrane.
  • the term “sensing region,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the region of a monitoring device responsible for the detection of a particular analyte.
  • the sensing region generally comprises a non-conductive body, at least one electrode, a reference electrode and a optionally a counter electrode passing through and secured within the body forming an electroactive surface at one location on the body and an electronic connection at another location on the body, and a membrane system affixed to the body and covering the electroactive surface.
  • electroactive surface is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the surface of an electrode where an electrochemical reaction takes place.
  • a working electrode measures hydrogen peroxide (H 2 O 2 ) creating a measurable electronic current.
  • baseline is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the component of an analyte sensor signal that is not related to the analyte concentration.
  • the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide).
  • the value of b (i.e., the baseline) can be zero or about zero. This can be the result of a baseline-subtracting electrode or low bias potential settings, for example.
  • inactive enzyme is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an enzyme (e.g., glucose oxidase, GOx) that has been rendered inactive (e.g., by denaturing of the enzyme) and has substantially no enzymatic activity.
  • Enzymes can be inactivated using a variety of techniques known in the art, such as but not limited to heating, freeze-thaw, denaturing in organic solvent, acids or bases, cross-linking, genetically changing enzymatically critical amino acids, and the like.
  • a solution containing active enzyme can be applied to the sensor, and the applied enzyme subsequently inactivated by heating or treatment with an inactivating solvent.
  • non-enzymatic is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a lack of enzyme activity.
  • a “non-enzymatic” membrane portion contains no enzyme; while in other embodiments, the “non-enzymatic” membrane portion contains inactive enzyme.
  • an enzyme solution containing inactive enzyme or no enzyme is applied.
  • ROM read-only memory
  • EEPROM electrically erasable programmable read-only memory
  • RAM is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a data storage device for which the order of access to different locations does not affect the speed of access.
  • RAM is broad enough to include SRAM, for example, which is static random access memory that retains data bits in its memory as long as power is being supplied.
  • A/D Converter is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to hardware and/or software that converts analog electrical signals into corresponding digital signals.
  • raw data stream and “data stream,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an analog or digital signal directly related to the analyte concentration measured by the analyte sensor.
  • the raw data stream is digital data in counts converted by an A/D converter from an analog signal (for example, voltage or amps) representative of an analyte concentration.
  • the terms broadly encompass a plurality of time spaced data points from a substantially continuous analyte sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
  • counts is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of a digital signal.
  • a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from a working electrode.
  • sensor electronics is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the components (for example, hardware and/or software) of a device configured to process data.
  • the data includes biological information obtained by a sensor regarding the concentration of the analyte in a biological fluid.
  • U.S. Pat. Nos. 4,757,022, 5,497,772 and 4,787,398 describe suitable electronic circuits that can be utilized with devices of certain embodiments.
  • potentiostat is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an electrical system that applies a potential between the working and reference electrodes of a two- or three-electrode cell at a preset value and measures the current flow through the working electrode.
  • the potentiostat forces whatever current is necessary to flow between the working and counter electrodes to keep the desired potential, as long as the needed cell voltage and current do not exceed the compliance limits of the potentiostat.
  • operably connected is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to one or more components being linked to another component(s) in a manner that allows transmission of signals between the components.
  • one or more electrodes can be used to detect the amount of glucose in a sample and convert that information into a signal; the signal can then be transmitted to an electronic circuit.
  • the electrode is “operably linked” to the electronic circuit.
  • filtering is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to modification of a set of data to make it smoother and more continuous and remove or diminish outlying points, for example, by performing a moving average of the raw data stream.
  • algorithm is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the computational processes (for example, programs) involved in transforming information from one state to another, for example using computer processing.
  • calibration is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the process of determining the graduation of a sensor giving quantitative measurements (e.g., analyte concentration).
  • calibration may be updated or recalibrated over time to account for changes associated with the sensor, such as changes in sensor sensitivity and sensor background.
  • calibration of the sensor can involve, automatic, self-calibration, e.g., without using reference analyte values after point of use.
  • sensor data is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to data received from a continuous analyte sensor, including one or more time-spaced sensor data points.
  • reference analyte values and “reference data,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to reference data from a reference analyte monitor, such as a blood glucose meter, or the like, including one or more reference data points.
  • the reference glucose values are obtained from a self-monitored blood glucose (SMBG) test (for example, from a finger or forearm blood test) or a YSI (Yellow Springs Instruments) test, for example.
  • SMBG self-monitored blood glucose
  • YSI Yellow Springs Instruments
  • interferents and “interfering species,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement.
  • interfering species are compounds with an oxidation potential that overlaps with the analyte to be measured, producing a false positive signal.
  • a sensor session is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the period of time the sensor is applied to (e.g. implanted in) the host or is being used to obtain sensor values.
  • a sensor session extends from the time of sensor implantation (e.g. including insertion of the sensor into subcutaneous tissue and placing the sensor into fluid communication with a host's circulatory system) to the time when the sensor is removed.
  • sensitivity or “sensor sensitivity,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to an amount of signal produced by a certain concentration of a measured analyte, or a measured species (e.g., H 2 O 2 ) associated with the measured analyte (e.g., glucose).
  • a sensor has a sensitivity of from about 1 to about 300 picoAmps of current for every 1 mg/dL of glucose analyte.
  • sensitivity profile or “sensitivity curve,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to a representation of a change in sensitivity over time
  • calibration of continuous analyte sensors is often performed by using, as reference, a calibration solution with a known concentration of the analyte.
  • This calibration procedure can be cumbersome, as a calibration bag, separate from (and an addition to) an IV (intravenous) bag, is typically used.
  • calibration of continuous analyte sensors has traditionally been performed by capillary blood glucose measurements (e.g., a finger stick glucose test), through which reference data is obtained and input into the continuous analyte sensor system.
  • This calibration procedure typically involves frequent finger stick measurements, which can be inconvenient and painful.
  • continuous analyte sensors that are capable of continuous, automatic self-calibration during a sensor session and capable of achieving high levels of accuracy, without (or with reduced) reliance on reference data from a reference analyte monitor (e.g., from a blood glucose meter).
  • the continuous analyte sensor is an invasive, minimally invasive, or non-invasive device.
  • the continuous analyte sensor can be a subcutaneous, transdermal, or intravascular device. In certain embodiments, one or more of these devices may form a continuous analyte sensor system.
  • the continuous analyte sensor system may be comprised of a combination of a subcutaneous device and a transdermal device, a combination of a subcutaneous device and an intravascular device, a combination of a transdermal device and an intravascular device, or a combination of a subcutaneous device, a transdermal device, and an intravascular device.
  • the continuous analyte sensor can analyze a plurality of intermittent biological samples (e.g., blood samples).
  • the continuous analyte sensor can use any glucose-measurement method, including methods involving enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, iontophoretic, and radiometric mechanisms, and the like.
  • the continuous analyte sensor includes one or more working electrodes and one or more reference electrode, which operate together to measure a signal associated with a concentration of the analyte in the host.
  • the output signal from the working electrode is typically a raw data stream that is calibrated, processed, and used to generate an estimated analyte (e.g., glucose) concentration.
  • the continuous analyte sensor may measure an additional signal associated with the baseline and/or sensitivity of the sensor, thereby enabling monitoring of baseline and/or additional monitoring of sensitivity changes or drift that may occur in a continuous analyte sensor over time.
  • the senor extends through a housing, which maintains the sensor on the skin and provides for electrical connection of the sensor to sensor electronics.
  • the sensor is formed from a wire.
  • the sensor can include an elongated conductive body, such as a bare elongated conductive core (e.g., a metal wire) or an elongated conductive core coated with one, two, three, four, five, or more layers of material, each of which may or may not be conductive.
  • the elongated sensor may be long and thin, yet flexible and strong.
  • the smallest dimension of the elongated conductive body is less than about 0.1 inches, 0.075 inches, 0.05 inches, 0.025 inches, 0.01 inches, 0.004 inches, or 0.002 inches.
  • Other embodiments of the elongated conductive body are disclosed in U.S. Patent Application Publication No. 2011/0027127, which is incorporated herein by reference in its entirety.
  • a membrane system is deposited over at least a portion of electroactive surfaces of the sensor 102 (including a working electrode and optionally a reference electrode) and provides protection of the exposed electrode surface from the biological environment, diffusion resistance (limitation) of the analyte if needed, a catalyst for enabling an enzymatic reaction, limitation or blocking of interferants, and/or hydrophilicity at the electrochemically reactive surfaces of the sensor interface. Disclosures regarding the different membrane systems that may be used with the embodiments described herein are described in U.S. Patent Publication No. US-2009-0247856-A1, which is incorporated herein by reference in its entirety.
  • Calibrating sensor data from continuous analyte sensors generally involves defining a relationship between sensor-generated measurements (e.g., in units of nA or digital counts after A/D conversion) and one or more reference measurement (e.g., in units of mg/dL or mmol/L).
  • sensor-generated measurements e.g., in units of nA or digital counts after A/D conversion
  • reference measurement e.g., in units of mg/dL or mmol/L.
  • one or more reference measurements obtained shortly after the analyte sensor is manufactured, and before sensor use, are used for calibration.
  • the reference measurement may be obtained in many forms.
  • the reference measurement may be determined from a ratio or correlation between the sensitivity of a sensor (e.g., from a certain sensor lot) with respect to in vivo analyte concentration measurements and the sensitivity of another sensor (e.g., from the same lot made in substantially the same way under substantially same conditions) with respect to in vitro analyte concentration measurements at a certain time period.
  • a sensor e.g., from a certain sensor lot
  • another sensor e.g., from the same lot made in substantially the same way under substantially same conditions
  • the need for recalibration, by using reference data during a sensor session may be eliminated, or else lessened, such that recalibration may be called for only in certain limited circumstances, such as when sensor failure is detected.
  • the continuous analyte sensor may be configured to request and accept one or more reference measurements (e.g., from a finger stick glucose measurement or a calibration solution) at the start of the sensor session.
  • reference measurements e.g., from a finger stick glucose measurement or a calibration solution
  • use of a reference measurement at the start of the sensor session in conjunction with a predetermined sensor sensitivity profile can eliminate or substantially reduce the need for further reference measurements.
  • the sensing mechanism depends on certain phenomena that have a generally linear relationship with glucose concentration, for example: (1) diffusion of an analyte through a membrane system situated between an implantation site (e.g., subcutaneous space) and an electroactive surface, (2) rate of an enzyme-catalyzed reaction of the analyte to produce a measured species within the membrane system (e.g., the rate of a glucose oxidase-catalyzed reaction of glucose with O 2 which produces gluconic acid and H 2 O 2 ), and (3) diffusion of the measured species (e.g., H 2 O 2 ) to the electroactive surface. Because of this generally linear relationship, calibration of the sensor is obtained by solving the equation:
  • y represents the sensor signal (counts)
  • x represents the estimated glucose concentration (mg/dL)
  • m represents the sensor sensitivity to analyte concentration (counts/mg/dL)
  • b represents the baseline signal (counts).
  • the value b i.e., the baseline
  • the continuous analyte sensor system is configured to estimate changes or drift in sensitivity of the sensor for an entire sensor session as a function of time (e.g., elapsed time since start of the sensor session). As described elsewhere herein, this sensitivity function plotted against time may resemble a curve. Additionally or alternatively, the system can also be configured to determine sensor sensitivity changes or drift as a function of time and one or more other parameters that can also affect sensor sensitivity or provide additional information about sensor sensitivity.
  • parameters can affect sensor sensitivity or provide additional information about sensor sensitivity prior to the sensor session, such as parameters associated with the sensor fabrication (e.g., materials used to fabricate sensor membrane, the thickness of the sensor membrane, the temperature at which the sensor membrane was cured, the length of time the sensor was dipped in a particular coating solution, etc.). In certain embodiments, some of the parameters involve information, obtained prior to the sensor session, which can be accounted for in a calibration code that is associated with a particular sensor lot. Other parameters can be associated with conditions surrounding the sensor after its manufacture, but before the sensor session, such as, for example, the level of exposure of the sensor to certain levels of humidity or temperature while the sensor is in a package in transit from the manufacturing facility to the patient. Yet other parameters (e.g., sensor membrane permeability, temperature at the sample site, pH at the sample site, oxygen level at the sample site, etc.) can affect sensor sensitivity or provide additional information about sensor sensitivity during the sensor session.
  • parameters associated with the sensor fabrication e.g., materials used to fabricate sensor membrane
  • Determination of sensor sensitivity at different times of a sensor session based on the predetermined sensor sensitivity profile can be performed prior to the sensor session or at the start of the sensor session. Additionally, in certain embodiments, determination of sensor sensitivity, based on the sensor sensitivity profile, can be continuously adjusted to account for parameters that affect sensor sensitivity or provide additional information about sensor sensitivity during the sensor session. These determinations of sensor sensitivity change or drift can be used to provide self-calibration, update calibration, supplement calibration based on measurements (e.g., from a reference analyte monitor), and/or validate or reject reference analyte measurements from a reference analyte monitor. In some embodiments, validation or rejection of reference analyte measurements can be based on whether the reference analyte measurements are within a range of values associated with the predetermined sensor sensitivity profile.
  • Some of the continuous analyte sensors described herein may be configured to measure a signal associated with a non-analyte constant in the host.
  • the non-analyte constant signal is measured beneath the membrane system on the sensor.
  • a non-glucose constant that can be measured is oxygen.
  • a change in oxygen transport which can be indicative of a change or drift in the sensitivity of the glucose signal, can be measured by switching the bias potential of the working electrode, an auxiliary oxygen-measuring electrode, an oxygen sensor, or the like.
  • the continuous analyte sensors described herein may be configured to measure changes in the amount of background noise in the signal. Detection of changes which exceed a certain threshold can provide the basis for triggering calibration, updating calibration, and/or validating or rejecting inaccurate reference analyte values from a reference analyte monitor.
  • the background noise is composed substantially of signal contribution from factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide).
  • the continuous glucose sensor is configured to measure a signal associated with the baseline (which includes substantially all non-glucose related current generated), as measured by the sensor in the host.
  • an auxiliary electrode located beneath a non-enzymatic portion of the membrane system is used to measure the baseline signal.
  • the baseline signal can be subtracted from the glucose+baseline signal to obtain a signal associated entirely or substantially entirely with glucose concentration. Subtraction may be accomplished electronically in the sensor using a differential amplifier, digitally in the receiver, and/or otherwise in the hardware or software of the sensor or receiver as described in more detail elsewhere herein.
  • the continuous analyte sensor can be continuously self-calibrated during a sensor session without (or with reduced) reliance on reference measurements from a reference analyte monitor or calibration solution.
  • self-calibration of the analyte sensor system can be performed by determining sensor sensitivity based on a sensitivity profile (and a measured or estimated baseline), so that the following equation can be solved:
  • y represents the sensor signal (counts)
  • x represents the estimated glucose concentration (mg/dL)
  • m represents the sensor sensitivity to the analyte (counts/mg/dL)
  • b represents the baseline signal (counts).
  • FIG. 1A illustrates this phenomenon and provides a plot of sensor sensitivities 110 of a group of continuous glucose sensors as a function of time during a sensor session.
  • FIG. 1B provides three plots of conversion functions at three different time periods of a sensor session. As shown in FIG. 1B , the three conversion functions have different slopes, each of which correspond to a different sensor sensitivity. Accordingly, the differences in slopes over time illustrate that changes or drift in sensor sensitivity occur over a sensor session.
  • the sensors were made in substantially the same way under substantially the same conditions.
  • the sensor sensitivities associated with the y-axis of the plot are expressed as a percentage of a substantially steady state sensitivity that was reached about three days after start of the sensor session.
  • these sensor sensitivities correspond to measurements obtained from YSI tests.
  • the sensitivities (expressed as a percentage of a steady state sensitivity) of each sensor, as measured, are very close to sensitivities of other sensors in the group at any given time of the sensor session.
  • an estimative algorithm function 120 can be used to define the relationship between time during the sensor session and sensor sensitivity.
  • the estimative algorithm function may be generated by testing a sample set (comprising one or more sensors) from a sensor lot under in vivo and/or in vitro conditions. Alternatively, the estimative algorithm function may be generated by testing each sensor under in vivo and/or in vitro conditions.
  • a sensor may undergo an in vitro sensor sensitivity drift test, in which the sensor is exposed to changing conditions (e.g., step changes of glucose concentrations in a solution), and an in vitro sensitivity profile of the sensor is generated over a certain time period.
  • the time period of the test may substantially match an entire sensor session of a corresponding in vivo sensor, or it may encompass a portion of the sensor session (e.g., the first day, the first two days, or the first three days of the sensor session, etc.). It is contemplated that the above-described test may be performed on each individual sensor, or alternatively on one or more sample sensors of a sensor lot. From this test, an in vitro sensitivity profile may be created, from which an in vivo sensitivity profile may be modeled and/or formed.
  • one or more data sets each comprising data points associating sensitivity with time, may be generated and plotted.
  • a sensitivity profile or curve can then be fitted to the data points. If the curve fit is determined to be satisfactory (e.g., if the standard deviation of the generated data points is less a certain threshold), then the sensor sensitivity profile or curve may be judged to have passed a quality control and suitable for release. From there, the sensor sensitivity profile can be transformed into an estimative algorithm function or alternatively into a look-up table.
  • the algorithm function or look-up table can be stored in a computer-readable memory, for example, and accessed by a computer processor.
  • the estimative algorithm function may be formed by applying curve fitting techniques that regressively fit a curve to data points by adjusting the function (e.g., by adjusting constants of the function) until an optimal fit to the available data points is obtained.
  • a “curve” i.e., a function sometimes referred to as a “model”
  • selection of the parameters of the curve may involve selection of coefficients of a polynomial function.
  • the curve fitting process may involve evaluating how closely the curve determined in the curve fitting process estimates the relationship between the data values, to determine the optimal fit.
  • curve is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers to a function or a graph of a function, which can involve a rounded curve or a straight curve, i.e., a line.
  • the curve may be formed by any of a variety of curve fitting techniques, such as, for example, the linear least squares fitting method, the non-linear least squares fitting method, the Nelder-Mead Simplex method, the Levenberg-Marquardt method, and variations thereof.
  • the curve may be fitted using any of a variety of functions, including, but not limited to, a linear function (including a constant function), logarithmic function, quadratic function, cubic function, square root function, power function, polynomial function, rational function, exponential function, sinusoidal function, and variations and combinations thereof.
  • the estimative algorithm comprises a linear function component which is accorded a first weight w1, a logarithmic function component which is accorded a second weight w2, and an exponential function component which is accorded a third weight w3.
  • the weights associated with each component can vary as a function of time and/or other parameters, but in alternative embodiment, one or more of these weights are constant as a function of time.
  • the estimative algorithm function's correlation (e.g., R2 value), which is a measure of the quality of the fit of the curve to the data points, with respect to data obtained from the sample sensors, may be one metric used to determine whether a function is optimal.
  • the estimative algorithm function formed from the curve fitting analysis may be adjusted to account for other parameters, e.g., other parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity.
  • the estimative algorithm function may be adjusted to account for the sensitivity of the sensor to hydrogen peroxide or other chemical species.
  • Estimative algorithms formed and used to accurately estimate an individual sensor's sensitivity, at any time during a sensor session, can be based on factory calibration and/or based on a single early reference measurement (e.g., using a single point blood glucose monitor).
  • sensors across a population of continuous analyte sensors manufactured in substantially the same way under substantially same conditions exhibit a substantially fixed in vivo to in vitro sensitivity relationship.
  • an initial value of in vivo sensitivity can be generated, from which an algorithmic function corresponding to the sensor sensitivity profile can be formed. Put another way, from this initial value (which represents one point in the sensor sensitivity profile), the rest of the entire sensor sensitivity profile can be determined and plotted.
  • the initial value of in vivo sensitivity can be associated with any portion of the sensor sensitivity profile.
  • multiple initial values of in vivo sensitivities which are time-spaced apart, and which correspond to multiple in vitro sensitivities, can be calculated and combined together to generate the sensor sensitivity profile.
  • the initial value 210 of in vivo sensitivity is associated with a time corresponding to the start (near the start) of the sensor session.
  • the rest of the sensor sensitivity profile 220 is plotted (i.e., plotted forward and backward across the x-axis corresponding to time).
  • the initial value 210 ′ may be associated with any other time of the sensor session. For example, as illustrated in FIG.
  • the in initial value 210 ′ of in vivo sensitivity is associated with a time (e.g., at about day 3) when the sensitivity has substantially reached steady state. From the initial value 210 ′, the rest of the sensor sensitivity profile 220 ′ is plotted, as illustrated in FIG. 2D .
  • the in vivo to in vitro sensitivity relationship was not equal, the relationship nonetheless involved a consistently fixed ratio.
  • some of the sensors described herein can be factory calibrated by evaluating the in vitro sensitivity characteristic (e.g., one or more sensitivity values measured at certain time periods) of a sensor from a particular sensor lot at a manufacturing facility, defining the in vivo sensitivity characteristic of other sensors in the same sensor lot based on its relationship with the measured in vitro sensitivity characteristic, and storing this calculated in vivo sensitivity characteristic onto electronics associated with the sensors (e.g., in computer memory of a sensor electronics, discussed more elsewhere herein, configured to be operably coupled to the sensor during sensor use).
  • electronics associated with the sensors e.g., in computer memory of a sensor electronics, discussed more elsewhere herein, configured to be operably coupled to the sensor during sensor use.
  • factory calibration is achieved in conjunction with high levels of sensor accuracy.
  • the sensor was capable of achieving an accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days, and sometimes at least about 4, 5, 6, 7, or 10 days.
  • the sensor was capable of achieving an accuracy, over a over a sensor session of at least about 3 days, corresponding to a mean absolute relative difference of no more than about 7%, 5%, or 3%.
  • the sensors were built with a working electrode configured to measure a glucose+baseline signal and a corresponding auxiliary electrode configured to measure only the baseline signal.
  • Sensor electronics in the sensor system subtracted the baseline signal from the glucose+baseline signal to obtain a signal associated entirely or substantially entirely to glucose concentration.
  • an algorithmic function was generated and stored in sensor electronics associated with the sensors to estimate the sensitivity of these sensors during their lives. This algorithmic function is plotted in FIG. 1A and shown closely overlying the measured sensor sensitivities of the sensors. With the determination of baseline and sensitivity at any given time during the life of a sensor, a conversion function is formed, whereby a sensor signal is converted into an estimated glucose concentration.
  • FIG. 3A which is a Bland-Altman plot showing differences between YSI reference measurements and certain in vivo continuous analyte sensors that were factory calibrated, the measurements from these sensors exhibited very high accuracy.
  • the lines in FIG. 3A represent accuracy standards corresponding to a deviation from actual measured values (using YSI tests) of less than ⁇ 10 mg/dL at glucose concentrations between about 40 and 75 mg/dL, and less than ⁇ 15% at glucose concentrations between about 75 mg/dL and 400 mg/dL.
  • the difference between estimated glucose concentration values, which are calculated using a predetermined sensor sensitivity profile, and actual measured values (using YSI tests) over a sensor life differed by no more than about 10 mg/dL at glucose concentrations between about 40 and 75 mg/dL, and no more than 15% at glucose concentrations between about 75 mg/dL and 400 mg/dL. Furthermore, at glucose concentrations between about 40 mg/dL and 75 mg/dL, about 97% of the estimated glucose concentrations values were within ⁇ 5 mg/dL of corresponding YSI measured values, and at glucose concentrations between about 70 mg/dL and 400 mg/dL, about 99% of the estimated glucose concentrations were within ⁇ 10% of corresponding YSI measured values.
  • FIG. 3B illustrates a Clarke error grid associated with the factory calibration study associated with FIG. 3A .
  • the Clarke error grid of FIG. 3B is a Clarke error grid is based on a correlation plot of the performance of the above-described factory calibration method with respect to a reference method in the form of YSI measurements. If the correlation was perfect, all points would fall on a 45° line. The area surrounding this line is divided into zones that predict the clinical consequences in terms of action taken by the patient, depending on where the measurements by the factory calibration method fall off the line. Zone A corresponds to a clinically accurate decision (e.g., take insulin, take glucose, or do nothing), zone B a clinically acceptable decision, and zone D corresponds to a clinically erroneous decision. As shown in FIG. 3B , all of data points from the factory calibration study fell within either zone A or zone B. In fact, almost all of the data points fell within Zone A, thus establishing that the above-described factory calibration study provided very accurate glucose concentration measurements.
  • the continuous analyte sensors are configured to request and accept one or more reference measurements (e.g., from a finger stick glucose measurement or from a calibration solution) at the start of the sensor session.
  • the request for one or more reference measurements can be made at about 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, etc., after activation of the sensor.
  • sensor electronics are configured to process and use the reference data to generate (or adjust) a sensor sensitivity profile in response to the input of one or more reference measurements into the sensor.
  • Use of the one of the one or more reference measurements at the start of the sensor in conjunction with a predetermined sensor sensitivity profile permits self-calibration of the sensor without or with a reduced need for further reference measurements.
  • FIG. 4 illustrates a Bland-Altman plot showing differences between YSI reference measurements and in vivo continuous analyte sensors that accepted one reference measurement about one hour after insertion into patients.
  • the lines in FIG. 4 represent accuracy standards corresponding to a deviation from actual measured values (using YSI tests) of less than about ⁇ 20 mg/dL at glucose concentrations between about 40 mg/dL and 75 mg/dL, and less than about ⁇ 20% at glucose concentrations between about 75 mg/dL and 400 mg/dL. From this reference measurement, an initial value of in vivo sensor sensitivity was generated, which in turned allow for the formation of an algorithmic function corresponding to the sensitivity profile for the rest of the sensor session.
  • the sensors were built with a working electrode and an auxiliary electrode used to measure a baseline signal, which was subtracted from the glucose+baseline signal obtained by the working electrode. As shown, about 85% of the estimated glucose concentrations were within the range 410, defined as ⁇ 20 mg/dL from corresponding YSI measured values for glucose concentrations between about 40 mg/dL and 75 mg/dL and ⁇ 20% from corresponding YSI measured values for glucose concentrations between about 75 mg/dL and 400 mg/dL. Additionally, at glucose concentrations between about 40 mg/dL and 75 mg/dL, about 95% of the estimated glucose concentrations values were within ⁇ 20 mg/dL of corresponding YSI measured values.
  • the sensors in this study obtained an overall accuracy level corresponding to a Mean Absolute Relative Difference of about 12% over a sensor session of at least seven days, and a first-day accuracy level corresponding to a Mean Absolute Relative Difference of about 11%.
  • the Median Absolute Relative Difference obtained were about 10% for both overall and fist-day accuracy levels.
  • FIG. 5 is a diagram illustrating different types of information that can be input into the sensor system to define the sensor sensitivity profile over time, in one embodiment.
  • Input information can include information obtained prior to the sensor session 510 and information obtained during the sensor session 520 .
  • both information obtained prior to the sensor session 510 and information obtained during the sensor session 520 are used to generate, adjust, or update a function 530 associated with the sensor sensitivity profile, but in another embodiment, the sensor system may be configured to use only information obtained prior to the sensor session.
  • formation of an initial sensor sensitivity profile can occur prior to the sensor session, at the start of the sensor session, or shortly after the start of the sensor session.
  • the sensor sensitivity profile can be continuously adjusted, regenerated, or updated to account for parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity during the sensor session.
  • Information obtained prior to the sensor session can include, for example, the sensor sensitivity profile that is generated before or at the start of the sensor session, as previously described. It can also include a sensitivity value associated with a substantially fixed in vivo to in vitro sensor sensitivity relationship, as previously described.
  • the in vivo to in vitro sensor sensitivity relationship may be defined as a function of time between completion of sensor fabrication (or the time calibration check was performed on sensors from the same lot) and the start of the sensor session.
  • FIG. 6 it has been discovered that a sensor's sensitivity to analyte concentration can change as a function of time between completion of sensor fabrication and the start of the sensor session.
  • FIG. 6 illustrates this phenomenon through a plot, which resembles a downward trend in sensitivity over time between completion of sensor fabrication and the start of the sensor session.
  • this change or drift in sensitivity over time between completion of sensor fabrication and the start of the sensor session is generally consistent among sensors that have not only been manufactured in substantially the same way under substantially same conditions, but that also have avoided exposure to certain conditions (e.g., exposure to radiation, extreme temperature, abnormal dehydration conditions, or any environment that can damage the enzyme in the sensor membrane or other parts of the sensor, etc.) Accordingly, the change or drift in sensitivity over time between completion of sensor fabrication and the start of the sensor session can also be modeled through a mathematical function 620 that accurately estimates this change or drift.
  • the estimative algorithm function 620 may be any of a variety of functions, such as, for example, a linear function (including a constant function), logarithmic function, quadratic function, cubic function, square root function, power function, polynomial function, rational function, exponential function, sinusoidal function, and combinations thereof.
  • Information obtained prior to the sensor session can also include information relating to certain sensor characteristics or properties.
  • information obtained prior to the sensor session may include the particular materials used to fabricate the sensor (e.g., materials used to form the sensor membrane), the thickness of the sensor membrane, the membrane's permeability to glucose or other chemical species, the in vivo or in vitro sensor sensitivity profile of another sensor made in substantially the same way under substantially same conditions, etc.
  • information obtained prior to the sensor session can include information relating to the process conditions under which the sensor is fabricated. This information can include, for example, the temperature at which the sensor membrane was cured, the length of time the sensor was dipped in a particular coating solution, etc.
  • information obtained prior to the sensor session can relate to patient physiological information.
  • the patient's age, body mass index, gender, and/or historic patient sensitivity profiles can be used as parameters to form the sensor sensitivity profile.
  • Other information obtained prior to the sensor session that may also be used includes information relating to sensor insertion, such as, for example, location (e.g., abdomen vs. back) or depth of sensor insertion.
  • the sensor sensitivity functions can be created by theoretical or empirical methods, or both, and stored as functions or as look-up-tables, thereby allowing for sensor self-calibration that eliminates (or substantially reduces) the need for reference measurements.
  • the sensor sensitivity functions can be generated at the manufacturing facility and shipped with the system or generated by the system shortly prior to (or during) use.
  • self-calibration is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to calibration of a sensor or device which is performed by a control system manufacturer or installer, the sensor manufacturer, or anyone other than the user of the sensor.
  • the sensor calibration can be performed on the individual sensor on which the control system is installed, or it can be performed on a reference sensor, for example one from the same sensor lot, and the calibration functions can be transferred from one control system to another.
  • systems may be shipped with some self-calibration functions and then have others added by the sensor user.
  • sensor systems may be shipped with self-calibration functions and only need adjustments or touch-up calibrations during use.
  • the sensor sensitivity profile may be adjusted during sensor use to account for, in real-time, certain parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity. These parameters may include, but are not limited to, parameters associated with sensor properties, such as, for example, sensor membrane permeability or the level of sensor hydration, or parameters associated with patient physiological information, such as, for example, patient temperature (e.g., temperature at the sample site or skin temperature), pH at the sample site, hematocrit level, or oxygen level at the sample site.
  • the continuous analyte sensor may be fitted with a thermistor on an ex vivo portion of the sensor and a thermal conductive line that extends from the thermistor to the sample site.
  • calibration methods can be improved by algorithmically quantifying each unique sensor/user environment. Quantification can be achieved by generation or adjustment of the sensitivity profile, which may involve an inference engine involving a causal probabilistic network such as a Bayesian network.
  • a Bayesian network includes a conditional probability-based network that relies on the Bayes theorem to characterize the likelihood of different outcomes based on known prior probabilities (e.g., prevalence of observed in vivo sensitivities under certain parameter conditions) and newly acquired information (e.g., occurrence or nonoccurrence of the aforementioned conditions).
  • quantification is achieved through the application of an analytical Bayesian framework to data already existing within the system algorithm.
  • Quantification can involve: (1) wedge (e.g., maximum or minimum) values for parameters related to sensitivity and baseline; (2) sensitivity values calculated during a sensor session; and (3) baselines calculated during the sensor session.
  • the first set of wedge values are based on parameter distributions of “prior” data (e.g., data collected from previous clinical studies).
  • a Bayesian network a system can learn from data collected during the sensor session, and adapt the wedge values (or other algorithm parameters and/or constraints) to a particular sensor/user environment. In turn, the system's calibration method can be improved to have better accuracy, reliability, and overall performance.
  • the Bayesian framework used involves using known prior information to establish a framework and then accounting for gathered new information to make inferences from their combination (i.e., combination of prior and new information), to generate posterior information.
  • the prior information and the new information are mathematically related and combined to form posterior information that can be represented functionally, the relationship is defined as conjugate.
  • the Bayesian framework of one embodiment employs conjugate distributional relationships that result in the posterior distributional parameters (e.g., mean, variance) being directly available. This can be advantageous under a computationally restrictive space where both time and resources are constrained.
  • an independent posterior distribution for sensitivity and/or baseline can be generated.
  • These two posterior distributions are then used in parallel to construct glucose threshold values used for accepting, rejecting, or modifying a user's manual calibration entry (e.g., entry from a fingerstick measurement).
  • the posterior distributions of sensitivity and baseline can also be used for semi-self-calibration, thereby reducing the number of fingerstick measurements required for manual calibration.
  • the wedge min/max values for a sensor's sensitivity to glucose are known to be A and B at the 95% confidence interval in a substantially normal distribution.
  • the previous three, four, five, six, seven, or more sensitivity values calculated through manual calibration can be used as new information to generate a posterior distribution, which will typically have reduced variability than the distribution based on prior information, and which is a direct quantification of a unique sensor/user environment. Because of reduced variability, the posterior distribution generated will typically have wedge values, which should be closer together than the difference between A and B, i.e., the wedge values of the distribution generated from prior information.
  • FIG. 7A depicts distribution curves of sensor sensitivity corresponding to the Bayesian learning process, in accordance with one embodiment.
  • FIG. 7B depicts confidence levels, associated with the sensor sensitivity profile, that correspond with the distribution curves shown in FIG. 7A .
  • Distribution curve 720 and confidence level 730 are associated with a lack of initial knowledge about certain parameters that affect sensor sensitivity or provide additional information about sensor sensitivity.
  • distribution curve 720 can be associated with factory information.
  • the distribution curve 720 ′ becomes steeper and the confidence interval 730 ′ becomes narrower, as certainty of sensor sensitivity profile 710 is increased.
  • Examples of information that may be used to change the distribution curves can include a reference analyte value, a cal-check of the sensor at the factory, patient history information, and any other information described elsewhere herein that can affect sensor sensitivity or provide information about sensor sensitivity.
  • the distribution curve 720 ′′ becomes even steeper and the confidence interval 730 ′′ becomes even narrower, as certainty of sensor sensitivity profile 710 is further increased.
  • the confidence interval curves 730 , 730 ′, and/or 730 ′′ may be used to form the sensitivity profile 710 , which provides an estimated sensitivity value at a given time.
  • the estimated sensitivity value may be used to calibrate the sensor, which allows for processing of sensor data to generate a glucose concentration value that is displayed to the user.
  • a first estimated sensitivity profile 710 formed from the confidence interval curves 730 , 730 ′, and/or 730 ′′, may be used to monitor and display glucose concentrations.
  • one or more of the confidence interval curves 730 , 730 ′, 730 ′′, or combinations thereof can be used to form a second estimated sensitivity profile that, while possibly not as accurate as the first estimated sensitivity profile, is nonetheless more likely to result in the detection of a hypoglycemic or hyperglycemic range than the first estimated sensitivity profile 710 .
  • Some implantable sensors measure a signal (e.g., counts) that comprises two components, the baseline signal and the analyte signal.
  • the baseline signal is substantially comprised of a signal contribution from factors other than the measure analyte (e.g., interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with the analyte or co-analyte).
  • the analyte signal e.g., glucose signal
  • the baseline is comprised of constant and non-constant non-analyte factors.
  • an analyte sensor (e.g., glucose sensor) is configured for insertion into a host for measuring an analyte in the host.
  • the sensor includes a working electrode disposed beneath an active enzymatic portion of a membrane on the sensor, an auxiliary electrode disposed beneath an inactive- or non-enzymatic portion of the membrane on the sensor, and sensor electronics operably connected to the working and auxiliary electrodes.
  • the sensor electronics are configured to process signals from the electrodes to generate an analyte (e.g., glucose) concentration estimate that substantially excludes signal contribution from non-glucose related noise artifacts.
  • the working electrode is configured to generate via sensor electronics a first signal associated with both the analyte and non-analyte related electroactive compounds that have a oxidation potential less than or similar to a first oxidation potential.
  • the auxiliary electrode is configured to generate a second signal associated with the non-analyte related electroactive compounds.
  • Non-analyte related electroactive compounds can be any compound, present in the sensor's local environment, which has an oxidation potential less than or similar to the oxidation potential of the measured species (e.g., H2O2).
  • both the signal directly related to the enzyme-catalyzed reaction of glucose which produces H2O2 that is oxidized at the first working electrode
  • signals from unknown compounds that are in the extracellular milieu surrounding the sensor can be measured.
  • These unknown compounds can be constant or non-constant (e.g., intermittent or transient) in concentration and/or effect.
  • some of these unknown compounds can be related to the host's disease state. For example, it is known that blood chemistry can change dramatically during/after a heart attack (e.g., pH changes, changes in the concentration of various blood components/protein, and the like).
  • the transcutaneous insertion of a needle-type sensor can initiate a cascade of events that includes the release of various reactive molecules by macrophages.
  • Other compounds that can contribute to the non-glucose related signal are compounds associated with the wound healing process, which can be initiated by implantation/insertion of the sensor into the host, as described in more detail with reference to U.S. Patent Publication No. US-2007-0027370-A1.
  • Non-analyte related electroactive species can include interfering species, non-reaction-related species (e.g., H2O2) that correspond to the measured species, and other electroactive species.
  • Interfering species includes any compound that is not directly related to the electrochemical signal generated by the enzyme-catalyzed reaction of the analyte, such as, electroactive species in the local environment produced by other bodily processes (e.g., cellular metabolism, wound healing, a disease process, and the like).
  • Non-reaction-related species includes any compound from sources other than the enzyme-catalyzed reaction, such as, H2O2 released by nearby cells during the course of the cells' metabolism, H2O2 produced by other enzymatic reactions (e.g., extracellular enzymes around the sensor or such as can be released during the death of nearby cells or such as can be released by activated macrophages), and the like.
  • Other electroactive species includes any compound that has an oxidation potential less than or similar to the oxidation potential of H2O2.
  • the non-analyte signal produced by compounds other than the analyte is considered as background noise and can obscure the signal related to the analyte, thereby contributing to sensor inaccuracy.
  • background noise can include both constant and non-constant components and can be removed to accurately calculate the analyte concentration.
  • the analyte sensor system is configured in a way (e.g., with a certain symmetry, coaxial design, and/or integral formation) such that the working and auxiliary electrodes are influenced by substantially the same external/environmental factors, thereby enabling substantially equivalent measurement of both the constant and non-constant species/noise.
  • This allows for the substantial elimination of noise on the sensor signal by using sensor electronics described elsewhere herein.
  • the substantial reduction or elimination of signal effects associated with noise, including non-constant noise increases accuracy of continuous sensor signals.
  • sensor electronics are operably connected to the working and auxiliary electrodes.
  • the sensor electronics may be configured to measure the current (or voltage) to generate the first and second signals.
  • the first and second signals can be used to produce glucose concentration data without substantial signal contribution from non-glucose-related noise. This can be performed, for example, by subtraction of the second signal from the first signal to produce a signal associated with analyte concentration and without substantial noise contribution, or by alternative data analysis techniques.
  • the sensor electronics are operably connected to one or more working electrodes only, as an auxiliary electrode is not needed.
  • the sensor membrane in some embodiments may comprise polymers that contain mediators and enzymes that chemically attach to the polymers.
  • the mediator used may oxidize at lower potentials than hydrogen peroxide, and thus fewer oxidizable interferents are oxidized at these low potentials.
  • a very low baseline i.e., a baseline that approaches a zero baseline and that does not receive substantial signal contribution from non-glucose-related noise
  • a very low baseline i.e., a baseline that approaches a zero baseline and that does not receive substantial signal contribution from non-glucose-related noise
  • the sensor electronics can be comprised of a potentiostat, A/D converter, RAM, ROM, transceiver, processor, and/or the like.
  • the potentiostat may be used to provide a bias to the electrodes and to convert the raw data (e.g., raw counts) collected from the sensor to an analyte concentration value (e.g., a glucose concentration value expressed in units of mg/dL).
  • the transmitter may be used to transmit the first and second signals to a receiver, where additional data analysis and/or calibration of analyte concentration can be processed.
  • the sensor electronics may perform additional operations, such as, for example, data filtering and noise analysis.
  • the sensor electronics may be configured to analyze an analyte equivalent baseline or normalized baseline, instead of the baseline.
  • the unit for analyte equivalent baseline may be expressed as the analyte concentration unit (mg/dL), which correlates with the output of the continuous analyte sensor.
  • the membrane system covering the working electrode is capable of substantially blocking interferents, and substantially reducing the baseline to a level that is negligible, such that the baseline can be estimated.
  • Estimation of the baseline can be based on an assumption of the sensor's baseline at physiological conditions associated with a typical patient. For example, baseline estimation can be modeled after in vivo or in vitro measurements of baseline in accordance with certain physiological levels of interferents that are inherent in the body.
  • the estimated glucose equivalent baseline was formed by conducting in vitro measurements of the baseline of glucose sensors in a solution that mimicked physiological levels of interferents in a human.
  • the interferents included uric acid with a concentration of about 4 mg/dL and ascorbic acid, with a concentration of about 1 mg/dL of ascorbic acid.
  • FIG. 8 it was found in this study that the estimated baseline closely resembled the detected baseline.
  • a single working electrode alone i.e., without use of an ancillary electrode, together with a predetermined sensor sensitivity profile, may be sufficient to provide a sensor system with self-calibration.
  • the concepts behind the methods and systems used to predict sensitivity drift can also be applied to create a model that predicts baseline drift over time.
  • the total signal received by the sensor electrode is comprised of a glucose signal component, an interference signal component, and a electrode-related baseline signal component that is a function of the electrode and that is substantially independent of the environment (e.g., extracellular matrix) surrounding the electrode.
  • baseline refers without limitation to the component of an analyte sensor signal that is not related to the analyte concentration. Accordingly, the baseline, as the term is defined herein, is comprised of the interference signal component and the electrode-related baseline signal component. While not wishing to be bound by theory, it is believed that increased membrane permeability typically not only results in an increased rate of glucose diffusion across the sensor membrane, but also to an increased rate of diffusion of interferents across the sensor membrane. Accordingly, changes in sensor membrane permeability over time which causes sensor sensitivity drift, will similarly also likely cause the interference signal component of the baseline to drift.
  • the interference signal component of the baseline is not static, and is typically changing as a function of time, which, in turn, causes the baseline to also drift over time.
  • a predictive model can be developed to predict how the baseline of a sensor will drift during a sensor session.
  • a self-calibrating continuous analyte sensor can be achieved, i.e., a sensor that does not require use of reference measurements (e.g., a fingerstick measurement) for calibration.
  • the process of manufacturing continuous analyte sensors may sometimes be subjected to a degree of variability between sensor lots.
  • one or more calibration codes may be assigned to each sensor or sensor set to define parameters that can affect sensor sensitivity or provide additional information about the sensitivity profile.
  • the calibration codes can reduce variability in the different sensors, ensuring that the results obtained from using sensors from different sensors lots will be generally equal and consistent by applying an algorithm that adjusts for the differences.
  • the analyte sensor system may be configured such that one or more calibration codes are to be manually entered into the system by a user.
  • the calibration codes may be part of a calibration encoded label that is adhered to (or inserted into) a package of multiple sensors.
  • the calibration encoded label itself may be read or interrogated by any of a variety of techniques, including, but not limited to, optical techniques, RFID (Radio-frequency identification), or the like, and combinations thereof.
  • These techniques for transferring the code to the sensor system may be more automatic, accurate, and convenient for the patient, and less prone to error, as compared to manual entry.
  • Manual entry for instance, possesses the inherent risk of an error caused by a patient or hospital staff entering the wrong code, which can lead to an incorrect calibration, and thus inaccurate glucose concentration readings. In turn, this may result in a patient or hospital staff taking an inappropriate action (e.g., injecting insulin while in a hypoglycemic state).
  • calibration codes assigned to a sensor may include a first calibration code associated with a predetermined logarithmic function corresponding to a sensitivity profile, a second calibration code associated with an initial in vivo sensitivity value, and other calibration codes, with each code defining parameter that affects sensor sensitivity or provides information about sensor sensitivity.
  • the other calibration codes may be associated with any priori information or parameter described elsewhere herein and/or any parameter that helps define a mathematical relationship between the measured signal and analyte concentration.
  • the package used to store and transport a continuous analyte sensor may include detectors configured to measure certain parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity or other sensor characteristics.
  • the sensor package may include a temperature detector configured to provide calibration information relating to whether the sensor has been exposed to a temperature state greater than (and or less than) one or more predetermined temperature values.
  • the one or more predetermined temperature value may be greater than about 75° F., greater than about 80° F., greater than about 85° F., greater than about 90° F., greater than about 95° F., greater than about 100° F., greater than about 105° F., and/or greater than about 110° F.
  • the one or more predetermined temperature value may be less than about 75° F., less than about 70° F., less than about 60° F., less than about 55° F., less than about 40° F., less than about 32° F., less than about 10° F., and/or less than about 0° F.
  • the sensor package may include a humidity exposure indicator configured to provide calibration information relating to whether the sensor has been exposed to humidity levels greater than or less than one or more predetermined humidity values.
  • the one or more predetermined humidity value may be greater than about 60% relative humidity, greater than about 70% relative humidity, greater than about 80% relative humidity, and/or greater than about 90% relative humidity.
  • the one or more predetermined humidity value may be less than about 30% relative humidity, less than about 20% relative humidity, and/or less than about 10% relative humidity.
  • a corresponding calibration code may be changed to account for possible effects of this exposure on sensor sensitivity or other sensor characteristics.
  • This calibration code change may be automatically performed by a control system associated with the sensor package.
  • an indicator e.g., a color indicator
  • the sensor package may include an indicator that irreversibly changes color from a blue color to a red color, upon exposure of the package to a temperature greater than about 85° F., and also include instructions to the user to enter a certain calibration code when the indicator has a red color.
  • the continuous analyte system may comprise a library of stored sensor sensitivity functions or calibration functions associated with one or more calibration codes. Each sensitivity function or calibration function results in calibrating the system for a different set of conditions. Different conditions during sensor use may be associated with temperature, body mass index, and any of a variety of conditions or parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity.
  • the library can also include sensitivity profiles or calibrations for different types of sensors or different sensor lots. For example, a single sensitivity profile library can include sub-libraries of sensitivity profiles for different sensors made from different sensor lots and/or made with different design configurations (e.g., different design configurations customized for patients with different body mass index).
  • Some embodiments apply one or more stimulus signals to a sensor to determine properties of a sensor and/or calibrate sensor data.
  • the term “stimulus signal,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a signal (e.g., any time-varying or spatial-varying quantity, such as an electric voltage, current or field strength) applied to a system being used (e.g., an analyte sensor) to cause or elicit a response.
  • Non-limiting examples of stimulus signals that can be used in the embodiments described herein can be a waveform including one or more of: a step increase in voltage of a first magnitude, a step decrease in voltage of a second magnitude (where the first and second magnitudes can be the same or different), an increase in voltage over time at first rate, a gradual decrease in voltage over time having a second rate (where the first rate and the second rate can be different or the same), one or more sine waves overlayed on the input signal having the same or different frequencies and/or amplitudes and the like.
  • a response to the stimulus signal can then be measured and analyzed (the response is also referred to herein as the “signal response”).
  • the analysis can include one or more of calculating impedance values, capacitance values, and correlating the signal response to one or more predetermined relationships.
  • the term “impendence value” can mean a value for expressing an electrical impedance, including but not limited to, a value that only represents a magnitude of impedance or a value that express both magnitude and phase of impendence, should impendence be represented in a polar form, or expresses a real impendence only or both a real and complex impendence, should impedance be represented in a Cartesian form.
  • various sensor properties can be determined and/or characterized, such as one or more of the sensor properties discussed herein.
  • the sensor information can then be used to determine if the analyte sensor is functioning properly or not, and/or to calibrate the sensor.
  • the techniques described herein can be used to generate calibration information (e.g., one or more of baseline, sensor sensitivity, and temperature information) that can in turn be used to form or modify a conversion function, or calibration factor, used to convert sensor data (e.g., in units of electrical current) into blood glucose data (e.g., glucose concentration values in units of mg/dL or mmol/L), as described in more detail elsewhere herein.
  • the sensor information can alternatively or additionally be used to first correct uncalibrated sensor data (e.g., raw sensor data) and then apply a conversion function to convert the corrected, uncalibrated data to calibrated sensor data (e.g., glucose concentration values in units of glucose concentration).
  • uncalibrated sensor data e.g., raw sensor data
  • calibrated sensor data e.g., glucose concentration values in units of glucose concentration
  • EIS Electrochemical Impedance Spectroscopy
  • EIS is an electrochemical technique based on the measurement of electrical impedance of the system being used over a range of different frequencies. Changes in the system being used can reflect changes in the frequency spectrum. As an example, a reduction in impedance may be observed at a particular frequency over a time period if the system being used has a sensitivity change over that period of time.
  • Other techniques can also be used to determine properties of a system being used as discussed further below.
  • Sensor circuit model 900 can represent electrical properties of an analyte sensor, such as an embodiment of a continuous glucose sensor.
  • Circuit 900 includes working electrode 904 and reference electrode 902 .
  • Operatively connected in serial to reference electrode is Rsolution, representative of a resistance of bulk between the working and reference electrodes.
  • the bulk can be a liquid or other medium in which the sensor is placed, such as a buffer solution in the example of a bench laboratory study, or, in the example of the use as a subcutaneously placed sensor, the bulk can be representative of the resistance of the subcutaneous tissue between the working and reference electrodes.
  • Cmembrane representative of a capacitance of the sensor membrane
  • Rmembrane representative of a resistance of the sensor membrane
  • a parallel network of Cdouble layer and Rpolarization are operatively connected to Rmembrane.
  • the parallel network of Cdouble layer and Rpolarization is representative of the reactions occurring at the surface of a platinum interface of the working electrode.
  • Cdouble layer is representative of the charge that is built up when a platinum electrode is in the bulk and Rpolarization is the polarization resistance of the electrochemical reactions that occur at the platinum interface.
  • FIG. 10 is a Bode plot (i.e.
  • vs. log ⁇ , wherein Z real is real impedance, ⁇ 2 ⁇ f and f is frequency) of an analyte sensor in accordance with one embodiment.
  • the analyte sensor can have properties of sensor circuit model 900 of FIG. 9 .
  • the x-axis is the frequency of a stimulus signal applied to the analyte sensor and the y-axis is the impedance derived from a response signal of the analyte sensor.
  • different frequencies can be used to measure or determine different material properties of the sensor. For example, in the plot of FIG.
  • the impedance value derived from the measured response to an input signal having a frequency of about 7 Hz can be indicative of Cdouble layer, a frequency of about 1 kHz can be indicative of Rmembrane, and a frequency in the range of about 10-20 kHz can indicative of Cmembrane.
  • a state of particular properties of the sensor by applying a stimulus signal of a particular frequency or comprising a plurality of frequencies to the sensor and determining a sensor impedance based on the signal response. For instance, a capacitance of a sensor having the characteristics of the Bode plot of FIG. 10 can be determined using a stimulus signal having a frequency in the range of about 1 Hz to 100 Hz, for example 10 Hz or greater than 10 kHz. In addition, a resistance of a sensor can be determined using a stimulus signal having a frequency in the range of about 100 Hz to 10 kHz, for example 1 kHz.
  • FIG. 11 is a flowchart illustrating a process 1100 for determining an impedance of a sensor in accordance with one embodiment.
  • a stimulus signal in the form of an active current (ac) voltage at a given frequency is applied to a working electrode of the sensor being studied.
  • the ac voltage can be overlayed on a bias potential and can be relatively small as compared to the bias potential, such as a voltage that is in the range of about 1% to 10% of the bias voltage.
  • the ac voltage is a sine wave having an amplitude in the range of 10-50 mV and a frequency in the range of between about 100-1 kHz.
  • the sine wave can be overlayed on a 600 mV bias voltage.
  • the response signal (e.g., in units of current) can then be measured in step 1104 and analyzed in step 1106 to determine an impedance at the given frequency. Should the impedance of the sensor at a range of frequencies be of interest, process 1100 can be repeated by applying an ac voltage at each frequency of interest and analyzing a corresponding output response.
  • FIG. 12 describes a process for determining an impedance or plurality of impedances of a sensor being studied by applying one or more stimulus signals and converting the response signal or signals to a frequency domain in accordance with one embodiment.
  • the data can be converted to the frequency domain using a Fourier transform technique, such as a fast Fourier transform (FFT), discrete time Fourier transform (DTFT) or the like.
  • FFT fast Fourier transform
  • DTFT discrete time Fourier transform
  • a stimulus signal in the form of a voltage step can be applied to a bias voltage of the sensor.
  • the voltage step can be in the range of 10-50 mV, for example 10 mV, and the bias voltage can be 600 mV.
  • the signal response can then be measured and recorded (e.g., an output current) at step 1204 , and a derivative of the response can be taken at step 1206 .
  • a Fourier transform of the derivative of the response can then be calculated to yield ac currents in the frequency domain.
  • One or more impedances of the sensor over a wide spectrum of frequencies can then be calculated based on the ac currents at step 1210 .
  • FIG. 13 is a flowchart of process 1300 for determining an impedance of a sensor being studied, such as the impedance of the sensor's membrane, in accordance with one embodiment.
  • a stimulus signal in the form of a voltage step above a bias voltage is applied to the sensor.
  • the signal response is measured at step 1304 , and, at step 1306 , a peak current of the response is determined.
  • one or more impedance characteristics e.g., resistance
  • the sensor membrane e.g., Rmembrane
  • the one or more impedance characteristics can then be correlated to a property of the sensor.
  • the peak current can be correlated to one or more predetermined sensor relationships to determine a property of the sensor, such as the sensor's sensitivity. That is, in the alternative embodiment, the step of calculating the one or more impendence characteristics is omitted.
  • FIG. 14A is a graph of an input voltage 1400 applied to an analyte sensor over time in accordance with one embodiment.
  • the input voltage 1400 applied to the analyte sensor initially corresponds to the bias voltage, which in one embodiment is about 600 mV.
  • a stimulus signal in the form of a voltage step is then applied to the input voltage at time t1.
  • the magnitude of the voltage step, ⁇ v can be in the range of 10-50 mV, for example 10 mV.
  • FIG. 14B is a graph of a current response 1402 of the analyte sensor to the input voltage 1400 of FIG. 14A .
  • the current response 1402 can include a sharp spike in current starting at time t2, which corresponds to the time in which the voltage step begins to impact the response.
  • the current response 1402 includes a peak current at point 1404 and then the current response 1402 gradually decreases and levels off to a slightly higher level due to the increase in input voltage 1400 as compared to before the voltage step.
  • a change in current, ⁇ i measured as the difference between the magnitude of the current response 1402 prior to the voltage step and the peak current 1404 resulting from the voltage step, can then be used to estimate the sensor membrane resistance, such as Rmembrane in FIG. 9 .
  • an estimated sensor membrane resistance can be calculated in accordance with Ohms Law, where
  • ⁇ v is the step voltage increase and ⁇ i is the change in current response due to the step voltage increase.
  • certain embodiments of sensors provide a direct relationship between a change in current in response to a voltage step to the sensor's membrane impendence characteristics (e.g., resistance).
  • the capacitance, Cmembrane is much smaller than the capacitance, Cdouble layer.
  • Cmembrane can have a value that is about 1/1000 smaller than Cdouble layer.
  • the bulk resistance, Rsolution, of sensor circuit 900 is typically much smaller than the resistance Rmembrane, and the resistance, Rpolarization, can be quite large, such as around 3 MOhms.
  • a voltage step, ⁇ v, applied to circuit 900 can cause the current to flow substantially through circuit 900 along a path from lead 902 , through Rsolution, Rmembrane, Cdouble layer and finally to lead 904 .
  • capacitive resistance is inversely proportional to the capacitance and the frequency
  • the capacitive resistance of Cmembrane is initially very large due to the voltage step, as the voltage step is, theoretically, an extremely high frequency.
  • the current substantially flows through Cdouble layer instead of Rpolarization because the capacitive resistance of Cdouble is initially small due to the voltage step (high capacitive value of Cdouble layer results in low capacitive resistance at high frequencies, e.g., at the time of a voltage step) and the relatively large resistance of Rpolarization. Consequently, the initial total resistance through which substantially all of the current flows through circuit 900 when the step voltage is applied to circuit 900 can be summed up as the series resistance of Rsolution plus Rmembrane. However, because Rsolution is much smaller than Rmembrane in this example, the total resistance can be estimated as the membrane resistance, Rmembrane.
  • the membrane resistance, Rmembrane is essentially the resistance of the circuit 900 at the time of the voltage step, it has been found that the value of Rmembrane can be estimated using Ohms Law using the known value of the step increase, ⁇ v, and the measured change in current response, ⁇ i, due to the voltage step.
  • a sensor's sensitivity to analyte concentration during a sensor session can often change as a function of time. This change in sensitivity can manifest itself as an increase in current for a particular level of sensitivity. In some embodiments, the sensitivity increases during the first 24-48 hours with a relative change in tens of percents.
  • system calibrations using reference meters e.g., strip-based blood glucose measurements
  • the rate of calibrations can be 1, 2 or more calibrations a day.
  • analyte sensors are believed to have a relationship between an impedance of a sensor's membrane and the diffusivity of the membrane.
  • a change in impedance of an analyte sensor can indicate a proportional change in diffusivity of the analyte sensor's membrane.
  • an increase in diffusivity can yield an increased transport of the analyte being measured (e.g., glucose) through the membrane, resulting in an increased sensor output current. That is, a change in diffusivity can result in a proportional change in sensor sensitivity.
  • other factors may also contribute to changes in sensitivity apart from just changes in diffusivity of the sensor membrane, depending upon the characteristics of sensor and the environment in which the sensor is used.
  • a relationship between sensitivity and impedance can be used to estimate a sensor sensitivity value and/or correct for sensitivity changes of the sensor over time, resulting in increased accuracy, a reduction in required calibrations or both.
  • some embodiments can detect other characteristics of an analyte sensor system based on measurements of electrical impedance over one or more frequencies. These characteristics include, but are not limited to, temperature, moisture ingress into sensor electronics components and sensor membrane damage.
  • a relationship between a sensor's impedance and the sensor's sensitivity can be used to calculate and compensate for sensitivity changes of an analyte sensor.
  • a change in impedance of an analyte sensor can correspond to a proportional change in sensitivity of the sensor.
  • an absolute value of an impedance of an analyte sensor can correspond to an absolute value of the analyte sensor's sensitivity and the corresponding sensitivity value can be determined based on a predetermined relationship determined from prior studies of similar sensors. Sensor data can then be compensated for changes in sensitivity based on an impedance-to-sensitivity relationship.
  • FIG. 15 is a flowchart of an exemplary process 1500 for compensating sensor data for changes in sensitivity in accordance with one embodiment.
  • a stimulus signal can be applied to the sensor that can be used to determine an impedance of the sensor's membrane, such as a signal having a given frequency, as discussed with respect to FIG. 11 , or a voltage step, as discussed with respect to FIGS. 12-14 .
  • a response to the applied signal is then measured at step 1504 and an impedance of the sensor's membrane is determined based on the response at step 1506 .
  • the determined impedance is compared to an established impedance-to-sensor sensitivity relationship.
  • the established relationship can be determined from prior studies of analyte sensors that exhibit similar sensitivity-to-impedance relationships as the analyte sensor currently being used; for example, sensors that were made in substantially the same way under substantially the same conditions as the sensor currently being used.
  • a sensor signal e.g., in units of electrical current or counts
  • An estimated analyte concentration value or values is then calculated based on the corrected sensor signal at step 1512 using, for example, a conversion function.
  • the estimated analyte concentration values can then be used for further processing and/or outputting, such as triggering alerts, displaying information representative of the estimated values on a user device and/or outputting the information to an external device.
  • process 1500 is but one example of using an impedance of a sensor to compensate for changes in sensor sensitivity, and that various modifications can be made to process 1500 that fall within the scope of the embodiments
  • an established impedance-to-sensitivity relationship can be used to determine a sensitivity value of the sensor being used, and the sensitivity value can then be used to modify or form a conversion function used to convert a sensor signal of the sensor being used into one or more estimated glucose concentration values.
  • one or more properties of the stimulus signal response e.g., peak current value, counts, etc.
  • Some embodiments use one or more impedance values of the sensor to form, modify or select a sensitivity profile of an analyte sensor.
  • a sensor can have a sensitivity profile that indicates the sensor's change in sensitivity over time.
  • sensors made in substantially the same way under substantially the same conditions can exhibit similar sensitivity profiles, the profiles can still vary.
  • the environment in which a particular sensor is used can cause the sensor's sensitivity profile to differ from other, similar sensors.
  • some embodiments can, for example, select a sensitivity profile out of a plurality of predetermined sensitivity profiles based on a correlation of the calculated one or more impedance values to the selected sensitivity profile.
  • some embodiments modify a sensor sensitivity profile already associated with the analyte sensor being used to more closely predict the sensor's sensitivity profile, where the modification is based on the one or more impedance values.
  • FIG. 16 is a flowchart of an exemplary process 1600 for determining a predicted sensitivity profile using one or more sensor membrane impedance measurements in accordance with one embodiment.
  • a stimulus signal is applied to an analyte sensor being used and a response is measured at step 1604 .
  • one or more sensor membrane impedance values are calculated based on the response at step 1606 .
  • Various techniques for calculating sensor membrane impedance values based on the response that can be used in process 1600 are described elsewhere herein, such as one or more of the techniques discussed with reference to FIGS. 11-14 .
  • a sensitivity profile is then determined based on the one or more calculated impedance values in step 1608 .
  • Process 1600 then calculates (which can include retrospectively correcting and/or prospectively calculating) estimated analyte concentration values using the determined sensitivity profile.
  • the estimated analyte concentration values can then be used for further processing and outputting, such as displaying information representative of the estimated values on a user device and/or outputting the information to an external computing device.
  • various techniques can be used to determine the sensitivity profile.
  • One exemplary technique can compare the one or more calculated impedance values to a plurality of different predicted sensitivity profiles and select a predicted sensitivity profile that best fits the one or more calculated impedance values.
  • the plurality of different predicted sensitivity profiles can be predetermined and stored in computer memory of sensor electronics, for example.
  • Another technique that can be used includes using an estimative algorithm to predict or determine a sensitivity profile based on the one or more calculated impedance values.
  • a further technique includes determining a sensitivity profile by modifying a sensitivity profile associated with the sensor being used (e.g., a sensor profile previously used to generate estimated glucose values using the sensor). Modifying the sensitivity profile can include using an estimative algorithm to modify the sensitivity profile to more closely track the sensitivity profile of the sensor being used based on the one or more calculated impedance values.
  • Some embodiments compare one or more impedance values of an analyte sensor being used to a predetermined or predicted sensitivity profile associated with the sensor to determine if the sensor is functioning properly.
  • a sensor can be predicted to have a particular sensitivity profile based on, for example, a study of sensitivity changes over time of sensors made in substantially the same way and used under substantially the same conditions.
  • it can be determined that a sensor is functioning improperly—due to, for example, improper sensor insertion, damage to the sensor during shipping, manufacturing defects and the like-if the sensor is found not to be sufficiently tracking its predicted sensitivity profile based on sensitivities derived from impedance measurements of the sensor.
  • a sensor it can be determined that a sensor is not functioning properly if one or more impedance values of a sensor's membrane do not sufficiently correspond to a predicted sensitivity profile (e.g., because the impedance of a sensor membrane can indicate a sensitivity of the sensor) of the sensor.
  • FIG. 17 is a flowchart of an exemplary process 1700 for determining whether an analyte sensor being used is functioning properly based on a predicted sensitivity profile and one or more impedance measurements.
  • a stimulus signal is applied to an analyte sensor being used and a response is measured at step 1704 .
  • one or more sensor membrane impedance values are calculated based on the signal response at step 1706 .
  • Various stimulus signals and techniques for calculating sensor membrane impedance values based on the signal response that can be used in process 1700 are described elsewhere herein, such as with any one of the techniques discussed with reference to FIGS. 11-14 .
  • Process 1700 determines a correspondence of the one or more calculated impedance values to a sensitivity profile in step 1708 .
  • process 1700 queries whether the one or more calculated impedance values sufficiently correspond to the predicted sensitivity profile. If it is determined that the one or more calculated impedance values sufficiently correspond to the predicted sensitivity profile, then process 1700 confirms proper operation of the analyte sensor being used. If confirmed to be proper in step 1710 , process 1700 may then be repeated after a predetermined time delay ranging from about 1 minute to 1 day, for example about 10 minutes, 1 hour, 12 hours, or 1 day.
  • process 1700 initiates an error routine 1712 if it is determined that the one or more calculated impedance values do not sufficiently correspond to the predicted sensitivity profile.
  • Error routine 1712 can include one or more of triggering and audible alarm, displaying an error message on a user display, discontinuing display of sensor data on a user display, sending a message to a remote communication device over a communication network, such as a mobile phone over a cellular network or remote computer over the internet, and the like.
  • the error routine can also include modifying the predicted sensitivity profile—based on the one or more impedance measurements, for example—or selecting a new predicted sensitivity profile based on the one or more impedance measurements.
  • the modified predicted sensitivity profile or new predicted sensitivity profile can be a sensitivity profile that more closely corresponds to changes in sensitivity of the sensor being used based on the one or more impedance measurements as compared to the unmodified or previously used predicted sensitivity profile.
  • various statistical analysis techniques can be used to determine a correspondence of the one or more impedance values to the predicted sensitivity profile.
  • correspondence can be determined based on whether a sensitivity value derived from the calculated impedance value (e.g., derived from a predetermined relationship of impedance and sensitivity) differs by no less than a predetermined threshold amount from a predicted sensitivity value as determined from the predicted sensitivity profile.
  • the predetermined threshold amount can be in terms of an absolute value or a percentage.
  • correspondence can be determined based on a data association function.
  • data association function is a broad term and is used in its ordinary sense, including, without limitation, a statistical analysis of data and particularly its correlation to, or deviation from, from a particular curve.
  • a data association function can be used to show data association.
  • sensor sensitivity data derived from impedance measurements described herein may be analyzed mathematically to determine its correlation to, or deviation from, a curve (e.g., line or set of lines) that defines a sensor sensitivity profile; this correlation or deviation is the data association.
  • Examples of a data association function that can be used includes, but is not limited to, linear regression, non-linear mapping/regression, rank (e.g., non-parametric) correlation, least mean square fit, mean absolute deviation (MAD), and mean absolute relative difference.
  • the correlation coefficient of linear regression is indicative of the amount of data association of sensitivity data derived from impedance measurements from a sensitivity profile, and thus the quality of the data and/or sensitivity profile.
  • rank e.g., non-parametric correlation
  • MAD mean absolute deviation
  • the correlation coefficient of linear regression is indicative of the amount of data association of sensitivity data derived from impedance measurements from a sensitivity profile, and thus the quality of the data and/or sensitivity profile.
  • other statistical analysis methods that determine a correlation of one or more points to a curve can be used in process 1700 in addition to those described herein.
  • processes 1600 and 1700 can use one or more impedance values.
  • each impedance value can be time-spaced from the other impedance value(s).
  • one impedance value can be taken at a first point in time t1 (indicative of a sensor impedance at time t1)
  • a second impedance value can be taken at a second, later point in time t2 (indicative of a sensor impedance at time t2)
  • the time between t1 and t2 can be a first amount of time and the time between t2 and t3 can be a second amount of time that is either the same or different than the first amount of time.
  • the time-spaced impedance values can then be used separately or combined using a statistical algorithm (e.g., calculating an average or median value of the time-spaced values).
  • the separate values or combined value can then be used to determine a sensitivity value and/or sensitivity profile in step 1608 of process 1600 or determine a correspondence with a sensitivity profile in step 1708 of process 1700 , for example.
  • more than one of the impedance values can be taken at substantially the same time, but each derived using a different measurement technique, such as using two of the measurement techniques described herein.
  • a first impedance can be calculated using a step voltage technique as described in the process of FIG. 13
  • a second impedance can be calculated using a sine wave overlay technique as described in the process of FIG. 11 .
  • the impedance values derived from different measurement techniques can then be applied to a statistical algorithm (e.g., calculating an average or median value) to determine a processed impedance value.
  • the processed impedance value can then be used to determine a sensitivity value and/or sensitivity profile in step 1608 of process 1600 or determine a correspondence with a sensitivity profile in step 1708 of process 1700 , for example.
  • Some embodiments can use signal processing techniques to determine a temperature of the sensor. For example, a stimulus signal can be applied to a sensor and a signal response measured and, based on the signal response, a temperature of the sensor can be derived.
  • An impedance of a sensor membrane can be used to estimate a temperature of the sensor in accordance with one embodiment.
  • sensitivity of a sensor is affected by temperature, where a higher temperature can result in a higher sensitivity and a lower temperature can result in a lower sensitivity.
  • an impedance of a sensor membrane can have a direct relationship to the sensor's sensitivity, it is believed that a higher temperature can result in lower impedance and a lower temperature can result in higher impedance. That is, sensitivity and impedance can have a direct relationship to the sensor's temperature. Accordingly, using a known relationship between impedance and temperature—based on previously conducted studies of substantially similar sensors, for example—one can estimate a sensor's temperature based on a sensor impedance measurement.
  • FIG. 18 is a flowchart of an exemplary process 1800 for determining a sensor temperature in accordance with one embodiment.
  • a stimulus signal is applied to an analyte sensor being used, and a response is measured and recorded at step 1804 .
  • Impedance is calculated based on the signal response at step 1806 .
  • the impedance can be calculated using, for example, any of the techniques described herein such as those described with reference to FIGS. 11-14 .
  • a temperature of the sensor is then estimated based on a predetermined relationship between impedance and temperature at step 1808 .
  • the temperature can then be used to estimate analyte concentration values (e.g., glucose concentration) using sensor data or otherwise used for further processing and/or outputting.
  • analyte concentration values e.g., glucose concentration
  • the temperature can be used to compensate for temperature effects on sensor sensitivity, more accurate analyte concentration values can be estimated based on the sensitivity compensation, and the more accurate analyte concentrations can be outputted to a display or used to trigger an alert using a glucose monitoring system.
  • a relationship between sensor sensitivity and different temperatures can be mathematically modeled (e.g., by fitting a mathematical curve to data using one of the modeling techniques described herein), and the mathematical model can then be used to compensate for temperature effects on the sensor sensitivity. That is, a sensitivity of a sensor (which is affected by the sensor's temperature) can be determined based on associating a measured impedance of the sensor to the mathematical curve.
  • the predetermined relationship between impedance and temperature can be determined by studying impedances of similar sensors over a range of temperatures. Sensor data can then be converted to estimated analyte concentration values based on the determined sensor sensitivity.
  • analyte sensors can have an essentially linear relationship of impedance to temperature after a sensor run-in period (e.g., a period of time after sensor implantation in which the sensor stabilizes, which can last one to five hours in some embodiments).
  • the slope of the linear relationship can be established by studying sensors made in substantially the same way as the sensor being used over a range of temperatures.
  • a sensor temperature can be estimated by measuring an impedance value of the sensor's membrane and applying the impedance value to the established linear relationship.
  • Other embodiments can have a non-linear relationship of impedance to temperature and with these other embodiments the relationship can be characterized using an established non-linear relationship.
  • Some embodiments can compare a first sensor temperature, where the first temperature is derived from an impedance measurement of an analyte sensor, with a second sensor temperature, where the second sensor temperature is derived independent from the impedance measurement.
  • the second estimated temperature can be measured using a thermistor, for example.
  • the thermistor can be configured to measure an in vivo or ex vivo temperature, and can be located on the analyte sensor or separate from the analyte sensor.
  • the thermistor can be integral with the analyte sensor, positioned on the surface of the skin of a host adjacent to an insertion site in which the analyte sensor is implanted, positioned on the skin of the host at a location away from the insertion site or spaced apart from the host entirely, such as on a handheld device carried by the host. Factors contributing to a change in sensor sensitivity or a change in other sensor properties can then be determined or confirmed based, at least in part, on the comparison of the first and second temperatures.
  • moisture ingress into sensor electronics can be determined based on measuring an impedance of the sensor at a particular frequency or range of frequencies. Should the measured impedance not correspond sufficiently with predetermined impedance value(s), then a sensor system operatively connected to the sensor can initiate a moisture ingress error routine. Correspondence can be determined using one or more threshold, a data association function, and the like. Further, it should be noted that it has been found that impedance phase information can provide beneficial information in determining moisture egress. Accordingly, in some embodiments, the impedance measurement can be broken into separate impendence magnitude and phase components, and one or both impendence components can be compared to predetermined values to determine the correspondence.
  • FIG. 19 is a flowchart of an exemplary process 1900 for determining moisture ingress.
  • a stimulus signal having a particular frequency or a signal comprising a spectrum of frequencies e.g., a voltage step
  • a signal response is measured and recorded at step 1904 .
  • Impedance magnitude and phase is calculated based on the signal response at step 1906 .
  • Process 1900 determines whether the impedance magnitude and phase values fall within respective predefined levels at decision step 1908 . If the impedance magnitude and phase values exceed one or both of the respective predefined levels, then process 1900 initiates an error routine at step 1910 .
  • the error routine can include one or more of triggering an audible alarm and/or visual alarm on a display screen to alert a user that the sensor system may not be functioning properly.
  • the alarm can notify a user that the current sensor system is defective, for example. If, on the other hand, one or both of the impedance and phase values fall within the respective predefined levels, then process 1900 ends.
  • the above process 1900 can determine a complex impedance value and determine a correspondence of the determined complex impedance value to one or more predetermined complex impedance value(s), such as by using a data association function or comparing the determined complex impedance to a threshold or range of predetermined complex impendence values.
  • the error routine can then be initiated responsive to the correspondence.
  • membrane damage can be detected based on measuring an impedance at a particular frequency or range of frequencies. Should the measured impedance not correspond sufficiently with predetermined one or more impedance values, then a sensor system operatively connected to the sensor can initiate a membrane damage error routine. Correspondence can be determined using a data association function.
  • FIG. 20 is a flowchart of an exemplary process 2000 for determining membrane damage.
  • a stimulus signal having a particular frequency, multiple signals having different frequencies and/or a signal comprising a spectrum of frequencies is applied to an analyte sensor being used, and the signal response(s) is/are measured and recorded at step 2004 .
  • Both impedance magnitude and phase is calculated based on the signal response(s) at step 2006 .
  • Process 2000 determines whether the impedance magnitude and phase value(s) fall within respective predefined levels at decision step 2008 . If the impedance magnitude and phase values exceed one or both of the respective predefined levels, then process 2000 initiates an error routine at step 2010 .
  • the error routine can include one or more of triggering an audible alarm and/or visual alarm on a display screen to alert a user that the sensor system is not functioning properly.
  • the alarm can notify a user that the currently used sensor is damaged and needs to be replaced, for example. If, on the other hand, one or both of the impedance magnitude and phase values fall within the respective predefined levels, then process 2000 ends.
  • the above process 2000 can use a complex impedance value and determine a correspondence of the complex impedance value to a predetermined values or levels.
  • the error routine can be initiated responsive to the determined correspondence.
  • sensor reuse can be detected.
  • Embodiments of glucose sensors described herein may have a defined life in which a sensor can provide reliable sensor data. After the defined life, the sensor may no longer be reliable, providing inaccurate sensor data. To prevent use beyond the predefined life, some embodiments notify a user to change the sensor after it has been determined that the sensor should no longer be used.
  • Various methods can be used to determine whether a sensor should no longer be used, such as a predetermined amount of time transpiring since the sensor was first used (e.g., when first implanted into a user or when first electrically connected to a sensor electronics module) or a determination that the sensor is defective (e.g., due to membrane rupture, unstable sensitivity and the like).
  • the sensor system can notify a user that a new sensor should be used by audibly and/or visually prompting a user to use a new sensor and/or shutting down a display or ceasing to display sensor data on the display, for example.
  • a user may try to reuse the same sensor instead of using a new sensor. This can be dangerous to the user because the sensor may provide inaccurate data upon which the user may rely.
  • some embodiments can be configured determine sensor reuse based at least in part on one or more measurements of the impedance of the sensor.
  • the impedance that relates to the membrane resistance of a sensor is typically initially high and then gradually decreases as the sensor is run-in.
  • sensor re-use can be detected if an impedance measured soon after sensor implantation is greater than what a sensor should typically have when a sensor is initially implanted, as this can indicate that the sensor had already been used.
  • FIG. 21 is a flowchart of an exemplary process 2100 for determining sensor reuse in accordance with one embodiment.
  • a sensor insertion event is triggered.
  • An insertion event can be one of any number of possible events that indicate a new sensor has been implanted, such as a user providing input to a sensor system that a new sensor has been implanted, the sensor system detecting electrical connection to a sensor, a predetermined amount of time transpiring since the system prompted a user to use a new sensor, and the like.
  • a stimulus signal is applied to an analyte sensor being used, and a response is measured and recorded at step 2106 . Impedance is calculated based on the signal response at step 2108 .
  • the stimulus signal and technique for calculating impedance in steps 2106 and 2108 can be any of the signals and techniques described herein such as those described with reference to FIGS. 11-14 .
  • the calculated impedance is compared to a predetermined threshold. Should it be determined that the impedance exceeds the threshold, then a sensor reuse routine is initiated at step 2112 . If it is determined in decision step 2110 that the impedance does not exceed the threshold, then the process 2100 ends at step 2114 .
  • the sensor reuse routine of step 2112 can include triggering an audible and/or visual alarm notifying the user of improper sensor reuse. The alarm can also inform the user why sensor reuse may be undesirable, such as potentially providing inaccurate and unreliable sensor readings.
  • the sensor reuse routine 2112 can alternatively or additionally cause the sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
  • recent impedance measurement information e.g., one or more recent impedance measurement values
  • a previously-used sensor such as the sensor used immediately prior to the newly implanted sensor
  • a predetermined sensor profile can be stored in computer memory and compared to impedance measurement information of a newly implanted sensor (e.g., what is supposed to be a newly used sensor).
  • the sensor system can trigger an error routine, which can include notifying the user via audible and/or visual alarms using a user interface of the sensor system of improper sensor reuse and prompting the user to use a new sensor, as discussed above with respect to step 2112 .
  • FIG. 22 is a flowchart of another exemplary process 2200 for determining sensor reuse in accordance with one embodiment.
  • a sensor insertion event is triggered.
  • a an insertion event can be one of any number of possible events that indicate a new sensor has been implanted, such as a user providing input to a sensor system that a new sensor has been implanted, the sensor system detecting electrical connection to a sensor, a predetermined amount of time transpiring since the system prompted a user to use a new sensor, and the like.
  • a stimulus signal is applied to an analyte sensor being used, and a response is measured and recorded at step 2206 . Impedance is calculated based on the signal response at step 2208 .
  • the stimulus signal and technique for calculating impedance in steps 2206 and 2208 can be any of the signals and techniques described herein such as those described with reference to FIGS. 11-14 .
  • the calculated impedance is compared to one or more previously measured impedance values measured using one or more previously implanted sensors (at what at least should have been a previously implanted sensor according to the sensor system). Should it be determined that the calculated impedance correlates within a predetermined amount with the one or more previously measured impedance measurements, then a sensor reuse routine is initiated at step 2112 . Correlation can be determined using a data association function, such as one of the data association functions described herein. If it is determined in decision step 2110 that the impedance does not correlate within the predetermined amount to previously measured impedance values, then the process 2100 ends at step 2114 , wherein the system continues to use the sensor to measure glucose concentrations of the host.
  • the sensor reuse routine of step 2212 can include triggering an audible and/or visual alarm notifying the user of improper sensor reuse. The alarm can also inform the user why sensor reuse may be undesirable, such as potentially providing inaccurate and unreliable sensor readings.
  • the sensor reuse routine 2212 can alternatively or additionally cause the sensor system to fully or partially shut down and/or cease display of sensor data on a display of the sensor system.
  • Some embodiments apply an overpotential routine based on one or more measured impedances of the sensor membrane. It has been found that applying an overpotential (e.g., a voltage potential greater than the bias potential applied to the sensor when used for continuous analyte sensing) to some embodiments of analyte sensors can aid in stabilizing the analyte sensor, thereby reducing a run-in period of the sensor. The overpotential may need to be discontinued once the sensor has sufficiently stabilized, otherwise damage to the sensor can occur. Accordingly, one or more impedance measurements of the sensor can be used to determine a sensitivity or change in sensitivity of the sensor. Any of the techniques described herein, such as those described with reference to FIGS.
  • the determined sensitivity or sensitivity change can be, in turn, used to indicate whether or not the sensor has stabilized or will stabilize within a determined amount of time by, for example, determining a correspondence of the measured impedance to predetermined sensitivity-to-impedance relationships.
  • application of the overpotential can be discontinued or reduced.
  • a magnitude of an overpotential and/or length of time in which the overpotential is to be applied to the sensor can be determined or modified based on one or more impedance measurements taken prior to application of the overpotential or during application of the overpotential. That is, an overpotential routine can be modified or discontinued according to one or more impedance measurements in accordance with some embodiments.
  • Some embodiments of sensor systems comprise a plurality of sensor electrodes.
  • some embodiments can include an auxiliary electrode to allow for the subtraction of a baseline signal from an analyte+baseline signal.
  • Some embodiments can also include one or more redundant analyte sensors.
  • a first stimulus signal can be applied to a first sensor and a second stimulus signal can be applied to a second sensor.
  • the first sensor can be configured to sense an analyte concentration (e.g., glucose) and, in this regard, can generate an analyte+baseline signal.
  • the second sensor can be an auxiliary sensor configured to measure a baseline signal that can be subtracted from the signal of the first sensor.
  • the first stimulus signal can have the same waveform or different waveform than the second stimulus signal.
  • a response to the first stimulus signal and a response to the second stimulus signal can each be measured and recorded.
  • the first response and the second response can be processed, and sensor characteristics can be determined based on the processing, such as impedance values associated with each sensor.
  • the processing can include a comparison (e.g., using a data association function described herein) of the first and second response signals to one another and/or compare each of the first and second response signals to established relationships.
  • the sensor characteristics can include any of the sensor characteristics described herein, including a sensitivity value or sensitivity change of the first and/or second electrodes, a temperature of the first and/or second electrodes, magnitude of detected membrane damage of the first electrode, and the like. Further, sensor data can be compensated for changes in sensor characteristics, such as changes in sensor sensitivity, based on the processing of the first and second response signals.
  • FIG. 23 is a schematic diagram of a dual-sensor configuration that can be used in a sensor system in accordance with some embodiments.
  • the dual-sensor configuration includes a first sensor 2302 , having a working electrode 2304 , reference electrode 2306 and membrane 2308 , and a second sensor 2310 , also having a working electrode 2312 , reference electrode 2314 and membrane 2316 .
  • Each sensor can be essentially the same, including having the same type of membrane, or each sensor can be different, such as having different membranes or even one of the sensors not having a membrane.
  • each sensor 2302 and 2310 is configured to measure an analyte concentration in a host.
  • the second sensor 2310 does not have a discrete reference electrode.
  • the reference electrode of the first sensor can also function as the reference electrode of the second sensor.
  • a stimulus signal can be applied to the first sensor 2302 using signal generator/detector 2318 (the stimulus signal can be any stimulus signal described herein, such as a voltage step).
  • the stimulus signal can elicit electric field lines 2320 to emanate from the first sensor 2302 and evoke an electrical response in the second sensor 2310 .
  • the electrical response can be measured using signal generator/detector 2322 electrically connected to the second sensor 2314 .
  • the signal generator/detectors 2318 and 2322 can include any known electrical circuitry capable of generating a desired stimulus signal discussed herein and capable of measuring a response to the stimulus signal.
  • the response measured in the second sensor 2310 can then be used to determine sensor properties, such as any sensor properties discussed herein.
  • the response can be used to calculate an impedance of the first sensor 2302 and thereafter used to determine a sensitivity of the first sensor 2302 and/or correct sensor data generated by the first sensor, using one of the processes described herein.
  • a first stimulus signal can be applied to the first sensor 2302 and measured using the second sensor 2310 and a second stimulus signal can be applied to the second sensor 2310 and measured using the first sensor 2302 .
  • the first and second stimulus signals can be essentially the same or can be different.
  • the responses to each of the first and second stimulus signals can then be used to determine a sensor property, such as any of the sensor properties discussed herein.
  • the sensor to which the stimulus signal is applied can also be used to measure a response to the stimulus signal in addition to the other sensor measuring a response to the stimulus signal.
  • a first stimulus signal can be applied to the first sensor 2302 and first and second responses to the first stimulus signal can be measured by the first sensor 2302 and the second sensor 2310 , respectively.
  • the first and second responses can then be used to determine sensor properties discussed herein of either or both of the first sensor 2302 and second sensor 2310 .
  • a scaling factor can be used to correct differences in responses of a dual-electrode analyte sensor.
  • a dual-electrode analyte sensor that can be used is a reference sensor/system, whereby reference data can be provided for calibration (e.g., internal to the system), without the use of an external (e.g., separate from the system) analyte-measuring device.
  • the dual-electrode analyte sensor includes a first electrode that includes an enzyme reactive with a particular analyte (which can be referred to as the plus-enzyme electrode) and a second electrode that does not include the enzyme (which can be referred to as the minus-enzyme electrode).
  • the sensor system (such as a sensor electronics module of the sensor system) is configured to determine a scaling factor (k).
  • a scaling factor defines a relationship between the electrodes of the dual-electrode analyte sensor.
  • the sensor system is configured to calibrate the analyte sensor data using the scaling factor, such that the calibrated sensor data does not include inaccuracies that can arise due to differences between the first and second working electrodes, respectively. That is, the scaling factor can be used to calculate estimated analyte values based on data generated by the sensor system
  • the membrane impedance of each electrode of a dual-electrode system can be used to determine or update a scaling factor.
  • the scaling factor can then be used to calculate estimated analyte concentration values based on data generated by the sensor system.
  • membrane impedance is measured for both electrodes of a dual-electrode sensor system.
  • Techniques described herein, such as those described with reference to FIGS. 11-14 and under the heading “Multi-electrode or multi-sensor configuration” can be used to measure the membrane impendence of each of the electrodes of the dual-electrode analyte sensor.
  • the impendence can be measured periodically during sensor use.
  • a scaling factor can be generated using a ratio of the measured membrane impendence of the two electrodes (e.g., a ratio of the membrane impendence of a plus-enzyme electrode and the membrane impedance of a minus-enzyme electrode).
  • a scaling factor to generate estimated analyte values can then be determined or updated based on the generated scaling factor. The determined or updated scaling factor can then be used to generate estimated analyte values.
  • acetaminophen can interfere with glucose measurements using some sensor embodiments. It has also been found that acetaminophen response can be proportional to its diffusion through a sensor membrane and sensor impedance can be indicated of membrane impedance.
  • the above illustrative process for determining a scaling factor can be used to periodically determine an acetaminophen scaling factor by determining a ratio of the plus-enzyme and minus-enzyme electrode impedance.
  • the acetaminophen scaling factor can be used to update a scale factor, such as one of those described above, used to calculate estimated glucose concentrations.
  • Calibration process 2400 can use one or more of pre-implant information 2402 , internal diagnostic information 2404 and external reference information 2406 as inputs to form or modify a conversion function 2408 .
  • Conversion function 2408 can be used to convert sensor data (e.g., in units of current or counts) into estimated analyte values 2410 (e.g., in units of analyte concentration).
  • Information representative of the estimated analyte values can then outputted 2412 , such as displayed on a user display, transmitted to an external device (e.g., an insulin pump, PC computer, mobile computing device, etc.) and/or otherwise processed further.
  • the analyte can be, glucose, for example.
  • pre-implant information 2402 can mean information that was generated prior to implantation of the sensor(s) presently being calibrated.
  • Pre-implant information 2402 can include any of the following types of information:
  • internal diagnostic information 2402 can mean information generated by the sensor system in which the implanted analyte sensor (the data of which is being calibrated) is being used.
  • Internal diagnostic information 2402 can include any of the following types of information:
  • external reference information 2402 can mean information generated from sources while the implanted analyte sensor (the data of which is being calibrated) is being used.
  • External reference information 2402 can include any of the following types of information:
  • Embodiments of the present invention are described above and below with reference to flowchart illustrations of methods, apparatus, and computer program products. It will be understood that each block of the flowchart illustrations, and combinations of blocks in the flowchart illustrations, can be implemented by execution of computer program instructions. These computer program instructions may be loaded onto a computer or other programmable data processing apparatus (such as a controller, microcontroller, microprocessor or the like) in a sensor electronics system to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create instructions for implementing the functions specified in the flowchart block or blocks.
  • a computer or other programmable data processing apparatus such as a controller, microcontroller, microprocessor or the like
  • These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instructions which implement the function specified in the flowchart block or blocks.
  • the computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks presented herein.
  • a sensor system for continuous measurement of an analyte (e.g., glucose) in a host that includes: a continuous analyte sensor configured to continuously measure a concentration of the analyte in the host and a sensor electronics module physically connected to the continuous analyte sensor during sensor use.
  • the sensor electronics module includes electronics configured to process a data stream associated with an analyte concentration measured by the continuous analyte sensor in order to process the sensor data and generate displayable sensor information that includes raw sensor data, transformed sensor data, and/or any other sensor data, for example.
  • the sensor electronics module can include electronics configured to process a data stream associated with an analyte concentration measured by the continuous analyte sensor in order to process the sensor data and generate displayable sensor information that includes raw sensor data, transformed sensor data, and/or any other sensor data, for example.
  • the sensor electronics module can include a processor and computer program instructions to implement the processes discussed herein, including the functions specified in the flowchart block or blocks presented herein.
  • a receiver which can also be referred to as a display device, is in communication with the sensor electronics module (e.g., via wired or wireless communication).
  • the receiver can be an application-specific hand-held device, or a general purpose device, such as a P.C., smart phone, tablet computer, and the like.
  • a receiver can be in data communication with the sensor electronics module for receiving sensor data, such as raw and/or displayable data, and include a processing module for processing and/or display the received sensor data.
  • the receiver can also and include an input module configured to receive input, such as calibration codes, reference analyte values, and any other information discussed herein, from a user via a keyboard or touch-sensitive display screen, for example, and can also be configured to receive information from external devices, such as insulin pumps and reference meters, via wired or wireless data communication.
  • the input can be processed alone or in combination with information received from the sensor electronics module.
  • the receiver's processing module can include a processor and computer program instructions to implement any of the processes discussed herein, including the functions specified in the flowchart block or blocks presented herein.
  • Embodiments are further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner.
  • studies have been conducted using a Gamry potentiostat system to analyze complex impedance of glucose sensors placed in a buffer.
  • the Gamry potentiostat system is commercially available from Gamry under the model name Ref600.
  • the buffer is a modified isolyte having a known concentration of glucose. In many of the examples, the glucose concentration is about 100 mg/dL.
  • the impedance measurement error in the examples was found to be about 1 to 5% by testing the system with a known impedance.
  • the sensors under test are configured to be used in vivo to continuously or substantially continuously measure a glucose concentration of a host.
  • Analyte sensors used in the following examples were selected from different types of sensors.
  • the sensors under test include sensors taken from different sensor lots, where sensors from a first lot may have been made in a different way and under different conditions, which can result in sensors for different lots exhibiting different sensitivity profiles.
  • some of the sensors studied in these examples are configured for placement in transcutaneous tissue of a host to measure the host's glucose concentration, while other sensors are configured to measure an intravenous blood glucose concentration of a host.
  • sensors intended to be used to measure an intravenous blood glucose concentration can be referred to as an “IVBG sensor type” and sensors intended to measure a blood glucose concentration in transcutaneous tissue of a host can be referred to as a “transcutaneous sensor type.”
  • Example 1 illustrates a relationship between sensitivity of a sensor and an impedance of the sensor.
  • an IVBG sensor was connected to a Gamry potentiostat system and placed in a in a buffer solution of a modified isolyte having a glucose concentration of 100 mg/dL.
  • the temperature during the experiment was 37 C.
  • An impedance spectrum was captured at fixed intervals of time.
  • the impedance spectrum analyzed in this experiment ranged from 1 Hz to 100 kHz and measurements of the sensor impedance and sensor sensitivity were taken at 15 minute intervals over a period of about 1200 minutes.
  • FIG. 25 is a graph showing absolute values of sensitivity and impedance of the sensor based on an input signal having a frequency of 1 kHz.
  • Data points 1104 represent measured values of impedance over the same time period.
  • the sensitivity and impedance values of FIG. 25 appear to have an inverse correlation. That is, the sensitivity initially increases quickly and then the rate of the increase gradually slows down and levels off, and the impedance initially deceases quickly and then the rate of the decrease gradually slows down and levels off. Although not wishing to be bound by theory, the initial increase in sensitivity and decrease in impedance is believed to be due to sensor run-in.
  • FIG. 26 is a plot of the data in FIG. 25 , but the sensitivity and impedance are in terms of percent change versus one hour instead of absolute values. As can be seen, the sensitivity 2602 and impedance 2604 relative changes versus one hour also appear to have an inverse correlation.
  • FIG. 27 is a plot of sensitivity and impedance points measured at various intervals over time using seven different sensors, Sensors A-G.
  • Sensors A-G were transcutaneous-type sensors, but selected from several different sensor lots. Thus, even though Sensors A-G were all transcutaneous sensors, sensors from different lots may have been made in a slightly different way or under slightly different conditions, which can result in sensors from different lots exhibiting different sensitivity profiles.
  • Sensors A and D were selected from a first lot
  • Sensor B was selected from a second lot
  • Sensors C, E, F and G were selected from a third lot.
  • the impedance and sensitivity values of each Sensor A-G have an essentially linear relationship, where the sensitivity gradually increases and the impedance decreases correspondingly over time.
  • the data taken from all seven Sensors A-G generally follow this linear relationship, although the data points of each sensor may be shifted as compared to the data points of the other sensors.
  • the initial impedance and sensitivity values for each sensor may be different, the change in sensitivity and impedance for each sensor changes at about the same linear rate.
  • FIG. 28 is a graph further illustrating the linear relationship of impedance and sensitivity of Sensors A-G.
  • the graph of FIG. 28 is based on the same data used in FIG. 27 , but the data is graphed in terms of percent change rather than in absolute values.
  • Sensors A-G appear to exhibit a very similar correspondence between the change in impedance and change in sensitivity.
  • a computer-implemented estimative algorithm function can be used to model a relationship between the change in sensitivity and change in impedance values of the sensor data generated by Sensors A-G.
  • the estimative algorithm function may be formed by applying curve fitting techniques that regressively fit a curve to data points by adjusting the function (e.g., by adjusting constants of the function) until an optimal fit to the available data points is obtained, as discussed above with respect to forming an estimative curve for a sensitivity profile. Additionally or alternatively, the relationship can be modeled into a look-up table stored in computer memory.
  • an estimative curve 2802 of the combined sensor data of Sensors A-G is also plotted.
  • the curve in FIG. 28 is a straight line, but can be other types of curves depending upon the relationship between impedance and sensitivity of the sensor. As discussed herein, the curve 2802 can be used to compensate for sensitivity drift of a sensor.
  • FIG. 29 and FIG. 30 illustrate compensating sensor data taken by the same sensors used to derive the estimative curve 2802 .
  • the measurements of FIGS. 29 and 30 were taken at 37 C. (Note that estimative curve 2802 was derived based on sensor measurements taken at 37 C, as discussed above with reference to FIGS. 27 and 28 .)
  • FIG. 29 is a plot of uncompensated measurements using Sensors A-G.
  • FIG. 30 is a plot of percent estimated sensitivity error of measurements compensated using the impedance to sensitivity relationship based on the estimative curve 2802 .
  • the Mean Absolute Relative Difference (MARD) of the uncompensated sensor data is 21.8%.
  • the MARD of the compensated data is 1.8%, which is a noticeable improvement over the uncompensated data.
  • MARD Mean Absolute Relative Difference
  • FIGS. 31 and 32 are also plots of uncompensated data and percent sensitivity error of compensated data, respectively.
  • the data in FIGS. 31 and 32 are based on measurements using Sensors H-L.
  • Sensors H, J, K and L were selected from the same lot of sensors as Sensors C, F and G described with reference to FIG. 27 and Sensor I was selected from the same lot as Sensors A and D described with reference to FIG. 27 .
  • the measurements plotted in FIGS. 31 and 32 were taken at 25 C instead of 37 C.
  • the estimative curve 2802 derived from Sensors A-G was used to compensate the data measured by Sensors H-L.
  • the MARD of the uncompensated data is 21.9%, nearly the same as the MARD of 21.8% calculated with respect to the sensor data in FIG. 29 .
  • the MARD of the compensated data of FIG. 18 is 4.4%, which is close to, although slightly higher than the MARD of the compensated data of FIG. 30 , but still much smaller than the uncompensated MARD.
  • FIGS. 33 and 34 are graphs of uncompensated data and percent sensitivity error of compensated data, respectively.
  • the data in FIGS. 33 and 34 are based on data obtained using Sensors M-Q.
  • Sensors M, O, P and Q were selected from the same lot as Sensors C, F and G described with reference to FIG. 27 and Sensor N was selected from the same lot as Sensors A and D described with reference to FIG. 27 .
  • the measurements of Sensors M-Q were taken at 42 C.
  • the estimative curve 2802 derived from Sensors A-G was also used to compensate the data in FIG. 34 .
  • the MARD of the uncompensated data is 13.1% and the MARD of the compensated data is 4.6%.
  • Example 2 illustrates that a change in sensitivity to change in impedance relationship determined at a first temperature can be used to compensate for sensitivity drift at temperatures different from the first temperature.
  • Example 5 pertains to prospective calibration. Further, in this experiment, calibration of sensor data is based on a change of sensitivity to change in impedance relationship previously derived from sensors from a different sensor lot. That is, in Example 3, the estimative curve 2802 is used to compensate data obtained using Sensors R-U, each of which was selected from a fourth sensor lot, the fourth sensor lot was not included in the group of sensors used to derive the estimative curve 2802 .
  • Example 5 shows that data can be calibrated using a change in sensitivity to change in impedance relationship derived from different sensor types than the type of sensor being calibrated. This can indicate that a sensor factory calibration code need not be used to compensate for sensitivity drift.
  • FIGS. 35 and 36 illustrate prospectively calibrating sensor data obtained from Sensors R-U.
  • FIG. 35 is a plot of the percent sensitivity change versus 30 minutes of each of the sensors over approximately 1400 minutes.
  • FIG. 36 illustrates the percent estimated sensitivity error of the compensated data.
  • the MARD of the uncompensated sensor data is 24.8% (the MARD of uncompensated data in the example of FIG. 15 was 21.8%) and the MARD of the compensated sensor data is 6.6% (the MARD of compensated data in the example of FIG. 16 was 1.8%).
  • FIGS. 37-39 Prospective calibration of sensors will now be discussed with reference to FIGS. 37-39 .
  • sensitivity and impedance data is collected from Sensors V-X, Z and AA having a membrane formed by a dipping process and Sensor Y having a membrane formed by a spray process.
  • an estimative curve 3702 is calculated based on the sensitivity and impedance data from all six Sensors V-Z and AA (i.e. using sensor data obtained from both sensors having dipped and sprayed membrane).
  • FIG. 39 is a graph of the percent sensitivity change of versus 60 minutes of the uncompensated data of each of the six sensors.
  • 39 is a graph of the percent estimated sensitivity error of the data of all six sensors after being compensated using estimative curve 3702 discussed above with respect to FIG. 37 .
  • the MARD of the uncompensated data is 25.3% and the MARD of the compensated data is 5.2%.
  • Example 5 indicates that using a change in sensitivity to change in impedance relationship derived from sensors selected from different lots than the sensor being calibrated can never-the-less significantly compensate for sensor sensitivity drift. It should be noted that curve 3702 is a straight line. It is contemplated that non-linear fits or correlations can be used instead, which may yield better results.
  • FIG. 40 illustrates a relationship of temperature on impedance and sensitivity of a sensor.
  • Points 4002 are sensitivity values of a sensor measured over a three day time period and points 4004 are impedance values of the sensor measured over the same time period.
  • the sensor is a transcutaneous-type of sensor. The temperature was initially set and maintained at 37 C, then raised to 45 C, and finally lowered to 25 C, as indicated in FIG. 40 .
  • both sensitivity and impedance of the sensor appear to have an inversely proportional relationship with changes in temperature.
  • FIG. 41 is a plot of the sensitivity measurement values versus the impedance measurement values of FIG. 40 .
  • FIG. 41 illustrates points measured during sensor run-in as diamonds and points measured after run-in as squares.
  • FIG. 42 illustrates compensating analyte concentration data measured by the sensor of Example 4 for effects of temperature after sensor run-in.
  • a relationship between impedance and temperature was used to compensate the sensor data.
  • the relationship was based on an estimative curve derived from the data of FIG. 41 .
  • the relationship between sensor sensitivity and different temperatures can then be mathematically modeled (e.g., by fitting a mathematical curve to data using one of the modeling techniques used herein), and the mathematical model can then be used to compensate for temperature effects on the sensor sensitivity. That is, a sensitivity of a sensor (which is affected by the sensor's temperature) can be determined based on a measured impedance of the sensor applied to the mathematical curve. Sensor data can then be converted to estimated glucose values based on the determined sensor sensitivity.
  • the MARD of the uncompensated data was calculated as 9.3% and the MARD of the compensated data was calculated as 2.8%.
  • Example 6 involves detection of moisture ingress in components of sensor electronics used to drive a sensor.
  • an input signal is applied to the sensor having a frequency ranging from 100 Hz to 1 kHz.
  • a response of the signal is then measured over the range of frequencies and both impedance and phase change derived therefrom.
  • contacts typically positioned inside a sealed section of a sensor electronics module are wetted.
  • the frequency of an input signal is varied between 100 and 1000 Hz.
  • a response is once again measured and both impedance and phase change is derived.
  • the contacts were wetted to the point of causing a gross failure of the sensor.
  • the current of the sensor increased from 2.3 nA when dry to 36 nA when wetted.
  • the contacts were only slightly wetted, where the current of the sensor increased from 2.3 nA when dry to 6 nA when wetted.
  • FIG. 43 is a graph of the impedance and phase changes of the first experiment, where the contacts were wetted to a point of causing a gross failure of the sensor system.
  • Curves 4302 and 4304 are impedance and phase values, respectively, of the sensor prior to the wetting of the contacts.
  • Curves 4306 and 4308 are impedance and phase values, respectively, of the sensor after wetting the contacts.
  • the impedance of the dry curve 4302 and the wet curve 4306 are noticeably different at around 1000 Hz and the phase of the dry curve 4304 and wet curve 4308 are noticeably different at about 100 Hz.
  • FIG. 44 is a graph of the impedance and phase changes of the second experiment, where the contacts are only slightly wetted.
  • Curves 4402 and 4404 are impedance and phase, respectively, of the sensor prior to the wetting of the contacts.
  • Curves 4406 and 4408 are impedance and phase, respectively of the sensor after wetting the contacts.
  • the impedance of the dry curve 4402 and the wet curve 44006 are noticeably different at around 100 Hz and the phase of the dry curve 4404 and wet curve 4408 are noticeably different around 1 kHz.
  • Example 7 involves detection of sensor membrane damage using impedance measurements.
  • the impedance of an analyte sensor is measured over a range of frequencies ranging from 100 to 1 kHz.
  • a portion of the sensor's membrane is then cut using a razor blade to cause membrane damage.
  • the impedance of the sensor is once again measured over the same range of frequencies.
  • the impedance measurements of the sensor before the membrane is cut are then compared to the measurements of the sensor after the membrane is cut to determine whether the impedance can be used to detect membrane damage.
  • FIG. 45 is a graph of the sensor measurements before and after the membrane damage.
  • Curves 4502 and 4504 are impedance and phase, respectively, of the sensor prior to membrane damage and curves 4506 and 4508 are impedance and phase, respectively, of the sensor after membrane damage. Both the impedance and phase relationships appear to change around the 1 kHz frequency. This relationship can then be used to detect membrane damage.
  • FIG. 46 is graph plotting impedance calculated using Fast Fourier Transform (FFT) and impedance measured using the Gamry for comparison.
  • FIG. 46 illustrates FFT and corresponding Gamry measurements for 30 min., 1.5 hrs., 3 hrs. and 13 hrs. of input data.
  • the FFT data substantially tracked the Gamry data until about the 1 kHz frequency. Note, the discrepancy after the 1 kHz frequency in FIG. 33 is believed to be due to known limitations on the system used to calculate the FFT. Thus, it is believed that using FFT can provide accurate impedance data even past the 1 kHz spectrum, thereby providing good correspondence to impedance measured using the Gamry.
  • FIGS. 47-49 relate to compensating for sensitivity changes in a human using an in vivo glucose sensor.
  • FIG. 47 is a graph illustrating in vivo data of sensor impedance and sensitivity of a subcutaneous continuous glucose sensor (also referred to herein as a CGM sensor) over about a 25 hour time period.
  • FIG. 47 is similar to FIG. 25 , but uses in vivo data instead of in vitro data.
  • Sensitivity data was generated using data obtained from a blood glucose finger stick monitor and raw sensor current measurements using the CGM sensor (i.e. dividing raw CGM sensor current in units of counts by time-corresponding meter glucose value in units of mg/dL to generate the sensitivity value).
  • the impedance data was generated by applying a step voltage to the CGM sensor and calculating an impedance based on the peak current of the response, as discussed herein with reference to FIG. 13 .
  • the impedance and sensitivity data appear to generally track a similar profile as the in vitro data of FIG. 25 .
  • FIG. 48 is a graph of estimated glucose values using the data generated by the CGM sensor before and after sensitivity compensation using the impedance measurements of FIG. 47 .
  • the compensated and uncompensated data was calibrated once using a blood glucose reference meter measurement at the one hour mark. The compensation was performed in a manner like that described above with respect to the in vitro study of FIG. 30 .
  • FIG. 48 also illustrates blood glucose reference measurements of the host. Based on the data of FIG. 48 , it appears that the compensated CGM sensor data more closely corresponds to the reference measurement data than the uncompensated CGM sensor data.
  • FIG. 49 is an accuracy plot showing differences between the uncompensated and compensated CGM sensor data and the finger-stick meter reference data, where the reference data corresponds to the zero line of the plot.
  • the MARD of the uncompensated CGM sensor data is 28.5% and the MARD of the compensated CGM sensor data is 7.8%. Thus, the compensation appears to improve accuracy of the CGM sensor data.
  • Sc is a sensitivity determined at calibration
  • t is the time since the last calibration
  • the sensor impendence change from time t is expressed as:
  • Ic is an impedance at the time of calibration.
  • the linear or non-linear correlation can then be applied to correct for changes in sensitivity of the sensor using impedance measurements of the sensor.
  • FIG. 50 illustrates process 5000 for correcting estimated glucose values used in this experiment.
  • Process 5000 then divides into two branches.
  • the first branch beings at block 5004 , where sensor data is generated using the continuous glucose sensor in the form of current or counts.
  • the first branch then proceeds to decision block 5006 , where process 5000 determines whether a calibration is needed. In this experiment, a calibration is determined to be needed one hour and 24 hours after sensor insertion. If it is determined that calibration is not needed, then the first branch essentially ends. On the other hand, if it is determined that calibration is required, then process 5000 acquires a reference measurement using a finger stick meter at blocks 5008 and 5010 . Sensor data corresponding in time to the reference measurement (at time Tc) is determined at block 5012 and used to calculate a sensor sensitivity, Sc, along with the reference data at block 5014 .
  • the second branch of process 5000 begins with measuring an impendence of the sensor at block 5016 .
  • the impedance is measured using the peak current technique discussed in this application with reference to FIG. 13 .
  • a compensation algorithm (using the linear or the non-linear compensation algorithm) is then used in block 5024 to calculate a change in sensitivity at block 5026 based on the change in impedance determined at block 5022 .
  • the first and second branches of process 5000 then merge at block 5028 where a corrected sensitivity is determined.
  • the corrected sensitivity is then used to convert sensor data in units of current or counts to an estimated glucose value in units of glucose concentration.
  • Process 5000 is repeated for each sensor data point that is converted into an estimated glucose value.
  • Some embodiments disclosed herein continuously or iteratively apply a stimulus signal during a continuous sensor session or use and extrapolate information from the output associated with the stimulus, such as using a peak current measurement, EIS, etc.
  • EIS peak current measurement
  • electrochemical analysis techniques were described herein, it is understood that many other techniques can be used instead to detect characteristics of sensors described herein, such as voltammetry, chronopotentiometry, current or potential step techniques, differential chrono-potentiometry, oxygen absorption rate measurements, potential/current sweep or pulse methods, etc.
  • the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like;
  • the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps;
  • the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as ‘known’, ‘normal’, ‘standard’, and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like ‘preferably,’ ‘preferred,’ ‘desi
  • a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise.
  • a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.

Abstract

Systems and methods for processing sensor data and self-calibration are provided. In some embodiments, systems and methods are provided which are capable of calibrating a continuous analyte sensor based on an initial sensitivity, and then continuously performing self-calibration without using, or with reduced use of, reference measurements. In certain embodiments, a sensitivity of the analyte sensor is determined by applying an estimative algorithm that is a function of certain parameters. Also described herein are systems and methods for determining a property of an analyte sensor using a stimulus signal. The sensor property can be used to compensate sensor data for sensitivity drift, or determine another property associated with the sensor, such as temperature, sensor membrane damage, moisture ingress in sensor electronics, and scaling factors.

Description

    INCORPORATION BY REFERENCE TO RELATED APPLICATIONS
  • Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. application Ser. No. 13/446,848, filed Apr. 13, 2012, which claims the benefit of U.S. Provisional Application No. 61/476,145, filed Apr. 15, 2011. Each of the aforementioned applications is incorporated by reference herein in its entirety, and each is hereby expressly made a part of this specification.
  • TECHNICAL FIELD
  • The embodiments described herein relate generally to systems and methods for processing sensor data from continuous analyte sensors and for self-calibration.
  • BACKGROUND
  • Diabetes mellitus is a chronic disease, which occurs when the pancreas does not produce enough insulin (Type I), or when the body cannot effectively use the insulin it produces (Type II). This condition typically leads to an increased concentration of glucose in the blood (hyperglycemia), which can cause an array of physiological derangements (e.g., kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. Sometimes, a hypoglycemic reaction (low blood sugar) is induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
  • A variety of sensor devices have been developed for continuously measuring blood glucose concentrations. Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically involves uncomfortable finger pricking methods. Due to a lack of comfort and convenience, a diabetic will often only measure his or her glucose levels two to four times per day. Unfortunately, these measurements can be spread far apart, such that a diabetic may sometimes learn too late of a hypoglycemic or hyperglycemic event, thereby potentially incurring dangerous side effects. In fact, not only is it unlikely that a diabetic will take a timely SMBG measurement, but even if the diabetic is able to obtain a timely SMBG value, the diabetic may not know whether his or her blood glucose value is increasing or decreasing, based on the SMBG alone.
  • Heretofore, a variety of glucose sensors have been developed for continuously measuring glucose values. Many implantable glucose sensors suffer from complications within the body and provide only short-term and less-than-accurate sensing of blood glucose. Similarly, transdermal sensors have run into problems in accurately sensing and reporting back glucose values continuously over extended periods of time. Some efforts have been made to obtain blood glucose data from implantable devices and retrospectively determine blood glucose trends for analysis; however these efforts do not aid the diabetic in determining real-time blood glucose information. Some efforts have also been made to obtain blood glucose data from transdermal devices for prospective data analysis, however similar problems have occurred.
  • SUMMARY OF THE INVENTION
  • In a first aspect, a method is provided for calibrating sensor data generated by a continuous analyte sensor, comprising: generating sensor data using a continuous analyte sensor; iteratively determining, with an electronic device, a sensitivity value of the continuous analyte sensor as a function of time by applying a priori information comprising sensor sensitivity information; and calibrating the sensor data based at least in part on the determined sensitivity value.
  • In an embodiment of the first aspect or any other embodiment thereof, calibrating the sensor data is performed iteratively throughout a substantially entire sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, iteratively determining a sensitivity value is performed at regular intervals or performed at irregular intervals, as determined by the a priori information.
  • In an embodiment of the first aspect or any other embodiment thereof, iteratively determining a sensitivity value is performed throughout a substantially entire sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, determining a sensitivity value is performed in substantially real time.
  • In an embodiment of the first aspect or any other embodiment thereof, the a priori information is associated with at least one predetermined sensitivity value that is associated with a predetermined time after start of a sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, at least one predetermined sensitivity value is associated with a correlation between a sensitivity determined from in vitro analyte concentration measurements and a sensitivity determined from in vivo analyte concentration measurements at the predetermined time.
  • In an embodiment of the first aspect or any other embodiment thereof, the a priori information is associated with a predetermined sensitivity function that uses time as input.
  • In an embodiment of the first aspect or any other embodiment thereof, time corresponds to time after start of a sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, time corresponds to at least one of time of manufacture or time since manufacture.
  • In an embodiment of the first aspect or any other embodiment thereof, the sensitivity value of the continuous analyte sensor is also a function of at least one other parameter.
  • In an embodiment of the first aspect or any other embodiment thereof, the at least one other parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • In an embodiment of the first aspect or any other embodiment thereof, calibrating the sensor data is performed without using reference blood glucose data.
  • In an embodiment of the first aspect or any other embodiment thereof, the electronic device is configured to provide a level of accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days, and wherein reference measurements associated with calculation of the mean absolute relative difference are determined by analysis of blood.
  • In an embodiment of the first aspect or any other embodiment thereof, the sensor session is at least about 4 days.
  • In an embodiment of the first aspect or any other embodiment thereof, the sensor session is at least about 5 days.
  • In an embodiment of the first aspect or any other embodiment thereof, the sensor session is at least about 6 days.
  • In an embodiment of the first aspect or any other embodiment thereof, the sensor session is at least about 7 days.
  • In an embodiment of the first aspect or any other embodiment thereof, the sensor session is at least about 10 days.
  • In an embodiment of the first aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 7% over the sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 5% over the sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 3% over the sensor session.
  • In an embodiment of the first aspect or any other embodiment thereof, the a priori information is associated with a calibration code.
  • In an embodiment of the first aspect or any other embodiment thereof, the a priori sensitivity information is stored in the sensor electronics prior to use of the sensor.
  • In a second aspect, a system is provided for implementing the method of the first aspect or any embodiments thereof.
  • In a third aspect, a method is provided for calibrating sensor data generated by a continuous analyte sensor, the method comprising: generating sensor data using a continuous analyte sensor; determining, with an electronic device, a plurality of different sensitivity values of the continuous analyte sensor as a function of time and of sensitivity information associated with a priori information; and calibrating the sensor data based at least in part on at least one of the plurality of different sensitivity values.
  • In an embodiment of the third aspect or any other embodiment thereof, calibrating the continuous analyte sensor is performed iteratively throughout a substantially entire sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, the plurality of different sensitivity values are stored in a lookup table in computer memory.
  • In an embodiment of the third aspect or any other embodiment thereof, determining a plurality of different sensitivity values is performed once throughout a substantially entire sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, the a priori information is associated with at least one predetermined sensitivity value that is associated with a predetermined time after start of a sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, the at least one predetermined sensitivity value is associated with a correlation between a sensitivity determined from in vitro analyte concentration measurements and a sensitivity determined from in vivo analyte concentration measurements at the predetermined time.
  • In an embodiment of the third aspect or any other embodiment thereof, the a priori information is associated with a predetermined sensitivity function that uses time as input.
  • In an embodiment of the third aspect or any other embodiment thereof, time corresponds to time after start of a sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, time corresponds to time of manufacture or time since manufacture.
  • In an embodiment of the third aspect or any other embodiment thereof, the plurality of sensitivity values are also a function of at least one parameter other than time.
  • In an embodiment of the third aspect or any other embodiment thereof, the at least one other parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • In an embodiment of the third aspect or any other embodiment thereof, calibrating the continuous analyte sensor is performed without using reference blood glucose data.
  • In an embodiment of the third aspect or any other embodiment thereof, the electronic device is configured to provide a level of accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days; and wherein reference measurements associated with calculation of the mean absolute relative difference are determined by analysis of blood.
  • In an embodiment of the third aspect or any other embodiment thereof, the sensor session is at least about 4 days.
  • In an embodiment of the third aspect or any other embodiment thereof, the sensor session is at least about 5 days.
  • In an embodiment of the third aspect or any other embodiment thereof, the sensor session is at least about 6 days.
  • In an embodiment of the third aspect or any other embodiment thereof, the sensor session is at least about 7 days.
  • In an embodiment of the third aspect or any other embodiment thereof, the sensor session is at least about 10 days.
  • In an embodiment of the third aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 7% over the sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 5% over the sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 3% over the sensor session.
  • In an embodiment of the third aspect or any other embodiment thereof, the a priori information is associated with a calibration code.
  • In a fourth aspect, a system is provided for implementing the method of the third aspect or any embodiments thereof.
  • In a fifth aspect, a method is provided for processing data from a continuous analyte sensor, the method comprising: receiving, with an electronic device, sensor data from a continuous analyte sensor, the sensor data comprising at least one sensor data point; iteratively determining a sensitivity value of the continuous analyte sensor as a function of time and of an at least one predetermined sensitivity value associated with a predetermined time after start of a sensor session; forming a conversion function based at least in part on the sensitivity value; and determining an analyte output value by applying the conversion function to the at least one sensor data point.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the iteratively determining a sensitivity of the continuous analyte sensor is performed continuously.
  • In an embodiment of the fifth aspect or any other embodiment thereof, iteratively determining a sensitivity is performed in substantially real time.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the method further comprises determining a baseline of the continuous analyte sensor, and wherein the conversion function is based at least in part on the baseline.
  • In an embodiment of the fifth aspect or any other embodiment thereof, determining a baseline of the continuous analyte sensor is performed continuously.
  • In an embodiment of the fifth aspect or any other embodiment thereof, determining a sensitivity of the continuous analyte sensor and determining a baseline of the analyte sensor are performed at substantially the same time.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the at least one predetermined sensitivity value is set at a manufacturing facility for the continuous analyte sensor.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the method further comprises receiving at least one calibration code; and applying the at least one calibration code to the electronic device at a predetermined time after start of the sensor session.
  • In an embodiment of the fifth aspect or any other embodiment thereof, iteratively determining a sensitivity is performed at regular intervals or performed at irregular intervals, as determined by the at least one calibration code.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the at least one calibration code is associated with the at least one predetermined sensitivity.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the at least one calibration code is associated with a predetermined sensitivity function that uses time of the function of time as input.
  • In an embodiment of the fifth aspect or any other embodiment thereof, time corresponds to time after start of the sensor session.
  • In an embodiment of the fifth aspect or any other embodiment thereof, time corresponds to time of manufacture or time since manufacture.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the sensitivity value of the continuous analyte sensor is also a function of at least one other parameter.
  • In an embodiment of the fifth aspect or any other embodiment thereof, the at least one other parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • In a sixth aspect, a system is provided for implementing the method of the fifth aspect or any embodiments thereof.
  • In a seventh aspect, a method is provided for calibrating a continuous analyte sensor, the method comprising: receiving sensor data from a continuous analyte sensor; forming or receiving a predetermined sensitivity profile corresponding to a change in sensor sensitivity to an analyte over a substantially entire sensor session, wherein the predetermined sensitivity profile is a function of at least one predetermined sensitivity value associated with a predetermined time after start of the sensor session; and applying, with an electronic device, the sensitivity profile in real-time calibrations.
  • In an embodiment of the seventh aspect or any other embodiment thereof, the at least one predetermined sensitivity value, the predetermined sensitivity profile, or both are set at a manufacturing facility for the continuous analyte sensor.
  • In an embodiment of the seventh aspect or any other embodiment thereof, the method further comprises receiving at least one calibration code; and applying the at least one calibration code to the electronic device at a predetermined time after start of the sensor session.
  • In an embodiment of the seventh aspect or any other embodiment thereof, the at least one calibration code is associated with the at least one predetermined sensitivity.
  • In an embodiment of the seventh aspect or any other embodiment thereof, the at least one calibration code is associated with a predetermined sensitivity function that uses time as input.
  • In an embodiment of the seventh aspect or any other embodiment thereof, the sensitivity profile is a function of time.
  • In an embodiment of the seventh aspect or any other embodiment thereof, time corresponds to time after start of the sensor session.
  • In an embodiment of the seventh aspect or any other embodiment thereof, time corresponds to time of manufacture or time since manufacture.
  • In an embodiment of the seventh aspect or any other embodiment thereof, the sensitivity value is a function of time, the predetermined sensitivity value, and at least one parameter selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • In an eighth aspect, a system is provided for implementing the method of the seventh aspect or any embodiments thereof.
  • In a ninth aspect, a method is provided for processing data from a continuous analyte sensor, the method comprising: receiving, with an electronic device, sensor data from a continuous analyte sensor, the sensor data comprising at least one sensor data point; receiving or forming a sensitivity profile corresponding to a change in sensor sensitivity over a substantially entire sensor session; forming a conversion function based at least in part on the sensitivity profile; and determining an analyte output value by applying the conversion function to the at least one sensor data point.
  • In an embodiment of the ninth aspect or any other embodiment thereof, the sensitivity profile is set at a manufacturing facility for the continuous analyte sensor.
  • In an embodiment of the ninth aspect or any other embodiment thereof, the method comprises receiving at least one calibration code; and applying the at least one calibration code to the electronic device at a predetermined time after start of the sensor session.
  • In an embodiment of the ninth aspect or any other embodiment thereof, the at least one calibration code is associated with the at least one predetermined sensitivity.
  • In an embodiment of the ninth aspect or any other embodiment thereof, the at least one calibration code is associated with the sensitivity profile.
  • In an embodiment of the ninth aspect or any other embodiment thereof, the sensitivity profile is a function of time.
  • In an embodiment of the ninth aspect or any other embodiment thereof, time corresponds to time after start of the sensor session.
  • In an embodiment of the ninth aspect or any other embodiment thereof, time corresponds to time of manufacture or time since manufacture.
  • In an embodiment of the ninth aspect or any other embodiment thereof, the sensitivity is a function of time and at least one parameter is selected from the group consisting of: temperature, pH, level or duration of hydration, curing condition, an analyte concentration of a fluid surrounding the continuous analyte sensor during startup of the sensor, and combinations thereof.
  • In a tenth aspect, a system is provided for implementing the method of the ninth aspect or any embodiments thereof.
  • In an eleventh aspect, a system is provided for monitoring analyte concentration in a host, the system comprising: a continuous analyte sensor configured to measure analyte concentration in a host and to provide factory-calibrated sensor data, the factory-calibrated sensor data being calibrated without reference blood glucose data; wherein the system is configured to provide a level of accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days, wherein reference measurements associated with calculation of the mean absolute relative difference are determined by analysis of blood.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the sensor session is at least about 4 days.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the sensor session is at least about 5 days.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the sensor session is at least about 6 days.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the sensor session is at least about 7 days.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the sensor session is at least about 10 days.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 7% over the sensor session.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 5% over the sensor session.
  • In an embodiment of the eleventh aspect or any other embodiment thereof, the mean absolute relative difference is no more than about 3% over the sensor session.
  • In a twelfth aspect, a method for determining a property of a continuous analyte sensor, the method comprising: applying a bias voltage to an analyte sensor; applying a voltage step above the bias voltage to the analyte sensor; measuring, using sensor electronics, a signal response of the voltage step; determining, using the sensor electronics, a peak current of the signal response; determining, using the sensor electronics, a property of the sensor by correlating the peak current to a predetermined relationship.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, correlating the peak current to the predetermined relationship comprises calculating an impedance of the sensor based on the peak current and correlating the sensor impedance to the predetermined relationship.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, the property of the sensor is a sensitivity of the sensor or a temperature of the sensor.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, the peak current is a difference between a magnitude of the response prior to the voltage step and a magnitude of the largest measured response resulting from the voltage step.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, the predetermined relationship is an impedance-to-sensor sensitivity relationship, and wherein the property of the sensor is a sensitivity of the sensor.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, the method further comprises compensating sensor data using the determined property of the sensor.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, the compensating comprises correlating a predetermined relationship of the peak current to sensor sensitivity or change in sensor sensitivity and modifying a value or values of the sensor data responsive to the correlated sensor sensitivity or change in sensor sensitivity.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, predetermined relationship is a linear relationship over time of use of the analyte sensor.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, the predetermined relationship is a non-linear relationship over time of use of the analyte sensor.
  • In an embodiment of the twelfth aspect or any other embodiment thereof, wherein the predetermined relationship is determined by prior testing of sensors similar to the analyte sensor.
  • In an embodiment of the thirteenth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processor of the sensor system, cause the sensor system to implement the method of the twelfth aspect or any embodiment thereof.
  • In a fourteenth aspect, a method is provided for calibrating an analyte sensor, the method comprising: applying a time-varying signal to the analyte sensor; measuring a signal response to the applied signal; determining, using sensor electronics, a sensitivity of the analyte sensor, the determining comprising correlating at least one property of the signal response to a predetermined sensor sensitivity profile; and generating, using sensor electronics, estimated analyte concentration values using the determined sensitivity and sensor data generated by the analyte sensor.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the sensitivity profile comprises varying sensitivity values over time since implantation of the sensor.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the predetermined sensitivity profile comprises a plurality of sensitivity values.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the predetermined sensitivity profile is based on sensor sensitivity data generated from studying sensitivity changes of analyte sensors similar to the analyte sensor.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the method further comprises applying a bias voltage to the sensor, wherein the time-varying signal comprises a step voltage above the bias voltage or a sine wave overlaying a voltage bias voltage.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the determining further comprises calculating an impedance value based on the measured signal response and correlating the impedance value to a sensitivity value of the predetermined sensitivity profile.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the method further comprises applying a DC bias voltage to the sensor to generate sensor data, wherein the estimating analyte concentration values includes generating corrected sensor data using the determined sensitivity.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the method further comprises applying a conversion function to the corrected sensor data to generate the estimated analyte concentration values.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the method further comprises forming a conversion function based at least in part of the determined sensitivity, and wherein the conversion function is applied to the sensor data to generate the estimated analyte concentration values.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the property is a peak current value of the signal response.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the determining further comprises using at least one of performing a Fast Fourier Transform on the signal response data, integrating at least a portion of a curve of the signal response, and determining a peak current of the signal response.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the determining further comprises selecting the predetermined sensitivity profile based on the determined sensor property from a plurality of different predetermined sensitivity profiles.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the selecting includes performing a data association analysis to determine a correlation between the determined sensor property and each of the plurality of different predetermined sensitivity profiles and wherein the selected predetermined sensitivity profile has the highest correlation.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the method further comprises generating estimated analyte concentration values using the selected sensitivity profile.
  • In an embodiment of the fourteenth aspect or any other embodiment thereof, the method further comprises determining a second sensitivity value using the selected sensitivity profile, wherein a first set of estimated analyte concentration values is generated using the determined sensitivity value and sensor data associated with a first time period, and wherein a second set of concentration values is generated using the second sensitivity value and sensor data associated with a second time period.
  • In a fifteenth aspect, a sensor system is provided for implementing the method of the fourteenth aspect or any embodiments thereof.
  • In an embodiment of the fifteenth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the fourteenth aspect or any embodiment thereof.
  • In a sixteenth aspect, a method is provided for determining whether an analyte sensor system is functioning properly, the method comprising: applying a stimulus signal to the analyte sensor; measuring a response to the stimulus signal; estimating a value of a sensor property based on the signal response; correlating the sensor property value with a predetermined relationship of the sensor property and a predetermined sensor sensitivity profile; and initiating an error routine if the correlation does not exceed a predetermined correlation threshold.
  • In an embodiment of the sixteenth aspect or any other embodiment thereof, correlating includes performing a data association analysis.
  • In an embodiment of the sixteenth aspect or any other embodiment thereof, the error routine comprises displaying a message to a user indicating that the analyte sensor is not functioning properly.
  • In an embodiment of the sixteenth aspect or any other embodiment thereof, the sensor property is an impedance of the sensor membrane.
  • In a seventeenth aspect, a sensor system is provided configured to implement the method of the sixteenth aspect or any embodiment thereof.
  • In an embodiment of the seventeenth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the sixteenth aspect or any embodiment thereof.
  • In an eighteenth aspect, a method is provided for determining a temperature associated with an analyte sensor, the method comprising: applying a stimulus signal to the analyte sensor; measuring a signal response of the signal; and determining a temperature associated with of the analyte sensor, the determining comprising correlating at least one property of the signal response to a predetermined relationship of the sensor property to temperature.
  • In an embodiment of the eighteenth aspect or any other embodiment thereof, the method further comprises generating estimated analyte concentration values using the determined temperature and sensor data generated from the analyst sensor.
  • In an embodiment of the eighteenth aspect or any other embodiment thereof, the generating includes compensating the sensor data using the determined temperature and converting the compensated sensor data to the generated estimated analyte values using a conversion function.
  • In an embodiment of the eighteenth aspect or any other embodiment thereof, the generating includes forming or modifying a conversion function using the determined temperature and converting the sensor data to the generated estimated analyte values using the formed or modified conversion function.
  • In an embodiment of the eighteenth aspect or any other embodiment thereof, the method further comprises measuring a temperature using a second sensor, wherein the determining further comprises using the measured temperature to determine the temperature associated with the analyte sensor.
  • In an embodiment of the eighteenth aspect or any other embodiment thereof, the second sensor is a thermistor.
  • In a nineteenth aspect, a sensor system is provided configured to implement the methods of the eighteenth aspect or any embodiment thereof.
  • In an embodiment of the nineteenth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the eighteenth aspect or any embodiment thereof.
  • In a twentieth aspect, a method is provided for determining moisture ingress in an electronic sensor system, comprising: applying a stimulus signal having a particular frequency or a signal comprising a spectrum of frequencies to an analyte sensor; measuring a response to the stimulus signal; calculating, using sensor electronics, an impedance based on the measured signal response; determining, using sensor electronics, whether the impedance falls within a predefined level corresponding to moisture ingress; initiating, using sensor electronics, an error routine if the impedance exceeds one or both of the respective predefined levels
  • In an embodiment of the twentieth aspect or any other embodiment thereof, the method further comprises the error routine includes one or more of triggering an audible alarm and a visual alarm on a display screen to alert a user that the sensor system may not be functioning properly.
  • In an embodiment of the twentieth aspect or any other embodiment thereof, the stimulus signal has a predetermined frequency.
  • In an embodiment of the twentieth aspect or any other embodiment thereof, the stimulus signal comprises a spectrum of frequencies.
  • In an embodiment of the twentieth aspect or any other embodiment thereof, the calculated impedance comprises a magnitude value and a phase value, and wherein the determination comprises comparing the impedance magnitude value to a predefined impedance magnitude threshold and the phase value to a predefined phase threshold.
  • In an embodiment of the twentieth aspect or any other embodiment thereof, the calculated impedance is a complex impedance value.
  • In a twenty-first aspect, a sensor system is provided configured to implement the methods of the twentieth aspect or any embodiment thereof.
  • In an embodiment of the twenty-first aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twentieth aspect or any embodiment thereof.
  • In an twenty-second aspect, a method is provided for determining membrane damage of an analyte sensor using a sensor system, comprising: applying a stimulus signal to an analyte sensor; measuring a response to the stimulus signal; calculating, using sensor electronics, an impedance based on the signal response; determining, using the sensor electronics, whether the impedance falls within a predefined level corresponding to membrane damage; and initiating, using the sensor electronics, an error routine if the impedance exceeds the predefined level.
  • In an embodiment of the twenty-second aspect or any other embodiment thereof, the error routine includes triggering one or more of an audible alarm and a visual alarm on a display screen.
  • In an embodiment of the twenty-second aspect or any other embodiment thereof, the stimulus signal has a predetermined frequency.
  • In an embodiment of the twenty-second aspect or any other embodiment thereof, the stimulus signal comprises a spectrum of frequencies.
  • In an embodiment of the twenty-second aspect or any other embodiment thereof, the calculated impedance comprises a magnitude value and a phase value, and wherein the determination comprises comparing the impedance magnitude value to a predefined impedance magnitude threshold and the phase value to a predefined phase threshold.
  • In an embodiment of the twenty-second aspect or any other embodiment thereof, the calculated impedance is a complex impedance value.
  • In a twenty-third aspect, a sensor system is provided configured to implement the methods of the twenty-second aspect or any embodiment thereof.
  • In an embodiment of the twenty-third aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-second aspect or any embodiment thereof.
  • In a twenty-fourth aspect, a method for determining reuse of an analyte sensor, comprising, applying a stimulus signal to an analyte sensor; measuring a response of the stimulus signal; calculating an impedance response based on the response; comparing the calculated impedance to a predetermined threshold; initiating a sensor reuse routine if it is determined that the impedance exceeds the threshold.
  • In an embodiment of the twenty-fourth aspect or any other embodiment thereof, the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
  • In an embodiment of the twenty-fourth aspect or any other embodiment thereof, the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
  • In a twenty-fifth aspect, a sensor system is provided configured to implement the methods of the twenty-fourth aspect or any embodiments thereof.
  • In an embodiment of the twenty-fifth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-fourth aspect or any embodiments thereof.
  • In a twenty-sixth aspect, a system is provided for determining reuse of an analyte sensor, comprising, applying a stimulus signal to an analyte sensor; measuring a response of the stimulus signal; calculating an impedance based on the response; using a data association function to determine a correlation of the calculated impedance to one or more recorded impedance values; and initiating a sensor reuse routine if it is determined that the correlation is above a predetermined threshold.
  • In an embodiment of the twenty-sixth aspect or any other embodiment thereof, the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
  • In an embodiment of the twenty-sixth aspect or any other embodiment thereof, the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
  • In an embodiment of the twenty-sixth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-fifth aspect.
  • In a twenty-seventh aspect, a method is provided for applying an overpotential to an analyte sensor, comprising, applying a stimulus signal to an analyte sensor; measuring a response of the stimulus signal; determining a sensor sensitivity or change in sensor sensitivity based on the response; and applying an over potential to the sensor based on the determined sensitivity or sensitivity change.
  • In an embodiment of the twenty-seventh aspect or any other embodiment thereof, the determining further comprises calculating an impedance based on the response and determining the sensitivity or sensitivity change based on the impedance.
  • In an embodiment of the twenty-seventh aspect or any other embodiment thereof, the determining the sensitivity or sensitivity change further comprises correlating the impedance to a predetermined impedance to sensitivity relationship.
  • In an embodiment of the twenty-seventh aspect or any other embodiment thereof, the applying comprises determining or modifying a length of time the over potential is applied to the sensor.
  • In an embodiment of the twenty-seventh aspect or any other embodiment thereof, the applying comprises determining or modifying a magnitude of the over potential applied to the sensor.
  • In a twenty-eighth aspect, a sensor system is provided configured to implement the methods of the twenty-seventh aspect or any embodiments thereof.
  • In an embodiment of the twenty-eighth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-seventh aspect or any embodiment thereof.
  • In a twenty-ninth aspect, a method is provided for determining a property of a continuous analyte sensor, the method comprising: applying a stimulus signal to a first analyte sensor having a first working electrode and a first reference electrode; measuring a signal response of the stimulus signal using a second analyte sensor having a second working electrode and a second reference electrode; and determining a property of the first sensor by correlating the response to a predetermined relationship.
  • In an embodiment of the twenty-ninth aspect or any other embodiment thereof, the method further comprises generating sensor data by applying a bias voltage to the first working electrode and measuring a response to the bias voltage.
  • In an embodiment of the twenty-ninth aspect or any other embodiment thereof, the method further comprises calibrating the sensor data using the determined property.
  • In an embodiment of the twenty-ninth aspect or any other embodiment thereof, the determined property is one of an impedance and a temperature.
  • In an embodiment of the twenty-ninth aspect or any other embodiment thereof, the method further comprises determining sensor membrane damage using the determined property.
  • In an embodiment of the twenty-ninth aspect or any other embodiment thereof, the method further comprises determining moisture ingress in a sensor system encompassing the first and second analyte sensors using the determined property.
  • In a thirtieth aspect, a sensor system is provided configured to implement the methods of one of the twenty-ninth aspect or any embodiments thereof.
  • In an embodiment of the thirtieth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the twenty-ninth aspect or any embodiments thereof.
  • In a thirty-first aspect, a method is provided for determining a scaling used in a continuous analyte sensor system, the method comprising: applying a first stimulus signal to a first working electrode of an analyte sensor; measuring a response to the first stimulus signal; applying a second stimulus signal to a second working electrode of the analyte sensor; measuring a response to the first stimulus signal; determining, using sensor electronics, a scaling factor based on the measured responses to the first and second stimulus signals; and using the scaling factor to generate estimated analyte values based on sensor data generated by the analyte sensor.
  • In an embodiment of the thirty-first aspect or any other embodiment thereof, the method further comprises the method is performed periodically.
  • In an embodiment of the thirty-first aspect or any other embodiment thereof, the determining comprises calculating a first impedance using the response to the first stimulus signal and calculating a second impedance using the response to the second stimulus signal, and wherein the scaling factor is a ratio of the first impedance and the second impedance.
  • In an embodiment of the thirty-first aspect or any other embodiment thereof, the first working electrode has a membrane comprising an enzyme configured to react with the analyte and the second working electrode has a membrane does not have the enzyme.
  • In an embodiment of the thirty-first aspect or any other embodiment thereof, determining the scaling factor comprises updating a previous scaling factor based on the measured responses to the first and second stimulus signals.
  • In an embodiment of the thirty-first aspect or any other embodiment thereof, scaling factor is an acetaminophen scaling factor, wherein the method further comprises updating a further scaling factor based on the acetaminophen scaling factor, and wherein the further scaling factor applied to the sensor data to generate the estimated analyte values.
  • In a thirty-second aspect, a sensor system is provided configured to implement the methods of the thirty-first aspect or any embodiments thereof.
  • In an embodiment of the thirty-second aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the thirty-first aspect or any embodiment thereof.
  • In a thirty-third aspect, a method is provided for calibrating an analyte sensor, the method comprising: applying a predetermined signal to an analyte sensor; measuring a response to the applied signal; determining, using sensor electronics, a change in impedance associated with a membrane of the analyte sensor based on the measured response; calculating a sensitivity change of the analyte sensor based on the determined impedance; calculating a corrected sensitivity based on the calculated sensitivity change and a previously used sensitivity of the analyte sensor; and generating estimated analyte values using the corrected sensitivity.
  • In an embodiment of the thirty-third aspect or any other embodiment thereof, calculating the sensitivity change comprises applying a non-linear compensation function.
  • In an embodiment of the thirty-third aspect or any other embodiment thereof, the non-linear compensation function is expressed as the equation ΔS=(a*log(t)+b)*ΔI, where ΔS is the change in sensitivity, t is a time since calibration of the analyte sensor, ΔI is the determined change in impedance, and a and b are a predetermined coefficients.
  • In an embodiment of the thirty-third aspect or any other embodiment thereof, a and b are determined by prior testing of similar analyte sensors.
  • In a thirty-fourth aspect, a sensor system is provided configured to implement the methods of the thirty-third aspect or any embodiments thereof.
  • In an embodiment of the thirty-fourth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the thirty-third aspect or any embodiments thereof.
  • In a thirty-fifth aspect, a method is provided for calibrating an analyte sensor, comprising: generating sensor data using a subcutaneous analyte sensor; forming or modifying a conversion function, wherein pre-implant information, internal diagnostic information, and/or external reference information are used as inputs to form or modify the conversion function; and calibrating the sensor data using the conversion function.
  • In an embodiment of the thirty-fifth aspect or any other embodiment thereof, the pre-implant information comprises information selected from the group consisting of: a predetermined sensitivity profile associated with the analyte sensor, a previously determined relationship between a measured sensor property and sensor sensitivity, one or more previously determined relationships between a measured sensor property and sensor temperature; sensor data obtained from previously used analyte sensors, a calibration code associated with the analyte sensor, patient specific relationships between the analyte sensor and one or more of sensitivity, baseline, drift and impedance, information indicative of a site of sensor implantation; time since manufacture of the analyte sensor, and information indicative of the analyte being exposed to temperature or humidity.
  • In an embodiment of the thirty-fifth aspect or any other embodiment thereof, the internal diagnostic information comprises information selected from the group consisting of: stimulus signal output; sensor data indicative of an analyte concentration measured by the sensor; temperature measurements using the sensor or a separate sensor; sensor data generated by a redundant sensor, where the redundant sensor is designed to be substantially the same as analyte sensor; sensor data generated by an auxiliary sensors, where the auxiliary sensor is having a different modality as the analyte sensor; a time since the sensor was implanted or connected to sensor electronics coupled to the sensor; data representative of a pressure on the sensor or sensor system generated by a pressure sensor; data generated by an accelerometer; a measure of moisture ingress; and a measure of noise in an analyte concentration signal.
  • In an embodiment of the thirty-fifth aspect or any other embodiment thereof, the reference information comprises information selected from the group consisting of: real-time and/or prior analyte concentration information obtained from a reference monitor, information relating to a type/brand of reference monitor used to provide reference data; information relating to an amount of carbohydrate consumed by a user; information received from a medicament delivery device, glucagon sensitivity information, and information gathered from population based data.
  • In a thirty-sixth aspect, a sensor system is provided configured to implement the methods of the thirty-fifth aspect or any embodiments thereof.
  • In an embodiment of the thirty-sixth aspect or any other embodiment thereof, the sensor system comprises instructions stored in computer memory, wherein the instructions, when executed by one or more processors of the sensor system, cause the sensor system to implement the method of the thirty-fifth aspect or any embodiment thereof.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • These and other features and advantages will be appreciated, as they become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
  • FIG. 1A illustrates a schematic diagram of sensor sensitivity as a function of time during a sensor session, in accordance with one embodiment; FIG. 1B illustrates schematic diagrams of conversion functions at different time periods of a sensor session, in accordance with the embodiment of FIG. 1A.
  • FIGS. 2A-2B and FIGS. 2C-2D collectively illustrate different embodiments of processes for generating a sensor sensitivity profile.
  • FIG. 3A is a Bland-Altman plot illustrating differences between YSI reference measurements and certain in vivo continuous analyte sensors that were factory calibrated, in accordance with one embodiment; FIG. 3B is a Clarke error grid associated with data from the continuous analyte sensors associated with FIG. 3A.
  • FIG. 4 illustrates data from one study that examined the accuracy level of continuous analyte sensors that accepted one reference measurement about one hour after insertion into patients, in accordance with one embodiment.
  • FIG. 5 illustrates a diagram showing different types of information that can be input into the sensor system to define the sensor sensitivity profile over time
  • FIG. 6 illustrates a schematic diagram of sensor sensitivity as a function of time between completion of sensor fabrication and the start of the sensor session, in accordance with one embodiment.
  • FIG. 7A is a schematic diagram depicting distribution curves of sensor sensitivity corresponding to the Bayesian learning process, in accordance with one embodiment; FIG. 7B is a schematic diagram depicting confidence levels, associated with the sensor sensitivity profile, that correspond with the distribution curves shown in FIG. 7A.
  • FIG. 8 illustrates a graph that provides a comparison between an estimated glucose equivalent baseline and detected glucose equivalent baseline, in accordance with one study.
  • FIG. 9 is a schematic of a model sensor circuit in accordance with one embodiment.
  • FIG. 10 is a Bode plot of an analyte sensor in accordance with one embodiment.
  • FIG. 11 is a flowchart describing a process for determining an impedance of a sensor in accordance with one embodiment.
  • FIG. 12 is a flowchart describing a process for determining an impedance of a sensor based on a derivative response in accordance with one embodiment.
  • FIG. 13 is a flowchart describing a process for determining an impedance of a sensor based on a peak current response in accordance with one embodiment.
  • FIG. 14A illustrates a step voltage applied to a sensor and FIG. 14B illustrates a response to the step voltage in accordance with one embodiment.
  • FIG. 15 is a flowchart describing a process for estimating analyte concentration values using a corrected signal based on an impedance measurement in accordance with one embodiment.
  • FIG. 16 is a flowchart describing a process for estimating analyte concentration values using a predetermined sensitivity profile selected based on an impedance measurement in accordance with one embodiment.
  • FIG. 17 is a flowchart describing a process for determining an error based whether a sensitivity determined using an impedance measurement sufficiently corresponds to a predetermined sensitivity in accordance with one embodiment.
  • FIG. 18 is a flowchart describing a process for determining a temperature associated with a sensor by correlating an impedance measurement to a predetermined temperature-to-impedance relationship in accordance with one embodiment.
  • FIG. 19 is a flowchart describing a process for determining moisture egress in sensor electronics associates with an analyte sensor accordance with one embodiment.
  • FIG. 20 is a flowchart describing a process for determining membrane damage associated with an analyte sensor in accordance with one embodiment.
  • FIG. 21 is a flowchart describing a first process for determining sensor reuse associated in accordance with one embodiment.
  • FIG. 22 is a flowchart describing a second process for determining sensor reuse associated in accordance with one embodiment.
  • FIG. 23 is a schematic of a dual-electrode configuration used to determine sensor properties in accordance with one embodiment.
  • FIG. 24 is a diagram of a calibration process that uses various inputs to form a conversion function in accordance with one embodiment.
  • FIGS. 25-49 collectively illustrate results of studies using stimulus signals to determine sensor properties.
  • FIG. 50 is a flowchart describing a process for generating estimated analyte values using a compensation algorithm based on a measured change in impedance in accordance with one embodiment.
  • FIGS. 51-53 are graphs of studies comparing use of compensation algorithms based on measured changes in impedance.
  • DETAILED DESCRIPTION Definitions
  • In order to facilitate an understanding of the embodiments described herein, a number of terms are defined below.
  • The term “analyte,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is are not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes may include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensor heads, devices, and methods disclosed herein is glucose. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobinopathies, A,S,C,E, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; analyte-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17 alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids may also constitute analytes in certain embodiments. The analyte may be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte may be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body may also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
  • The terms “continuous analyte sensor,” and “continuous glucose sensor,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a device that continuously or continually measures a concentration of an analyte/glucose and/or calibrates the device (e.g., by continuously or continually adjusting or determining the sensor's sensitivity and background), for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.
  • The term “biological sample,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to sample derived from the body or tissue of a host, such as, for example, blood, interstitial fluid, spinal fluid, saliva, urine, tears, sweat, or other like fluids.
  • The term “host,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to animals, including humans.
  • The term “membrane system,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a permeable or semi-permeable membrane that can be comprised of two or more domains and is typically constructed of materials of a few microns thickness or more, which may be permeable to oxygen and are optionally permeable to glucose. In one example, the membrane system comprises an immobilized glucose oxidase enzyme, which enables an electrochemical reaction to occur to measure a concentration of glucose.
  • The term “domain,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to regions of a membrane that can be layers, uniform or non-uniform gradients (for example, anisotropic), functional aspects of a material, or provided as portions of the membrane.
  • The term “sensing region,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the region of a monitoring device responsible for the detection of a particular analyte. In one embodiment, the sensing region generally comprises a non-conductive body, at least one electrode, a reference electrode and a optionally a counter electrode passing through and secured within the body forming an electroactive surface at one location on the body and an electronic connection at another location on the body, and a membrane system affixed to the body and covering the electroactive surface.
  • The term “electroactive surface,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the surface of an electrode where an electrochemical reaction takes place. In one embodiment, a working electrode measures hydrogen peroxide (H2O2) creating a measurable electronic current.
  • The term “baseline,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the component of an analyte sensor signal that is not related to the analyte concentration. In one example of a glucose sensor, the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide). In some embodiments wherein a calibration is defined by solving for the equation y=mx+b, the value of b represents the baseline of the signal. In certain embodiments, the value of b (i.e., the baseline) can be zero or about zero. This can be the result of a baseline-subtracting electrode or low bias potential settings, for example. As a result, for these embodiments, calibration can be defined by solving for the equation y=mx.
  • The term “inactive enzyme,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an enzyme (e.g., glucose oxidase, GOx) that has been rendered inactive (e.g., by denaturing of the enzyme) and has substantially no enzymatic activity. Enzymes can be inactivated using a variety of techniques known in the art, such as but not limited to heating, freeze-thaw, denaturing in organic solvent, acids or bases, cross-linking, genetically changing enzymatically critical amino acids, and the like. In some embodiments, a solution containing active enzyme can be applied to the sensor, and the applied enzyme subsequently inactivated by heating or treatment with an inactivating solvent.
  • The term “non-enzymatic,” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a lack of enzyme activity. In some embodiments, a “non-enzymatic” membrane portion contains no enzyme; while in other embodiments, the “non-enzymatic” membrane portion contains inactive enzyme. In some embodiments, an enzyme solution containing inactive enzyme or no enzyme is applied.
  • The term “substantially,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to being largely but not necessarily wholly that which is specified.
  • The term “about,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and when associated with any numerical values or ranges, refers without limitation to the understanding that the amount or condition the terms modify can vary some beyond the stated amount so long as the function of the disclosure is realized.
  • The term “ROM,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to read-only memory, which is a type of data storage device manufactured with fixed contents. ROM is broad enough to include EEPROM, for example, which is electrically erasable programmable read-only memory (ROM).
  • The term “RAM,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a data storage device for which the order of access to different locations does not affect the speed of access. RAM is broad enough to include SRAM, for example, which is static random access memory that retains data bits in its memory as long as power is being supplied.
  • The term “A/D Converter,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to hardware and/or software that converts analog electrical signals into corresponding digital signals.
  • The terms “raw data stream” and “data stream,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an analog or digital signal directly related to the analyte concentration measured by the analyte sensor. In one example, the raw data stream is digital data in counts converted by an A/D converter from an analog signal (for example, voltage or amps) representative of an analyte concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous analyte sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
  • The term “counts,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from a working electrode.
  • The term “sensor electronics,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the components (for example, hardware and/or software) of a device configured to process data. In the case of an analyte sensor, the data includes biological information obtained by a sensor regarding the concentration of the analyte in a biological fluid. U.S. Pat. Nos. 4,757,022, 5,497,772 and 4,787,398 describe suitable electronic circuits that can be utilized with devices of certain embodiments.
  • The term “potentiostat,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an electrical system that applies a potential between the working and reference electrodes of a two- or three-electrode cell at a preset value and measures the current flow through the working electrode. The potentiostat forces whatever current is necessary to flow between the working and counter electrodes to keep the desired potential, as long as the needed cell voltage and current do not exceed the compliance limits of the potentiostat.
  • The term “operably connected,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to one or more components being linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of glucose in a sample and convert that information into a signal; the signal can then be transmitted to an electronic circuit. In this case, the electrode is “operably linked” to the electronic circuit. These terms are broad enough to include wired and wireless connectivity.
  • The term “filtering,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to modification of a set of data to make it smoother and more continuous and remove or diminish outlying points, for example, by performing a moving average of the raw data stream.
  • The term “algorithm,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the computational processes (for example, programs) involved in transforming information from one state to another, for example using computer processing.
  • The term “calibration,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the process of determining the graduation of a sensor giving quantitative measurements (e.g., analyte concentration). As an example, calibration may be updated or recalibrated over time to account for changes associated with the sensor, such as changes in sensor sensitivity and sensor background. In addition, calibration of the sensor can involve, automatic, self-calibration, e.g., without using reference analyte values after point of use.
  • The terms “sensor data,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to data received from a continuous analyte sensor, including one or more time-spaced sensor data points.
  • The terms “reference analyte values” and “reference data,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to reference data from a reference analyte monitor, such as a blood glucose meter, or the like, including one or more reference data points. In some embodiments, the reference glucose values are obtained from a self-monitored blood glucose (SMBG) test (for example, from a finger or forearm blood test) or a YSI (Yellow Springs Instruments) test, for example.
  • The terms “interferents” and “interfering species,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In one example of an electrochemical sensor, interfering species are compounds with an oxidation potential that overlaps with the analyte to be measured, producing a false positive signal.
  • The term “sensor session,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the period of time the sensor is applied to (e.g. implanted in) the host or is being used to obtain sensor values. For example, in some embodiments, a sensor session extends from the time of sensor implantation (e.g. including insertion of the sensor into subcutaneous tissue and placing the sensor into fluid communication with a host's circulatory system) to the time when the sensor is removed.
  • The terms “sensitivity” or “sensor sensitivity,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to an amount of signal produced by a certain concentration of a measured analyte, or a measured species (e.g., H2O2) associated with the measured analyte (e.g., glucose). For example, in one embodiment, a sensor has a sensitivity of from about 1 to about 300 picoAmps of current for every 1 mg/dL of glucose analyte.
  • The term “sensitivity profile” or “sensitivity curve,” as used herein, are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to a representation of a change in sensitivity over time
  • Overview
  • Conventional in vivo continuous analyte sensing technology has typically relied on reference measurements performed during a sensor session for calibration of the continuous analyte sensor. The reference measurements are matched with substantially time corresponding sensor data to create matched data pairs. Regression is then performed on the matched data pairs (e.g., by using least squares regression) to generate a conversion function that defines a relationship between a sensor signal and an estimated glucose concentration.
  • In critical care settings, calibration of continuous analyte sensors is often performed by using, as reference, a calibration solution with a known concentration of the analyte. This calibration procedure can be cumbersome, as a calibration bag, separate from (and an addition to) an IV (intravenous) bag, is typically used. In the ambulatory setting, calibration of continuous analyte sensors has traditionally been performed by capillary blood glucose measurements (e.g., a finger stick glucose test), through which reference data is obtained and input into the continuous analyte sensor system. This calibration procedure typically involves frequent finger stick measurements, which can be inconvenient and painful.
  • Heretofore, systems and methods for in vitro calibration of a continuous analyte sensor by the manufacturer (e.g., factory calibration), without reliance on periodic recalibration, have for the most part been inadequate with respect to high levels of sensor accuracy. Part of this can be attributed to changes in sensor properties (e.g., sensor sensitivity) that can occur during sensor use. Thus, calibration of continuous analyte sensors has typically involved periodic inputs of reference data, whether they are associated with a calibration solution or with a finger stick measurement. This can be very burdensome to the patient in the ambulatory setting or the hospital staff in the critical care setting.
  • Described herein are continuous analyte sensors that are capable of continuous, automatic self-calibration during a sensor session and capable of achieving high levels of accuracy, without (or with reduced) reliance on reference data from a reference analyte monitor (e.g., from a blood glucose meter). In some embodiments, the continuous analyte sensor is an invasive, minimally invasive, or non-invasive device. The continuous analyte sensor can be a subcutaneous, transdermal, or intravascular device. In certain embodiments, one or more of these devices may form a continuous analyte sensor system. For instance, the continuous analyte sensor system may be comprised of a combination of a subcutaneous device and a transdermal device, a combination of a subcutaneous device and an intravascular device, a combination of a transdermal device and an intravascular device, or a combination of a subcutaneous device, a transdermal device, and an intravascular device. In some embodiments, the continuous analyte sensor can analyze a plurality of intermittent biological samples (e.g., blood samples). The continuous analyte sensor can use any glucose-measurement method, including methods involving enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, iontophoretic, and radiometric mechanisms, and the like.
  • In certain embodiments, the continuous analyte sensor includes one or more working electrodes and one or more reference electrode, which operate together to measure a signal associated with a concentration of the analyte in the host. The output signal from the working electrode is typically a raw data stream that is calibrated, processed, and used to generate an estimated analyte (e.g., glucose) concentration. In certain embodiments, the continuous analyte sensor may measure an additional signal associated with the baseline and/or sensitivity of the sensor, thereby enabling monitoring of baseline and/or additional monitoring of sensitivity changes or drift that may occur in a continuous analyte sensor over time.
  • In some embodiments, the sensor extends through a housing, which maintains the sensor on the skin and provides for electrical connection of the sensor to sensor electronics. In one embodiment, the sensor is formed from a wire. For example, the sensor can include an elongated conductive body, such as a bare elongated conductive core (e.g., a metal wire) or an elongated conductive core coated with one, two, three, four, five, or more layers of material, each of which may or may not be conductive. The elongated sensor may be long and thin, yet flexible and strong. For example, in some embodiments the smallest dimension of the elongated conductive body is less than about 0.1 inches, 0.075 inches, 0.05 inches, 0.025 inches, 0.01 inches, 0.004 inches, or 0.002 inches. Other embodiments of the elongated conductive body are disclosed in U.S. Patent Application Publication No. 2011/0027127, which is incorporated herein by reference in its entirety. Preferably, a membrane system is deposited over at least a portion of electroactive surfaces of the sensor 102 (including a working electrode and optionally a reference electrode) and provides protection of the exposed electrode surface from the biological environment, diffusion resistance (limitation) of the analyte if needed, a catalyst for enabling an enzymatic reaction, limitation or blocking of interferants, and/or hydrophilicity at the electrochemically reactive surfaces of the sensor interface. Disclosures regarding the different membrane systems that may be used with the embodiments described herein are described in U.S. Patent Publication No. US-2009-0247856-A1, which is incorporated herein by reference in its entirety.
  • Calibrating sensor data from continuous analyte sensors generally involves defining a relationship between sensor-generated measurements (e.g., in units of nA or digital counts after A/D conversion) and one or more reference measurement (e.g., in units of mg/dL or mmol/L). In certain embodiments, one or more reference measurements obtained shortly after the analyte sensor is manufactured, and before sensor use, are used for calibration. The reference measurement may be obtained in many forms. For example, in certain embodiments, the reference measurement may be determined from a ratio or correlation between the sensitivity of a sensor (e.g., from a certain sensor lot) with respect to in vivo analyte concentration measurements and the sensitivity of another sensor (e.g., from the same lot made in substantially the same way under substantially same conditions) with respect to in vitro analyte concentration measurements at a certain time period. By providing a continuous analyte sensor with a predetermined in vivo to in vitro ratio and a predetermined sensitivity profile (as described in more detail elsewhere herein), self-calibration of the sensor can be achieved in conjunction with high levels of sensor accuracy.
  • With self-calibration, the need for recalibration, by using reference data during a sensor session, may be eliminated, or else lessened, such that recalibration may be called for only in certain limited circumstances, such as when sensor failure is detected. Additionally or alternatively, in some embodiments, the continuous analyte sensor may be configured to request and accept one or more reference measurements (e.g., from a finger stick glucose measurement or a calibration solution) at the start of the sensor session. In some embodiments, use of a reference measurement at the start of the sensor session in conjunction with a predetermined sensor sensitivity profile can eliminate or substantially reduce the need for further reference measurements.
  • With certain implantable enzyme-based electrochemical glucose sensors, the sensing mechanism depends on certain phenomena that have a generally linear relationship with glucose concentration, for example: (1) diffusion of an analyte through a membrane system situated between an implantation site (e.g., subcutaneous space) and an electroactive surface, (2) rate of an enzyme-catalyzed reaction of the analyte to produce a measured species within the membrane system (e.g., the rate of a glucose oxidase-catalyzed reaction of glucose with O2 which produces gluconic acid and H2O2), and (3) diffusion of the measured species (e.g., H2O2) to the electroactive surface. Because of this generally linear relationship, calibration of the sensor is obtained by solving the equation:

  • y=mx+b
  • wherein y represents the sensor signal (counts), x represents the estimated glucose concentration (mg/dL), m represents the sensor sensitivity to analyte concentration (counts/mg/dL), and b represents the baseline signal (counts). As described elsewhere herein, in certain embodiments, the value b (i.e., the baseline) can be zero or about zero. As a result, for these embodiments, calibration can be defined by solving for the equation y=mx.
  • In some embodiments, the continuous analyte sensor system is configured to estimate changes or drift in sensitivity of the sensor for an entire sensor session as a function of time (e.g., elapsed time since start of the sensor session). As described elsewhere herein, this sensitivity function plotted against time may resemble a curve. Additionally or alternatively, the system can also be configured to determine sensor sensitivity changes or drift as a function of time and one or more other parameters that can also affect sensor sensitivity or provide additional information about sensor sensitivity. These parameters can affect sensor sensitivity or provide additional information about sensor sensitivity prior to the sensor session, such as parameters associated with the sensor fabrication (e.g., materials used to fabricate sensor membrane, the thickness of the sensor membrane, the temperature at which the sensor membrane was cured, the length of time the sensor was dipped in a particular coating solution, etc.). In certain embodiments, some of the parameters involve information, obtained prior to the sensor session, which can be accounted for in a calibration code that is associated with a particular sensor lot. Other parameters can be associated with conditions surrounding the sensor after its manufacture, but before the sensor session, such as, for example, the level of exposure of the sensor to certain levels of humidity or temperature while the sensor is in a package in transit from the manufacturing facility to the patient. Yet other parameters (e.g., sensor membrane permeability, temperature at the sample site, pH at the sample site, oxygen level at the sample site, etc.) can affect sensor sensitivity or provide additional information about sensor sensitivity during the sensor session.
  • Determination of sensor sensitivity at different times of a sensor session based on the predetermined sensor sensitivity profile can be performed prior to the sensor session or at the start of the sensor session. Additionally, in certain embodiments, determination of sensor sensitivity, based on the sensor sensitivity profile, can be continuously adjusted to account for parameters that affect sensor sensitivity or provide additional information about sensor sensitivity during the sensor session. These determinations of sensor sensitivity change or drift can be used to provide self-calibration, update calibration, supplement calibration based on measurements (e.g., from a reference analyte monitor), and/or validate or reject reference analyte measurements from a reference analyte monitor. In some embodiments, validation or rejection of reference analyte measurements can be based on whether the reference analyte measurements are within a range of values associated with the predetermined sensor sensitivity profile.
  • Some of the continuous analyte sensors described herein may be configured to measure a signal associated with a non-analyte constant in the host. Preferably, the non-analyte constant signal is measured beneath the membrane system on the sensor. In one example of a continuous glucose sensor, a non-glucose constant that can be measured is oxygen. In some embodiments, a change in oxygen transport, which can be indicative of a change or drift in the sensitivity of the glucose signal, can be measured by switching the bias potential of the working electrode, an auxiliary oxygen-measuring electrode, an oxygen sensor, or the like.
  • Additionally, some of the continuous analyte sensors described herein may be configured to measure changes in the amount of background noise in the signal. Detection of changes which exceed a certain threshold can provide the basis for triggering calibration, updating calibration, and/or validating or rejecting inaccurate reference analyte values from a reference analyte monitor. In one example of a continuous glucose sensor, the background noise is composed substantially of signal contribution from factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with hydrogen peroxide). Namely, the continuous glucose sensor is configured to measure a signal associated with the baseline (which includes substantially all non-glucose related current generated), as measured by the sensor in the host. In some embodiments, an auxiliary electrode located beneath a non-enzymatic portion of the membrane system is used to measure the baseline signal. The baseline signal can be subtracted from the glucose+baseline signal to obtain a signal associated entirely or substantially entirely with glucose concentration. Subtraction may be accomplished electronically in the sensor using a differential amplifier, digitally in the receiver, and/or otherwise in the hardware or software of the sensor or receiver as described in more detail elsewhere herein.
  • Together, by determining sensor sensitivity based on a sensitivity profile and by measuring a baseline signal, the continuous analyte sensor can be continuously self-calibrated during a sensor session without (or with reduced) reliance on reference measurements from a reference analyte monitor or calibration solution.
  • Determination of Sensor Sensitivity
  • As described elsewhere herein, in certain embodiments, self-calibration of the analyte sensor system can be performed by determining sensor sensitivity based on a sensitivity profile (and a measured or estimated baseline), so that the following equation can be solved:

  • y=mx+b
  • wherein y represents the sensor signal (counts), x represents the estimated glucose concentration (mg/dL), m represents the sensor sensitivity to the analyte (counts/mg/dL), and b represents the baseline signal (counts). From this equation, a conversion function can be formed, whereby a sensor signal is converted into an estimated glucose concentration.
  • It has been found that a sensor's sensitivity to analyte concentration during a sensor session will often change or drift as a function of time. FIG. 1A illustrates this phenomenon and provides a plot of sensor sensitivities 110 of a group of continuous glucose sensors as a function of time during a sensor session. FIG. 1B provides three plots of conversion functions at three different time periods of a sensor session. As shown in FIG. 1B, the three conversion functions have different slopes, each of which correspond to a different sensor sensitivity. Accordingly, the differences in slopes over time illustrate that changes or drift in sensor sensitivity occur over a sensor session.
  • Referring back to the study associated with FIG. 1A, the sensors were made in substantially the same way under substantially the same conditions. The sensor sensitivities associated with the y-axis of the plot are expressed as a percentage of a substantially steady state sensitivity that was reached about three days after start of the sensor session. In addition, these sensor sensitivities correspond to measurements obtained from YSI tests. As shown in the plot, the sensitivities (expressed as a percentage of a steady state sensitivity) of each sensor, as measured, are very close to sensitivities of other sensors in the group at any given time of the sensor session. While not wishing to be bound by theory, it is believed that the observed upward trend in sensitivity (over time), which is particularly pronounced in the early part of the sensor session, can be attributed to conditioning and hydration of sensing regions of the working electrode. It is also believed that the glucose concentration of the fluid surrounding the continuous glucose sensor during startup of the sensor can also affect the sensitivity drift.
  • With the sensors tested in this study, the change in sensor sensitivity (expressed as a percentage of a substantially steady state sensitivity), over a time defined by a sensor session, resembled a logarithmic growth curve. It should be understood that other continuous analyte sensors fabricated with different techniques, with different specifications (e.g., different membrane thickness or composition), or under different manufacturing conditions, may exhibit a different sensor sensitivity profile (e.g., one associated with a linear function). Nonetheless, with improved control over operating conditions of the sensor fabrication process, high levels of reproducibility have been achieved, such that sensitivity profiles exhibited by individual sensors of a sensor population (e.g., a sensor lot) are substantially similar and sometimes nearly identical.
  • It has been discovered that the change or drift in sensitivity over a sensor session is not only substantially consistent among sensors manufactured in substantially the same way under substantially same conditions, but also that modeling can be performed through mathematical functions that can accurately estimate this change or drift. As illustrated in FIG. 1A, an estimative algorithm function 120 can be used to define the relationship between time during the sensor session and sensor sensitivity. The estimative algorithm function may be generated by testing a sample set (comprising one or more sensors) from a sensor lot under in vivo and/or in vitro conditions. Alternatively, the estimative algorithm function may be generated by testing each sensor under in vivo and/or in vitro conditions.
  • In some embodiments, a sensor may undergo an in vitro sensor sensitivity drift test, in which the sensor is exposed to changing conditions (e.g., step changes of glucose concentrations in a solution), and an in vitro sensitivity profile of the sensor is generated over a certain time period. The time period of the test may substantially match an entire sensor session of a corresponding in vivo sensor, or it may encompass a portion of the sensor session (e.g., the first day, the first two days, or the first three days of the sensor session, etc.). It is contemplated that the above-described test may be performed on each individual sensor, or alternatively on one or more sample sensors of a sensor lot. From this test, an in vitro sensitivity profile may be created, from which an in vivo sensitivity profile may be modeled and/or formed.
  • From the in vivo or in vitro testing, one or more data sets, each comprising data points associating sensitivity with time, may be generated and plotted. A sensitivity profile or curve can then be fitted to the data points. If the curve fit is determined to be satisfactory (e.g., if the standard deviation of the generated data points is less a certain threshold), then the sensor sensitivity profile or curve may be judged to have passed a quality control and suitable for release. From there, the sensor sensitivity profile can be transformed into an estimative algorithm function or alternatively into a look-up table. The algorithm function or look-up table can be stored in a computer-readable memory, for example, and accessed by a computer processor.
  • The estimative algorithm function may be formed by applying curve fitting techniques that regressively fit a curve to data points by adjusting the function (e.g., by adjusting constants of the function) until an optimal fit to the available data points is obtained. Simply put, a “curve” (i.e., a function sometimes referred to as a “model”) is fitted and generated that relates one data value to one or more other data values and selecting parameters of the curve such that the curve estimates the relationship between the data values. By way of example, selection of the parameters of the curve may involve selection of coefficients of a polynomial function. In some embodiments, the curve fitting process may involve evaluating how closely the curve determined in the curve fitting process estimates the relationship between the data values, to determine the optimal fit. The term “curve,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers to a function or a graph of a function, which can involve a rounded curve or a straight curve, i.e., a line.
  • The curve may be formed by any of a variety of curve fitting techniques, such as, for example, the linear least squares fitting method, the non-linear least squares fitting method, the Nelder-Mead Simplex method, the Levenberg-Marquardt method, and variations thereof. In addition, the curve may be fitted using any of a variety of functions, including, but not limited to, a linear function (including a constant function), logarithmic function, quadratic function, cubic function, square root function, power function, polynomial function, rational function, exponential function, sinusoidal function, and variations and combinations thereof. For example, in some embodiments, the estimative algorithm comprises a linear function component which is accorded a first weight w1, a logarithmic function component which is accorded a second weight w2, and an exponential function component which is accorded a third weight w3. In further embodiments, the weights associated with each component can vary as a function of time and/or other parameters, but in alternative embodiment, one or more of these weights are constant as a function of time.
  • In certain embodiments, the estimative algorithm function's correlation (e.g., R2 value), which is a measure of the quality of the fit of the curve to the data points, with respect to data obtained from the sample sensors, may be one metric used to determine whether a function is optimal. In certain embodiments, the estimative algorithm function formed from the curve fitting analysis may be adjusted to account for other parameters, e.g., other parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity. For example, the estimative algorithm function may be adjusted to account for the sensitivity of the sensor to hydrogen peroxide or other chemical species.
  • Estimative algorithms formed and used to accurately estimate an individual sensor's sensitivity, at any time during a sensor session, can be based on factory calibration and/or based on a single early reference measurement (e.g., using a single point blood glucose monitor). In some embodiments, sensors across a population of continuous analyte sensors manufactured in substantially the same way under substantially same conditions exhibit a substantially fixed in vivo to in vitro sensitivity relationship. For example, in one embodiment, the in vivo sensitivity of a sensor at a certain time after start of sensor use (e.g., at t=about 5, 10, 15, 30, 60, 120, or 180 minutes after sensor use) is consistently equal to a measured in vitro sensitivity of the sensor or of an equivalent sensor. From this relationship, an initial value of in vivo sensitivity can be generated, from which an algorithmic function corresponding to the sensor sensitivity profile can be formed. Put another way, from this initial value (which represents one point in the sensor sensitivity profile), the rest of the entire sensor sensitivity profile can be determined and plotted. The initial value of in vivo sensitivity can be associated with any portion of the sensor sensitivity profile. In certain embodiments, multiple initial values of in vivo sensitivities, which are time-spaced apart, and which correspond to multiple in vitro sensitivities, can be calculated and combined together to generate the sensor sensitivity profile.
  • In some embodiments, as illustrated in FIG. 2A, the initial value 210 of in vivo sensitivity is associated with a time corresponding to the start (near the start) of the sensor session. As illustrated in FIG. 2B, based on this initial value 210, the rest of the sensor sensitivity profile 220 is plotted (i.e., plotted forward and backward across the x-axis corresponding to time). However, as illustrated in FIG. 2C, in some embodiments, the initial value 210′ may be associated with any other time of the sensor session. For example, as illustrated in FIG. 2C, in one embodiment, the in initial value 210′ of in vivo sensitivity is associated with a time (e.g., at about day 3) when the sensitivity has substantially reached steady state. From the initial value 210′, the rest of the sensor sensitivity profile 220′ is plotted, as illustrated in FIG. 2D.
  • With other embodiments, although the in vivo to in vitro sensitivity relationship was not equal, the relationship nonetheless involved a consistently fixed ratio. By having a substantially fixed in vivo to in vitro sensitivity relationship, some of the sensors described herein can be factory calibrated by evaluating the in vitro sensitivity characteristic (e.g., one or more sensitivity values measured at certain time periods) of a sensor from a particular sensor lot at a manufacturing facility, defining the in vivo sensitivity characteristic of other sensors in the same sensor lot based on its relationship with the measured in vitro sensitivity characteristic, and storing this calculated in vivo sensitivity characteristic onto electronics associated with the sensors (e.g., in computer memory of a sensor electronics, discussed more elsewhere herein, configured to be operably coupled to the sensor during sensor use).
  • Accordingly, with information obtained prior to the sensor session relating to an in vivo to in vitro sensor sensitivity relationship and a predetermined sensor sensitivity profile, factory calibration is achieved in conjunction with high levels of sensor accuracy. For example, in some embodiments, the sensor was capable of achieving an accuracy corresponding to a mean absolute relative difference of no more than about 10% over a sensor session of at least about 3 days, and sometimes at least about 4, 5, 6, 7, or 10 days. In some embodiments, the sensor was capable of achieving an accuracy, over a over a sensor session of at least about 3 days, corresponding to a mean absolute relative difference of no more than about 7%, 5%, or 3%. With factory calibration, the need for recalibration may be eliminated, or else required only in certain circumstances, such as in response to detection of sensor failure.
  • With reference back to the study associated with FIG. 1A, the sensors were built with a working electrode configured to measure a glucose+baseline signal and a corresponding auxiliary electrode configured to measure only the baseline signal. Sensor electronics in the sensor system subtracted the baseline signal from the glucose+baseline signal to obtain a signal associated entirely or substantially entirely to glucose concentration. In addition, an algorithmic function was generated and stored in sensor electronics associated with the sensors to estimate the sensitivity of these sensors during their lives. This algorithmic function is plotted in FIG. 1A and shown closely overlying the measured sensor sensitivities of the sensors. With the determination of baseline and sensitivity at any given time during the life of a sensor, a conversion function is formed, whereby a sensor signal is converted into an estimated glucose concentration.
  • As illustrated in FIG. 3A, which is a Bland-Altman plot showing differences between YSI reference measurements and certain in vivo continuous analyte sensors that were factory calibrated, the measurements from these sensors exhibited very high accuracy. The lines in FIG. 3A represent accuracy standards corresponding to a deviation from actual measured values (using YSI tests) of less than ±10 mg/dL at glucose concentrations between about 40 and 75 mg/dL, and less than ±15% at glucose concentrations between about 75 mg/dL and 400 mg/dL. Indeed, the difference between estimated glucose concentration values, which are calculated using a predetermined sensor sensitivity profile, and actual measured values (using YSI tests) over a sensor life, differed by no more than about 10 mg/dL at glucose concentrations between about 40 and 75 mg/dL, and no more than 15% at glucose concentrations between about 75 mg/dL and 400 mg/dL. Furthermore, at glucose concentrations between about 40 mg/dL and 75 mg/dL, about 97% of the estimated glucose concentrations values were within ±5 mg/dL of corresponding YSI measured values, and at glucose concentrations between about 70 mg/dL and 400 mg/dL, about 99% of the estimated glucose concentrations were within ±10% of corresponding YSI measured values.
  • FIG. 3B illustrates a Clarke error grid associated with the factory calibration study associated with FIG. 3A. The Clarke error grid of FIG. 3B is a Clarke error grid is based on a correlation plot of the performance of the above-described factory calibration method with respect to a reference method in the form of YSI measurements. If the correlation was perfect, all points would fall on a 45° line. The area surrounding this line is divided into zones that predict the clinical consequences in terms of action taken by the patient, depending on where the measurements by the factory calibration method fall off the line. Zone A corresponds to a clinically accurate decision (e.g., take insulin, take glucose, or do nothing), zone B a clinically acceptable decision, and zone D corresponds to a clinically erroneous decision. As shown in FIG. 3B, all of data points from the factory calibration study fell within either zone A or zone B. In fact, almost all of the data points fell within Zone A, thus establishing that the above-described factory calibration study provided very accurate glucose concentration measurements.
  • While individual sensors of a sensor group manufactured under substantially identical conditions have been found to generally exhibit a substantially similar or a nearly identical sensor sensitivity profile and have a substantially similar or a nearly identical in vivo to in vitro sensor sensitivity relationship, it has been found that at times the actual sensor sensitivity (i.e., sensitivity expressed as an actual sensitivity value, and not as a percentage of a substantially steady state sensitivity) can vary between sensors. For example, even though individual sensors may have been manufactured under substantially identical conditions, they can have different sensitivity characteristics during use if they are exposed to different environment conditions (e.g., exposure to radiation, extreme temperature, abnormal dehydration conditions, or any environment that can damage the enzyme in the sensor membrane or other parts of the sensor, etc.) during the time period between sensor fabrication and sensor use.
  • Accordingly, to compensate for potential effects resulting from these conditions, in certain embodiments, the continuous analyte sensors are configured to request and accept one or more reference measurements (e.g., from a finger stick glucose measurement or from a calibration solution) at the start of the sensor session. For example, the request for one or more reference measurements can be made at about 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, etc., after activation of the sensor. In some embodiments, sensor electronics are configured to process and use the reference data to generate (or adjust) a sensor sensitivity profile in response to the input of one or more reference measurements into the sensor. For example, if a reference measurement of glucose concentration is taken and input into the sensor at time=x, an algorithmic function of sensor sensitivity can be generated by matching the sensor sensitivity profile at time=x with the reference measurement. Use of the one of the one or more reference measurements at the start of the sensor in conjunction with a predetermined sensor sensitivity profile permits self-calibration of the sensor without or with a reduced need for further reference measurements.
  • FIG. 4 illustrates a Bland-Altman plot showing differences between YSI reference measurements and in vivo continuous analyte sensors that accepted one reference measurement about one hour after insertion into patients. The lines in FIG. 4 represent accuracy standards corresponding to a deviation from actual measured values (using YSI tests) of less than about ±20 mg/dL at glucose concentrations between about 40 mg/dL and 75 mg/dL, and less than about ±20% at glucose concentrations between about 75 mg/dL and 400 mg/dL. From this reference measurement, an initial value of in vivo sensor sensitivity was generated, which in turned allow for the formation of an algorithmic function corresponding to the sensitivity profile for the rest of the sensor session. The sensors were built with a working electrode and an auxiliary electrode used to measure a baseline signal, which was subtracted from the glucose+baseline signal obtained by the working electrode. As shown, about 85% of the estimated glucose concentrations were within the range 410, defined as ±20 mg/dL from corresponding YSI measured values for glucose concentrations between about 40 mg/dL and 75 mg/dL and ±20% from corresponding YSI measured values for glucose concentrations between about 75 mg/dL and 400 mg/dL. Additionally, at glucose concentrations between about 40 mg/dL and 75 mg/dL, about 95% of the estimated glucose concentrations values were within ±20 mg/dL of corresponding YSI measured values. The sensors in this study obtained an overall accuracy level corresponding to a Mean Absolute Relative Difference of about 12% over a sensor session of at least seven days, and a first-day accuracy level corresponding to a Mean Absolute Relative Difference of about 11%. The Median Absolute Relative Difference obtained were about 10% for both overall and fist-day accuracy levels.
  • FIG. 5 is a diagram illustrating different types of information that can be input into the sensor system to define the sensor sensitivity profile over time, in one embodiment. Input information can include information obtained prior to the sensor session 510 and information obtained during the sensor session 520. In the embodiment depicted in FIG. 5, both information obtained prior to the sensor session 510 and information obtained during the sensor session 520 are used to generate, adjust, or update a function 530 associated with the sensor sensitivity profile, but in another embodiment, the sensor system may be configured to use only information obtained prior to the sensor session. In certain embodiments, formation of an initial sensor sensitivity profile can occur prior to the sensor session, at the start of the sensor session, or shortly after the start of the sensor session. Additionally, in certain embodiments, the sensor sensitivity profile can be continuously adjusted, regenerated, or updated to account for parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity during the sensor session. Information obtained prior to the sensor session can include, for example, the sensor sensitivity profile that is generated before or at the start of the sensor session, as previously described. It can also include a sensitivity value associated with a substantially fixed in vivo to in vitro sensor sensitivity relationship, as previously described.
  • Alternatively, instead of a fixed sensitivity value, the in vivo to in vitro sensor sensitivity relationship may be defined as a function of time between completion of sensor fabrication (or the time calibration check was performed on sensors from the same lot) and the start of the sensor session. As shown in FIG. 6, it has been discovered that a sensor's sensitivity to analyte concentration can change as a function of time between completion of sensor fabrication and the start of the sensor session. FIG. 6 illustrates this phenomenon through a plot, which resembles a downward trend in sensitivity over time between completion of sensor fabrication and the start of the sensor session. Similar to the discovered change or drift in sensitivity over time of a sensor session, this change or drift in sensitivity over time between completion of sensor fabrication and the start of the sensor session is generally consistent among sensors that have not only been manufactured in substantially the same way under substantially same conditions, but that also have avoided exposure to certain conditions (e.g., exposure to radiation, extreme temperature, abnormal dehydration conditions, or any environment that can damage the enzyme in the sensor membrane or other parts of the sensor, etc.) Accordingly, the change or drift in sensitivity over time between completion of sensor fabrication and the start of the sensor session can also be modeled through a mathematical function 620 that accurately estimates this change or drift. The estimative algorithm function 620 may be any of a variety of functions, such as, for example, a linear function (including a constant function), logarithmic function, quadratic function, cubic function, square root function, power function, polynomial function, rational function, exponential function, sinusoidal function, and combinations thereof.
  • Information obtained prior to the sensor session can also include information relating to certain sensor characteristics or properties. By way of example and not to be limiting, information obtained prior to the sensor session may include the particular materials used to fabricate the sensor (e.g., materials used to form the sensor membrane), the thickness of the sensor membrane, the membrane's permeability to glucose or other chemical species, the in vivo or in vitro sensor sensitivity profile of another sensor made in substantially the same way under substantially same conditions, etc. In certain embodiments, information obtained prior to the sensor session can include information relating to the process conditions under which the sensor is fabricated. This information can include, for example, the temperature at which the sensor membrane was cured, the length of time the sensor was dipped in a particular coating solution, etc. In other embodiments, information obtained prior to the sensor session can relate to patient physiological information. For example, the patient's age, body mass index, gender, and/or historic patient sensitivity profiles, can be used as parameters to form the sensor sensitivity profile. Other information obtained prior to the sensor session that may also be used includes information relating to sensor insertion, such as, for example, location (e.g., abdomen vs. back) or depth of sensor insertion.
  • In general, the sensor sensitivity functions can be created by theoretical or empirical methods, or both, and stored as functions or as look-up-tables, thereby allowing for sensor self-calibration that eliminates (or substantially reduces) the need for reference measurements. The sensor sensitivity functions can be generated at the manufacturing facility and shipped with the system or generated by the system shortly prior to (or during) use. The term “self-calibration,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to calibration of a sensor or device which is performed by a control system manufacturer or installer, the sensor manufacturer, or anyone other than the user of the sensor. The sensor calibration can be performed on the individual sensor on which the control system is installed, or it can be performed on a reference sensor, for example one from the same sensor lot, and the calibration functions can be transferred from one control system to another. In some embodiments, systems may be shipped with some self-calibration functions and then have others added by the sensor user. Also, sensor systems may be shipped with self-calibration functions and only need adjustments or touch-up calibrations during use.
  • In certain embodiments, the sensor sensitivity profile may be adjusted during sensor use to account for, in real-time, certain parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity. These parameters may include, but are not limited to, parameters associated with sensor properties, such as, for example, sensor membrane permeability or the level of sensor hydration, or parameters associated with patient physiological information, such as, for example, patient temperature (e.g., temperature at the sample site or skin temperature), pH at the sample site, hematocrit level, or oxygen level at the sample site. In some embodiments, the continuous analyte sensor may be fitted with a thermistor on an ex vivo portion of the sensor and a thermal conductive line that extends from the thermistor to the sample site.
  • In some embodiments, calibration methods can be improved by algorithmically quantifying each unique sensor/user environment. Quantification can be achieved by generation or adjustment of the sensitivity profile, which may involve an inference engine involving a causal probabilistic network such as a Bayesian network. A Bayesian network includes a conditional probability-based network that relies on the Bayes theorem to characterize the likelihood of different outcomes based on known prior probabilities (e.g., prevalence of observed in vivo sensitivities under certain parameter conditions) and newly acquired information (e.g., occurrence or nonoccurrence of the aforementioned conditions).
  • In certain embodiments, quantification is achieved through the application of an analytical Bayesian framework to data already existing within the system algorithm. Quantification can involve: (1) wedge (e.g., maximum or minimum) values for parameters related to sensitivity and baseline; (2) sensitivity values calculated during a sensor session; and (3) baselines calculated during the sensor session. In some embodiments, the first set of wedge values are based on parameter distributions of “prior” data (e.g., data collected from previous clinical studies). By using a Bayesian network, a system can learn from data collected during the sensor session, and adapt the wedge values (or other algorithm parameters and/or constraints) to a particular sensor/user environment. In turn, the system's calibration method can be improved to have better accuracy, reliability, and overall performance.
  • In one embodiment, the Bayesian framework used involves using known prior information to establish a framework and then accounting for gathered new information to make inferences from their combination (i.e., combination of prior and new information), to generate posterior information. When the prior information and the new information are mathematically related and combined to form posterior information that can be represented functionally, the relationship is defined as conjugate. The Bayesian framework of one embodiment employs conjugate distributional relationships that result in the posterior distributional parameters (e.g., mean, variance) being directly available. This can be advantageous under a computationally restrictive space where both time and resources are constrained.
  • In some embodiments, under the Bayesian framework, in which the wedge parameters follow a prior substantially normal distribution for each parameter, and in which the algorithmically calculated sensitivity and baseline values follow their own substantially normal distribution representing the new information, an independent posterior distribution for sensitivity and/or baseline can be generated. These two posterior distributions are then used in parallel to construct glucose threshold values used for accepting, rejecting, or modifying a user's manual calibration entry (e.g., entry from a fingerstick measurement). In certain embodiments, the posterior distributions of sensitivity and baseline can also be used for semi-self-calibration, thereby reducing the number of fingerstick measurements required for manual calibration.
  • In one exemplary embodiment, from prior information, the wedge min/max values for a sensor's sensitivity to glucose are known to be A and B at the 95% confidence interval in a substantially normal distribution. Using algorithmically calculated sensitivity values as new information, the previous three, four, five, six, seven, or more sensitivity values calculated through manual calibration can be used as new information to generate a posterior distribution, which will typically have reduced variability than the distribution based on prior information, and which is a direct quantification of a unique sensor/user environment. Because of reduced variability, the posterior distribution generated will typically have wedge values, which should be closer together than the difference between A and B, i.e., the wedge values of the distribution generated from prior information. This tightening of the difference between the wedge values between the prior distribution and the posterior distribution allow the system to more reliably reject manual calibration entries that are clearly erroneous, such as, for example, a calibration entry of 60 mg/dL that was intended by the user to be an entry of 160 mg/dL
  • Bayesian networks use causal knowledge and model probabilistic dependence and independence relationships between different events. FIG. 7A depicts distribution curves of sensor sensitivity corresponding to the Bayesian learning process, in accordance with one embodiment. FIG. 7B depicts confidence levels, associated with the sensor sensitivity profile, that correspond with the distribution curves shown in FIG. 7A. Distribution curve 720 and confidence level 730 (e.g., 25%, 33%, 50%, 75%, 95%, or 99% confidence level) are associated with a lack of initial knowledge about certain parameters that affect sensor sensitivity or provide additional information about sensor sensitivity. For example, distribution curve 720 can be associated with factory information. As information regarding a certain parameter is acquired, the distribution curve 720′ becomes steeper and the confidence interval 730′ becomes narrower, as certainty of sensor sensitivity profile 710 is increased. Examples of information that may be used to change the distribution curves can include a reference analyte value, a cal-check of the sensor at the factory, patient history information, and any other information described elsewhere herein that can affect sensor sensitivity or provide information about sensor sensitivity. As information regarding still another parameter is acquired, the distribution curve 720″ becomes even steeper and the confidence interval 730″ becomes even narrower, as certainty of sensor sensitivity profile 710 is further increased.
  • During sensor use, the confidence interval curves 730, 730′, and/or 730″ may be used to form the sensitivity profile 710, which provides an estimated sensitivity value at a given time. In turn the estimated sensitivity value may be used to calibrate the sensor, which allows for processing of sensor data to generate a glucose concentration value that is displayed to the user. In some embodiments, a first estimated sensitivity profile 710, formed from the confidence interval curves 730, 730′, and/or 730″, may be used to monitor and display glucose concentrations. In addition, one or more of the confidence interval curves 730, 730′, 730″, or combinations thereof, can be used to form a second estimated sensitivity profile that, while possibly not as accurate as the first estimated sensitivity profile, is nonetheless more likely to result in the detection of a hypoglycemic or hyperglycemic range than the first estimated sensitivity profile 710.
  • Determination of Baseline
  • A variety of types of noise can occur when a sensor is implanted in a host. Some implantable sensors measure a signal (e.g., counts) that comprises two components, the baseline signal and the analyte signal. The baseline signal is substantially comprised of a signal contribution from factors other than the measure analyte (e.g., interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation potential that overlaps with the analyte or co-analyte). The analyte signal (e.g., glucose signal) is substantially comprised of a signal contribution from the analyte. Consequently, because the signal includes these two components, calibration can be performed to determine the analyte (e.g., glucose) concentration by solving for the equation y=mx+b, wherein the value of b represents the baseline of the signal. In some circumstances, the baseline is comprised of constant and non-constant non-analyte factors. Generally, it is desirable to reduce or remove the background signal, to provide a more accurate analyte concentration to the patient or health care professional.
  • In certain embodiments, an analyte sensor (e.g., glucose sensor) is configured for insertion into a host for measuring an analyte in the host. The sensor includes a working electrode disposed beneath an active enzymatic portion of a membrane on the sensor, an auxiliary electrode disposed beneath an inactive- or non-enzymatic portion of the membrane on the sensor, and sensor electronics operably connected to the working and auxiliary electrodes. The sensor electronics are configured to process signals from the electrodes to generate an analyte (e.g., glucose) concentration estimate that substantially excludes signal contribution from non-glucose related noise artifacts.
  • In some embodiments, the working electrode is configured to generate via sensor electronics a first signal associated with both the analyte and non-analyte related electroactive compounds that have a oxidation potential less than or similar to a first oxidation potential. The auxiliary electrode is configured to generate a second signal associated with the non-analyte related electroactive compounds. Non-analyte related electroactive compounds can be any compound, present in the sensor's local environment, which has an oxidation potential less than or similar to the oxidation potential of the measured species (e.g., H2O2). While not wishing to be bound by theory, it is believed that with a glucose-measuring electrode, both the signal directly related to the enzyme-catalyzed reaction of glucose (which produces H2O2 that is oxidized at the first working electrode) and signals from unknown compounds that are in the extracellular milieu surrounding the sensor can be measured. These unknown compounds can be constant or non-constant (e.g., intermittent or transient) in concentration and/or effect. In some circumstances, it is believed that some of these unknown compounds can be related to the host's disease state. For example, it is known that blood chemistry can change dramatically during/after a heart attack (e.g., pH changes, changes in the concentration of various blood components/protein, and the like). As another example, the transcutaneous insertion of a needle-type sensor can initiate a cascade of events that includes the release of various reactive molecules by macrophages. Other compounds that can contribute to the non-glucose related signal are compounds associated with the wound healing process, which can be initiated by implantation/insertion of the sensor into the host, as described in more detail with reference to U.S. Patent Publication No. US-2007-0027370-A1.
  • As described above, the auxiliary electrode is configured to generate a second signal associated with the non-analyte related electroactive compounds that have an oxidation potential less than or similar to the first oxidation potential. Non-analyte related electroactive species can include interfering species, non-reaction-related species (e.g., H2O2) that correspond to the measured species, and other electroactive species. Interfering species includes any compound that is not directly related to the electrochemical signal generated by the enzyme-catalyzed reaction of the analyte, such as, electroactive species in the local environment produced by other bodily processes (e.g., cellular metabolism, wound healing, a disease process, and the like). Non-reaction-related species includes any compound from sources other than the enzyme-catalyzed reaction, such as, H2O2 released by nearby cells during the course of the cells' metabolism, H2O2 produced by other enzymatic reactions (e.g., extracellular enzymes around the sensor or such as can be released during the death of nearby cells or such as can be released by activated macrophages), and the like. Other electroactive species includes any compound that has an oxidation potential less than or similar to the oxidation potential of H2O2.
  • The non-analyte signal produced by compounds other than the analyte (e.g., glucose) is considered as background noise and can obscure the signal related to the analyte, thereby contributing to sensor inaccuracy. As described in greater detail elsewhere herein, background noise can include both constant and non-constant components and can be removed to accurately calculate the analyte concentration.
  • In certain embodiments, the analyte sensor system is configured in a way (e.g., with a certain symmetry, coaxial design, and/or integral formation) such that the working and auxiliary electrodes are influenced by substantially the same external/environmental factors, thereby enabling substantially equivalent measurement of both the constant and non-constant species/noise. This allows for the substantial elimination of noise on the sensor signal by using sensor electronics described elsewhere herein. In turn, the substantial reduction or elimination of signal effects associated with noise, including non-constant noise (e.g., transient, unpredictable biologically related noise) increases accuracy of continuous sensor signals.
  • In some embodiments, sensor electronics are operably connected to the working and auxiliary electrodes. The sensor electronics may be configured to measure the current (or voltage) to generate the first and second signals. Collectively, the first and second signals can be used to produce glucose concentration data without substantial signal contribution from non-glucose-related noise. This can be performed, for example, by subtraction of the second signal from the first signal to produce a signal associated with analyte concentration and without substantial noise contribution, or by alternative data analysis techniques.
  • In other embodiments, the sensor electronics are operably connected to one or more working electrodes only, as an auxiliary electrode is not needed. For example, the sensor membrane in some embodiments may comprise polymers that contain mediators and enzymes that chemically attach to the polymers. The mediator used may oxidize at lower potentials than hydrogen peroxide, and thus fewer oxidizable interferents are oxidized at these low potentials. Accordingly, in some embodiments, a very low baseline (i.e., a baseline that approaches a zero baseline and that does not receive substantial signal contribution from non-glucose-related noise) may be achieved, thereby potentially eliminating (or reducing) the need for an auxiliary electrode that measures signal contribution from non-glucose-related noise.
  • The sensor electronics can be comprised of a potentiostat, A/D converter, RAM, ROM, transceiver, processor, and/or the like. The potentiostat may be used to provide a bias to the electrodes and to convert the raw data (e.g., raw counts) collected from the sensor to an analyte concentration value (e.g., a glucose concentration value expressed in units of mg/dL). The transmitter may be used to transmit the first and second signals to a receiver, where additional data analysis and/or calibration of analyte concentration can be processed. In certain embodiments, the sensor electronics may perform additional operations, such as, for example, data filtering and noise analysis.
  • In certain embodiments, the sensor electronics may be configured to analyze an analyte equivalent baseline or normalized baseline, instead of the baseline. The normalized baseline is calculated as the b/m or y-intercept divided by slope (from the equation y=mx+b). The unit for analyte equivalent baseline may be expressed as the analyte concentration unit (mg/dL), which correlates with the output of the continuous analyte sensor. By using the analyte equivalent baseline (normalized baseline), the influence of glucose sensitivity on the baseline may be eliminated, thereby making it possible to evaluate the baselines of different sensors (e.g., from the same sensor lot or from different sensor lots) with different glucose sensitivities.
  • Although some embodiments have been described herein which employ an auxiliary electrode to allow for the subtraction of a baseline signal from a glucose+baseline signal, it should be understood that the use of this electrode is optional and may not be used in other embodiments. For example, in certain embodiments, the membrane system covering the working electrode is capable of substantially blocking interferents, and substantially reducing the baseline to a level that is negligible, such that the baseline can be estimated. Estimation of the baseline can be based on an assumption of the sensor's baseline at physiological conditions associated with a typical patient. For example, baseline estimation can be modeled after in vivo or in vitro measurements of baseline in accordance with certain physiological levels of interferents that are inherent in the body. FIG. 8 is a graph that provides a comparison between an estimated glucose equivalent baseline and detected glucose equivalent baseline, in accordance with one study. The estimated glucose equivalent baseline was formed by conducting in vitro measurements of the baseline of glucose sensors in a solution that mimicked physiological levels of interferents in a human. The interferents included uric acid with a concentration of about 4 mg/dL and ascorbic acid, with a concentration of about 1 mg/dL of ascorbic acid. As shown in FIG. 8, it was found in this study that the estimated baseline closely resembled the detected baseline. Accordingly, with the possibility of accurate estimation of baseline and/or with a baseline that is negligible, a single working electrode alone (i.e., without use of an ancillary electrode), together with a predetermined sensor sensitivity profile, may be sufficient to provide a sensor system with self-calibration.
  • With some embodiments, it has been found that not only does the sensor's sensitivity tend to drift over time, but that the sensor's baseline also drifts over time. Accordingly, in certain embodiments, the concepts behind the methods and systems used to predict sensitivity drift can also be applied to create a model that predicts baseline drift over time. Although not wishing to be bound by theory, it is believed that the total signal received by the sensor electrode is comprised of a glucose signal component, an interference signal component, and a electrode-related baseline signal component that is a function of the electrode and that is substantially independent of the environment (e.g., extracellular matrix) surrounding the electrode. As noted above, the term “baseline,” as used herein, refers without limitation to the component of an analyte sensor signal that is not related to the analyte concentration. Accordingly, the baseline, as the term is defined herein, is comprised of the interference signal component and the electrode-related baseline signal component. While not wishing to be bound by theory, it is believed that increased membrane permeability typically not only results in an increased rate of glucose diffusion across the sensor membrane, but also to an increased rate of diffusion of interferents across the sensor membrane. Accordingly, changes in sensor membrane permeability over time which causes sensor sensitivity drift, will similarly also likely cause the interference signal component of the baseline to drift. Simply put, the interference signal component of the baseline is not static, and is typically changing as a function of time, which, in turn, causes the baseline to also drift over time. By analyzing how each of the aforementioned components of the baseline reacts to changing conditions and to time (e.g., as a function of time, temperature), a predictive model can be developed to predict how the baseline of a sensor will drift during a sensor session. By being able to prospectively predict both sensitivity and baseline of the sensor, it is believed that a self-calibrating continuous analyte sensor can be achieved, i.e., a sensor that does not require use of reference measurements (e.g., a fingerstick measurement) for calibration.
  • Calibration Code
  • The process of manufacturing continuous analyte sensors may sometimes be subjected to a degree of variability between sensor lots. To compensate for this variability, one or more calibration codes may be assigned to each sensor or sensor set to define parameters that can affect sensor sensitivity or provide additional information about the sensitivity profile. The calibration codes can reduce variability in the different sensors, ensuring that the results obtained from using sensors from different sensors lots will be generally equal and consistent by applying an algorithm that adjusts for the differences. In one embodiment, the analyte sensor system may be configured such that one or more calibration codes are to be manually entered into the system by a user. In other embodiments, the calibration codes may be part of a calibration encoded label that is adhered to (or inserted into) a package of multiple sensors. The calibration encoded label itself may be read or interrogated by any of a variety of techniques, including, but not limited to, optical techniques, RFID (Radio-frequency identification), or the like, and combinations thereof. These techniques for transferring the code to the sensor system may be more automatic, accurate, and convenient for the patient, and less prone to error, as compared to manual entry. Manual entry, for instance, possesses the inherent risk of an error caused by a patient or hospital staff entering the wrong code, which can lead to an incorrect calibration, and thus inaccurate glucose concentration readings. In turn, this may result in a patient or hospital staff taking an inappropriate action (e.g., injecting insulin while in a hypoglycemic state).
  • In some embodiments, calibration codes assigned to a sensor may include a first calibration code associated with a predetermined logarithmic function corresponding to a sensitivity profile, a second calibration code associated with an initial in vivo sensitivity value, and other calibration codes, with each code defining parameter that affects sensor sensitivity or provides information about sensor sensitivity. The other calibration codes may be associated with any priori information or parameter described elsewhere herein and/or any parameter that helps define a mathematical relationship between the measured signal and analyte concentration.
  • In some embodiments, the package used to store and transport a continuous analyte sensor (or sensor set) may include detectors configured to measure certain parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity or other sensor characteristics. For example, in one embodiment, the sensor package may include a temperature detector configured to provide calibration information relating to whether the sensor has been exposed to a temperature state greater than (and or less than) one or more predetermined temperature values. In some embodiments, the one or more predetermined temperature value may be greater than about 75° F., greater than about 80° F., greater than about 85° F., greater than about 90° F., greater than about 95° F., greater than about 100° F., greater than about 105° F., and/or greater than about 110° F. Additionally or alternatively, the one or more predetermined temperature value may be less than about 75° F., less than about 70° F., less than about 60° F., less than about 55° F., less than about 40° F., less than about 32° F., less than about 10° F., and/or less than about 0° F. In certain embodiments, the sensor package may include a humidity exposure indicator configured to provide calibration information relating to whether the sensor has been exposed to humidity levels greater than or less than one or more predetermined humidity values. In some embodiments, the one or more predetermined humidity value may be greater than about 60% relative humidity, greater than about 70% relative humidity, greater than about 80% relative humidity, and/or greater than about 90% relative humidity. Alternatively or additionally, the one or more predetermined humidity value may be less than about 30% relative humidity, less than about 20% relative humidity, and/or less than about 10% relative humidity.
  • Upon detection of exposure of the sensor to certain levels of temperature and/or humidity, a corresponding calibration code may be changed to account for possible effects of this exposure on sensor sensitivity or other sensor characteristics. This calibration code change may be automatically performed by a control system associated with the sensor package. Alternatively, in other embodiments, an indicator (e.g., a color indicator) that is adapted to undergo a change (e.g., a change in color) upon exposure to certain environments may be used. By way of example and not to be limiting, the sensor package may include an indicator that irreversibly changes color from a blue color to a red color, upon exposure of the package to a temperature greater than about 85° F., and also include instructions to the user to enter a certain calibration code when the indicator has a red color. Although exposure to temperature and humidity are described herein as examples of conditions that may be detected by the sensor package, and used to activate a change in calibration code information, it should be understood that other conditions may also be detected and used to activate a change in calibration code information.
  • In certain embodiments, the continuous analyte system may comprise a library of stored sensor sensitivity functions or calibration functions associated with one or more calibration codes. Each sensitivity function or calibration function results in calibrating the system for a different set of conditions. Different conditions during sensor use may be associated with temperature, body mass index, and any of a variety of conditions or parameters that may affect sensor sensitivity or provide additional information about sensor sensitivity. The library can also include sensitivity profiles or calibrations for different types of sensors or different sensor lots. For example, a single sensitivity profile library can include sub-libraries of sensitivity profiles for different sensors made from different sensor lots and/or made with different design configurations (e.g., different design configurations customized for patients with different body mass index).
  • Determining Sensor Properties and Calibrating Sensor Data Using One or More Stimulus Signals
  • Some embodiments apply one or more stimulus signals to a sensor to determine properties of a sensor and/or calibrate sensor data. The term “stimulus signal,” as used herein, is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a signal (e.g., any time-varying or spatial-varying quantity, such as an electric voltage, current or field strength) applied to a system being used (e.g., an analyte sensor) to cause or elicit a response.
  • Non-limiting examples of stimulus signals that can be used in the embodiments described herein can be a waveform including one or more of: a step increase in voltage of a first magnitude, a step decrease in voltage of a second magnitude (where the first and second magnitudes can be the same or different), an increase in voltage over time at first rate, a gradual decrease in voltage over time having a second rate (where the first rate and the second rate can be different or the same), one or more sine waves overlayed on the input signal having the same or different frequencies and/or amplitudes and the like. A response to the stimulus signal can then be measured and analyzed (the response is also referred to herein as the “signal response”). The analysis can include one or more of calculating impedance values, capacitance values, and correlating the signal response to one or more predetermined relationships. As used herein, the term “impendence value” can mean a value for expressing an electrical impedance, including but not limited to, a value that only represents a magnitude of impedance or a value that express both magnitude and phase of impendence, should impendence be represented in a polar form, or expresses a real impendence only or both a real and complex impendence, should impedance be represented in a Cartesian form. Based on the calculated impedance values, capacitance values and/or predetermined relationships, various sensor properties can be determined and/or characterized, such as one or more of the sensor properties discussed herein.
  • The sensor information can then be used to determine if the analyte sensor is functioning properly or not, and/or to calibrate the sensor. For example, the techniques described herein can be used to generate calibration information (e.g., one or more of baseline, sensor sensitivity, and temperature information) that can in turn be used to form or modify a conversion function, or calibration factor, used to convert sensor data (e.g., in units of electrical current) into blood glucose data (e.g., glucose concentration values in units of mg/dL or mmol/L), as described in more detail elsewhere herein. The sensor information can alternatively or additionally be used to first correct uncalibrated sensor data (e.g., raw sensor data) and then apply a conversion function to convert the corrected, uncalibrated data to calibrated sensor data (e.g., glucose concentration values in units of glucose concentration).
  • For example, one technique that can be used to determine properties of a system being used (e.g., an analyte sensor) is Electrochemical Impedance Spectroscopy (EIS). EIS is an electrochemical technique based on the measurement of electrical impedance of the system being used over a range of different frequencies. Changes in the system being used can reflect changes in the frequency spectrum. As an example, a reduction in impedance may be observed at a particular frequency over a time period if the system being used has a sensitivity change over that period of time. Other techniques can also be used to determine properties of a system being used as discussed further below.
  • As one illustrative example of how a stimulus signal can be used to determine sensor properties, reference will now be made to a schematic diagram of an equivalent sensor circuit model 900 illustrated in FIG. 9. Sensor circuit model 900 can represent electrical properties of an analyte sensor, such as an embodiment of a continuous glucose sensor. Circuit 900 includes working electrode 904 and reference electrode 902. Operatively connected in serial to reference electrode is Rsolution, representative of a resistance of bulk between the working and reference electrodes. The bulk can be a liquid or other medium in which the sensor is placed, such as a buffer solution in the example of a bench laboratory study, or, in the example of the use as a subcutaneously placed sensor, the bulk can be representative of the resistance of the subcutaneous tissue between the working and reference electrodes. Operatively connected to Rsolution is Cmembrane, representative of a capacitance of the sensor membrane, and Rmembrane, representative of a resistance of the sensor membrane. A parallel network of Cdouble layer and Rpolarization are operatively connected to Rmembrane. The parallel network of Cdouble layer and Rpolarization is representative of the reactions occurring at the surface of a platinum interface of the working electrode. In particular, Cdouble layer is representative of the charge that is built up when a platinum electrode is in the bulk and Rpolarization is the polarization resistance of the electrochemical reactions that occur at the platinum interface.
  • FIG. 10 is a Bode plot (i.e. |Zreal| vs. log ω, wherein Zreal is real impedance, ω=2πf and f is frequency) of an analyte sensor in accordance with one embodiment. The analyte sensor can have properties of sensor circuit model 900 of FIG. 9. Referring back to the Bode plot of FIG. 10, the x-axis is the frequency of a stimulus signal applied to the analyte sensor and the y-axis is the impedance derived from a response signal of the analyte sensor. Although not wishing to be bound by theory, it is believed that different frequencies can be used to measure or determine different material properties of the sensor. For example, in the plot of FIG. 10, the impedance value derived from the measured response to an input signal having a frequency of about 7 Hz can be indicative of Cdouble layer, a frequency of about 1 kHz can be indicative of Rmembrane, and a frequency in the range of about 10-20 kHz can indicative of Cmembrane.
  • Based on this information, one can determine a state of particular properties of the sensor by applying a stimulus signal of a particular frequency or comprising a plurality of frequencies to the sensor and determining a sensor impedance based on the signal response. For instance, a capacitance of a sensor having the characteristics of the Bode plot of FIG. 10 can be determined using a stimulus signal having a frequency in the range of about 1 Hz to 100 Hz, for example 10 Hz or greater than 10 kHz. In addition, a resistance of a sensor can be determined using a stimulus signal having a frequency in the range of about 100 Hz to 10 kHz, for example 1 kHz.
  • FIG. 11 is a flowchart illustrating a process 1100 for determining an impedance of a sensor in accordance with one embodiment. At step 1102, a stimulus signal in the form of an active current (ac) voltage at a given frequency is applied to a working electrode of the sensor being studied. The ac voltage can be overlayed on a bias potential and can be relatively small as compared to the bias potential, such as a voltage that is in the range of about 1% to 10% of the bias voltage. In one embodiment, the ac voltage is a sine wave having an amplitude in the range of 10-50 mV and a frequency in the range of between about 100-1 kHz. The sine wave can be overlayed on a 600 mV bias voltage. The response signal (e.g., in units of current) can then be measured in step 1104 and analyzed in step 1106 to determine an impedance at the given frequency. Should the impedance of the sensor at a range of frequencies be of interest, process 1100 can be repeated by applying an ac voltage at each frequency of interest and analyzing a corresponding output response.
  • Reference will now be made to FIG. 12, which describes a process for determining an impedance or plurality of impedances of a sensor being studied by applying one or more stimulus signals and converting the response signal or signals to a frequency domain in accordance with one embodiment. The data can be converted to the frequency domain using a Fourier transform technique, such as a fast Fourier transform (FFT), discrete time Fourier transform (DTFT) or the like. At step 1202, a stimulus signal in the form of a voltage step can be applied to a bias voltage of the sensor. The voltage step can be in the range of 10-50 mV, for example 10 mV, and the bias voltage can be 600 mV. The signal response can then be measured and recorded (e.g., an output current) at step 1204, and a derivative of the response can be taken at step 1206. At step 1208, a Fourier transform of the derivative of the response can then be calculated to yield ac currents in the frequency domain. One or more impedances of the sensor over a wide spectrum of frequencies can then be calculated based on the ac currents at step 1210.
  • FIG. 13 is a flowchart of process 1300 for determining an impedance of a sensor being studied, such as the impedance of the sensor's membrane, in accordance with one embodiment. At step 1302, a stimulus signal in the form of a voltage step above a bias voltage is applied to the sensor. The signal response is measured at step 1304, and, at step 1306, a peak current of the response is determined. Next, at step 1308, one or more impedance characteristics (e.g., resistance) of the sensor membrane (e.g., Rmembrane) is calculated based on the peak current. The one or more impedance characteristics can then be correlated to a property of the sensor.
  • In an alternative embodiment, instead of calculating a sensor impedance based on the peak current, the peak current can be correlated to one or more predetermined sensor relationships to determine a property of the sensor, such as the sensor's sensitivity. That is, in the alternative embodiment, the step of calculating the one or more impendence characteristics is omitted.
  • The relationship between a signal response resulting from a stimulus signal in the form of a voltage step and a sensor membrane resistance of embodiments of analyte sensors will now be discussed further with reference to FIGS. 14A, 14B and FIG. 9.
  • FIG. 14A is a graph of an input voltage 1400 applied to an analyte sensor over time in accordance with one embodiment. The input voltage 1400 applied to the analyte sensor initially corresponds to the bias voltage, which in one embodiment is about 600 mV. A stimulus signal in the form of a voltage step is then applied to the input voltage at time t1. The magnitude of the voltage step, Δv, can be in the range of 10-50 mV, for example 10 mV.
  • FIG. 14B is a graph of a current response 1402 of the analyte sensor to the input voltage 1400 of FIG. 14A. As illustrated in FIG. 14B, the current response 1402 can include a sharp spike in current starting at time t2, which corresponds to the time in which the voltage step begins to impact the response. The current response 1402 includes a peak current at point 1404 and then the current response 1402 gradually decreases and levels off to a slightly higher level due to the increase in input voltage 1400 as compared to before the voltage step.
  • In one embodiment, a change in current, Δi, measured as the difference between the magnitude of the current response 1402 prior to the voltage step and the peak current 1404 resulting from the voltage step, can then be used to estimate the sensor membrane resistance, such as Rmembrane in FIG. 9. In one embodiment, an estimated sensor membrane resistance can be calculated in accordance with Ohms Law, where

  • Rmembrane=Δv/Δi
  • As discussed above, Δv is the step voltage increase and Δi is the change in current response due to the step voltage increase.
  • Although not wishing to be bound by theory, it is believed that certain embodiments of sensors provide a direct relationship between a change in current in response to a voltage step to the sensor's membrane impendence characteristics (e.g., resistance).
  • As a non-limiting example of such a relationship, the following description refers back to sensor circuit model 900 of FIG. 9. In some embodiments, the capacitance, Cmembrane, is much smaller than the capacitance, Cdouble layer. For example, Cmembrane can have a value that is about 1/1000 smaller than Cdouble layer. The bulk resistance, Rsolution, of sensor circuit 900 is typically much smaller than the resistance Rmembrane, and the resistance, Rpolarization, can be quite large, such as around 3 MOhms. Due to such sensor properties, a voltage step, Δv, applied to circuit 900 can cause the current to flow substantially through circuit 900 along a path from lead 902, through Rsolution, Rmembrane, Cdouble layer and finally to lead 904. Specifically, because capacitive resistance is inversely proportional to the capacitance and the frequency, the capacitive resistance of Cmembrane is initially very large due to the voltage step, as the voltage step is, theoretically, an extremely high frequency. Substantially all of the current flows through Rmembrane, rather than through Cmembrane because of the high capacitive resistance of Cmembrane. Further, the current substantially flows through Cdouble layer instead of Rpolarization because the capacitive resistance of Cdouble is initially small due to the voltage step (high capacitive value of Cdouble layer results in low capacitive resistance at high frequencies, e.g., at the time of a voltage step) and the relatively large resistance of Rpolarization. Consequently, the initial total resistance through which substantially all of the current flows through circuit 900 when the step voltage is applied to circuit 900 can be summed up as the series resistance of Rsolution plus Rmembrane. However, because Rsolution is much smaller than Rmembrane in this example, the total resistance can be estimated as the membrane resistance, Rmembrane.
  • Thus, because the membrane resistance, Rmembrane, is essentially the resistance of the circuit 900 at the time of the voltage step, it has been found that the value of Rmembrane can be estimated using Ohms Law using the known value of the step increase, Δv, and the measured change in current response, Δi, due to the voltage step.
  • a. Sensitivity
  • As discussed herein, a sensor's sensitivity to analyte concentration during a sensor session can often change as a function of time. This change in sensitivity can manifest itself as an increase in current for a particular level of sensitivity. In some embodiments, the sensitivity increases during the first 24-48 hours with a relative change in tens of percents. In order to provide an accurate analyte concentration reading to a user, system calibrations using reference meters (e.g., strip-based blood glucose measurements) may be needed. Typically, the rate of calibrations can be 1, 2 or more calibrations a day.
  • As discussed further below, a relationship between sensitivity and impedance has been observed in embodiments of analyte sensors. Although not wishing to be bound by theory, embodiments of analyte sensors are believed to have a relationship between an impedance of a sensor's membrane and the diffusivity of the membrane. For example, a change in impedance of an analyte sensor can indicate a proportional change in diffusivity of the analyte sensor's membrane. Further, an increase in diffusivity can yield an increased transport of the analyte being measured (e.g., glucose) through the membrane, resulting in an increased sensor output current. That is, a change in diffusivity can result in a proportional change in sensor sensitivity. It is noted that other factors may also contribute to changes in sensitivity apart from just changes in diffusivity of the sensor membrane, depending upon the characteristics of sensor and the environment in which the sensor is used.
  • A relationship between sensitivity and impedance can be used to estimate a sensor sensitivity value and/or correct for sensitivity changes of the sensor over time, resulting in increased accuracy, a reduction in required calibrations or both. In addition to detection of sensitivity, some embodiments can detect other characteristics of an analyte sensor system based on measurements of electrical impedance over one or more frequencies. These characteristics include, but are not limited to, temperature, moisture ingress into sensor electronics components and sensor membrane damage.
  • In some exemplary embodiments, a relationship between a sensor's impedance and the sensor's sensitivity can be used to calculate and compensate for sensitivity changes of an analyte sensor. For example, a change in impedance of an analyte sensor can correspond to a proportional change in sensitivity of the sensor. In addition, an absolute value of an impedance of an analyte sensor can correspond to an absolute value of the analyte sensor's sensitivity and the corresponding sensitivity value can be determined based on a predetermined relationship determined from prior studies of similar sensors. Sensor data can then be compensated for changes in sensitivity based on an impedance-to-sensitivity relationship.
  • FIG. 15 is a flowchart of an exemplary process 1500 for compensating sensor data for changes in sensitivity in accordance with one embodiment. At step 1502, a stimulus signal can be applied to the sensor that can be used to determine an impedance of the sensor's membrane, such as a signal having a given frequency, as discussed with respect to FIG. 11, or a voltage step, as discussed with respect to FIGS. 12-14. A response to the applied signal is then measured at step 1504 and an impedance of the sensor's membrane is determined based on the response at step 1506. Next, at step 1508, the determined impedance is compared to an established impedance-to-sensor sensitivity relationship. The established relationship can be determined from prior studies of analyte sensors that exhibit similar sensitivity-to-impedance relationships as the analyte sensor currently being used; for example, sensors that were made in substantially the same way under substantially the same conditions as the sensor currently being used. At step 1510, a sensor signal (e.g., in units of electrical current or counts) of the sensor currently being used is corrected using the impedance to sensitivity relationship. An estimated analyte concentration value or values is then calculated based on the corrected sensor signal at step 1512 using, for example, a conversion function. The estimated analyte concentration values can then be used for further processing and/or outputting, such as triggering alerts, displaying information representative of the estimated values on a user device and/or outputting the information to an external device.
  • It should be understood that process 1500 is but one example of using an impedance of a sensor to compensate for changes in sensor sensitivity, and that various modifications can be made to process 1500 that fall within the scope of the embodiments For example, an established impedance-to-sensitivity relationship can be used to determine a sensitivity value of the sensor being used, and the sensitivity value can then be used to modify or form a conversion function used to convert a sensor signal of the sensor being used into one or more estimated glucose concentration values. In addition, instead of calculating an impedance based on the stimulus signal response, one or more properties of the stimulus signal response (e.g., peak current value, counts, etc.) can be directly correlated to a sensitivity based on a predetermined relationship between the stimulus signal property and the sensitivity.
  • Some embodiments use one or more impedance values of the sensor to form, modify or select a sensitivity profile of an analyte sensor. As discussed above, a sensor can have a sensitivity profile that indicates the sensor's change in sensitivity over time. Although sensors made in substantially the same way under substantially the same conditions can exhibit similar sensitivity profiles, the profiles can still vary. For example, the environment in which a particular sensor is used can cause the sensor's sensitivity profile to differ from other, similar sensors. Accordingly, some embodiments can, for example, select a sensitivity profile out of a plurality of predetermined sensitivity profiles based on a correlation of the calculated one or more impedance values to the selected sensitivity profile. Further, some embodiments modify a sensor sensitivity profile already associated with the analyte sensor being used to more closely predict the sensor's sensitivity profile, where the modification is based on the one or more impedance values.
  • FIG. 16 is a flowchart of an exemplary process 1600 for determining a predicted sensitivity profile using one or more sensor membrane impedance measurements in accordance with one embodiment. At step 1602, a stimulus signal is applied to an analyte sensor being used and a response is measured at step 1604. Next, one or more sensor membrane impedance values are calculated based on the response at step 1606. Various techniques for calculating sensor membrane impedance values based on the response that can be used in process 1600 are described elsewhere herein, such as one or more of the techniques discussed with reference to FIGS. 11-14. A sensitivity profile is then determined based on the one or more calculated impedance values in step 1608. Process 1600 then calculates (which can include retrospectively correcting and/or prospectively calculating) estimated analyte concentration values using the determined sensitivity profile. The estimated analyte concentration values can then be used for further processing and outputting, such as displaying information representative of the estimated values on a user device and/or outputting the information to an external computing device.
  • Further to step 1608, various techniques can be used to determine the sensitivity profile. One exemplary technique can compare the one or more calculated impedance values to a plurality of different predicted sensitivity profiles and select a predicted sensitivity profile that best fits the one or more calculated impedance values. The plurality of different predicted sensitivity profiles can be predetermined and stored in computer memory of sensor electronics, for example. Another technique that can be used includes using an estimative algorithm to predict or determine a sensitivity profile based on the one or more calculated impedance values. A further technique includes determining a sensitivity profile by modifying a sensitivity profile associated with the sensor being used (e.g., a sensor profile previously used to generate estimated glucose values using the sensor). Modifying the sensitivity profile can include using an estimative algorithm to modify the sensitivity profile to more closely track the sensitivity profile of the sensor being used based on the one or more calculated impedance values.
  • Some embodiments compare one or more impedance values of an analyte sensor being used to a predetermined or predicted sensitivity profile associated with the sensor to determine if the sensor is functioning properly. As discussed above, a sensor can be predicted to have a particular sensitivity profile based on, for example, a study of sensitivity changes over time of sensors made in substantially the same way and used under substantially the same conditions. However, it can be determined that a sensor is functioning improperly—due to, for example, improper sensor insertion, damage to the sensor during shipping, manufacturing defects and the like-if the sensor is found not to be sufficiently tracking its predicted sensitivity profile based on sensitivities derived from impedance measurements of the sensor. Put another way, it can be determined that a sensor is not functioning properly if one or more impedance values of a sensor's membrane do not sufficiently correspond to a predicted sensitivity profile (e.g., because the impedance of a sensor membrane can indicate a sensitivity of the sensor) of the sensor.
  • FIG. 17 is a flowchart of an exemplary process 1700 for determining whether an analyte sensor being used is functioning properly based on a predicted sensitivity profile and one or more impedance measurements. At step 1702, a stimulus signal is applied to an analyte sensor being used and a response is measured at step 1704. Next, one or more sensor membrane impedance values are calculated based on the signal response at step 1706. Various stimulus signals and techniques for calculating sensor membrane impedance values based on the signal response that can be used in process 1700 are described elsewhere herein, such as with any one of the techniques discussed with reference to FIGS. 11-14. Process 1700 then determines a correspondence of the one or more calculated impedance values to a sensitivity profile in step 1708. Next, in decision step 1710, process 1700 queries whether the one or more calculated impedance values sufficiently correspond to the predicted sensitivity profile. If it is determined that the one or more calculated impedance values sufficiently correspond to the predicted sensitivity profile, then process 1700 confirms proper operation of the analyte sensor being used. If confirmed to be proper in step 1710, process 1700 may then be repeated after a predetermined time delay ranging from about 1 minute to 1 day, for example about 10 minutes, 1 hour, 12 hours, or 1 day. However, process 1700 initiates an error routine 1712 if it is determined that the one or more calculated impedance values do not sufficiently correspond to the predicted sensitivity profile. Error routine 1712 can include one or more of triggering and audible alarm, displaying an error message on a user display, discontinuing display of sensor data on a user display, sending a message to a remote communication device over a communication network, such as a mobile phone over a cellular network or remote computer over the internet, and the like. The error routine can also include modifying the predicted sensitivity profile—based on the one or more impedance measurements, for example—or selecting a new predicted sensitivity profile based on the one or more impedance measurements. The modified predicted sensitivity profile or new predicted sensitivity profile can be a sensitivity profile that more closely corresponds to changes in sensitivity of the sensor being used based on the one or more impedance measurements as compared to the unmodified or previously used predicted sensitivity profile.
  • Further to step 1708 of process 1700, various statistical analysis techniques can be used to determine a correspondence of the one or more impedance values to the predicted sensitivity profile. As one example, correspondence can be determined based on whether a sensitivity value derived from the calculated impedance value (e.g., derived from a predetermined relationship of impedance and sensitivity) differs by no less than a predetermined threshold amount from a predicted sensitivity value as determined from the predicted sensitivity profile. The predetermined threshold amount can be in terms of an absolute value or a percentage. As another example, correspondence can be determined based on a data association function. The term “data association function,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a statistical analysis of data and particularly its correlation to, or deviation from, from a particular curve. A data association function can be used to show data association. For example, sensor sensitivity data derived from impedance measurements described herein may be analyzed mathematically to determine its correlation to, or deviation from, a curve (e.g., line or set of lines) that defines a sensor sensitivity profile; this correlation or deviation is the data association. Examples of a data association function that can be used includes, but is not limited to, linear regression, non-linear mapping/regression, rank (e.g., non-parametric) correlation, least mean square fit, mean absolute deviation (MAD), and mean absolute relative difference. In one such example, the correlation coefficient of linear regression is indicative of the amount of data association of sensitivity data derived from impedance measurements from a sensitivity profile, and thus the quality of the data and/or sensitivity profile. Of course, other statistical analysis methods that determine a correlation of one or more points to a curve can be used in process 1700 in addition to those described herein.
  • As discussed above, processes 1600 and 1700 can use one or more impedance values. When more than one impedance value is used, each impedance value can be time-spaced from the other impedance value(s). In other words, one impedance value can be taken at a first point in time t1 (indicative of a sensor impedance at time t1), a second impedance value can be taken at a second, later point in time t2 (indicative of a sensor impedance at time t2), and third impedance value taken at a third, even later point in time t3 (indicative of a sensor impedance at time t3), and so on. Further, the time between t1 and t2 can be a first amount of time and the time between t2 and t3 can be a second amount of time that is either the same or different than the first amount of time. The time-spaced impedance values can then be used separately or combined using a statistical algorithm (e.g., calculating an average or median value of the time-spaced values). The separate values or combined value can then be used to determine a sensitivity value and/or sensitivity profile in step 1608 of process 1600 or determine a correspondence with a sensitivity profile in step 1708 of process 1700, for example. Additionally or alternatively, more than one of the impedance values can be taken at substantially the same time, but each derived using a different measurement technique, such as using two of the measurement techniques described herein. For example, a first impedance can be calculated using a step voltage technique as described in the process of FIG. 13, and a second impedance can be calculated using a sine wave overlay technique as described in the process of FIG. 11. The impedance values derived from different measurement techniques can then be applied to a statistical algorithm (e.g., calculating an average or median value) to determine a processed impedance value. The processed impedance value can then be used to determine a sensitivity value and/or sensitivity profile in step 1608 of process 1600 or determine a correspondence with a sensitivity profile in step 1708 of process 1700, for example.
  • b. Temperature
  • Some embodiments can use signal processing techniques to determine a temperature of the sensor. For example, a stimulus signal can be applied to a sensor and a signal response measured and, based on the signal response, a temperature of the sensor can be derived.
  • An impedance of a sensor membrane, as determined using one of the techniques described with reference to FIGS. 11-14, for example, can be used to estimate a temperature of the sensor in accordance with one embodiment. Although not wishing to be bound by theory, it is believed that sensitivity of a sensor is affected by temperature, where a higher temperature can result in a higher sensitivity and a lower temperature can result in a lower sensitivity. Similarly, because an impedance of a sensor membrane can have a direct relationship to the sensor's sensitivity, it is believed that a higher temperature can result in lower impedance and a lower temperature can result in higher impedance. That is, sensitivity and impedance can have a direct relationship to the sensor's temperature. Accordingly, using a known relationship between impedance and temperature—based on previously conducted studies of substantially similar sensors, for example—one can estimate a sensor's temperature based on a sensor impedance measurement.
  • FIG. 18 is a flowchart of an exemplary process 1800 for determining a sensor temperature in accordance with one embodiment. At step 1802, a stimulus signal is applied to an analyte sensor being used, and a response is measured and recorded at step 1804. Impedance is calculated based on the signal response at step 1806. The impedance can be calculated using, for example, any of the techniques described herein such as those described with reference to FIGS. 11-14. A temperature of the sensor is then estimated based on a predetermined relationship between impedance and temperature at step 1808. The temperature can then be used to estimate analyte concentration values (e.g., glucose concentration) using sensor data or otherwise used for further processing and/or outputting. For example, the temperature can be used to compensate for temperature effects on sensor sensitivity, more accurate analyte concentration values can be estimated based on the sensitivity compensation, and the more accurate analyte concentrations can be outputted to a display or used to trigger an alert using a glucose monitoring system.
  • A relationship between sensor sensitivity and different temperatures can be mathematically modeled (e.g., by fitting a mathematical curve to data using one of the modeling techniques described herein), and the mathematical model can then be used to compensate for temperature effects on the sensor sensitivity. That is, a sensitivity of a sensor (which is affected by the sensor's temperature) can be determined based on associating a measured impedance of the sensor to the mathematical curve. The predetermined relationship between impedance and temperature can be determined by studying impedances of similar sensors over a range of temperatures. Sensor data can then be converted to estimated analyte concentration values based on the determined sensor sensitivity.
  • As a non-limiting example, some embodiments of analyte sensors can have an essentially linear relationship of impedance to temperature after a sensor run-in period (e.g., a period of time after sensor implantation in which the sensor stabilizes, which can last one to five hours in some embodiments). The slope of the linear relationship can be established by studying sensors made in substantially the same way as the sensor being used over a range of temperatures. Thus, a sensor temperature can be estimated by measuring an impedance value of the sensor's membrane and applying the impedance value to the established linear relationship. Other embodiments can have a non-linear relationship of impedance to temperature and with these other embodiments the relationship can be characterized using an established non-linear relationship.
  • Some embodiments can compare a first sensor temperature, where the first temperature is derived from an impedance measurement of an analyte sensor, with a second sensor temperature, where the second sensor temperature is derived independent from the impedance measurement. The second estimated temperature can be measured using a thermistor, for example. In the example of using a thermistor, the thermistor can be configured to measure an in vivo or ex vivo temperature, and can be located on the analyte sensor or separate from the analyte sensor. As non-limiting examples, the thermistor can be integral with the analyte sensor, positioned on the surface of the skin of a host adjacent to an insertion site in which the analyte sensor is implanted, positioned on the skin of the host at a location away from the insertion site or spaced apart from the host entirely, such as on a handheld device carried by the host. Factors contributing to a change in sensor sensitivity or a change in other sensor properties can then be determined or confirmed based, at least in part, on the comparison of the first and second temperatures.
  • c. Moisture Ingress
  • In some embodiments, moisture ingress into sensor electronics can be determined based on measuring an impedance of the sensor at a particular frequency or range of frequencies. Should the measured impedance not correspond sufficiently with predetermined impedance value(s), then a sensor system operatively connected to the sensor can initiate a moisture ingress error routine. Correspondence can be determined using one or more threshold, a data association function, and the like. Further, it should be noted that it has been found that impedance phase information can provide beneficial information in determining moisture egress. Accordingly, in some embodiments, the impedance measurement can be broken into separate impendence magnitude and phase components, and one or both impendence components can be compared to predetermined values to determine the correspondence.
  • FIG. 19 is a flowchart of an exemplary process 1900 for determining moisture ingress. At step 1902, a stimulus signal having a particular frequency or a signal comprising a spectrum of frequencies (e.g., a voltage step) is applied to an analyte sensor being used, and a signal response is measured and recorded at step 1904. Impedance magnitude and phase is calculated based on the signal response at step 1906. Process 1900 then determines whether the impedance magnitude and phase values fall within respective predefined levels at decision step 1908. If the impedance magnitude and phase values exceed one or both of the respective predefined levels, then process 1900 initiates an error routine at step 1910. The error routine can include one or more of triggering an audible alarm and/or visual alarm on a display screen to alert a user that the sensor system may not be functioning properly. The alarm can notify a user that the current sensor system is defective, for example. If, on the other hand, one or both of the impedance and phase values fall within the respective predefined levels, then process 1900 ends.
  • Although the above description describes calculating separate impedance and phase values, it is understood that the above process 1900 can determine a complex impedance value and determine a correspondence of the determined complex impedance value to one or more predetermined complex impedance value(s), such as by using a data association function or comparing the determined complex impedance to a threshold or range of predetermined complex impendence values. The error routine can then be initiated responsive to the correspondence.
  • d. Membrane Damage
  • In some embodiments, membrane damage can be detected based on measuring an impedance at a particular frequency or range of frequencies. Should the measured impedance not correspond sufficiently with predetermined one or more impedance values, then a sensor system operatively connected to the sensor can initiate a membrane damage error routine. Correspondence can be determined using a data association function.
  • FIG. 20 is a flowchart of an exemplary process 2000 for determining membrane damage. At step 2002, a stimulus signal having a particular frequency, multiple signals having different frequencies and/or a signal comprising a spectrum of frequencies is applied to an analyte sensor being used, and the signal response(s) is/are measured and recorded at step 2004. Both impedance magnitude and phase is calculated based on the signal response(s) at step 2006. Process 2000 then determines whether the impedance magnitude and phase value(s) fall within respective predefined levels at decision step 2008. If the impedance magnitude and phase values exceed one or both of the respective predefined levels, then process 2000 initiates an error routine at step 2010. The error routine can include one or more of triggering an audible alarm and/or visual alarm on a display screen to alert a user that the sensor system is not functioning properly. The alarm can notify a user that the currently used sensor is damaged and needs to be replaced, for example. If, on the other hand, one or both of the impedance magnitude and phase values fall within the respective predefined levels, then process 2000 ends.
  • Although the above description describes using separate impedance magnitude and phase values, it is understood that the above process 2000 can use a complex impedance value and determine a correspondence of the complex impedance value to a predetermined values or levels. The error routine can be initiated responsive to the determined correspondence.
  • e. Sensor Reuse
  • In some embodiments, sensor reuse can be detected. Embodiments of glucose sensors described herein may have a defined life in which a sensor can provide reliable sensor data. After the defined life, the sensor may no longer be reliable, providing inaccurate sensor data. To prevent use beyond the predefined life, some embodiments notify a user to change the sensor after it has been determined that the sensor should no longer be used. Various methods can be used to determine whether a sensor should no longer be used, such as a predetermined amount of time transpiring since the sensor was first used (e.g., when first implanted into a user or when first electrically connected to a sensor electronics module) or a determination that the sensor is defective (e.g., due to membrane rupture, unstable sensitivity and the like). Once it is determined that the sensor should no longer be used, the sensor system can notify a user that a new sensor should be used by audibly and/or visually prompting a user to use a new sensor and/or shutting down a display or ceasing to display sensor data on the display, for example. However, a user may try to reuse the same sensor instead of using a new sensor. This can be dangerous to the user because the sensor may provide inaccurate data upon which the user may rely.
  • Accordingly, some embodiments can be configured determine sensor reuse based at least in part on one or more measurements of the impedance of the sensor. As discussed in more detail elsewhere herein, the impedance that relates to the membrane resistance of a sensor is typically initially high and then gradually decreases as the sensor is run-in. Thus, in one embodiment, sensor re-use can be detected if an impedance measured soon after sensor implantation is greater than what a sensor should typically have when a sensor is initially implanted, as this can indicate that the sensor had already been used.
  • FIG. 21 is a flowchart of an exemplary process 2100 for determining sensor reuse in accordance with one embodiment. At step 2102, a sensor insertion event is triggered. An insertion event can be one of any number of possible events that indicate a new sensor has been implanted, such as a user providing input to a sensor system that a new sensor has been implanted, the sensor system detecting electrical connection to a sensor, a predetermined amount of time transpiring since the system prompted a user to use a new sensor, and the like. Next, at step 2104, a stimulus signal is applied to an analyte sensor being used, and a response is measured and recorded at step 2106. Impedance is calculated based on the signal response at step 2108. The stimulus signal and technique for calculating impedance in steps 2106 and 2108 can be any of the signals and techniques described herein such as those described with reference to FIGS. 11-14. Then, at decision step 2110, the calculated impedance is compared to a predetermined threshold. Should it be determined that the impedance exceeds the threshold, then a sensor reuse routine is initiated at step 2112. If it is determined in decision step 2110 that the impedance does not exceed the threshold, then the process 2100 ends at step 2114.
  • The sensor reuse routine of step 2112 can include triggering an audible and/or visual alarm notifying the user of improper sensor reuse. The alarm can also inform the user why sensor reuse may be undesirable, such as potentially providing inaccurate and unreliable sensor readings. The sensor reuse routine 2112 can alternatively or additionally cause the sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
  • In an embodiment, recent impedance measurement information (e.g., one or more recent impedance measurement values) of a previously-used sensor (such as the sensor used immediately prior to the newly implanted sensor) or a predetermined sensor profile can be stored in computer memory and compared to impedance measurement information of a newly implanted sensor (e.g., what is supposed to be a newly used sensor). It can then be determined that the sensor is being reused should the comparison indicate that the impedances of the previously used sensor at a time close to when the use of the prior sensor was discontinued (e.g., removed) and the newly inserted sensor are too similar using, for example, a data association function, as a new sensor should have a significantly different impedance soon after initial implantation than the impedance of the previously used sensor substantially prior to its discontinuation of use. If it is determined that the sensor is being reused, then the sensor system can trigger an error routine, which can include notifying the user via audible and/or visual alarms using a user interface of the sensor system of improper sensor reuse and prompting the user to use a new sensor, as discussed above with respect to step 2112.
  • FIG. 22 is a flowchart of another exemplary process 2200 for determining sensor reuse in accordance with one embodiment. At step 2202, a sensor insertion event is triggered. A an insertion event can be one of any number of possible events that indicate a new sensor has been implanted, such as a user providing input to a sensor system that a new sensor has been implanted, the sensor system detecting electrical connection to a sensor, a predetermined amount of time transpiring since the system prompted a user to use a new sensor, and the like. Next, at step 2204, a stimulus signal is applied to an analyte sensor being used, and a response is measured and recorded at step 2206. Impedance is calculated based on the signal response at step 2208. The stimulus signal and technique for calculating impedance in steps 2206 and 2208 can be any of the signals and techniques described herein such as those described with reference to FIGS. 11-14. Then, at decision step 2210, the calculated impedance is compared to one or more previously measured impedance values measured using one or more previously implanted sensors (at what at least should have been a previously implanted sensor according to the sensor system). Should it be determined that the calculated impedance correlates within a predetermined amount with the one or more previously measured impedance measurements, then a sensor reuse routine is initiated at step 2112. Correlation can be determined using a data association function, such as one of the data association functions described herein. If it is determined in decision step 2110 that the impedance does not correlate within the predetermined amount to previously measured impedance values, then the process 2100 ends at step 2114, wherein the system continues to use the sensor to measure glucose concentrations of the host.
  • The sensor reuse routine of step 2212 can include triggering an audible and/or visual alarm notifying the user of improper sensor reuse. The alarm can also inform the user why sensor reuse may be undesirable, such as potentially providing inaccurate and unreliable sensor readings. The sensor reuse routine 2212 can alternatively or additionally cause the sensor system to fully or partially shut down and/or cease display of sensor data on a display of the sensor system.
  • f. Sensor Overpotential
  • Some embodiments apply an overpotential routine based on one or more measured impedances of the sensor membrane. It has been found that applying an overpotential (e.g., a voltage potential greater than the bias potential applied to the sensor when used for continuous analyte sensing) to some embodiments of analyte sensors can aid in stabilizing the analyte sensor, thereby reducing a run-in period of the sensor. The overpotential may need to be discontinued once the sensor has sufficiently stabilized, otherwise damage to the sensor can occur. Accordingly, one or more impedance measurements of the sensor can be used to determine a sensitivity or change in sensitivity of the sensor. Any of the techniques described herein, such as those described with reference to FIGS. 11-14, can be used to measure an impendence of the sensor. The determined sensitivity or sensitivity change can be, in turn, used to indicate whether or not the sensor has stabilized or will stabilize within a determined amount of time by, for example, determining a correspondence of the measured impedance to predetermined sensitivity-to-impedance relationships. Upon determining that the sensor has stabilized or will stabilize within a determined amount of time, application of the overpotential can be discontinued or reduced. In addition, a magnitude of an overpotential and/or length of time in which the overpotential is to be applied to the sensor can be determined or modified based on one or more impedance measurements taken prior to application of the overpotential or during application of the overpotential. That is, an overpotential routine can be modified or discontinued according to one or more impedance measurements in accordance with some embodiments.
  • g. Multi-Electrode or Multi-Sensor Configuration
  • Some embodiments of sensor systems comprise a plurality of sensor electrodes. For example, as discussed above, in addition to an analyte sensing electrode, some embodiments can include an auxiliary electrode to allow for the subtraction of a baseline signal from an analyte+baseline signal. Some embodiments can also include one or more redundant analyte sensors.
  • In accordance with one embodiment, a first stimulus signal can be applied to a first sensor and a second stimulus signal can be applied to a second sensor. The first sensor can be configured to sense an analyte concentration (e.g., glucose) and, in this regard, can generate an analyte+baseline signal. The second sensor can be an auxiliary sensor configured to measure a baseline signal that can be subtracted from the signal of the first sensor. In addition, the first stimulus signal can have the same waveform or different waveform than the second stimulus signal. A response to the first stimulus signal and a response to the second stimulus signal can each be measured and recorded. The first response and the second response can be processed, and sensor characteristics can be determined based on the processing, such as impedance values associated with each sensor. The processing can include a comparison (e.g., using a data association function described herein) of the first and second response signals to one another and/or compare each of the first and second response signals to established relationships. The sensor characteristics can include any of the sensor characteristics described herein, including a sensitivity value or sensitivity change of the first and/or second electrodes, a temperature of the first and/or second electrodes, magnitude of detected membrane damage of the first electrode, and the like. Further, sensor data can be compensated for changes in sensor characteristics, such as changes in sensor sensitivity, based on the processing of the first and second response signals.
  • FIG. 23 is a schematic diagram of a dual-sensor configuration that can be used in a sensor system in accordance with some embodiments. The dual-sensor configuration includes a first sensor 2302, having a working electrode 2304, reference electrode 2306 and membrane 2308, and a second sensor 2310, also having a working electrode 2312, reference electrode 2314 and membrane 2316. Each sensor can be essentially the same, including having the same type of membrane, or each sensor can be different, such as having different membranes or even one of the sensors not having a membrane. In one embodiment, each sensor 2302 and 2310 is configured to measure an analyte concentration in a host. In an alternative embodiment, the second sensor 2310 does not have a discrete reference electrode. In this alternative embodiment, the reference electrode of the first sensor can also function as the reference electrode of the second sensor.
  • As illustrated in FIG. 23, a stimulus signal can be applied to the first sensor 2302 using signal generator/detector 2318 (the stimulus signal can be any stimulus signal described herein, such as a voltage step). The stimulus signal can elicit electric field lines 2320 to emanate from the first sensor 2302 and evoke an electrical response in the second sensor 2310. The electrical response can be measured using signal generator/detector 2322 electrically connected to the second sensor 2314. The signal generator/ detectors 2318 and 2322 can include any known electrical circuitry capable of generating a desired stimulus signal discussed herein and capable of measuring a response to the stimulus signal.
  • Further to FIG. 23, the response measured in the second sensor 2310 can then be used to determine sensor properties, such as any sensor properties discussed herein. For example, the response can be used to calculate an impedance of the first sensor 2302 and thereafter used to determine a sensitivity of the first sensor 2302 and/or correct sensor data generated by the first sensor, using one of the processes described herein.
  • Alternatively or in addition, a first stimulus signal can be applied to the first sensor 2302 and measured using the second sensor 2310 and a second stimulus signal can be applied to the second sensor 2310 and measured using the first sensor 2302. The first and second stimulus signals can be essentially the same or can be different. The responses to each of the first and second stimulus signals can then be used to determine a sensor property, such as any of the sensor properties discussed herein.
  • The sensor to which the stimulus signal is applied can also be used to measure a response to the stimulus signal in addition to the other sensor measuring a response to the stimulus signal. For example, a first stimulus signal can be applied to the first sensor 2302 and first and second responses to the first stimulus signal can be measured by the first sensor 2302 and the second sensor 2310, respectively. The first and second responses can then be used to determine sensor properties discussed herein of either or both of the first sensor 2302 and second sensor 2310.
  • h. Scaling Factor
  • In some embodiments, a scaling factor can be used to correct differences in responses of a dual-electrode analyte sensor. In some embodiments, a dual-electrode analyte sensor that can be used is a reference sensor/system, whereby reference data can be provided for calibration (e.g., internal to the system), without the use of an external (e.g., separate from the system) analyte-measuring device. In some embodiments, the dual-electrode analyte sensor includes a first electrode that includes an enzyme reactive with a particular analyte (which can be referred to as the plus-enzyme electrode) and a second electrode that does not include the enzyme (which can be referred to as the minus-enzyme electrode).
  • In some embodiments, the sensor system (such as a sensor electronics module of the sensor system) is configured to determine a scaling factor (k). Briefly, a scaling factor defines a relationship between the electrodes of the dual-electrode analyte sensor. Accordingly, in some embodiments, the sensor system is configured to calibrate the analyte sensor data using the scaling factor, such that the calibrated sensor data does not include inaccuracies that can arise due to differences between the first and second working electrodes, respectively. That is, the scaling factor can be used to calculate estimated analyte values based on data generated by the sensor system
  • U.S. Patent Publication No. US-2009-0242399-A1, the contents of which are hereby incorporated by reference in its entirety, describes in more detail dual-electrode analyte sensor systems, scaling factors and methods for using scaling factors that can be used in some embodiments.
  • In accordance with some embodiments, the membrane impedance of each electrode of a dual-electrode system can be used to determine or update a scaling factor. The scaling factor can then be used to calculate estimated analyte concentration values based on data generated by the sensor system.
  • The following illustrates an exemplary process for determining a scaling factor using impendence in accordance with one embodiment. First, membrane impedance is measured for both electrodes of a dual-electrode sensor system. Techniques described herein, such as those described with reference to FIGS. 11-14 and under the heading “Multi-electrode or multi-sensor configuration” can be used to measure the membrane impendence of each of the electrodes of the dual-electrode analyte sensor. The impendence can be measured periodically during sensor use. A scaling factor can be generated using a ratio of the measured membrane impendence of the two electrodes (e.g., a ratio of the membrane impendence of a plus-enzyme electrode and the membrane impedance of a minus-enzyme electrode). A scaling factor to generate estimated analyte values can then be determined or updated based on the generated scaling factor. The determined or updated scaling factor can then be used to generate estimated analyte values.
  • It has been found that acetaminophen can interfere with glucose measurements using some sensor embodiments. It has also been found that acetaminophen response can be proportional to its diffusion through a sensor membrane and sensor impedance can be indicated of membrane impedance. Thus, the above illustrative process for determining a scaling factor can be used to periodically determine an acetaminophen scaling factor by determining a ratio of the plus-enzyme and minus-enzyme electrode impedance. The acetaminophen scaling factor can be used to update a scale factor, such as one of those described above, used to calculate estimated glucose concentrations.
  • i. Calibration
  • An exemplary calibration process in accordance with some embodiments will now be discussed with reference to FIG. 24. Calibration process 2400 can use one or more of pre-implant information 2402, internal diagnostic information 2404 and external reference information 2406 as inputs to form or modify a conversion function 2408. Conversion function 2408 can be used to convert sensor data (e.g., in units of current or counts) into estimated analyte values 2410 (e.g., in units of analyte concentration). Information representative of the estimated analyte values can then outputted 2412, such as displayed on a user display, transmitted to an external device (e.g., an insulin pump, PC computer, mobile computing device, etc.) and/or otherwise processed further. The analyte can be, glucose, for example.
  • In process 2400, pre-implant information 2402 can mean information that was generated prior to implantation of the sensor(s) presently being calibrated. Pre-implant information 2402 can include any of the following types of information:
      • predetermined sensitivity profile(s) associated with the currently used (e.g., implanted) sensor, such a predicted profile of sensitivity change over time of a sensor;
      • previously determined relationships between particular stimulus signal output (e.g., output indicative of an impedance, capacitance or other electrical or chemical property of the sensor) to sensor sensitivity (e.g., determined from prior in vivo and/or ex vivo studies);
      • previously determined relationships between particular stimulus signal output (e.g., output indicative of an impedance, capacitance or other electrical or chemical property of the sensor) to sensor temperature (e.g., determined from prior in vivo and/or ex vivo studies);
      • sensor data obtained from previously implanted analyte concentration sensors;
      • calibration code(s) associated with a sensor being calibrated, as discussed herein;
      • patient specific relationships between sensor and sensitivity, baseline, drift, impedance, impedance/temperature relationship (e.g., determined from prior studies of the patient or other patients having common characteristics with the patient);
      • site of sensor implantation (abdomen, arm, etc.) specific relationships (different sites may have different vascular density);
      • time since sensor manufacture (e.g., time sensor on shelf, date when sensor was manufactured and or shipped, time between when the sensor was manufactured an/or shipped and when the sensor is implanted); and
      • exposure of sensor to temperature, humidity, external factors, on shelf.
  • In process 2400, internal diagnostic information 2402 can mean information generated by the sensor system in which the implanted analyte sensor (the data of which is being calibrated) is being used. Internal diagnostic information 2402 can include any of the following types of information:
      • stimulus signal output (e.g., the output of which can be indicative of the sensor's impedance) of sensor using any of the stimulus signal techniques described herein (the stimulus signal output can be obtained and processed in real time);
      • sensor data measured by the implanted sensor indicative of an analyte concentration (real-time data and/or previously generated sensor data using the currently implanted sensor);
      • temperature measurements using the implanted sensor or an auxiliary sensor (such as a thermistor) co-located with the implanted analyte sensor or separately from the implanted analyte sensor;
      • sensor data from multi-electrode sensors; for example, where one electrode of the sensor is designed to determine a baseline signal as described herein;
      • sensor data generated by redundant sensors, where one or more of the redundant sensors is designed to be substantially the same as at least some (e.g., have the same sensor membrane type), if not all, of the other redundant sensors;
      • sensor data generated by one or more auxiliary sensors, where the auxiliary sensor is having a different modality such (as optical, thermal, capacitive, etc.) co-located with analyte sensor or located apart from the analyte sensor;
      • time since sensor was implanted and/or connected (e.g., physically or electronically) to a sensor electronics of a sensor system;
      • data representative of a pressure on sensor/sensor system generated by, for example, a pressure sensor (e.g., to detect compression artifact);
      • data generated by an accelerometer (e.g., indicative of exercise/movement/activity of a host);
      • measure of moisture ingress (e.g., indicative of an integrity of a moisture seal of the sensor system); and
      • a measure of noise in an analyte concentration signal (which can be referred to as a residual between raw and filtered signals in some embodiments).
  • In process 2400, external reference information 2402 can mean information generated from sources while the implanted analyte sensor (the data of which is being calibrated) is being used. External reference information 2402 can include any of the following types of information:
      • real-time and/or prior analyte concentration information obtained from a reference monitor (e.g., an analyte concentration value obtained from separate sensor, such as a finger stick glucose meter);
      • type/brand of reference meter (different meters can have different bias/precision);
      • information indicative of carbohydrates consumed by patient;
      • information from a medicament pen/pump, such as insulin on board, insulin sensitivity, glucagon on board;
      • glucagon sensitivity information; and
      • information gathered from population based data (e.g., based on data collected from sensors having similar characteristics, such as sensors from the same lot).
    Exemplary Sensor System Configurations
  • Embodiments of the present invention are described above and below with reference to flowchart illustrations of methods, apparatus, and computer program products. It will be understood that each block of the flowchart illustrations, and combinations of blocks in the flowchart illustrations, can be implemented by execution of computer program instructions. These computer program instructions may be loaded onto a computer or other programmable data processing apparatus (such as a controller, microcontroller, microprocessor or the like) in a sensor electronics system to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create instructions for implementing the functions specified in the flowchart block or blocks. These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instructions which implement the function specified in the flowchart block or blocks. The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks presented herein.
  • In some embodiments, a sensor system is provided for continuous measurement of an analyte (e.g., glucose) in a host that includes: a continuous analyte sensor configured to continuously measure a concentration of the analyte in the host and a sensor electronics module physically connected to the continuous analyte sensor during sensor use. In one embodiment, the sensor electronics module includes electronics configured to process a data stream associated with an analyte concentration measured by the continuous analyte sensor in order to process the sensor data and generate displayable sensor information that includes raw sensor data, transformed sensor data, and/or any other sensor data, for example. The sensor electronics module can include electronics configured to process a data stream associated with an analyte concentration measured by the continuous analyte sensor in order to process the sensor data and generate displayable sensor information that includes raw sensor data, transformed sensor data, and/or any other sensor data, for example. The sensor electronics module can include a processor and computer program instructions to implement the processes discussed herein, including the functions specified in the flowchart block or blocks presented herein.
  • In some embodiments, a receiver, which can also be referred to as a display device, is in communication with the sensor electronics module (e.g., via wired or wireless communication). The receiver can be an application-specific hand-held device, or a general purpose device, such as a P.C., smart phone, tablet computer, and the like. In one embodiment, a receiver can be in data communication with the sensor electronics module for receiving sensor data, such as raw and/or displayable data, and include a processing module for processing and/or display the received sensor data. The receiver can also and include an input module configured to receive input, such as calibration codes, reference analyte values, and any other information discussed herein, from a user via a keyboard or touch-sensitive display screen, for example, and can also be configured to receive information from external devices, such as insulin pumps and reference meters, via wired or wireless data communication. The input can be processed alone or in combination with information received from the sensor electronics module. The receiver's processing module can include a processor and computer program instructions to implement any of the processes discussed herein, including the functions specified in the flowchart block or blocks presented herein.
  • EXAMPLES
  • Embodiments are further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. As disclosed herein, studies have been conducted using a Gamry potentiostat system to analyze complex impedance of glucose sensors placed in a buffer. The Gamry potentiostat system is commercially available from Gamry under the model name Ref600. The buffer is a modified isolyte having a known concentration of glucose. In many of the examples, the glucose concentration is about 100 mg/dL. The impedance measurement error in the examples was found to be about 1 to 5% by testing the system with a known impedance.
  • Although some of the following examples were performed on a lab bench, the sensors under test are configured to be used in vivo to continuously or substantially continuously measure a glucose concentration of a host.
  • Analyte sensors used in the following examples were selected from different types of sensors. The sensors under test include sensors taken from different sensor lots, where sensors from a first lot may have been made in a different way and under different conditions, which can result in sensors for different lots exhibiting different sensitivity profiles. Further, some of the sensors studied in these examples are configured for placement in transcutaneous tissue of a host to measure the host's glucose concentration, while other sensors are configured to measure an intravenous blood glucose concentration of a host. In the following experiments, sensors intended to be used to measure an intravenous blood glucose concentration can be referred to as an “IVBG sensor type” and sensors intended to measure a blood glucose concentration in transcutaneous tissue of a host can be referred to as a “transcutaneous sensor type.”
  • Example 1 Sensitivity and Impedance Relationship
  • Example 1 illustrates a relationship between sensitivity of a sensor and an impedance of the sensor. In this example, an IVBG sensor was connected to a Gamry potentiostat system and placed in a in a buffer solution of a modified isolyte having a glucose concentration of 100 mg/dL. The temperature during the experiment was 37 C. An impedance spectrum was captured at fixed intervals of time. The impedance spectrum analyzed in this experiment ranged from 1 Hz to 100 kHz and measurements of the sensor impedance and sensor sensitivity were taken at 15 minute intervals over a period of about 1200 minutes.
  • Reference is now made to FIG. 25, which is a graph showing absolute values of sensitivity and impedance of the sensor based on an input signal having a frequency of 1 kHz. Data points 2502 represent measured values of sensor sensitivity over a time period of 1200 minutes (20 hours), where t=0 corresponds to the time when the sensor is initially placed in the buffer. Data points 1104 represent measured values of impedance over the same time period.
  • The sensitivity and impedance values of FIG. 25 appear to have an inverse correlation. That is, the sensitivity initially increases quickly and then the rate of the increase gradually slows down and levels off, and the impedance initially deceases quickly and then the rate of the decrease gradually slows down and levels off. Although not wishing to be bound by theory, the initial increase in sensitivity and decrease in impedance is believed to be due to sensor run-in.
  • FIG. 26 is a plot of the data in FIG. 25, but the sensitivity and impedance are in terms of percent change versus one hour instead of absolute values. As can be seen, the sensitivity 2602 and impedance 2604 relative changes versus one hour also appear to have an inverse correlation.
  • Example 2 Retrospectively Compensating for Sensitivity Drift Using Impedance
  • FIG. 27 is a plot of sensitivity and impedance points measured at various intervals over time using seven different sensors, Sensors A-G. Sensors A-G were transcutaneous-type sensors, but selected from several different sensor lots. Thus, even though Sensors A-G were all transcutaneous sensors, sensors from different lots may have been made in a slightly different way or under slightly different conditions, which can result in sensors from different lots exhibiting different sensitivity profiles. In this Example, Sensors A and D were selected from a first lot, Sensor B was selected from a second lot, and Sensors C, E, F and G were selected from a third lot.
  • Further to FIG. 27, the plotted data points are sensitivity and impedance values for each Sensor A-G. Because the sensitivity of each Sensor A-G gradually increases over time, the right most points of each Sensor's plotted data points tend to correspond to values measured around t=0 and the left most points tend to correspond to values at around t=24 hr.
  • As can be seen in FIG. 27, the impedance and sensitivity values of each Sensor A-G have an essentially linear relationship, where the sensitivity gradually increases and the impedance decreases correspondingly over time. The data taken from all seven Sensors A-G generally follow this linear relationship, although the data points of each sensor may be shifted as compared to the data points of the other sensors. Put another way, while the initial impedance and sensitivity values for each sensor may be different, the change in sensitivity and impedance for each sensor changes at about the same linear rate.
  • FIG. 28 is a graph further illustrating the linear relationship of impedance and sensitivity of Sensors A-G. The graph of FIG. 28 is based on the same data used in FIG. 27, but the data is graphed in terms of percent change rather than in absolute values. As can be seen in FIG. 28, Sensors A-G appear to exhibit a very similar correspondence between the change in impedance and change in sensitivity.
  • A computer-implemented estimative algorithm function can be used to model a relationship between the change in sensitivity and change in impedance values of the sensor data generated by Sensors A-G. The estimative algorithm function may be formed by applying curve fitting techniques that regressively fit a curve to data points by adjusting the function (e.g., by adjusting constants of the function) until an optimal fit to the available data points is obtained, as discussed above with respect to forming an estimative curve for a sensitivity profile. Additionally or alternatively, the relationship can be modeled into a look-up table stored in computer memory.
  • Further to FIG. 28, an estimative curve 2802 of the combined sensor data of Sensors A-G is also plotted. The curve in FIG. 28 is a straight line, but can be other types of curves depending upon the relationship between impedance and sensitivity of the sensor. As discussed herein, the curve 2802 can be used to compensate for sensitivity drift of a sensor.
  • FIG. 29 and FIG. 30 illustrate compensating sensor data taken by the same sensors used to derive the estimative curve 2802. The measurements of FIGS. 29 and 30 were taken at 37 C. (Note that estimative curve 2802 was derived based on sensor measurements taken at 37 C, as discussed above with reference to FIGS. 27 and 28.) FIG. 29 is a plot of uncompensated measurements using Sensors A-G. FIG. 30 is a plot of percent estimated sensitivity error of measurements compensated using the impedance to sensitivity relationship based on the estimative curve 2802. The Mean Absolute Relative Difference (MARD) of the uncompensated sensor data is 21.8%. The MARD of the compensated data is 1.8%, which is a noticeable improvement over the uncompensated data.
  • FIGS. 31 and 32 are also plots of uncompensated data and percent sensitivity error of compensated data, respectively. The data in FIGS. 31 and 32 are based on measurements using Sensors H-L. Sensors H, J, K and L were selected from the same lot of sensors as Sensors C, F and G described with reference to FIG. 27 and Sensor I was selected from the same lot as Sensors A and D described with reference to FIG. 27. Further, the measurements plotted in FIGS. 31 and 32 were taken at 25 C instead of 37C. The estimative curve 2802 derived from Sensors A-G, however, was used to compensate the data measured by Sensors H-L. (Note the estimative curve 2802 was also based on measurements taken at 37 C.) The MARD of the uncompensated data is 21.9%, nearly the same as the MARD of 21.8% calculated with respect to the sensor data in FIG. 29. The MARD of the compensated data of FIG. 18 is 4.4%, which is close to, although slightly higher than the MARD of the compensated data of FIG. 30, but still much smaller than the uncompensated MARD.
  • FIGS. 33 and 34 are graphs of uncompensated data and percent sensitivity error of compensated data, respectively. The data in FIGS. 33 and 34 are based on data obtained using Sensors M-Q. Sensors M, O, P and Q were selected from the same lot as Sensors C, F and G described with reference to FIG. 27 and Sensor N was selected from the same lot as Sensors A and D described with reference to FIG. 27. The measurements of Sensors M-Q were taken at 42 C. The estimative curve 2802 derived from Sensors A-G was also used to compensate the data in FIG. 34. Here, the MARD of the uncompensated data is 13.1% and the MARD of the compensated data is 4.6%.
  • Accordingly, Example 2 illustrates that a change in sensitivity to change in impedance relationship determined at a first temperature can be used to compensate for sensitivity drift at temperatures different from the first temperature.
  • Example 3 Prospective Calibration of Sensor Data Using Impedance Measurements
  • Example 5 pertains to prospective calibration. Further, in this experiment, calibration of sensor data is based on a change of sensitivity to change in impedance relationship previously derived from sensors from a different sensor lot. That is, in Example 3, the estimative curve 2802 is used to compensate data obtained using Sensors R-U, each of which was selected from a fourth sensor lot, the fourth sensor lot was not included in the group of sensors used to derive the estimative curve 2802. Example 5 shows that data can be calibrated using a change in sensitivity to change in impedance relationship derived from different sensor types than the type of sensor being calibrated. This can indicate that a sensor factory calibration code need not be used to compensate for sensitivity drift.
  • FIGS. 35 and 36 illustrate prospectively calibrating sensor data obtained from Sensors R-U. FIG. 35 is a plot of the percent sensitivity change versus 30 minutes of each of the sensors over approximately 1400 minutes. FIG. 36 illustrates the percent estimated sensitivity error of the compensated data. The MARD of the uncompensated sensor data is 24.8% (the MARD of uncompensated data in the example of FIG. 15 was 21.8%) and the MARD of the compensated sensor data is 6.6% (the MARD of compensated data in the example of FIG. 16 was 1.8%).
  • Prospective calibration of sensors will now be discussed with reference to FIGS. 37-39. Here, sensitivity and impedance data is collected from Sensors V-X, Z and AA having a membrane formed by a dipping process and Sensor Y having a membrane formed by a spray process. Referring to FIG. 37, an estimative curve 3702 is calculated based on the sensitivity and impedance data from all six Sensors V-Z and AA (i.e. using sensor data obtained from both sensors having dipped and sprayed membrane). FIG. 39 is a graph of the percent sensitivity change of versus 60 minutes of the uncompensated data of each of the six sensors. FIG. 39 is a graph of the percent estimated sensitivity error of the data of all six sensors after being compensated using estimative curve 3702 discussed above with respect to FIG. 37. The MARD of the uncompensated data is 25.3% and the MARD of the compensated data is 5.2%.
  • Thus, Example 5 indicates that using a change in sensitivity to change in impedance relationship derived from sensors selected from different lots than the sensor being calibrated can never-the-less significantly compensate for sensor sensitivity drift. It should be noted that curve 3702 is a straight line. It is contemplated that non-linear fits or correlations can be used instead, which may yield better results.
  • Example 4 Effect of Temperature
  • FIG. 40 illustrates a relationship of temperature on impedance and sensitivity of a sensor. Points 4002 are sensitivity values of a sensor measured over a three day time period and points 4004 are impedance values of the sensor measured over the same time period. In Example 4, the sensor is a transcutaneous-type of sensor. The temperature was initially set and maintained at 37 C, then raised to 45 C, and finally lowered to 25 C, as indicated in FIG. 40.
  • As illustrated in FIG. 40, both sensitivity and impedance of the sensor appear to have an inversely proportional relationship with changes in temperature.
  • FIG. 41 is a plot of the sensitivity measurement values versus the impedance measurement values of FIG. 40. FIG. 41 illustrates points measured during sensor run-in as diamonds and points measured after run-in as squares.
  • Example 5 Temperature Compensation
  • FIG. 42 illustrates compensating analyte concentration data measured by the sensor of Example 4 for effects of temperature after sensor run-in. Here, a relationship between impedance and temperature was used to compensate the sensor data. In this example, the relationship was based on an estimative curve derived from the data of FIG. 41.
  • The relationship between sensor sensitivity and different temperatures can then be mathematically modeled (e.g., by fitting a mathematical curve to data using one of the modeling techniques used herein), and the mathematical model can then be used to compensate for temperature effects on the sensor sensitivity. That is, a sensitivity of a sensor (which is affected by the sensor's temperature) can be determined based on a measured impedance of the sensor applied to the mathematical curve. Sensor data can then be converted to estimated glucose values based on the determined sensor sensitivity.
  • Further to FIG. 42, the MARD of the uncompensated data was calculated as 9.3% and the MARD of the compensated data was calculated as 2.8%.
  • Example 6 Moisture Ingress Detection
  • Example 6 involves detection of moisture ingress in components of sensor electronics used to drive a sensor. In this example, an input signal is applied to the sensor having a frequency ranging from 100 Hz to 1 kHz. A response of the signal is then measured over the range of frequencies and both impedance and phase change derived therefrom. Next, contacts typically positioned inside a sealed section of a sensor electronics module are wetted. The frequency of an input signal is varied between 100 and 1000 Hz. A response is once again measured and both impedance and phase change is derived.
  • In a first experiment, the contacts were wetted to the point of causing a gross failure of the sensor. The current of the sensor increased from 2.3 nA when dry to 36 nA when wetted. In a second experiment, the contacts were only slightly wetted, where the current of the sensor increased from 2.3 nA when dry to 6 nA when wetted.
  • FIG. 43 is a graph of the impedance and phase changes of the first experiment, where the contacts were wetted to a point of causing a gross failure of the sensor system. Curves 4302 and 4304 are impedance and phase values, respectively, of the sensor prior to the wetting of the contacts. Curves 4306 and 4308 are impedance and phase values, respectively, of the sensor after wetting the contacts. As illustrated in FIG. 43, the impedance of the dry curve 4302 and the wet curve 4306 are noticeably different at around 1000 Hz and the phase of the dry curve 4304 and wet curve 4308 are noticeably different at about 100 Hz.
  • FIG. 44 is a graph of the impedance and phase changes of the second experiment, where the contacts are only slightly wetted. Curves 4402 and 4404 are impedance and phase, respectively, of the sensor prior to the wetting of the contacts. Curves 4406 and 4408 are impedance and phase, respectively of the sensor after wetting the contacts. As illustrated in FIG. 44, the impedance of the dry curve 4402 and the wet curve 44006 are noticeably different at around 100 Hz and the phase of the dry curve 4404 and wet curve 4408 are noticeably different around 1 kHz.
  • Example 7 Membrane Damage Detection
  • Example 7 involves detection of sensor membrane damage using impedance measurements. In this example, the impedance of an analyte sensor is measured over a range of frequencies ranging from 100 to 1 kHz. A portion of the sensor's membrane is then cut using a razor blade to cause membrane damage. The impedance of the sensor is once again measured over the same range of frequencies. The impedance measurements of the sensor before the membrane is cut are then compared to the measurements of the sensor after the membrane is cut to determine whether the impedance can be used to detect membrane damage.
  • FIG. 45 is a graph of the sensor measurements before and after the membrane damage. Curves 4502 and 4504 are impedance and phase, respectively, of the sensor prior to membrane damage and curves 4506 and 4508 are impedance and phase, respectively, of the sensor after membrane damage. Both the impedance and phase relationships appear to change around the 1 kHz frequency. This relationship can then be used to detect membrane damage.
  • Example 8 Study Using FFT to Calculate Impedance
  • FIG. 46 is graph plotting impedance calculated using Fast Fourier Transform (FFT) and impedance measured using the Gamry for comparison. FIG. 46 illustrates FFT and corresponding Gamry measurements for 30 min., 1.5 hrs., 3 hrs. and 13 hrs. of input data. The FFT data substantially tracked the Gamry data until about the 1 kHz frequency. Note, the discrepancy after the 1 kHz frequency in FIG. 33 is believed to be due to known limitations on the system used to calculate the FFT. Thus, it is believed that using FFT can provide accurate impedance data even past the 1 kHz spectrum, thereby providing good correspondence to impedance measured using the Gamry.
  • Example 9 In Vivo Sensitivity Change Compensation
  • FIGS. 47-49 relate to compensating for sensitivity changes in a human using an in vivo glucose sensor.
  • FIG. 47 is a graph illustrating in vivo data of sensor impedance and sensitivity of a subcutaneous continuous glucose sensor (also referred to herein as a CGM sensor) over about a 25 hour time period. FIG. 47 is similar to FIG. 25, but uses in vivo data instead of in vitro data. Sensitivity data was generated using data obtained from a blood glucose finger stick monitor and raw sensor current measurements using the CGM sensor (i.e. dividing raw CGM sensor current in units of counts by time-corresponding meter glucose value in units of mg/dL to generate the sensitivity value). The impedance data was generated by applying a step voltage to the CGM sensor and calculating an impedance based on the peak current of the response, as discussed herein with reference to FIG. 13. As illustrated in FIG. 47, the impedance and sensitivity data appear to generally track a similar profile as the in vitro data of FIG. 25.
  • FIG. 48 is a graph of estimated glucose values using the data generated by the CGM sensor before and after sensitivity compensation using the impedance measurements of FIG. 47. The compensated and uncompensated data was calibrated once using a blood glucose reference meter measurement at the one hour mark. The compensation was performed in a manner like that described above with respect to the in vitro study of FIG. 30. FIG. 48 also illustrates blood glucose reference measurements of the host. Based on the data of FIG. 48, it appears that the compensated CGM sensor data more closely corresponds to the reference measurement data than the uncompensated CGM sensor data.
  • FIG. 49 is an accuracy plot showing differences between the uncompensated and compensated CGM sensor data and the finger-stick meter reference data, where the reference data corresponds to the zero line of the plot. The MARD of the uncompensated CGM sensor data is 28.5% and the MARD of the compensated CGM sensor data is 7.8%. Thus, the compensation appears to improve accuracy of the CGM sensor data.
  • Example 9 Comparison of a Linear Impendence-to-Sensitivity Correlation to a Non-Linear Impendence-to-Sensitivity Correlation
  • Laboratory experiments showed that there is an inverse relationship between the changes in sensor sensitivity (drift) and the changes in impedance. Based on the measured impedance, the sensor sensitivity drift could be compensated using either linear or non-linear sensor sensitivity-impedance correlation.
  • The linear correlation can be expressed as the equation ΔS=a*ΔI+b, where a and b can be pre-determined coefficients determined from prior testing of similar sensors. The non-linear correlation can be expressed as ΔS=(a*log(t)+b)*ΔI, where a and b are pre-determined constants determined from prior testing of similar sensors. The prior testing of similar sensors was performed using in vitro bench testing and the constants were derived using conventional computer plotting techniques in this experiment.
  • The linear and non-linear equations are derived from the relationships of change in sensitivity and change of impedance at time t since the last calibration. The percent the change of sensitivity at time t is expressed as:

  • ΔS=% change in sensitivity=(Sensitivity at t−Sc)/Sc*100%
  • where Sc is a sensitivity determined at calibration, and t is the time since the last calibration.
  • The sensor impendence change from time t is expressed as:

  • ΔI=% impedance change=(impedance at t−Ic)/Ic*100%
  • where Ic is an impedance at the time of calibration.
  • To calculate the linear correlation, conventional computer plotting software was used to plot change in sensitivity (y-axis) versus change in impendence (x-axis) based on in vitro test data and determine the linear best fit of the data. In this experiment, the linear best fit was ΔS=−4.807*ΔI−0.742. The linear best fit can is used as the linear sensitivity-to-impedance correlation.
  • To calculate the non-linear correlation, conventional computer plotting software was used to plot change in sensitivity over change in impedance ΔS/ΔI (y-axis) versus log(t). The linear best fit of the plotted data is then determined using the plotting software to yield ΔS/ΔI=a*log(t)+b, from which the change is sensitivity is derived: ΔS=(a*log(t)+b)*ΔI. In this experiment, the plotting software yielded ΔS/ΔI=−1.175*log(t)−1.233. From this equation, ΔS is derived: ΔS=(−1.175*log(t)−1.233)*ΔI.
  • The linear or non-linear correlation can then be applied to correct for changes in sensitivity of the sensor using impedance measurements of the sensor.
  • FIG. 50 illustrates process 5000 for correcting estimated glucose values used in this experiment. Process 5000 begins at block 5002 with sensor insertion at time t=0. Process 5000 then divides into two branches.
  • The first branch beings at block 5004, where sensor data is generated using the continuous glucose sensor in the form of current or counts. The first branch then proceeds to decision block 5006, where process 5000 determines whether a calibration is needed. In this experiment, a calibration is determined to be needed one hour and 24 hours after sensor insertion. If it is determined that calibration is not needed, then the first branch essentially ends. On the other hand, if it is determined that calibration is required, then process 5000 acquires a reference measurement using a finger stick meter at blocks 5008 and 5010. Sensor data corresponding in time to the reference measurement (at time Tc) is determined at block 5012 and used to calculate a sensor sensitivity, Sc, along with the reference data at block 5014.
  • The second branch of process 5000 begins with measuring an impendence of the sensor at block 5016. The impedance is measured using the peak current technique discussed in this application with reference to FIG. 13. Next it is determined if calibration is needed in decision block 5018. In this experiment, this is the same decision made in decision block 5006. If calibration is determined to be needed, then the impedance measured in block 5016 is flagged and stored as impedance Ic (impedance calibration) at block 5020. If calibration is not needed, then process 5000 skips block 5020 and proceeds to determine a change in impedance at block 5022 from the impedance flagged as impedance Ic, which in this experiment is the difference between the impendence measured in block 5016 and the impedance Ic. A compensation algorithm (using the linear or the non-linear compensation algorithm) is then used in block 5024 to calculate a change in sensitivity at block 5026 based on the change in impedance determined at block 5022.
  • The first and second branches of process 5000 then merge at block 5028 where a corrected sensitivity is determined. The corrected sensitivity is then used to convert sensor data in units of current or counts to an estimated glucose value in units of glucose concentration.
  • Process 5000 is repeated for each sensor data point that is converted into an estimated glucose value.
  • In this experiment, sensor performance improvement by impedance compensation is demonstrated below. The sensors were tested using continuous glucose sensors placed in sheep serum for 2 days. The sensor sensitivity was calculated at 1 hour and 24 hours. In FIG. 51, the sensor sensitivity obtained at calibrations (1 hour or 24 hours) was used throughout the day without any correction. In FIG. 52, sensitivity was corrected using linear impedance correction in accordance with the process illustrated in FIG. 50. In FIG. 53, sensitivity was adjusted with non-linear sensitivity-impedance correlation in accordance with the process illustrated in FIG. 50. While both linear and non-linear corrections demonstrated improved sensor performance, the non-linear correction produced better results.
  • Some embodiments disclosed herein continuously or iteratively apply a stimulus signal during a continuous sensor session or use and extrapolate information from the output associated with the stimulus, such as using a peak current measurement, EIS, etc. Although certain electrochemical analysis techniques were described herein, it is understood that many other techniques can be used instead to detect characteristics of sensors described herein, such as voltammetry, chronopotentiometry, current or potential step techniques, differential chrono-potentiometry, oxygen absorption rate measurements, potential/current sweep or pulse methods, etc.
  • While the disclosure has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive. The disclosure is not limited to the disclosed embodiments. Variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed disclosure, from a study of the drawings, the disclosure and the appended claims.
  • All references cited herein are incorporated herein by reference in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
  • Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to a person of ordinary skill in the art, and are not to be limited to a special or customized meaning unless expressly so defined herein. It should be noted that the use of particular terminology when describing certain features or aspects of the disclosure should not be taken to imply that the terminology is being re-defined herein to be restricted to include any specific characteristics of the features or aspects of the disclosure with which that terminology is associated. Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as ‘known’, ‘normal’, ‘standard’, and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like ‘preferably,’ ‘preferred,’ ‘desired,’ or ‘desirable,’ and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the invention, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the invention. Likewise, a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise. Similarly, a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.
  • Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.
  • With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article “a” or “an” does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.
  • It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
  • All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term ‘about.’ Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
  • Furthermore, although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it is apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather to also cover all modification and alternatives coming with the true scope and spirit of the invention.

Claims (15)

1-10. (canceled)
11. A method for determining reuse of an analyte sensor using sensor electronics coupled to the sensor, comprising:
generating a data stream indicative of an analyte concentration of a host by applying a bias voltage to a first analyte sensor at least partially positioned within tissue of a host;
applying a stimulus signal to the analyte sensor;
measuring a response of the stimulus signal;
comparing the measured response to one or more predetermined criteria; and
initiating a sensor reuse routine if it is determined that the measured response satisfies the one or more predetermined criteria.
12. The method of claim 11, wherein the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
13. The method of claim 11, wherein the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
14. The method of claim 11, further comprising calculating an impedance based on the measured response, wherein the comparing comprises comparing the impedance to the one or more predetermined criteria.
15. An analyte monitoring system configured to determine reuse of an analyte sensor; the system comprising:
an analyte sensor configured for transcutaneous implantation into a host; and
sensor electronics coupled to the analyte sensor, the sensor electronics configured to:
generate a data stream indicative of an analyte concentration of a host by applying a bias voltage to a first analyte sensor at least partially positioned within tissue of a host,
apply a stimulus signal to the analyte sensor,
measure a response of the stimulus signal,
compare the measured response to one or more predetermined criteria, and
initiate a sensor reuse routine if it is determined that the measured response satisfies the one or more predetermined criteria.
16. The system of claim 15, wherein the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
17. The system of claim 15, wherein the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
18. The system of claim 15, wherein the sensor electronics are further configured to calculate an impedance based on the measured response, wherein the comparing comprises comparing the impedance to the one or more predetermined criteria.
19. The system of claim 15, wherein the sensor electronics comprise one or more processors and computer-readable instructions stored in computer memory, wherein the instructions, when executed by the one or more processors of the sensor system, cause the sensor electronics to generate, apply, measure, compare and initiate.
20. A method for determining reuse of an analyte sensor, comprising,
generating a data stream indicative of an analyte concentration of a host by applying a bias voltage to a first analyte sensor at least partially positioned within tissue of a host;
applying a stimulus signal to an analyte sensor;
measuring a response of the stimulus signal;
using a data association function to determine a correlation of the response to one or more recorded responses; and
initiating a sensor reuse routine if it is determined that the correlation is above a predetermined threshold.
21. The method of claim 20, wherein the sensor reuse routine includes triggering an audible and/or visual alarm notifying the user of improper sensor reuse.
22. The method of claim 20, wherein the sensor reuse routing includes causing a sensor system to fully or partially shut down and/or cease display of sensor data on a user interface of the sensor system.
23. The method of claim 20, further comprising processing the data stream and displaying glucose concentration values indicative of the host's analyte concentration on a display device based on the processed data stream.
24. The method of claim 20, further comprising comparing the data stream to one or more alarm thresholds and triggering an audible and/or visual alert on a display device notifying the user of the user's glucose concentration exceeding a predefined limit.
US14/144,343 2011-04-15 2013-12-30 Advanced analyte sensor calibration and error detection Abandoned US20140114156A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/144,343 US20140114156A1 (en) 2011-04-15 2013-12-30 Advanced analyte sensor calibration and error detection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161476145P 2011-04-15 2011-04-15
US13/446,848 US9801575B2 (en) 2011-04-15 2012-04-13 Advanced analyte sensor calibration and error detection
US14/144,343 US20140114156A1 (en) 2011-04-15 2013-12-30 Advanced analyte sensor calibration and error detection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/446,848 Continuation US9801575B2 (en) 2008-11-07 2012-04-13 Advanced analyte sensor calibration and error detection

Publications (1)

Publication Number Publication Date
US20140114156A1 true US20140114156A1 (en) 2014-04-24

Family

ID=47006011

Family Applications (34)

Application Number Title Priority Date Filing Date
US13/446,848 Active 2034-12-17 US9801575B2 (en) 2008-11-07 2012-04-13 Advanced analyte sensor calibration and error detection
US13/446,977 Active 2033-04-12 US9149220B2 (en) 2008-11-07 2012-04-13 Advanced analyte sensor calibration and error detection
US13/446,983 Active 2035-01-27 US9848809B2 (en) 2011-04-15 2012-04-13 Advanced analyte sensor calibration and error detection
US13/446,866 Abandoned US20120265036A1 (en) 2011-04-15 2012-04-13 Advanced analyte sensor calibration and error detection
US14/144,276 Active 2034-08-23 US9808190B2 (en) 2011-04-15 2013-12-30 Advanced analyte sensor calibration and error detection
US14/144,343 Abandoned US20140114156A1 (en) 2011-04-15 2013-12-30 Advanced analyte sensor calibration and error detection
US14/860,392 Active US10004442B2 (en) 2008-11-07 2015-09-21 Advanced analyte sensor calibration and error detection
US14/956,192 Active US10448873B2 (en) 2011-04-15 2015-12-01 Advanced analyte sensor calibration and error detection
US14/956,170 Abandoned US20160198986A1 (en) 2011-04-15 2015-12-01 Advanced analyte sensor calibration and error detection
US14/956,210 Abandoned US20160073941A1 (en) 2011-04-15 2015-12-01 Advanced analyte sensor calibration and error detection
US15/713,450 Abandoned US20180008174A1 (en) 2011-04-15 2017-09-22 Advanced analyte sensor calibration and error detection
US15/726,272 Abandoned US20180042530A1 (en) 2011-04-15 2017-10-05 Advanced analyte sensor calibration and error detection
US15/993,006 Abandoned US20180271415A1 (en) 2011-04-15 2018-05-30 Advanced analyte sensor calibration and error detection
US15/994,905 Active US10327688B2 (en) 2008-11-07 2018-05-31 Advanced analyte sensor calibration and error detection
US16/405,887 Active US10682084B2 (en) 2008-11-07 2019-05-07 Advanced analyte sensor calibration and error detection
US16/405,931 Abandoned US20190261903A1 (en) 2011-04-15 2019-05-07 Advanced analyte sensor calibration and error detection
US16/459,158 Abandoned US20190336051A1 (en) 2011-04-15 2019-07-01 Advanced analyte sensor calibration and error detection
US16/460,906 Active US10555695B2 (en) 2011-04-15 2019-07-02 Advanced analyte sensor calibration and error detection
US16/460,943 Active US10561354B2 (en) 2008-11-07 2019-07-02 Advanced analyte sensor calibration and error detection
US16/527,666 Abandoned US20190380627A1 (en) 2011-04-15 2019-07-31 Advanced analyte sensor calibration and error detection
US16/527,865 Abandoned US20190350499A1 (en) 2011-04-15 2019-07-31 Advanced analyte sensor calibration and error detection
US16/539,945 Active US10624568B2 (en) 2011-04-15 2019-08-13 Advanced analyte sensor calibration and error detection
US16/586,610 Active US10835162B2 (en) 2008-11-07 2019-09-27 Advanced analyte sensor calibration and error detection
US16/586,434 Abandoned US20200037935A1 (en) 2011-04-15 2019-09-27 Advanced analyte sensor calibration and error detection
US16/586,389 Active US10610141B2 (en) 2011-04-15 2019-09-27 Advanced analyte sensor calibration and error detection
US16/586,407 Active US10722162B2 (en) 2011-04-15 2019-09-27 Advanced analyte sensor calibration and error detection
US17/026,852 Abandoned US20210000394A1 (en) 2011-04-15 2020-09-21 Advanced analyte sensor calibration and error detection
US17/078,609 Abandoned US20210038128A1 (en) 2011-04-15 2020-10-23 Advanced analyte sensor calibration and error detection
US17/082,627 Active US10980461B2 (en) 2008-11-07 2020-10-28 Advanced analyte sensor calibration and error detection
US16/951,596 Abandoned US20210076989A1 (en) 2011-04-15 2020-11-18 Advanced analyte sensor calibration and error detection
US16/951,759 Abandoned US20210068720A1 (en) 2011-04-15 2020-11-18 Advanced analyte sensor calibration and error detection
US17/398,628 Abandoned US20210369149A1 (en) 2011-04-15 2021-08-10 Advanced analyte sensor calibration and error detection
US18/180,809 Pending US20230309881A1 (en) 2008-11-07 2023-03-08 Analyte sensor
US18/129,556 Pending US20230240570A1 (en) 2011-04-15 2023-03-31 Advanced analyte sensor calibration and error detection

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US13/446,848 Active 2034-12-17 US9801575B2 (en) 2008-11-07 2012-04-13 Advanced analyte sensor calibration and error detection
US13/446,977 Active 2033-04-12 US9149220B2 (en) 2008-11-07 2012-04-13 Advanced analyte sensor calibration and error detection
US13/446,983 Active 2035-01-27 US9848809B2 (en) 2011-04-15 2012-04-13 Advanced analyte sensor calibration and error detection
US13/446,866 Abandoned US20120265036A1 (en) 2011-04-15 2012-04-13 Advanced analyte sensor calibration and error detection
US14/144,276 Active 2034-08-23 US9808190B2 (en) 2011-04-15 2013-12-30 Advanced analyte sensor calibration and error detection

Family Applications After (28)

Application Number Title Priority Date Filing Date
US14/860,392 Active US10004442B2 (en) 2008-11-07 2015-09-21 Advanced analyte sensor calibration and error detection
US14/956,192 Active US10448873B2 (en) 2011-04-15 2015-12-01 Advanced analyte sensor calibration and error detection
US14/956,170 Abandoned US20160198986A1 (en) 2011-04-15 2015-12-01 Advanced analyte sensor calibration and error detection
US14/956,210 Abandoned US20160073941A1 (en) 2011-04-15 2015-12-01 Advanced analyte sensor calibration and error detection
US15/713,450 Abandoned US20180008174A1 (en) 2011-04-15 2017-09-22 Advanced analyte sensor calibration and error detection
US15/726,272 Abandoned US20180042530A1 (en) 2011-04-15 2017-10-05 Advanced analyte sensor calibration and error detection
US15/993,006 Abandoned US20180271415A1 (en) 2011-04-15 2018-05-30 Advanced analyte sensor calibration and error detection
US15/994,905 Active US10327688B2 (en) 2008-11-07 2018-05-31 Advanced analyte sensor calibration and error detection
US16/405,887 Active US10682084B2 (en) 2008-11-07 2019-05-07 Advanced analyte sensor calibration and error detection
US16/405,931 Abandoned US20190261903A1 (en) 2011-04-15 2019-05-07 Advanced analyte sensor calibration and error detection
US16/459,158 Abandoned US20190336051A1 (en) 2011-04-15 2019-07-01 Advanced analyte sensor calibration and error detection
US16/460,906 Active US10555695B2 (en) 2011-04-15 2019-07-02 Advanced analyte sensor calibration and error detection
US16/460,943 Active US10561354B2 (en) 2008-11-07 2019-07-02 Advanced analyte sensor calibration and error detection
US16/527,666 Abandoned US20190380627A1 (en) 2011-04-15 2019-07-31 Advanced analyte sensor calibration and error detection
US16/527,865 Abandoned US20190350499A1 (en) 2011-04-15 2019-07-31 Advanced analyte sensor calibration and error detection
US16/539,945 Active US10624568B2 (en) 2011-04-15 2019-08-13 Advanced analyte sensor calibration and error detection
US16/586,610 Active US10835162B2 (en) 2008-11-07 2019-09-27 Advanced analyte sensor calibration and error detection
US16/586,434 Abandoned US20200037935A1 (en) 2011-04-15 2019-09-27 Advanced analyte sensor calibration and error detection
US16/586,389 Active US10610141B2 (en) 2011-04-15 2019-09-27 Advanced analyte sensor calibration and error detection
US16/586,407 Active US10722162B2 (en) 2011-04-15 2019-09-27 Advanced analyte sensor calibration and error detection
US17/026,852 Abandoned US20210000394A1 (en) 2011-04-15 2020-09-21 Advanced analyte sensor calibration and error detection
US17/078,609 Abandoned US20210038128A1 (en) 2011-04-15 2020-10-23 Advanced analyte sensor calibration and error detection
US17/082,627 Active US10980461B2 (en) 2008-11-07 2020-10-28 Advanced analyte sensor calibration and error detection
US16/951,596 Abandoned US20210076989A1 (en) 2011-04-15 2020-11-18 Advanced analyte sensor calibration and error detection
US16/951,759 Abandoned US20210068720A1 (en) 2011-04-15 2020-11-18 Advanced analyte sensor calibration and error detection
US17/398,628 Abandoned US20210369149A1 (en) 2011-04-15 2021-08-10 Advanced analyte sensor calibration and error detection
US18/180,809 Pending US20230309881A1 (en) 2008-11-07 2023-03-08 Analyte sensor
US18/129,556 Pending US20230240570A1 (en) 2011-04-15 2023-03-31 Advanced analyte sensor calibration and error detection

Country Status (6)

Country Link
US (34) US9801575B2 (en)
EP (4) EP3575796B1 (en)
JP (6) JP6141827B2 (en)
DK (1) DK3575796T3 (en)
ES (1) ES2847578T3 (en)
WO (1) WO2012142502A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017117416A1 (en) * 2015-12-30 2017-07-06 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile
WO2017172391A1 (en) * 2016-03-30 2017-10-05 Dexcom, Inc. Systems, devices and methods for analyte monitoring system
US9936909B2 (en) 2012-09-28 2018-04-10 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US10172564B2 (en) 2016-11-24 2019-01-08 Olympus Corporation Apparatus, computer-readable medium, and method for detecting biological data of target patient from attachable sensor attached to target patient
US10413227B2 (en) 2013-03-15 2019-09-17 Dexcom, Inc. Membrane for continuous analyte sensors
WO2019213428A2 (en) 2018-05-03 2019-11-07 Dexcom, Inc. Automatic analyte sensor calibration and error detection
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10987040B2 (en) 2012-03-16 2021-04-27 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11112377B2 (en) 2015-12-30 2021-09-07 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US9589686B2 (en) 2006-11-16 2017-03-07 General Electric Company Apparatus for detecting contaminants in a liquid and a system for use thereof
US10914698B2 (en) 2006-11-16 2021-02-09 General Electric Company Sensing method and system
US9658178B2 (en) 2012-09-28 2017-05-23 General Electric Company Sensor systems for measuring an interface level in a multi-phase fluid composition
US9536122B2 (en) 2014-11-04 2017-01-03 General Electric Company Disposable multivariable sensing devices having radio frequency based sensors
US9389296B2 (en) * 2012-07-26 2016-07-12 General Electric Company Method for sensor reader calibration
US9538657B2 (en) 2012-06-29 2017-01-03 General Electric Company Resonant sensor and an associated sensing method
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US8583204B2 (en) * 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
ES2912584T3 (en) 2009-08-31 2022-05-26 Abbott Diabetes Care Inc A glucose monitoring system and method
US9066680B1 (en) 2009-10-15 2015-06-30 Masimo Corporation System for determining confidence in respiratory rate measurements
US9724016B1 (en) 2009-10-16 2017-08-08 Masimo Corp. Respiration processor
US9307928B1 (en) 2010-03-30 2016-04-12 Masimo Corporation Plethysmographic respiration processor
US8542023B2 (en) 2010-11-09 2013-09-24 General Electric Company Highly selective chemical and biological sensors
CA2843008A1 (en) 2011-07-26 2013-01-31 Glysens Incorporated Tissue implantable sensor with hermetically sealed housing
ES2608592T3 (en) 2011-08-16 2017-04-12 Instrumentation Laboratory Company Extrapolation of data from interpolated sensors to increase sample throughput
US9615779B2 (en) 2012-04-04 2017-04-11 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
JP5927013B2 (en) * 2012-04-16 2016-05-25 日本光電工業株式会社 Biological information monitor device
US10453573B2 (en) 2012-06-05 2019-10-22 Dexcom, Inc. Dynamic report building
US10881339B2 (en) * 2012-06-29 2021-01-05 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US10598627B2 (en) * 2012-06-29 2020-03-24 Dexcom, Inc. Devices, systems, and methods to compensate for effects of temperature on implantable sensors
US20140012117A1 (en) 2012-07-09 2014-01-09 Dexcom, Inc. Systems and methods for leveraging smartphone features in continuous glucose monitoring
US10660550B2 (en) 2015-12-29 2020-05-26 Glysens Incorporated Implantable sensor apparatus and methods
US10561353B2 (en) 2016-06-01 2020-02-18 Glysens Incorporated Biocompatible implantable sensor apparatus and methods
US10598650B2 (en) 2012-08-22 2020-03-24 General Electric Company System and method for measuring an operative condition of a machine
EA030927B1 (en) 2012-08-22 2018-10-31 Дженерал Электрик Компани Wireless system and method for measuring an operative condition of a machine
US20140062717A1 (en) * 2012-08-31 2014-03-06 The University Of Iowa Research Foundation Method for RFID Communication Using Inductive Orthogonal Coupling For Wireless Medical Implanted Sensors and Other Short-Range Communication Applications
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10684268B2 (en) 2012-09-28 2020-06-16 Bl Technologies, Inc. Sensor systems for measuring an interface level in a multi-phase fluid composition
US20140129151A1 (en) 2012-11-07 2014-05-08 Dexcom, Inc. Systems and methods for managing glycemic variability
EP4331659A2 (en) 2012-11-29 2024-03-06 Abbott Diabetes Care, Inc. Methods, devices, and systems related to analyte monitoring
US9730620B2 (en) 2012-12-31 2017-08-15 Dexcom, Inc. Remote monitoring of analyte measurements
US9801541B2 (en) 2012-12-31 2017-10-31 Dexcom, Inc. Remote monitoring of analyte measurements
US9211092B2 (en) 2013-01-03 2015-12-15 Dexcom, Inc. End of life detection for analyte sensors
WO2014121035A1 (en) * 2013-02-01 2014-08-07 Edwards Lifesciences, Llc Determination of sample dilution in a calibrated analyte sensor
WO2014128638A1 (en) * 2013-02-20 2014-08-28 Università Degli Studi Di Padova Area Trasfermiento Di Tecnologia Retrospective retrofitting method to generate a continuous glucose concentration profile
US20140251836A1 (en) * 2013-03-08 2014-09-11 Magellan Diagnostics, Inc. Apparatus and method for analyzing multiple samples
US10441181B1 (en) 2013-03-13 2019-10-15 Masimo Corporation Acoustic pulse and respiration monitoring system
US9445445B2 (en) 2013-03-14 2016-09-13 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP3401818B1 (en) 2013-03-14 2023-12-06 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US10335075B2 (en) * 2013-03-14 2019-07-02 Dexcom, Inc. Advanced calibration for analyte sensors
US20140262833A1 (en) * 2013-03-14 2014-09-18 Magellan Diagnostics, Inc. Sensor with a bifurcated flowpath
GB2512842A (en) * 2013-04-08 2014-10-15 Sphere Medical Ltd Sensor calibration method and apparatus
DE102013105994A1 (en) * 2013-06-10 2014-12-11 Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG Measuring system with at least one field device with at least one display device and method for operating the same
EP3008454A1 (en) * 2013-06-10 2016-04-20 Roche Diagnostics GmbH Method and system for detecting an analyte in a body fluid
US9702769B2 (en) * 2013-06-11 2017-07-11 Intel Corporation Self-calibrated thermal sensors of an integrated circuit die
US9480401B2 (en) 2013-11-14 2016-11-01 Dexcom, Inc. Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods
US9307830B2 (en) * 2013-12-13 2016-04-12 Elwha Llc Grooming systems, devices, and methods including detection of hair-covered skin lesions during grooming and including topographical analysis
US20150164385A1 (en) * 2013-12-16 2015-06-18 Medtronic Minimed, Inc. Methods and systems for improving the reliability of orthogonally redundant sensors
US10638947B2 (en) 2013-12-16 2020-05-05 Medtronic Minimed, Inc. Use of electrochemical impedance spectroscopy (EIS) in intelligent diagnostics
EP3780689A1 (en) 2013-12-27 2021-02-17 Abbott Diabetes Care, Inc. Systems, devices, and methods for authentication in an analyte monitoring environment
EP3111230B1 (en) 2014-02-24 2021-02-24 Mocon, Inc. Instrument and method for target-analyte permeation testing with sensor feed line conditioning system
CA2936773C (en) 2014-04-10 2024-01-09 Dexcom, Inc. Sensors for continuous analyte monitoring, and related methods
US10545486B2 (en) * 2014-04-17 2020-01-28 Masitek Instruments Inc. Systems, methods, devices, and computer readable medium for real and near-real time sensor data capture and analysis
US10001450B2 (en) * 2014-04-18 2018-06-19 Medtronic Minimed, Inc. Nonlinear mapping technique for a physiological characteristic sensor
JP2017516548A (en) 2014-06-06 2017-06-22 デックスコム・インコーポレーテッド Fault identification and response processing based on data and context
JP2016061731A (en) * 2014-09-19 2016-04-25 ソニー株式会社 Electrical characteristic measuring device and program
EP3197356B1 (en) 2014-09-22 2020-12-16 Dexcom, Inc. Method for mode switching
US10890558B2 (en) 2014-10-06 2021-01-12 Smartwash Solutions, Llc Portable sensor validation system
US9904890B2 (en) * 2015-03-13 2018-02-27 Instrumentation Laboratory Company Detecting a transient error in a body fluid sample
US10410538B2 (en) 2015-05-07 2019-09-10 Dexcom, Inc. System and method for educating users, including responding to patterns
US9625892B2 (en) * 2015-06-15 2017-04-18 Honeywell International Inc. System and method for monitoring device calibration
US9858412B2 (en) * 2015-06-25 2018-01-02 Intel Corporation Secure trusted execution environment data store
US10716500B2 (en) * 2015-06-29 2020-07-21 Cardiac Pacemakers, Inc. Systems and methods for normalization of chemical sensor data based on fluid state changes
CN113974619A (en) 2015-09-10 2022-01-28 德克斯康公司 Transcutaneous analyte sensors and monitors, calibrations thereof, and associated methods
US10470661B2 (en) 2015-09-10 2019-11-12 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
TWI627403B (en) * 2015-10-08 2018-06-21 五鼎生物技術股份有限公司 Biochemical test chip
US10278732B2 (en) 2015-10-21 2019-05-07 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and associated methods
DE102015226622B4 (en) * 2015-12-23 2017-09-14 Siemens Healthcare Gmbh Recognition of approach and collision
JP2019506201A (en) * 2015-12-28 2019-03-07 メドトロニック ミニメド インコーポレイテッド Method for continuous glucose monitoring
CA3002096C (en) 2015-12-28 2023-08-01 Dexcom, Inc. Systems and methods for remote and host monitoring communications
US10349872B2 (en) 2015-12-28 2019-07-16 Medtronic Minimed, Inc. Methods, systems, and devices for sensor fusion
EP3922172A1 (en) 2015-12-30 2021-12-15 Dexcom, Inc. Transcutaneous analyte sensor systems and methods
US11080612B2 (en) 2015-12-30 2021-08-03 International Business Machines Corporation Detecting anomalous sensors
US10386324B2 (en) * 2016-02-22 2019-08-20 Analog Devices Global Susceptance measurement for identifying biochemical sensors
CA3133253A1 (en) 2016-03-31 2017-10-05 Dexcom, Inc. Systems and methods for display device and sensor electronics unit communication
CN105938116B (en) * 2016-06-20 2019-09-10 吉林大学 Gas sensor array concentration detection method based on fuzzy division and model integrated
US10638962B2 (en) 2016-06-29 2020-05-05 Glysens Incorporated Bio-adaptable implantable sensor apparatus and methods
US10441252B2 (en) * 2016-11-23 2019-10-15 Hall Labs Llc Medical toilet with user customized health metric validation system
EP4014864A1 (en) 2017-04-19 2022-06-22 Senseonics, Incorporated Detecting and correcting for changes to an analyte indicator
CN110868928B (en) * 2017-05-03 2022-11-08 雅培糖尿病护理公司 Systems, devices, and methods with duration-based adjustment of sensor data
CA3061348C (en) * 2017-06-08 2023-02-14 F. Hoffmann-La Roche Ag Electrode break detection
HUE063121T2 (en) 2017-06-23 2024-01-28 Dexcom Inc Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature
RU2745479C1 (en) * 2017-07-03 2021-03-25 Ф. Хоффманн-Ля Рош Аг Method and the electronics unit for determining biosensor properties under in vivo conditions
US20190008424A1 (en) * 2017-07-04 2019-01-10 Arkray, Inc. Measuring Apparatus, Computer Readable Medium Storing Measuring Program and Measuring Method
US10638979B2 (en) 2017-07-10 2020-05-05 Glysens Incorporated Analyte sensor data evaluation and error reduction apparatus and methods
DE202018006591U1 (en) 2017-08-18 2021-07-21 Abbott Diabetes Care, Inc. Systems and devices relating to the individualized calibration and / or manufacture of medical devices
US10601678B2 (en) 2017-08-24 2020-03-24 Nternational Business Machines Corporation Localized sensor quality analysis and control
US11445951B2 (en) * 2017-09-13 2022-09-20 Medtronic Minimed, Inc. Methods, systems, and devices for calibration and optimization of glucose sensors and sensor output
JP7301818B2 (en) 2017-10-19 2023-07-03 サノフイ Specimen measurement device
US11484227B2 (en) * 2017-11-01 2022-11-01 Waveform Technologies, Inc. Method for conditioning of a sensor
US11035825B2 (en) * 2017-11-15 2021-06-15 Infineon Technologies Ag Sensing systems and methods for the estimation of analyte concentration
EP3485801A1 (en) * 2017-11-19 2019-05-22 Indigo Diabetes N.V. Implantable integrated sensor device
KR101933457B1 (en) * 2017-11-21 2018-12-28 (주) 비비비 Biosensor
US11213230B2 (en) 2017-12-13 2022-01-04 Medtronic Minimed, Inc. Optional sensor calibration in continuous glucose monitoring
US11471082B2 (en) * 2017-12-13 2022-10-18 Medtronic Minimed, Inc. Complex redundancy in continuous glucose monitoring
US11278668B2 (en) 2017-12-22 2022-03-22 Glysens Incorporated Analyte sensor and medicant delivery data evaluation and error reduction apparatus and methods
US11255839B2 (en) 2018-01-04 2022-02-22 Glysens Incorporated Apparatus and methods for analyte sensor mismatch correction
CN111629660A (en) 2018-01-23 2020-09-04 德克斯康公司 System, apparatus and method for compensating for temperature effects on a sensor
CA3096181A1 (en) * 2018-04-12 2019-10-17 Smartwash Solutions, Llc Portable sensor validation system
JP7337841B2 (en) * 2018-05-03 2023-09-04 デックスコム・インコーポレーテッド Systems and methods for operating analyte sensor electronics
US10678313B2 (en) * 2018-05-04 2020-06-09 Dell Products L.P. Impedance-based cooling controls
DE102018213725A1 (en) * 2018-08-15 2020-02-20 Continental Teves Ag & Co. Ohg Procedure for testing a sensor
US10980488B2 (en) * 2018-09-20 2021-04-20 Pacific Delta Llc Determination of blood pressure measurement confidence using variable monitor inaccuracy
WO2020092890A1 (en) * 2018-11-02 2020-05-07 Senseonics, Incorporated Environmental detection and/or temperature compensation in an analyte monitoring system
US11003420B2 (en) * 2018-11-13 2021-05-11 ICE Benchmark Administration Limited Systems and methods for generating enhanced data metrics
US20200205694A1 (en) * 2018-12-28 2020-07-02 Dexcom, Inc. Analyte sensor with impedance determination
US20200245910A1 (en) * 2019-02-01 2020-08-06 Medtronic Minimed, Inc Methods, systems, and devices for continuous glucose monitoring
WO2020161099A1 (en) 2019-02-05 2020-08-13 Ascensia Diabetes Care Holdings Ag Apparatus and methods for probing sensor operation of continuous analyte sensing and auto-calibration
KR20200127470A (en) 2019-05-02 2020-11-11 삼성전자주식회사 Personalized bio-information correction apparatus and method
US11544161B1 (en) * 2019-05-31 2023-01-03 Amazon Technologies, Inc. Identifying anomalous sensors
WO2021011683A1 (en) 2019-07-16 2021-01-21 Dexcom, Inc. Analyte sensor electrode arrangements
JP7267865B2 (en) * 2019-07-19 2023-05-02 株式会社日立ハイテク Analysis device and analysis method
JP7371219B2 (en) * 2019-07-24 2023-10-30 ライフスキャン アイピー ホールディングス エルエルシー Determination of contamination of biosensors used in analyte measurement systems
JP7173354B2 (en) * 2019-08-01 2022-11-16 株式会社村田製作所 Detection device, detection method and program
KR102475913B1 (en) 2019-08-08 2022-12-09 주식회사 아이센스 Method for managing reference information
US11270321B2 (en) 2019-08-27 2022-03-08 International Business Machines Corporation Association analysis on noisy transaction data
CA3165705A1 (en) * 2020-01-23 2021-07-29 Waveform Technologies, Inc. Adjunct data to improve the performance of a continuous glucose monitoring system
KR20220148834A (en) * 2020-03-10 2022-11-07 에프. 호프만-라 로슈 아게 Methods and systems for determining at least one membrane property of an analyte sensor
KR102346791B1 (en) * 2020-03-13 2022-01-05 주식회사 아이센스 Method for calculating sensitivity of sensor
US11562137B2 (en) 2020-04-14 2023-01-24 Bank Of America Corporation System to correct model drift for natural language understanding
US11580456B2 (en) 2020-04-27 2023-02-14 Bank Of America Corporation System to correct model drift in machine learning application
CA3181858A1 (en) * 2020-06-16 2021-12-23 Abbott Diabetes Care Inc. Analyte sensors featuring working electrode asperity planing for decreasing interferent signal
US20220125348A1 (en) * 2020-10-22 2022-04-28 Medtronic Minimed, Inc. Detection of interferent in analyte sensing
KR102480277B1 (en) * 2020-11-20 2022-12-22 두산에너빌리티 주식회사 System for validating validity of sensor using control limit and method thereof
US20220307872A1 (en) * 2021-03-24 2022-09-29 Cirrus Logic International Semiconductor Ltd. Sensitivity equalization in multi-sensor inductive sensing applications
WO2022212867A1 (en) 2021-04-02 2022-10-06 Dexcom, Inc. Personalized modeling of blood glucose concentration impacted by individualized sensor characteristics and individualized physiological characteristics
CN112836180B (en) * 2021-04-19 2021-07-23 北京瑞莱智慧科技有限公司 Sensing data determination method and device, electronic equipment and readable storage medium
DE102021114988A1 (en) * 2021-06-10 2022-12-15 Valeo Schalter Und Sensoren Gmbh METHOD OF OPERATING AN ULTRASONIC SENSOR, COMPUTER PROGRAM PRODUCT, ULTRASONIC SENSOR SYSTEM AND VEHICLE
US20230004815A1 (en) * 2021-07-01 2023-01-05 Medtronic Minimed, Inc. Glucose sensor identification using electrical parameters
WO2023049509A1 (en) * 2021-09-27 2023-03-30 Abbott Diabetes Care Inc. Adaptive sensor sensitivity for analyte monitoring systems
WO2023078715A1 (en) * 2021-11-08 2023-05-11 Biotronik Se & Co. Kg A method for correcting a drift effect in measured data obtained using an implantable pressure sensor
US20230181065A1 (en) 2021-12-13 2023-06-15 Dexcom, Inc. End-of-life detection for analyte sensors experiencing progressive sensor decline
US20230190151A1 (en) 2021-12-17 2023-06-22 Dexcom, Inc. Analyte sensor deployment testing
CN114145738B (en) * 2022-02-10 2022-06-24 苏州百孝医疗科技有限公司 Analyte concentration data generation method and device, and system for monitoring analyte level
US20230355140A1 (en) * 2022-05-05 2023-11-09 Know Labs, Inc. High performance glucose sensor
DE102022111828A1 (en) 2022-05-11 2023-11-16 Endress+Hauser SE+Co. KG Condition monitoring of a vibronic sensor
WO2024005837A1 (en) * 2022-07-01 2024-01-04 Brewer Science, Inc. Differential current limiting for voltammetry sensor lifetime extension

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060001538A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20080000779A1 (en) * 2005-12-30 2008-01-03 Medtronic Minimed, Inc. Method and System for Remedying Sensor Malfunctions Detected by Electrochemical Impedance Spectroscopy
US20080214910A1 (en) * 2007-03-01 2008-09-04 Buck Harvey B System and method for operating an electrochemical analyte sensor
US20110040163A1 (en) * 2009-08-14 2011-02-17 Bayer Healthcare Llc Electrochemical impedance spectroscopy enabled continuous glucose monitoring sensor systems
US7985330B2 (en) * 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
US20110230741A1 (en) * 2008-12-29 2011-09-22 Medtronic Minimed, Inc. Methods and systems for observing sensor parameters
US20120097554A1 (en) * 2010-10-18 2012-04-26 Medtronic Minimed, Inc. Analyte sensors comprising electrodes having selected electrochemical and mechanical properties

Family Cites Families (1854)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US65604A (en) 1867-06-11 Napoleon b
US62334A (en) 1867-02-26 Arthur-holmes
US52641A (en) 1866-02-13 Improvement in stamping-heads
US1044887A (en) 1908-10-02 1912-11-19 Sloan & Company Safety suspension or chatelaine pin.
US1018833A (en) 1909-06-26 1912-02-27 John C Lincoln Convertible motor.
US1032768A (en) 1910-08-13 1912-07-16 Frank Gebbie Can-filling apparatus.
US1000444A (en) 1911-01-28 1911-08-15 David S Sensenig Lock.
DE19852258A1 (en) 1998-11-11 2000-05-18 Agfa Gevaert Ag Radiation-sensitive recording material for the production of waterless offset printing plates
US1564641A (en) 1922-04-10 1925-12-08 Chicago Miniature Lamp Works Detector for wireless systems
US2402306A (en) 1943-10-07 1946-06-18 Turkel Henry Retaining guard guide for needles
US2719797A (en) 1950-05-23 1955-10-04 Baker & Co Inc Platinizing tantalum
US3210578A (en) 1962-01-12 1965-10-05 Westinghouse Electric Corp Multispeed motor connector
BE629985A (en) 1962-11-29
US3539455A (en) 1965-10-08 1970-11-10 Leland C Clark Jr Membrane polarographic electrode system and method with electrochemical compensation
GB1172356A (en) 1966-03-25 1969-11-26 Atomic Energy Authority Uk Improvements in or relating to Valves for Fluid Lines
US3556950A (en) 1966-07-15 1971-01-19 Ibm Method and apparatus for automatic electrochemical analysis
US3610230A (en) 1967-03-20 1971-10-05 H W Anderson Products Inc Manometer with a balloon sealing the upper end thereof and method of using same
GB1191363A (en) 1968-02-19 1970-05-13 Pavelle Ltd Improvements in or relating to Electronic Thermostats.
US3610226A (en) 1968-02-27 1971-10-05 Anthony M Albisser A double lumen cannula for blood sampling
JPS4810633B1 (en) 1969-04-25 1973-04-05
USRE31916E (en) 1970-11-10 1985-06-18 Becton Dickinson & Company Electrochemical detection cell
US3933593A (en) 1971-02-22 1976-01-20 Beckman Instruments, Inc. Rate sensing batch analysis method
US3791871A (en) 1971-04-14 1974-02-12 Lockheed Aircraft Corp Electrochemical cell
CH559912A5 (en) 1971-09-09 1975-03-14 Hoffmann La Roche
GB1412983A (en) 1971-11-30 1975-11-05 Debell & Richardson Method of producing porous plastic materials
US3943918A (en) 1971-12-02 1976-03-16 Tel-Pac, Inc. Disposable physiological telemetric device
US3837339A (en) 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US3775182A (en) 1972-02-25 1973-11-27 Du Pont Tubular electrochemical cell with coiled electrodes and compressed central spindle
US3780727A (en) 1972-02-25 1973-12-25 Hoffmann La Roche Cardiac pacer monitoring means with rate and pulse discrimination
US3874850A (en) 1972-07-24 1975-04-01 Radiometer As Blood analyzing method and apparatus
GB1442303A (en) 1972-09-08 1976-07-14 Radiometer As Cell for electro-chemical analysis
CS164231B2 (en) 1972-09-28 1975-11-07
US3949388A (en) 1972-11-13 1976-04-06 Monitron Industries, Inc. Physiological sensor and transmitter
US3910256A (en) 1972-12-29 1975-10-07 Primary Childrens Hospital Automated blood analysis system
US3838682A (en) 1972-12-29 1974-10-01 Primary Childrens Hospital Automated blood analysis system
US3908657A (en) 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
US3929971A (en) 1973-03-30 1975-12-30 Research Corp Porous biomaterials and method of making same
US3826244A (en) 1973-07-20 1974-07-30 Us Health Education & Welfare Thumbtack microelectrode and method of making same
US3926760A (en) 1973-09-28 1975-12-16 Du Pont Process for electrophoretic deposition of polymer
US3898984A (en) 1974-02-04 1975-08-12 Us Navy Ambulatory patient monitoring system
US4067322A (en) 1974-07-19 1978-01-10 Johnson Joseph H Disposable, pre-gel body electrodes
US4109505A (en) 1974-07-22 1978-08-29 Primary Children's Hospital Automated blood analysis system
US3966580A (en) 1974-09-16 1976-06-29 The University Of Utah Novel protein-immobilizing hydrophobic polymeric membrane, process for producing same and apparatus employing same
US3957613A (en) 1974-11-01 1976-05-18 General Electric Company Miniature probe having multifunctional electrodes for sensing ions and gases
US4245634A (en) 1975-01-22 1981-01-20 Hospital For Sick Children Artificial beta cell
US3978856A (en) 1975-03-20 1976-09-07 Michel Walter A Heart beat waveform monitoring apparatus
US3982530A (en) 1975-04-22 1976-09-28 Egon Storch Penial appliance
US4036749A (en) 1975-04-30 1977-07-19 Anderson Donald R Purification of saline water
YU139076A (en) 1975-06-09 1982-05-31 B Pk Ts Zwiazku Spoldz Mleczar Reactor for stirring and aeration of waste water
US4052754A (en) 1975-08-14 1977-10-11 Homsy Charles A Implantable structure
US3960497A (en) 1975-08-19 1976-06-01 Beckman Instruments, Inc. Chemical analyzer with automatic calibration
US3979274A (en) 1975-09-24 1976-09-07 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
CH591237A5 (en) 1975-11-06 1977-09-15 Bbc Brown Boveri & Cie
US4030640A (en) 1975-11-10 1977-06-21 Indicon Inc. Method and apparatus for dispensing viscous materials
US4016866A (en) 1975-12-18 1977-04-12 General Electric Company Implantable electrochemical sensor
US4040908A (en) 1976-03-12 1977-08-09 Children's Hospital Medical Center Polarographic analysis of cholesterol and other macromolecular substances
US4037563A (en) 1976-03-29 1977-07-26 John M. Pflueger Aquarium viewing window
US4119406A (en) 1976-05-06 1978-10-10 Miles Laboratories, Inc. Calibration apparatus
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4024312A (en) 1976-06-23 1977-05-17 Johnson & Johnson Pressure-sensitive adhesive tape having extensible and elastic backing composed of a block copolymer
GB1527801A (en) 1976-07-21 1978-10-11 Rolfe P Catheters
DE2658734C3 (en) 1976-12-24 1979-10-31 Draegerwerk Ag, 2400 Luebeck Function monitoring for an electrochemical gas sensor
US4129128A (en) 1977-02-23 1978-12-12 Mcfarlane Richard H Securing device for catheter placement assembly
FR2387659A1 (en) 1977-04-21 1978-11-17 Armines GLYCEMIA CONTROL AND REGULATION DEVICE
DE2726450C3 (en) 1977-06-11 1982-01-14 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG Apparatebau KG, 6380 Bad Homburg Catheter measuring arrangement for electrochemical analysis
DE2734247C2 (en) 1977-07-29 1984-07-19 Fresenius AG, 6380 Bad Homburg Device for continuous chemical analysis in the living body
US4151845A (en) 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
JPS5921500B2 (en) 1978-01-28 1984-05-21 東洋紡績株式会社 Enzyme membrane for oxygen electrode
US4172770A (en) 1978-03-27 1979-10-30 Technicon Instruments Corporation Flow-through electrochemical system analytical method
US4259540A (en) 1978-05-30 1981-03-31 Bell Telephone Laboratories, Incorporated Filled cables
US4344438A (en) 1978-08-02 1982-08-17 The United States Of America As Represented By The Department Of Health, Education And Welfare Optical sensor of plasma constituents
US4215703A (en) 1978-08-29 1980-08-05 Willson James K V Variable stiffness guide wire
US4240438A (en) 1978-10-02 1980-12-23 Wisconsin Alumni Research Foundation Method for monitoring blood glucose levels and elements
AU530979B2 (en) 1978-12-07 1983-08-04 Aus. Training Aids Pty. Ltd., Detecting position of bullet fired at target
US4255500A (en) 1979-03-29 1981-03-10 General Electric Company Vibration resistant electrochemical cell having deformed casing and method of making same
US4253469A (en) 1979-04-20 1981-03-03 The Narda Microwave Corporation Implantable temperature probe
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4731051A (en) 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
USRE32361E (en) 1979-05-14 1987-02-24 Medtronic, Inc. Implantable telemetry transmission system for analog and digital data
CS210174B1 (en) 1979-07-12 1982-01-29 Ivan Emmer Method of making the electric hygrometric sensor
DE2932761A1 (en) 1979-08-13 1981-02-26 Akzo Gmbh POLYCARBONATE-POLYAETHER-COPOLYMER MEMBRANE
JPS5627643A (en) 1979-08-14 1981-03-18 Toshiba Corp Electrochemical measuring device
US4783250A (en) 1979-08-21 1988-11-08 Pons B Stanley Immobilized electrochemical cell devices and methods of manufacture
US4300572A (en) 1979-12-13 1981-11-17 Knighton David R Fluid administering and pressure sensing apparatus
US4403984A (en) 1979-12-28 1983-09-13 Biotek, Inc. System for demand-based adminstration of insulin
US4369785A (en) 1980-02-21 1983-01-25 Contemporary Ocu-Flo, Inc. Surgical fluid flow system
US4861830A (en) 1980-02-29 1989-08-29 Th. Goldschmidt Ag Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming
SE419903B (en) 1980-03-05 1981-08-31 Enfors Sven Olof enzyme electrode
NL8001420A (en) 1980-03-10 1981-10-01 Cordis Europ ELECTRODE COMPOSITIVE COMPOSITE, FOR AN ELECTROCHEMICAL MEASUREMENT, IN PARTICULAR AN ISFET-CONSTRUCTED COMPOSITION, AND METHOD FOR MANUFACTURING THE ASSEMBLY.
DE3173564D1 (en) 1980-09-02 1986-03-06 Medtronic Inc Subcutaneously implantable lead with drug dispenser means
DE3134275C2 (en) 1980-09-10 1986-11-20 AVL AG, Schaffhausen Capillary body for a capillary reference electrode
IE51643B1 (en) 1980-10-15 1987-01-21 Smith & Nephew Ass Coated articles and materials suitable for coating
US4425920A (en) 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US4420564A (en) 1980-11-21 1983-12-13 Fuji Electric Company, Ltd. Blood sugar analyzer having fixed enzyme membrane sensor
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS57118152A (en) 1981-01-14 1982-07-22 Matsushita Electric Ind Co Ltd Enzyme electrode
US4436094A (en) 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4442841A (en) 1981-04-30 1984-04-17 Mitsubishi Rayon Company Limited Electrode for living bodies
US4426621A (en) 1981-06-29 1984-01-17 International Business Machines Corporation Detection circuitry for electrochemical analysis
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US4402694A (en) 1981-07-16 1983-09-06 Biotek, Inc. Body cavity access device containing a hormone source
US4407298A (en) 1981-07-16 1983-10-04 Critikon Inc. Connector for thermodilution catheter
US4392849A (en) 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
US4419535A (en) 1981-07-31 1983-12-06 Hara Robert J O Multi-cable conduit for floors and walls
DE3138194A1 (en) 1981-09-25 1983-04-14 Basf Ag, 6700 Ludwigshafen WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE
DE3278334D1 (en) 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US4431004A (en) 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
IT1142930B (en) 1981-11-04 1986-10-15 Luigi Bernardi PORTABLE APPARATUS THAT INFUSES INSULIN ON THE BASIS OF GLYCEMIC DETECTION
US4415666A (en) 1981-11-05 1983-11-15 Miles Laboratories, Inc. Enzyme electrode membrane
US4418148A (en) 1981-11-05 1983-11-29 Miles Laboratories, Inc. Multilayer enzyme electrode membrane
NL193256C (en) 1981-11-10 1999-04-02 Cordis Europ Sensor system.
US4454295A (en) 1981-11-16 1984-06-12 Uco Optics, Inc. Cured cellulose ester, method of curing same, and use thereof
US4432366A (en) 1981-11-27 1984-02-21 Cordis Corporation Reference electrode catheter
US4494950A (en) 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4462048A (en) 1982-02-11 1984-07-24 Rca Corporation Noise reduction circuitry for audio signals
US4448188A (en) 1982-02-18 1984-05-15 Laserscope, Inc. Method for providing an oxygen bearing liquid to a blood vessel for the performance of a medical procedure
US4457339A (en) 1982-03-03 1984-07-03 Coulter Electronics, Inc. Multiprogrammable pinch valve module
US4403847A (en) 1982-03-29 1983-09-13 Eastman Kodak Company Electrographic transfer apparatus
FI831399L (en) 1982-04-29 1983-10-30 Agripat Sa KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL
FR2528693B1 (en) 1982-06-22 1985-01-11 Mabille Pierre DENTAL PROPHYLAXIS DEVICE
EP0098592A3 (en) 1982-07-06 1985-08-21 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
US6248077B1 (en) 1982-07-19 2001-06-19 Edwards Lifesciences Corp. System for sensing a characteristic of fluid flowing to or from a body
US4509531A (en) 1982-07-28 1985-04-09 Teledyne Industries, Inc. Personal physiological monitor
EP0100682A1 (en) 1982-08-03 1984-02-15 Peritronic Medical Industries Plc Fluid flow control process and apparatus
US4571292A (en) 1982-08-12 1986-02-18 Case Western Reserve University Apparatus for electrochemical measurements
DE3379589D1 (en) 1982-10-25 1989-05-18 Hellgren Lars G I Enzyme composition for cleaning, the use thereof and preparation of the composition
US4527240A (en) 1982-12-29 1985-07-02 Kvitash Vadim I Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems
US5059654A (en) 1983-02-14 1991-10-22 Cuno Inc. Affinity matrices of modified polysaccharide supports
US4614514A (en) 1983-02-16 1986-09-30 M/A Com, Inc. Microwave sterilizer
US4506680A (en) 1983-03-17 1985-03-26 Medtronic, Inc. Drug dispensing body implantable lead
US5682884A (en) 1983-05-05 1997-11-04 Medisense, Inc. Strip electrode with screen printing
US5509410A (en) 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
CA1226036A (en) 1983-05-05 1987-08-25 Irving J. Higgins Analytical equipment and sensor electrodes therefor
CA1219040A (en) 1983-05-05 1987-03-10 Elliot V. Plotkin Measurement of enzyme-catalysed reactions
US4650547A (en) 1983-05-19 1987-03-17 The Regents Of The University Of California Method and membrane applicable to implantable sensor
US4484987A (en) 1983-05-19 1984-11-27 The Regents Of The University Of California Method and membrane applicable to implantable sensor
WO1985000463A1 (en) 1983-07-05 1985-01-31 Matsushita Electric Industrial Co., Ltd. Aluminum electrolytic capacitor and method of manufacture thereof
US4535786A (en) 1983-07-25 1985-08-20 Kater John A R Measurement of body fluid chemistry
US4538616A (en) 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
US4655880A (en) 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4600495A (en) 1983-08-03 1986-07-15 Medtronic, Inc. Flow through ion selective electrode
US4519973A (en) 1983-08-03 1985-05-28 Medtronic, Inc. Ion selective membranes for use in ion sensing electrodes
US4486290A (en) 1983-08-03 1984-12-04 Medtronic, Inc. Combination ion selective sensing electrode
US4565666A (en) 1983-08-03 1986-01-21 Medtronic, Inc. Method of producing combination ion selective sensing electrode
US4565665A (en) 1983-08-03 1986-01-21 Medtronic, Inc. Flow through ion selective electrode
US4578215A (en) 1983-08-12 1986-03-25 Micro-Circuits Company Electrical conductivity-enhancing and protecting material
US4573968A (en) 1983-08-16 1986-03-04 Ivac Corporation Infusion and blood chemistry monitoring system
US4554927A (en) 1983-08-30 1985-11-26 Thermometrics Inc. Pressure and temperature sensor
US4496454A (en) 1983-10-19 1985-01-29 Hewlett-Packard Company Self cleaning electrochemical detector and cell for flowing stream analysis
GB2149918A (en) 1983-11-03 1985-06-19 John Anderson Sudden infant death syndrome monitor
US4867741A (en) 1983-11-04 1989-09-19 Portnoy Harold D Physiological draining system with differential pressure and compensating valves
GB8331422D0 (en) 1983-11-24 1984-01-04 Bates W & A Ltd Mixing particulate materials
US6846654B1 (en) 1983-11-29 2005-01-25 Igen International, Inc. Catalytic antibodies as chemical sensors
US4685903A (en) 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US5562614A (en) 1993-11-22 1996-10-08 Advanced Cardiovascular Systems, Inc. Programmable manifold system for automatic fluid delivery
JPS60231156A (en) 1984-04-30 1985-11-16 Kuraray Co Ltd Liquid junction type reference electrode
US4753652A (en) 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US4883057A (en) 1984-05-09 1989-11-28 Research Foundation, The City University Of New York Cathodic electrochemical current arrangement with telemetric application
US4583976A (en) 1984-05-31 1986-04-22 E. R. Squibb & Sons, Inc. Catheter support
US4747822A (en) 1984-07-09 1988-05-31 Peabody Alan M Continuous flow peritoneal dialysis system and method
CA1258496A (en) 1984-07-30 1989-08-15 Teruyoshi Uchida Insulated noble metal wire and porous membrane as po.sub.2 bioelectrode
US4561963A (en) 1984-07-30 1985-12-31 Zinetics Medical Technology Corporation Antimony and graphite hydrogen ion electrode and method of making such electrode
DE3429596A1 (en) 1984-08-10 1986-02-20 Siemens AG, 1000 Berlin und 8000 München DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE
EP0192712A1 (en) 1984-09-05 1986-09-03 Intra Optics Laboratories Pty. Limited Control of blood flow
US5030333A (en) 1984-09-13 1991-07-09 Children's Hospital Medical Center Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor
CA1254091A (en) 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US4613328A (en) 1984-10-22 1986-09-23 Cecil Boyd Bio-medical injector apparatus
US5171689A (en) 1984-11-08 1992-12-15 Matsushita Electric Industrial Co., Ltd. Solid state bio-sensor
US5235003A (en) 1985-01-04 1993-08-10 Thoratec Laboratories Corporation Polysiloxane-polylactone block copolymers
US4963595A (en) 1985-01-04 1990-10-16 Thoratec Laboratories Corporation Polysiloxane-polylactone block copolymers
US4810243A (en) 1985-01-18 1989-03-07 Intelligent Medicine, Inc. Device and method for effecting application of a therapeutic agent
US5088981A (en) 1985-01-18 1992-02-18 Howson David C Safety enhanced device and method for effecting application of a therapeutic agent
US4577642A (en) 1985-02-27 1986-03-25 Medtronic, Inc. Drug dispensing body implantable lead employing molecular sieves and methods of fabrication
US4838281A (en) 1985-02-28 1989-06-13 Alcon Laboratories, Inc. Linear suction control system
DE3536693A1 (en) 1985-03-20 1986-09-25 Lasertechnik GmbH, 6050 Heusenstamm DEVICE FOR EXCITING A DISCHARGE IN A LASER GAS
US4958148A (en) 1985-03-22 1990-09-18 Elmwood Sensors, Inc. Contrast enhancing transparent touch panel device
JPS61232859A (en) 1985-04-05 1986-10-17 呉羽化学工業株式会社 Medical pump apparatus
US5279294A (en) 1985-04-08 1994-01-18 Cascade Medical, Inc. Medical diagnostic system
US4787398A (en) 1985-04-08 1988-11-29 Garid, Inc. Glucose medical monitoring system
US4781798A (en) 1985-04-19 1988-11-01 The Regents Of The University Of California Transparent multi-oxygen sensor array and method of using same
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4786394A (en) 1985-08-29 1988-11-22 Diamond Sensor Systems, Inc. Apparatus for chemical measurement of blood characteristics
US4805624A (en) 1985-09-09 1989-02-21 The Montefiore Hospital Association Of Western Pa Low-potential electrochemical redox sensors
US4592824A (en) 1985-09-13 1986-06-03 Centre Suisse D'electronique Et De Microtechnique S.A. Miniature liquid junction reference electrode and an integrated solid state electrochemical sensor including the same
US4680268A (en) 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4890620A (en) 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4689309A (en) 1985-09-30 1987-08-25 Miles Laboratories, Inc. Test device, method of manufacturing same and method of determining a component in a sample
JPS6283849A (en) 1985-10-04 1987-04-17 Reiji Yoshinaka Method of purifying collagen
DE3537919A1 (en) 1985-10-24 1987-04-30 Kessler Manfred ARRANGEMENT FOR STABILIZING A GAS REFERENCE ELECTRODE
JPS62174260A (en) 1986-01-20 1987-07-31 Shin Etsu Chem Co Ltd Fluorosilicone rubber composition
US4705503A (en) 1986-02-03 1987-11-10 Regents Of The University Of Minnesota Metabolite sensor including a chemical concentration sensitive flow controller for a drug delivery system
GB8602732D0 (en) 1986-02-04 1986-03-12 Univ Brunel Taking samples from patients
JPS62180263A (en) 1986-02-04 1987-08-07 Terumo Corp Oxygen sensor
US4791932A (en) 1986-03-05 1988-12-20 Cordis Corporation Extracorporeal sensing module
US4685912A (en) 1986-03-05 1987-08-11 Patent Research And Development Corp. I.V. drip chamber with built-in pump activated by external means
US4759366A (en) 1986-03-19 1988-07-26 Telectronics N.V. Rate responsive pacing using the ventricular gradient
US4776944A (en) 1986-03-20 1988-10-11 Jiri Janata Chemical selective sensors utilizing admittance modulated membranes
JPS62225513A (en) 1986-03-26 1987-10-03 Shin Etsu Chem Co Ltd Block-graft copolymer and production thereof
JPS62224361A (en) 1986-03-26 1987-10-02 アイシン精機株式会社 Auxiliary circulation machinery driving apparatus
US4685463A (en) 1986-04-03 1987-08-11 Williams R Bruce Device for continuous in vivo measurement of blood glucose concentrations
JPS6340532A (en) 1986-04-05 1988-02-20 日本光電工業株式会社 Apparatus for monitoring blood component
JPS62240025A (en) 1986-04-10 1987-10-20 住友電気工業株式会社 Catheter type sensor
US4757022A (en) 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4994167A (en) 1986-04-15 1991-02-19 Markwell Medical Institute, Inc. Biological fluid measuring device
CA1273399A (en) 1986-04-15 1990-08-28 Mark C. Shults Biological fluid measuring device
US4789467A (en) 1986-04-30 1988-12-06 Baxter Travenol Laboratories, Inc. Automated disinfection system
EP0265519B1 (en) 1986-04-30 1995-09-13 IGEN, INC. (a California corporation) Electrochemiluminescent assays
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US4750496A (en) 1987-01-28 1988-06-14 Xienta, Inc. Method and apparatus for measuring blood glucose concentration
JPS636451A (en) 1986-06-27 1988-01-12 Terumo Corp Enzyme sensor
US4874363A (en) 1986-07-25 1989-10-17 Abell Walter L Colon hydrotherapy and evacuator system
US4935346A (en) 1986-08-13 1990-06-19 Lifescan, Inc. Minimum procedure system for the determination of analytes
US4800495A (en) 1986-08-18 1989-01-24 Physio-Control Corporation Method and apparatus for processing signals used in oximetry
EP0259668B1 (en) 1986-09-01 1990-12-12 Siemens Aktiengesellschaft Piston pump for a dosed medicament delivery device
US5002572A (en) 1986-09-11 1991-03-26 Picha George J Biological implant with textured surface
US4763648A (en) 1986-09-12 1988-08-16 Migada, Inc. Method and apparatus for arterial and venous blood sampling
US5055171A (en) 1986-10-06 1991-10-08 T And G Corporation Ionic semiconductor materials and applications thereof
AU617667B2 (en) 1986-11-04 1991-12-05 Allergan, Inc. Open-cell, silicone-elastomer medical implant and method for making
US5007929B1 (en) 1986-11-04 1994-08-30 Medical Products Dev Open-cell silicone-elastomer medical implant
FR2607591B1 (en) 1986-11-28 1989-12-08 Thomson Cgr CURVED BAR PROBE FOR ECHOGRAPH
FR2607696B1 (en) 1986-12-03 1995-08-11 Gosserez Olivier IMPLANTABLE BREAST PROSTHESIS CONTRARY TO THE FORMATION OF A RETRACTILE SHELL
EP0273258B1 (en) 1986-12-22 1991-11-21 Siemens Aktiengesellschaft Arrangement for the analysis of liquids, and method of applying it
US4694861A (en) 1986-12-22 1987-09-22 Beckman Instruments, Inc. Rotary pinch valve
JPS63160635A (en) 1986-12-23 1988-07-04 三菱レイヨン株式会社 Living body component measuring utensil
DE3700119A1 (en) 1987-01-03 1988-07-14 Inst Diabetestechnologie Gemei IMPLANTABLE ELECTROCHEMICAL SENSOR
AT391063B (en) 1987-01-08 1990-08-10 Blum Gmbh Julius CONNECTING FITTING FOR FASTENING THE RAILING OF A DRAWER
US4755168A (en) 1987-01-27 1988-07-05 Pat Romanelli Medical drainage pump with irrigation
US4951669A (en) 1987-01-30 1990-08-28 Minnesota Mining And Manufacturing Company Blood parameter measurement system
US5048525A (en) 1987-01-30 1991-09-17 Minnesota Mining And Manufacturing Company Blood parameter measurement system with compliant element
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
US4934369A (en) 1987-01-30 1990-06-19 Minnesota Mining And Manufacturing Company Intravascular blood parameter measurement system
AT391998B (en) 1987-02-02 1990-12-27 Falko Dr Skrabal Device for determining the concentration of at least one medicinal substance in living organisms
US5002054A (en) 1987-02-25 1991-03-26 Ash Medical Systems, Inc. Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
US4777953A (en) 1987-02-25 1988-10-18 Ash Medical Systems, Inc. Capillary filtration and collection method for long-term monitoring of blood constituents
US4854322A (en) 1987-02-25 1989-08-08 Ash Medical Systems, Inc. Capillary filtration and collection device for long-term monitoring of blood constituents
DE3851358D1 (en) 1987-02-27 1994-10-13 Shimadzu Corp Infusion rate control device.
US5365426A (en) 1987-03-13 1994-11-15 The University Of Maryland Advanced signal processing methodology for the detection, localization and quantification of acute myocardial ischemia
US4923819A (en) 1987-03-27 1990-05-08 Chimerix Corporation Time-resolved fluorescence immunoassay
EP0284518B1 (en) 1987-03-27 1992-10-07 Isao Karube Miniaturized oxygen electrode and miniaturized biosensor and production process thereof
US4935345A (en) 1987-04-07 1990-06-19 Arizona Board Of Regents Implantable microelectronic biochemical sensor incorporating thin film thermopile
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US5352348A (en) 1987-04-09 1994-10-04 Nova Biomedical Corporation Method of using enzyme electrode
US4749985A (en) 1987-04-13 1988-06-07 United States Of America As Represented By The United States Department Of Energy Functional relationship-based alarm processing
EP0288793A3 (en) 1987-04-22 1990-04-25 Abbott Laboratories Cartridge and methods for performing a solid-phase immunoassay
EP0287920B1 (en) 1987-04-22 1991-05-15 Siemens Aktiengesellschaft Piston pump for a device for dosing medicaments
EP0290683A3 (en) 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
US4976687A (en) 1987-05-11 1990-12-11 James Martin Apparatus for controlling the supplying of intravenous fluids
US4988671A (en) 1987-05-20 1991-01-29 Hoechst Celanese Corp. Process for producing a superconductive complex metal oxide
US4820281A (en) 1987-05-21 1989-04-11 Ivy Medical, Inc. Drop volume measurement system
US5540828A (en) 1987-06-08 1996-07-30 Yacynych; Alexander Method for making electrochemical sensors and biosensors having a polymer modified surface
US4810470A (en) 1987-06-19 1989-03-07 Miles Inc. Volume independent diagnostic device
US4834101A (en) 1987-06-26 1989-05-30 The University Of Michigan Catheter-type electrochemical sensors
JPH07122624B2 (en) 1987-07-06 1995-12-25 ダイキン工業株式会社 Biosensor
US4805625A (en) 1987-07-08 1989-02-21 Ad-Tech Medical Instrument Corporation Sphenoidal electrode and insertion method
US4997627A (en) 1987-07-17 1991-03-05 Fisher Scientific Company Sample analysis
US5207642A (en) 1987-08-07 1993-05-04 Baxter International Inc. Closed multi-fluid delivery system and method
US4925444A (en) 1987-08-07 1990-05-15 Baxter Travenol Laboratories, Inc. Closed multi-fluid delivery system and method
US4974929A (en) 1987-09-22 1990-12-04 Baxter International, Inc. Fiber optical probe connector for physiologic measurement devices
US4919649A (en) 1987-09-30 1990-04-24 Sherwood Medical Company Fluid delivery system
NL8702370A (en) 1987-10-05 1989-05-01 Groningen Science Park METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY.
CA1321522C (en) 1987-10-14 1993-08-24 Rickey Paul Davis Surgical irrigation and aspiration system
US4863265A (en) 1987-10-16 1989-09-05 Mine Safety Appliances Company Apparatus and method for measuring blood constituents
US4831070A (en) 1987-11-02 1989-05-16 Dow Corning Corporation Moldable elastomeric pressure sensitive adhesives
GB8725936D0 (en) 1987-11-05 1987-12-09 Genetics Int Inc Sensing system
US4852573A (en) 1987-12-04 1989-08-01 Kennedy Philip R Implantable neural electrode
NL8802307A (en) 1987-12-17 1989-07-17 Mr W M H Kerbosch B V Handelen DEVICE FOR CONTROLLING THE FLOW RATE OF AN INFUSION FLUID IN AN INFUSION SYSTEM.
EP0323605B1 (en) 1987-12-21 1994-01-26 Abbott Laboratories Chromatographic binding assay devices and methods
US4890621A (en) 1988-01-19 1990-01-02 Northstar Research Institute, Ltd. Continuous glucose monitoring and a system utilized therefor
US4898578A (en) 1988-01-26 1990-02-06 Baxter International Inc. Drug infusion system with calculator
US5362307A (en) 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
US5082147A (en) 1988-02-29 1992-01-21 Richard Jacobs Composition dispensing system
US4934375A (en) 1988-03-04 1990-06-19 Spectramed, Inc. Flush-valve assembly for blood pressure measurement catheter
US4822336A (en) 1988-03-04 1989-04-18 Ditraglia John Blood glucose level sensing
DE3812584A1 (en) 1988-04-13 1989-10-26 Mic Medical Instr Corp DEVICE FOR BIOFEEDBACK CONTROL OF BODY FUNCTIONS
US4955861A (en) 1988-04-21 1990-09-11 Therex Corp. Dual access infusion and monitoring system
US5244630A (en) 1988-04-22 1993-09-14 Abbott Laboratories Device for performing solid-phase diagnostic assay
US5034112A (en) 1988-05-19 1991-07-23 Nissan Motor Company, Ltd. Device for measuring concentration of nitrogen oxide in combustion gas
DE3817411A1 (en) 1988-05-21 1989-11-30 Fresenius Ag MULTIPLE INFUSION SYSTEM
NL8801400A (en) 1988-06-01 1990-01-02 Akzo Nv Apparatus for withdrawing an optimum amount of blood per unit time from a donor.
US5026348A (en) 1988-06-06 1991-06-25 The General Hospital Corporation Apparatus and method for the detection of IV catheter obstruction and extravasation
JPH022913A (en) 1988-06-16 1990-01-08 Bridgestone Corp Modified electrode
US4849458A (en) 1988-06-17 1989-07-18 Matrix Medica, Inc. Segmented polyether polyurethane
US4900305A (en) 1988-06-27 1990-02-13 Queen's University At Kingston Ambulatory infusion pump
CA1299653C (en) 1988-07-07 1992-04-28 Markwell Medical Institute, Inc. Biological fluid measuring device
US5208147A (en) 1988-07-21 1993-05-04 Radiometer A/S Means for measuring a characteristic in a sample fluid
DK409188D0 (en) 1988-07-21 1988-07-21 Radiometer As PROCEDURE FOR MEASURING A CHARACTERISTICS IN A FLUIDUM
EP0352631A3 (en) 1988-07-25 1991-07-10 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
US4907857A (en) 1988-07-25 1990-03-13 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
US4925268A (en) 1988-07-25 1990-05-15 Abbott Laboratories Fiber-optic physiological probes
GB8817997D0 (en) 1988-07-28 1988-09-01 Cambridge Life Sciences Enzyme electrodes & improvements in manufacture thereof
US4815471A (en) 1988-08-01 1989-03-28 Precision Interconnect Corporation Catheter assembly
EP0353328A1 (en) 1988-08-03 1990-02-07 Dräger Nederland B.V. A polarographic-amperometric three-electrode sensor
US4946439A (en) 1988-08-15 1990-08-07 Critikon, Inc. Dual source parenteral infusion system with secondary infusion module
US5340722A (en) 1988-08-24 1994-08-23 Avl Medical Instruments Ag Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method
US4994026A (en) 1988-08-31 1991-02-19 W. R. Grace & Co.-Conn. Gravity flow fluid balance system
US5098377A (en) 1988-09-06 1992-03-24 Baxter International Inc. Multimodal displacement pump and dissolution system for same
US5096669A (en) 1988-09-15 1992-03-17 I-Stat Corporation Disposable sensing device for real time fluid analysis
US5108889A (en) 1988-10-12 1992-04-28 Thorne, Smith, Astill Technologies, Inc. Assay for determining analyte using mercury release followed by detection via interaction with aluminum
US4957483A (en) 1988-10-21 1990-09-18 Den-Tal-Ez, Inc. Sterilizable syringe
US5200051A (en) 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US4974592A (en) 1988-11-14 1990-12-04 American Sensor Systems Corporation Continuous on-line blood monitoring system
US6306594B1 (en) 1988-11-14 2001-10-23 I-Stat Corporation Methods for microdispensing patterened layers
US5009251A (en) 1988-11-15 1991-04-23 Baxter International, Inc. Fluid flow control
US4921480A (en) 1988-11-21 1990-05-01 Sealfon Andrew I Fixed volume infusion device
US5006050A (en) 1988-12-09 1991-04-09 James E. Cooke High accuracy disposable cassette infusion pump
JPH073321Y2 (en) 1988-12-10 1995-01-30 株式会社堀場製作所 Flow-through hydrogen peroxide electrode
US5372709A (en) 1988-12-13 1994-12-13 Bio-Flo Limited Fluid flow control apparatus
US5360404A (en) 1988-12-14 1994-11-01 Inviro Medical Devices Ltd. Needle guard and needle assembly for syringe
US4947845A (en) 1989-01-13 1990-08-14 Pacesetter Infusion, Ltd. Method of maximizing catheter longevity in an implantable medication infusion system
US5068536A (en) 1989-01-19 1991-11-26 Futrex, Inc. Method for providing custom calibration for near infrared instruments for measurement of blood glucose
US5077476A (en) 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
US5089421A (en) 1989-02-06 1992-02-18 Susan Dieffenbach Method and apparatus for analyzing blood
US4967940A (en) 1989-02-21 1990-11-06 Minnesota Mining And Manufacturing Co. Method and apparatus for precision squeeze tube valving, pumping and dispensing of work fluid(s)
EP0385805B1 (en) 1989-03-03 1996-06-05 Edward W. Stark Signal processing method and apparatus
DK115989D0 (en) 1989-03-09 1989-03-09 Nordisk Gentofte METHOD AND METHOD FOR MEASURING A LIQUID COMPONENT
US5269891A (en) 1989-03-09 1993-12-14 Novo Nordisk A/S Method and apparatus for determination of a constituent in a fluid
US4963131A (en) 1989-03-16 1990-10-16 Surgin Surgical Instrumentation, Inc. Disposable cassette for ophthalmic surgery applications
JPH02298855A (en) 1989-03-20 1990-12-11 Assoc Univ Inc Electrochemical biosensor using immobilized enzyme and redox polymer
US5089112A (en) 1989-03-20 1992-02-18 Associated Universities, Inc. Electrochemical biosensor based on immobilized enzymes and redox polymers
CA1328359C (en) 1989-03-27 1994-04-12 Michael D. Mintz Fluid sample collection and delivery system and methods particularly adapted for body fluid sampling
US4986671A (en) 1989-04-12 1991-01-22 Luxtron Corporation Three-parameter optical fiber sensor and system
US4953552A (en) 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
US5046496A (en) 1989-04-26 1991-09-10 Ppg Industries, Inc. Sensor assembly for measuring analytes in fluids
US4975636A (en) 1989-05-01 1990-12-04 Hewlett-Packard Company Method and apparatus for selecting and displaying a high resolution window from a main display
US5145565A (en) 1989-05-01 1992-09-08 Spacelabs, Inc. Contamination-free method and apparatus for measuring body fluid chemical parameters
US5178957A (en) 1989-05-02 1993-01-12 Minnesota Mining And Manufacturing Company Noble metal-polymer composites and flexible thin-film conductors prepared therefrom
EP0396788A1 (en) 1989-05-08 1990-11-14 Dräger Nederland B.V. Process and sensor for measuring the glucose content of glucosecontaining fluids
US5178142A (en) 1989-05-23 1993-01-12 Vivascan Corporation Electromagnetic method and apparatus to measure constituents of human or animal tissue
US5298022A (en) 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
IT1231916B (en) 1989-05-29 1992-01-15 Ampliscientifica S R L WEARABLE ARTIFICIAL PANCREAS
US4988341A (en) 1989-06-05 1991-01-29 Eastman Kodak Company Sterilizing dressing device and method for skin puncture
US5000419A (en) 1989-06-07 1991-03-19 Electromedics, Inc. Tube clamp
FR2648353B1 (en) 1989-06-16 1992-03-27 Europhor Sa MICRODIALYSIS PROBE
US4927407A (en) 1989-06-19 1990-05-22 Regents Of The University Of Minnesota Cardiac assist pump with steady rate supply of fluid lubricant
CA1341592C (en) 1989-07-07 2009-04-14 Abbott Laboratories Ion capture reagents and methods for performing binding assays
CH677149A5 (en) 1989-07-07 1991-04-15 Disetronic Ag
US4986271A (en) 1989-07-19 1991-01-22 The University Of New Mexico Vivo refillable glucose sensor
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US4979509A (en) 1989-07-19 1990-12-25 Northstar Research Institute, Ltd. Continuous glucose monitoring and a system utilized therefor
US5264104A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5320725A (en) 1989-08-02 1994-06-14 E. Heller & Company Electrode and method for the detection of hydrogen peroxide
US5264105A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5262035A (en) 1989-08-02 1993-11-16 E. Heller And Company Enzyme electrodes
US4944299A (en) 1989-08-08 1990-07-31 Siemens-Pacesetter, Inc. High speed digital telemetry system for implantable device
US5101814A (en) 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
US5190041A (en) 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5041092A (en) 1989-08-29 1991-08-20 Medical Engineering Corporation Urethral indwelling catheter with magnetically controlled drainage valve and method
US5352349A (en) 1989-08-30 1994-10-04 Daikin Industries, Ltd. Method for reviving an electrode of a biosensor
CA1325149C (en) 1989-08-31 1993-12-14 Gavin Mcgregor Variable intensity remote controlled needleless injector
US5568400A (en) 1989-09-01 1996-10-22 Stark; Edward W. Multiplicative signal correction method and apparatus
CA2024548C (en) 1989-09-05 2002-05-28 David Issachar Analyte specific chemical sensor
US5050612A (en) 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5512246A (en) 1989-09-21 1996-04-30 Anthony P. Russell Method and means for detecting polyhydroxyl compounds
US5216598A (en) 1989-10-04 1993-06-01 Colin Electronics Co., Ltd. System for correction of trends associated with pulse wave forms in oximeters
FR2652736A1 (en) 1989-10-06 1991-04-12 Neftel Frederic IMPLANTABLE DEVICE FOR EVALUATING THE RATE OF GLUCOSE.
JPH03133440A (en) 1989-10-18 1991-06-06 Nishitomo:Kk Clinical thermometer for ladies
IT1251509B (en) 1989-11-24 1995-05-16 Leonardo Cammilli IMPLANTABLE DEFIBRILLATOR WITH AUTOMATIC RECOGNITION OF VENTRICULAR FIBRILLATION, WITH PHARMACOLOGICAL ACTION
US5067491A (en) 1989-12-08 1991-11-26 Becton, Dickinson And Company Barrier coating on blood contacting devices
US5140985A (en) 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5030199A (en) 1989-12-11 1991-07-09 Medical Engineering Corporation Female incontinence control device with magnetically operable valve and method
US5082550A (en) 1989-12-11 1992-01-21 The United States Of America As Represented By The Department Of Energy Enzyme electrochemical sensor electrode and method of making it
US5985129A (en) 1989-12-14 1999-11-16 The Regents Of The University Of California Method for increasing the service life of an implantable sensor
US5342789A (en) 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
CA2071829C (en) 1989-12-14 2001-11-13 David A. Gough Method for increasing the service life of an implantable sensor
FR2656423A1 (en) 1989-12-22 1991-06-28 Rhone Poulenc Chimie Electrochemical biosensor
US5243696A (en) 1989-12-29 1993-09-07 General Signal Corporation Programmable electronic display for a chart recorder
US5188591A (en) 1990-01-26 1993-02-23 Dorsey Iii James H Irrigation control valve for endoscopic instrument
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
EP0441252B1 (en) 1990-02-07 1997-09-03 Abbott Laboratories Alkaline phosphatase enzymes having improved specific activity for use in indicator reagents
CA2034285A1 (en) 1990-02-09 1991-08-10 Masao Yafuso Method and system for monitoring of blood constituents in vivo
US5109850A (en) 1990-02-09 1992-05-05 Massachusetts Institute Of Technology Automatic blood monitoring for medication delivery method and apparatus
US5108819A (en) 1990-02-14 1992-04-28 Eli Lilly And Company Thin film electrical component
US5127405A (en) 1990-02-16 1992-07-07 The Boc Group, Inc. Biomedical fiber optic probe with frequency domain signal processing
US5315993A (en) 1990-02-16 1994-05-31 The Boc Group, Inc. Luminescence monitoring with modulation frequency multiplexing
US5055198A (en) 1990-03-07 1991-10-08 Shettigar U Ramakrishna Autologous blood recovery membrane system and method
US5031618A (en) 1990-03-07 1991-07-16 Medtronic, Inc. Position-responsive neuro stimulator
US5158437A (en) 1990-03-15 1992-10-27 Abbott Laboratories Volumetric pump with spring-biased cracking valves
US5219279A (en) 1990-03-15 1993-06-15 Abbott Laboratories Volumetric pump with pump plunger support and method
US5316008A (en) 1990-04-06 1994-05-31 Casio Computer Co., Ltd. Measurement of electrocardiographic wave and sphygmus
JPH07101215B2 (en) 1990-04-11 1995-11-01 国立身体障害者リハビリテーションセンター総長 Analytical method using biofunctional substance-immobilized electrode
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
US5161532A (en) 1990-04-19 1992-11-10 Teknekron Sensor Development Corporation Integral interstitial fluid sensor
GB2243211A (en) 1990-04-20 1991-10-23 Philips Electronic Associated Analytical instrument and method of calibrating an analytical instrument
AU7854891A (en) 1990-04-26 1991-11-11 Markwell Medical Institute, Inc. Wearable blood glucose monitor
US5152746A (en) 1990-04-30 1992-10-06 Zimmer, Inc. Low pressure irrigation system
US5331555A (en) 1990-05-11 1994-07-19 Sharp Kabushiki Kaisha Electronic apparatus
IT1248934B (en) 1990-06-01 1995-02-11 Fidia Spa BIOCOMPATIBLE PERFORATED MEMBRANES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS A SUPPORT FOR THE IN VITRO GROWTH OF EPITHELIAL CELLS, ARTIFICIAL LEATHER THUS OBTAINED AND THEIR USE IN LEATHER TRANSPLANTS
US5282844A (en) 1990-06-15 1994-02-01 Medtronic, Inc. High impedance, low polarization, low threshold miniature steriod eluting pacing lead electrodes
EP0465708B1 (en) 1990-07-11 1996-05-22 Siemens Aktiengesellschaft Device for electrochemically determining the partial pressure of oxygen in a liquid and method for operating the device
EP0467078B1 (en) 1990-07-18 1996-05-08 Abbott Laboratories An analyte-subtitute reagent for use in specific binding assay methods, devices and kits
AT398694B (en) 1990-07-19 1995-01-25 Avl Verbrennungskraft Messtech DEVICE FOR DETERMINING THE CONCENTRATION OF AT LEAST ONE SUBSTANCE IN ORGANIC TISSUE
US5202261A (en) 1990-07-19 1993-04-13 Miles Inc. Conductive sensors and their use in diagnostic assays
JPH0820412B2 (en) 1990-07-20 1996-03-04 松下電器産業株式会社 Quantitative analysis method and device using disposable sensor
US5112455A (en) 1990-07-20 1992-05-12 I Stat Corporation Method for analytically utilizing microfabricated sensors during wet-up
US5113869A (en) 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
WO1992003107A1 (en) 1990-08-28 1992-03-05 Meadox Medicals, Inc. Self-supporting woven vascular graft
US5165406A (en) 1990-09-13 1992-11-24 Via Medical Corporation Electrochemical sensor apparatus and method
KR960012335B1 (en) 1990-09-17 1996-09-18 후지쓰 가부시끼가이샤 Oxygen electrode
ATE106015T1 (en) 1990-09-28 1994-06-15 Pfizer METER DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT.
US5232434A (en) 1990-10-05 1993-08-03 Aisin Seiki Kabushiki Kaisha Fluid feeding pump unit
US5380536A (en) 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
DE59007402D1 (en) 1990-10-30 1994-11-10 Siemens Ag Arrangement or fan for regulating the flow rate of a flowing medium, in particular a gas.
US5344454A (en) 1991-07-24 1994-09-06 Baxter International Inc. Closed porous chambers for implanting tissue in a host
WO1992007525A1 (en) 1990-10-31 1992-05-14 Baxter International Inc. Close vascularization implant material
US5314471A (en) 1991-07-24 1994-05-24 Baxter International Inc. Tissue inplant systems and methods for sustaining viable high cell densities within a host
JP2704672B2 (en) 1990-12-12 1998-01-26 シャーウッド・アイエムエス・インコーポレイテッド Infrared thermometer using calibration mapping
US5243983A (en) 1990-12-14 1993-09-14 Georgia Tech Research Corporation Non-invasive blood glucose measurement system and method using stimulated raman spectroscopy
US5224929A (en) 1990-12-21 1993-07-06 C. R. Bard, Inc. Irrigation/aspiration cannula and valve assembly
US5354449A (en) 1991-01-10 1994-10-11 Band David M pH electrode
AU1356792A (en) 1991-01-25 1992-08-27 Markwell Medical Institute, Inc. Implantable biological fluid measuring device
US5348788A (en) 1991-01-30 1994-09-20 Interpore Orthopaedics, Inc. Mesh sheet with microscopic projections and holes
US5237123A (en) 1991-02-06 1993-08-17 Laurence G. Broadmoore Velocity, position and direction-tracking sensor for moving components of musical instruments
FR2672219B1 (en) 1991-02-06 1998-09-11 Hospal Ind METHOD FOR CONTROLLING THE BLOOD CIRCULATION IN A SINGLE NEEDLE CIRCUIT.
US5148812A (en) 1991-02-20 1992-09-22 Georgetown University Non-invasive dynamic tracking of cardiac vulnerability by analysis of t-wave alternans
JPH04278450A (en) 1991-03-04 1992-10-05 Adam Heller Biosensor and method for analyzing subject
US5262305A (en) 1991-03-04 1993-11-16 E. Heller & Company Interferant eliminating biosensors
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5490505A (en) 1991-03-07 1996-02-13 Masimo Corporation Signal processing apparatus
US5632272A (en) 1991-03-07 1997-05-27 Masimo Corporation Signal processing apparatus
US5469855A (en) 1991-03-08 1995-11-28 Exergen Corporation Continuous temperature monitor
US5135004A (en) 1991-03-12 1992-08-04 Incontrol, Inc. Implantable myocardial ischemia monitor and related method
US5204264A (en) 1991-03-14 1993-04-20 E. I. Du Pont De Nemours And Company Method for validation of calibration standards in an automatic chemical analyzer
US5199428A (en) 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5122925A (en) 1991-04-22 1992-06-16 Control Products, Inc. Package for electronic components
US5397848A (en) 1991-04-25 1995-03-14 Allergan, Inc. Enhancing the hydrophilicity of silicone polymers
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5868711A (en) 1991-04-29 1999-02-09 Board Of Regents, The University Of Texas System Implantable intraosseous device for rapid vascular access
US5176658A (en) 1991-05-03 1993-01-05 Sherwood Medical Company Valve assembly for use in medical devices
US5271736A (en) 1991-05-13 1993-12-21 Applied Medical Research Collagen disruptive morphology for implants
JP3118015B2 (en) 1991-05-17 2000-12-18 アークレイ株式会社 Biosensor and separation and quantification method using the same
FI88223C (en) 1991-05-22 1993-04-13 Polar Electro Oy Telemetric transmitter unit
CA2069537A1 (en) 1991-06-07 1992-12-08 Thomas A. Cook Multiple output referencing system for evanescent wave sensor
US5112301A (en) 1991-06-19 1992-05-12 Strato Medical Corporation Bidirectional check valve catheter
US5328460A (en) 1991-06-21 1994-07-12 Pacesetter Infusion, Ltd. Implantable medication infusion pump including self-contained acoustic fault detection apparatus
US5284570A (en) 1991-06-26 1994-02-08 Ppg Industries, Inc. Fluid sample analyte collector and calibration assembly
JP2816262B2 (en) 1991-07-09 1998-10-27 工業技術院長 Carbon microsensor electrode and method of manufacturing the same
US5273517A (en) 1991-07-09 1993-12-28 Haemonetics Corporation Blood processing method and apparatus with disposable cassette
US5766151A (en) 1991-07-16 1998-06-16 Heartport, Inc. Endovascular system for arresting the heart
US5453278A (en) 1991-07-24 1995-09-26 Baxter International Inc. Laminated barriers for tissue implants
US5409666A (en) 1991-08-08 1995-04-25 Minnesota Mining And Manufacturing Company Sensors and methods for sensing
US5231988A (en) 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
KR930003929A (en) 1991-08-23 1993-03-22 겐시로 오가와 Sap volume control device
US5198771A (en) 1991-09-03 1993-03-30 Transducer Research, Inc. Potentiostatic apparatus and methods
US5312361A (en) 1991-09-13 1994-05-17 Zadini Filiberto P Automatic cannulation device
DE4130742A1 (en) 1991-09-16 1993-03-18 Inst Diabetestechnologie Gemei METHOD AND ARRANGEMENT FOR DETERMINING THE CONCENTRATION OF INGREDIENTS IN BODY LIQUIDS
GB9120144D0 (en) 1991-09-20 1991-11-06 Imperial College A dialysis electrode device
US5322063A (en) 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
US5605162A (en) 1991-10-15 1997-02-25 Advanced Cardiovascular Systems, Inc. Method for using a variable stiffness guidewire
US5321392A (en) 1991-10-18 1994-06-14 Baxter International Inc. Infusion pump with battery back-up
US5264103A (en) 1991-10-18 1993-11-23 Matsushita Electric Industrial Co., Ltd. Biosensor and a method for measuring a concentration of a substrate in a sample
GB2278235B (en) 1991-10-21 1996-05-08 Holm Kennedy James W Method and device for biochemical sensing
US5249576A (en) 1991-10-24 1993-10-05 Boc Health Care, Inc. Universal pulse oximeter probe
US5220920A (en) 1991-11-08 1993-06-22 Via Medical Corporation Electrochemical measurement system having interference reduction circuit
US5248300A (en) 1991-12-16 1993-09-28 Abbott Laboratories Ambulatory infusion system with spring-pressurized reservoir
CZ149294A3 (en) 1991-12-18 1994-11-16 Icu Medical Inc Medicinal valve
US5203326A (en) 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5372427A (en) 1991-12-19 1994-12-13 Texas Instruments Incorporated Temperature sensor
WO1993012825A1 (en) 1991-12-20 1993-07-08 Abbott Laboratories Automated drug infusion system with autopriming
US5271815A (en) 1991-12-26 1993-12-21 Via Medical Corporation Method for measuring glucose
AU2245092A (en) 1991-12-31 1993-07-28 Vivascan Corporation Blood constituent determination based on differential spectral analysis
AU3274693A (en) 1991-12-31 1993-07-28 Abbott Laboratories Composite membrane
US5310469A (en) 1991-12-31 1994-05-10 Abbott Laboratories Biosensor with a membrane containing biologically active material
US5285792A (en) 1992-01-10 1994-02-15 Physio-Control Corporation System for producing prioritized alarm messages in a medical instrument
US5313953A (en) 1992-01-14 1994-05-24 Incontrol, Inc. Implantable cardiac patient monitor
US5275169A (en) 1992-01-15 1994-01-04 Innovation Associates Apparatus and method for determining physiologic characteristics of body lumens
US5246867A (en) 1992-01-17 1993-09-21 University Of Maryland At Baltimore Determination and quantification of saccharides by luminescence lifetimes and energy transfer
EP0554716B1 (en) 1992-01-22 1997-12-03 Alaris Medical Systems, Inc. Fluid line condition detection
EP0553372B1 (en) 1992-01-29 1996-11-13 Hewlett-Packard GmbH Method and system for monitoring vital signs
US5582497A (en) 1992-01-29 1996-12-10 Wing Labo Co., Ltd. Automatic warehouse system
IL104365A0 (en) 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
WO1993014693A1 (en) 1992-02-01 1993-08-05 The Victoria University Of Manchester Electrode
NL9200207A (en) 1992-02-05 1993-09-01 Nedap Nv IMPLANTABLE BIOMEDICAL SENSOR DEVICE, IN PARTICULAR FOR MEASUREMENT OF THE GLUCOSE CONCENTRATION.
US5284140A (en) 1992-02-11 1994-02-08 Eli Lilly And Company Acrylic copolymer membranes for biosensors
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
US5423738A (en) 1992-03-13 1995-06-13 Robinson; Thomas C. Blood pumping and processing system
DE69319771T2 (en) 1992-03-31 1999-04-22 Dainippon Printing Co Ltd Immobilized enzyme electrode, composition for its production and electrically conductive enzymes
US5356375A (en) 1992-04-06 1994-10-18 Namic U.S.A. Corporation Positive pressure fluid delivery and waste removal system
JPH0650792A (en) 1992-04-15 1994-02-25 Fisher & Paykel Ltd Apparatus and method for controlling liquid supply
US5324322A (en) 1992-04-20 1994-06-28 Case Western Reserve University Thin film implantable electrode and method of manufacture
JP3857306B2 (en) 1992-04-24 2006-12-13 ザ ポリマー テクノロジー グループ,インコーポレイティド Copolymers and their non-porous, semi-permeable membranes and their use to permeate molecules of a given molecular weight range
US5589563A (en) 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
FR2690622B1 (en) 1992-04-29 1995-01-20 Chronotec Programmable ambulatory infusion pump system.
US5302093A (en) 1992-05-01 1994-04-12 Mcgaw, Inc. Disposable cassette with negative head height fluid supply and method
US5287753A (en) 1992-05-02 1994-02-22 Advanced Technology Laboratories, Inc. Continuous display of peak and mean blood flow velocities
US5437635A (en) 1992-05-06 1995-08-01 Mcgaw, Inc. Tube flow limiter, safety flow clip, and tube pincher mechanism
US5711001A (en) 1992-05-08 1998-01-20 Motorola, Inc. Method and circuit for acquisition by a radio receiver
US5316452A (en) 1992-05-11 1994-05-31 Gilbert Corporation Dispensing assembly with interchangeable cartridge pumps
GB9211402D0 (en) 1992-05-29 1992-07-15 Univ Manchester Sensor devices
GB9212010D0 (en) 1992-06-05 1992-07-15 Medisense Inc Mediators to oxidoreductase enzymes
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5335658A (en) 1992-06-29 1994-08-09 Minnesota Mining And Manufacturing Company Intravascular blood parameter sensing system
US5330521A (en) 1992-06-29 1994-07-19 Cohen Donald M Low resistance implantable electrical leads
US5422829A (en) 1992-07-14 1995-06-06 Pollock; Eugene J. Closed-loop control for scanning application
US5434412A (en) 1992-07-15 1995-07-18 Myron J. Block Non-spectrophotometric measurement of analyte concentrations and optical properties of objects
DK95792A (en) 1992-07-24 1994-01-25 Radiometer As Sensor for non-invasive, in vivo determination of an analyte and blood flow
US5306294A (en) 1992-08-05 1994-04-26 Ultrasonic Sensing And Monitoring Systems, Inc. Stent construction of rolled configuration
US5324328A (en) 1992-08-05 1994-06-28 Siemens Pacesetter, Inc. Conductor for a defibrillator patch lead
US5676651A (en) 1992-08-06 1997-10-14 Electric Boat Corporation Surgically implantable pump arrangement and method for pumping body fluids
US5378227A (en) 1992-08-11 1995-01-03 Cobe Laboratories, Inc. Biological/pharmaceutical method and apparatus for collecting and mixing fluids
DE69331951T2 (en) 1992-08-19 2003-01-09 Lawrence A Lynn DEVICE FOR DISPLAYING APNOE WHILE SLEEPING
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
JP2541081B2 (en) 1992-08-28 1996-10-09 日本電気株式会社 Biosensor and method of manufacturing and using biosensor
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5298144A (en) 1992-09-15 1994-03-29 The Yellow Springs Instrument Company, Inc. Chemically wired fructose dehydrogenase electrodes
US5376070A (en) 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
EP1130388A1 (en) 1992-10-01 2001-09-05 Australian Membrane And Biotechnology Research Institute Improved sensor membranes
GB9221099D0 (en) 1992-10-07 1992-11-18 Ecossensors Ltd Improvements in and relating to gas permeable membranes for amperometric gas electrodes
US5314406A (en) 1992-10-09 1994-05-24 Symbiosis Corporation Endoscopic electrosurgical suction-irrigation instrument
WO1994008647A1 (en) 1992-10-15 1994-04-28 The General Hospital Corporation An infusion pump with an electronically loadable drug library
US5750029A (en) 1992-10-16 1998-05-12 Suprex Corporation Method and apparatus for determination of analyte concentration
US5387327A (en) 1992-10-19 1995-02-07 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
US5368224A (en) 1992-10-23 1994-11-29 Nellcor Incorporated Method for reducing ambient noise effects in electronic monitoring instruments
WO1994010553A1 (en) 1992-10-23 1994-05-11 Optex Biomedical, Inc. Fibre-optic probe for the measurement of fluid parameters
JPH0824680B2 (en) 1992-10-26 1996-03-13 日本電気株式会社 Suction leachate sampling device
US5606152A (en) 1992-10-28 1997-02-25 The Furukawa Electric Co., Ltd. Multilayer insulated wire and a manufacturing method therefor
EP0721360A1 (en) 1992-11-09 1996-07-17 SIPIN, Anatole J. Controlled fluid transfer system
US5601435A (en) 1994-11-04 1997-02-11 Intercare Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US5307263A (en) 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US20010011224A1 (en) 1995-06-07 2001-08-02 Stephen James Brown Modular microprocessor-based health monitoring system
US5933136A (en) 1996-12-23 1999-08-03 Health Hero Network, Inc. Network media access control system for encouraging patient compliance with a treatment plan
US7624028B1 (en) 1992-11-17 2009-11-24 Health Hero Network, Inc. Remote health monitoring and maintenance system
US5918603A (en) 1994-05-23 1999-07-06 Health Hero Network, Inc. Method for treating medical conditions using a microprocessor-based video game
US5899855A (en) 1992-11-17 1999-05-04 Health Hero Network, Inc. Modular microprocessor-based health monitoring system
DE4336336A1 (en) 1992-11-23 1994-05-26 Lang Volker Cassette infusion system
US6256522B1 (en) 1992-11-23 2001-07-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Sensors for continuous monitoring of biochemicals and related method
ZA938555B (en) 1992-11-23 1994-08-02 Lilly Co Eli Technique to improve the performance of electrochemical sensors
US5378231A (en) 1992-11-25 1995-01-03 Abbott Laboratories Automated drug infusion system
US5285513A (en) 1992-11-30 1994-02-08 At&T Bell Laboratories Optical fiber cable provided with stabilized waterblocking material
FR2698535B1 (en) 1992-11-30 1995-01-20 Drevet Jean Baptiste Device for regulating and controlling the flow of cerebrospinal fluid in a drainage circuit.
US5356217A (en) * 1992-12-04 1994-10-18 The Edward Orton, Jr. Ceramic Foundation Enthalpimetric analyzer and method of use
US5448992A (en) 1992-12-10 1995-09-12 Sunshine Medical Instruments, Inc. Method and apparatus for non-invasive phase sensitive measurement of blood glucose concentration
GB2273533B (en) 1992-12-18 1996-09-25 Minnesota Mining & Mfg Pumping cassette with integral manifold
US5626563A (en) 1993-01-12 1997-05-06 Minnesota Mining And Manufacturing Company Irrigation system with tubing cassette
US5445610A (en) 1993-01-15 1995-08-29 University Of Cincinnati Portable peritoneal dialysis cycler
US5380491A (en) 1993-01-21 1995-01-10 Cdc Technologies, Inc. Apparatus for pumping and directing fluids for hematology testing
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
US5354272A (en) 1993-03-02 1994-10-11 Baxter International Inc. Improved injectate delivery system
WO1994022367A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Radiotelemetry impedance plethysmography device
US5411866A (en) 1993-03-30 1995-05-02 National Research Council Of Canada Method and system for determining bioactive substances
US5387329A (en) 1993-04-09 1995-02-07 Ciba Corning Diagnostics Corp. Extended use planar sensors
SE9301270D0 (en) 1993-04-19 1993-04-17 BIOSENSOR
EP0622626B1 (en) 1993-04-23 2002-03-06 Roche Diagnostics GmbH System for analysing the components of fluid samples
US5425717A (en) 1993-05-07 1995-06-20 The Kendall Company Epidural catheter system utilizing splittable needle
US5380268A (en) 1993-06-07 1995-01-10 Wheeler; Douglas E. Body fluid flow control valve and method
US5352351A (en) 1993-06-08 1994-10-04 Boehringer Mannheim Corporation Biosensing meter with fail/safe procedures to prevent erroneous indications
SE9302157D0 (en) 1993-06-22 1993-06-22 Siemens-Elema Ab PROCEDURE AND DEVICE CLEANING A CATHETER
WO1995002426A1 (en) 1993-07-13 1995-01-26 Sims Deltec, Inc. Medical pump and method of programming
CA2142598A1 (en) 1993-07-20 1995-02-02 Volker Lang Apparatus for monitoring infusion
US5515851A (en) 1993-07-30 1996-05-14 Goldstein; James A. Angiographic fluid control system
US5368562A (en) 1993-07-30 1994-11-29 Pharmacia Deltec, Inc. Systems and methods for operating ambulatory medical devices such as drug delivery devices
US5384547A (en) 1993-08-02 1995-01-24 Motorola, Inc. Apparatus and method for attenuating a multicarrier input signal of a linear device
DE4427363A1 (en) 1993-08-03 1995-03-09 A & D Co Ltd A disposable chemical sensor
CA2127172C (en) 1993-08-05 1998-07-14 Amy H. Chu Analyte detection device and process
US5508203A (en) 1993-08-06 1996-04-16 Fuller; Milton E. Apparatus and method for radio frequency spectroscopy using spectral analysis
DE4329898A1 (en) 1993-09-04 1995-04-06 Marcus Dr Besson Wireless medical diagnostic and monitoring device
US5425375A (en) 1993-09-09 1995-06-20 Cardiac Pathways Corporation Reusable medical device with usage memory, system using same
WO1995007109A1 (en) 1993-09-10 1995-03-16 Ottawa Heart Institute Research Corporation Electrohydraulic ventricular assist device
US5438983A (en) 1993-09-13 1995-08-08 Hewlett-Packard Company Patient alarm detection using trend vector analysis
US5425749A (en) 1993-09-16 1995-06-20 Angeion Corporation Preemptive cardioversion therapy in an implantable cardioverter defibrillator
FR2710413B1 (en) 1993-09-21 1995-11-03 Asulab Sa Measuring device for removable sensors.
US5885844A (en) 1993-09-21 1999-03-23 Eev Limited Method of identifying analytes
DE4334247B4 (en) 1993-10-08 2006-11-02 Codman Neuro Sciences Sàrl A method of adjusting a switchable flow restricting device and a device operating according to the method
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
JPH07122009A (en) 1993-10-22 1995-05-12 Sony Corp Tracking traverse control circuit
US5400795A (en) 1993-10-22 1995-03-28 Telectronics Pacing Systems, Inc. Method of classifying heart rhythms by analyzing several morphology defining metrics derived for a patient's QRS complex
EP0649628B1 (en) 1993-10-22 1999-01-07 Siemens-Elema AB Processes and devices for continuously monitoring levels of anolyte
US5781455A (en) 1993-11-02 1998-07-14 Kyoto Daiichi Kagaku Co., Ltd. Article of manufacture comprising computer usable medium for a portable blood sugar value measuring apparatus
KR970010981B1 (en) 1993-11-04 1997-07-05 엘지전자 주식회사 Alcohol concentration measuring bio-sensor, manufacturing method and related apparatus
US5545220A (en) 1993-11-04 1996-08-13 Lipomatrix Incorporated Implantable prosthesis with open cell textured surface and method for forming same
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5423749A (en) 1993-11-18 1995-06-13 Minnesota Mining And Manufacturing Company Cardioplegia administration system and method
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5497772A (en) 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5512248A (en) 1993-11-23 1996-04-30 Van; Jack F. J. Twin-probe blood sample diluting device
DE4339811C2 (en) 1993-11-23 1996-07-18 Fresenius Ag Dosing device for volumetric dosing of a liquid additive
US5553616A (en) 1993-11-30 1996-09-10 Florida Institute Of Technology Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator
US5443080A (en) 1993-12-22 1995-08-22 Americate Transtech, Inc. Integrated system for biological fluid constituent analysis
US5320715A (en) 1994-01-14 1994-06-14 Lloyd Berg Separation of 1-pentanol from cyclopentanol by extractive distillation
DE4401400A1 (en) 1994-01-19 1995-07-20 Ernst Prof Dr Pfeiffer Method and arrangement for continuously monitoring the concentration of a metabolite
US5378229A (en) 1994-01-25 1995-01-03 Cordis Corporation Check valve manifold assembly for use in angioplasty
US5553615A (en) 1994-01-31 1996-09-10 Minnesota Mining And Manufacturing Company Method and apparatus for noninvasive prediction of hematocrit
US6127154A (en) 1994-02-10 2000-10-03 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US5522804A (en) 1994-02-15 1996-06-04 Lynn; Lawrence A. Aspiration, mixing, and injection syringe
US5549651A (en) 1994-05-25 1996-08-27 Lynn; Lawrence A. Luer-receiving medical valve and fluid transfer method
US5562615A (en) 1994-02-28 1996-10-08 Corpak, Inc. Free flow detector for an enternal feeding pump
US5543326A (en) 1994-03-04 1996-08-06 Heller; Adam Biosensor including chemically modified enzymes
US5630710A (en) 1994-03-09 1997-05-20 Baxter International Inc. Ambulatory infusion pump
US5482446A (en) 1994-03-09 1996-01-09 Baxter International Inc. Ambulatory infusion pump
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5531679A (en) 1994-03-14 1996-07-02 Schulman; Joseph H. Fluidic infusion system for catheter or probe
US5391250A (en) 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5390671A (en) 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5431174A (en) 1994-04-04 1995-07-11 Via Medical Corporation Method of fluid delivery and collection
US5609575A (en) 1994-04-11 1997-03-11 Graseby Medical Limited Infusion pump and method with dose-rate calculation
AUPM506894A0 (en) 1994-04-14 1994-05-05 Memtec Limited Novel electrochemical cells
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US5584876A (en) 1994-04-29 1996-12-17 W. L. Gore & Associates, Inc. Cell excluding sheath for vascular grafts
DE4415896A1 (en) 1994-05-05 1995-11-09 Boehringer Mannheim Gmbh Analysis system for monitoring the concentration of an analyte in the blood of a patient
US5484404A (en) 1994-05-06 1996-01-16 Alfred E. Mann Foundation For Scientific Research Replaceable catheter system for physiological sensors, tissue stimulating electrodes and/or implantable fluid delivery systems
US5651767A (en) 1994-05-06 1997-07-29 Alfred F. Mann Foundation For Scientific Research Replaceable catheter system for physiological sensors, stimulating electrodes and/or implantable fluid delivery systems
US5482473A (en) 1994-05-09 1996-01-09 Minimed Inc. Flex circuit connector
US5714931A (en) 1994-05-16 1998-02-03 Petite; Thomas D. Personalized security system
US5472317A (en) 1994-06-03 1995-12-05 Minimed Inc. Mounting clip for a medication infusion pump
DE59509994D1 (en) 1994-06-03 2002-02-21 Metrohm Ag Herisau Device for voltammetry, indicator electrode arrangement for such a device, in particular as part of a tape cassette, and row analysis method for voltammetry
US5624409A (en) 1994-06-10 1997-04-29 Fluidsense Corporation Variable-pulse dynamic fluid flow controller
US5645077A (en) 1994-06-16 1997-07-08 Massachusetts Institute Of Technology Inertial orientation tracker apparatus having automatic drift compensation for tracking human head and other similarly sized body
DE4422068A1 (en) 1994-06-23 1996-01-04 Siemens Ag Electro-catalytic glucose sensor in catheter form
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5494562A (en) 1994-06-27 1996-02-27 Ciba Corning Diagnostics Corp. Electrochemical sensors
US5429735A (en) 1994-06-27 1995-07-04 Miles Inc. Method of making and amperometric electrodes
US5474552A (en) 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5514253A (en) 1994-07-13 1996-05-07 I-Stat Corporation Method of measuring gas concentrations and microfabricated sensing device for practicing same
US5605152A (en) 1994-07-18 1997-02-25 Minimed Inc. Optical glucose sensor
US5582593A (en) 1994-07-21 1996-12-10 Hultman; Barry W. Ambulatory medication delivery system
US5509888A (en) 1994-07-26 1996-04-23 Conceptek Corporation Controller valve device and method
US5513636A (en) 1994-08-12 1996-05-07 Cb-Carmel Biotechnology Ltd. Implantable sensor chip
US5462051A (en) 1994-08-31 1995-10-31 Colin Corporation Medical communication system
US5569219A (en) 1994-09-13 1996-10-29 Hakki; A-Hamid Collapsible catheter
AT402452B (en) 1994-09-14 1997-05-26 Avl Verbrennungskraft Messtech PLANAR SENSOR FOR DETECTING A CHEMICAL PARAMETER OF A SAMPLE
US5624537A (en) 1994-09-20 1997-04-29 The University Of British Columbia - University-Industry Liaison Office Biosensor and interface membrane
US5840026A (en) 1994-09-21 1998-11-24 Medrad, Inc. Patient specific dosing contrast delivery systems and methods
ZA958073B (en) 1994-09-28 1996-04-23 Anthony William Manicom Method of and apparatus for administering a drug to a patient
US5486776A (en) 1994-09-29 1996-01-23 Xilinx, Inc. Antifuse-based programmable logic circuit
US5577499A (en) 1994-10-03 1996-11-26 Teves; Leonides Y. Blood analyzer
US5520191A (en) 1994-10-07 1996-05-28 Ortivus Medical Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US5807406A (en) 1994-10-07 1998-09-15 Baxter International Inc. Porous microfabricated polymer membrane structures
US6038469A (en) 1994-10-07 2000-03-14 Ortivus Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US5522798A (en) 1994-10-17 1996-06-04 Abbott Laboratories Control of a multi-channel drug infusion pump using a pharmacokinetic model
CA2159052C (en) 1994-10-28 2007-03-06 Rainer Alex Injection device
IE72524B1 (en) 1994-11-04 1997-04-23 Elan Med Tech Analyte-controlled liquid delivery device and analyte monitor
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
EP0722691A1 (en) 1994-12-24 1996-07-24 Roche Diagnostics GmbH System for determining properties of tissue
US5685844A (en) 1995-01-06 1997-11-11 Abbott Laboratories Medicinal fluid pump having multiple stored protocols
US5590651A (en) 1995-01-17 1997-01-07 Temple University - Of The Commonwealth System Of Higher Education Breathable liquid elimination analysis
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5697366A (en) 1995-01-27 1997-12-16 Optical Sensors Incorporated In situ calibration system for sensors located in a physiologic line
US5676820A (en) 1995-02-03 1997-10-14 New Mexico State University Technology Transfer Corp. Remote electrochemical sensor
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5517313A (en) 1995-02-21 1996-05-14 Colvin, Jr.; Arthur E. Fluorescent optical sensor
US5628619A (en) 1995-03-06 1997-05-13 Sabratek Corporation Infusion pump having power-saving modes
KR100449615B1 (en) 1995-03-10 2004-12-08 메소 스케일 테크놀러지즈, 엘엘시 Multi-array, multi-specific electrochemiluminescence test
DE19510712C2 (en) 1995-03-15 2001-03-29 Dmv Medizintechnik Gmbh Method and device for introducing a gas
US5582697A (en) 1995-03-17 1996-12-10 Matsushita Electric Industrial Co., Ltd. Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same
ES2187647T3 (en) 1995-03-27 2003-06-16 Zevex Inc PELLIZCO CLAMP OBSTRUCTION DEVICE FOR PERFUSERS.
US5640470A (en) 1995-03-27 1997-06-17 Abbott Laboratories Fiber-optic detectors with terpolymeric analyte-permeable matrix coating
US6749591B1 (en) 1995-03-27 2004-06-15 Zevex, Inc. Pinch clip occluder system for infusion sets
US6142979A (en) 1995-03-27 2000-11-07 Zevex Pinch clip occluder system for infusion sets
US5786439A (en) 1996-10-24 1998-07-28 Minimed Inc. Hydrophilic, swellable coatings for biosensors
US5882494A (en) 1995-03-27 1999-03-16 Minimed, Inc. Polyurethane/polyurea compositions containing silicone for biosensor membranes
US5569188A (en) 1995-04-11 1996-10-29 Mackool; Richard J. Apparatus for controlling fluid flow through a surgical instrument and the temperature of an ultrasonic instrument
US6656157B1 (en) 1995-04-20 2003-12-02 Acist Medical Systems, Inc. Infinitely refillable syringe
US5620579A (en) 1995-05-05 1997-04-15 Bayer Corporation Apparatus for reduction of bias in amperometric sensors
US5752512A (en) 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US5628310A (en) 1995-05-19 1997-05-13 Joseph R. Lakowicz Method and apparatus to perform trans-cutaneous analyte monitoring
US5665065A (en) 1995-05-26 1997-09-09 Minimed Inc. Medication infusion device with blood glucose data input
US5806517A (en) 1995-05-26 1998-09-15 The Regents Of The University Of Colorado In vivo electrochemistry computer system and method
US5584813A (en) 1995-06-07 1996-12-17 Minimed Inc. Subcutaneous injection set
CA2190628C (en) 1995-06-07 2000-05-30 Mark D. Butler An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US6165154A (en) 1995-06-07 2000-12-26 Deka Products Limited Partnership Cassette for intravenous-line flow-control system
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US5743262A (en) 1995-06-07 1998-04-28 Masimo Corporation Blood glucose monitoring system
US5656707A (en) 1995-06-16 1997-08-12 Regents Of The University Of Minnesota Highly cross-linked polymeric supports
AUPN363995A0 (en) 1995-06-19 1995-07-13 Memtec Limited Electrochemical cell
US6413410B1 (en) 1996-06-19 2002-07-02 Lifescan, Inc. Electrochemical cell
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US5688239A (en) 1995-07-10 1997-11-18 Walker; Frank J. Urinary tract treating assembly with prostate flushing
US6183437B1 (en) 1995-07-10 2001-02-06 Frank J. Walker Electronic control unit and tubing assembly system for automatically controlling urinary irrigation
US6024720A (en) 1995-07-18 2000-02-15 Aquarius Medical Corporation Fluid management system for arthroscopic surgery
US5800383A (en) 1996-07-17 1998-09-01 Aquarius Medical Corporation Fluid management system for arthroscopic surgery
US5611900A (en) 1995-07-20 1997-03-18 Michigan State University Microbiosensor used in-situ
US7016713B2 (en) 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte
US6212424B1 (en) 1998-10-29 2001-04-03 Rio Grande Medical Technologies, Inc. Apparatus and method for determination of the adequacy of dialysis by non-invasive near-infrared spectroscopy
US6001471A (en) 1995-08-11 1999-12-14 3M Innovative Properties Company Removable adhesive tape with controlled sequential release
AUPN487495A0 (en) 1995-08-18 1995-09-14 Cardiac Crc Nominees Pty Limited A multipolar transmural probe
US5827223A (en) 1995-08-31 1998-10-27 Alaris Medical Systems, Inc. Upstream occulsion detection system
US5735273A (en) 1995-09-12 1998-04-07 Cygnus, Inc. Chemical signal-impermeable mask
US5628890A (en) 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US6689265B2 (en) 1995-10-11 2004-02-10 Therasense, Inc. Electrochemical analyte sensors using thermostable soybean peroxidase
US5665222A (en) 1995-10-11 1997-09-09 E. Heller & Company Soybean peroxidase electrochemical sensor
US5972199A (en) 1995-10-11 1999-10-26 E. Heller & Company Electrochemical analyte sensors using thermostable peroxidase
US5855613A (en) 1995-10-13 1999-01-05 Islet Sheet Medical, Inc. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
JP3592416B2 (en) 1995-10-31 2004-11-24 晃敏 吉田 Measuring device for intraocular substances
AUPN661995A0 (en) 1995-11-16 1995-12-07 Memtec America Corporation Electrochemical cell 2
US5711861A (en) 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
AU1058297A (en) 1995-11-22 1997-06-11 Minimed, Inc. Detection of biological molecules using chemical amplification and optical sensors
US6162201A (en) 1995-12-01 2000-12-19 Cohen; Kenneth L. Internal urinary catheter
US5745378A (en) 1995-12-04 1998-04-28 Abbott Laboratories Parameter input for drug delivery pump
US6063637A (en) 1995-12-13 2000-05-16 California Institute Of Technology Sensors for sugars and other metal binding analytes
US6261440B1 (en) 1995-12-18 2001-07-17 Abbott Laboratories Interference free biosensor
US5730654A (en) 1995-12-18 1998-03-24 Raya Systems, Inc. Multi-player video game for health education
EP0879012A1 (en) 1995-12-18 1998-11-25 Abbott Laboratories Extraction and monitoring of bodily fluids
ES2236759T3 (en) 1995-12-19 2005-07-16 Abbott Laboratories DETECTION DEVICE OF AN ANALYTIC AND ADMINISTRATION OF A THERAPEUTIC SUBSTANCE.
CA2212826C (en) 1995-12-28 2002-02-19 Cygnus, Inc. Methods for monitoring a physiological analyte
US5588560A (en) 1996-01-11 1996-12-31 Dow Corning Corporation Ergonomeric dispenser for viscous materials
US5637083A (en) 1996-01-19 1997-06-10 Pudenz-Schulte Medical Research Corporation Implantable adjustable fluid flow control valve
WO1997027829A1 (en) 1996-01-31 1997-08-07 The Trustees Of The University Of Pennsylvania Remote control drug delivery device
FI960636A (en) 1996-02-12 1997-08-13 Nokia Mobile Phones Ltd A procedure for monitoring the health of a patient
FI118509B (en) 1996-02-12 2007-12-14 Nokia Oyj A method and apparatus for predicting blood glucose levels in a patient
DE19605246A1 (en) 1996-02-13 1997-08-14 Siemens Ag Method for the calibration of gas measuring sensors for dissolved gases and method for measuring the concentration of CO2 in blood with the aid of such a calibration method
US5833603A (en) 1996-03-13 1998-11-10 Lipomatrix, Inc. Implantable biosensing transponder
US6990422B2 (en) 1996-03-27 2006-01-24 World Energy Labs (2), Inc. Method of analyzing the time-varying electrical response of a stimulated target substance
US5785660A (en) 1996-03-28 1998-07-28 Pacesetter, Inc. Methods and apparatus for storing intracardiac electrograms
GB9606829D0 (en) 1996-03-30 1996-06-05 Jeffrey Peter Supplying materials etc
US5766432A (en) 1996-04-17 1998-06-16 University Of Massachusetts Method and device for eliminating electrode drift
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
DE19618597B4 (en) 1996-05-09 2005-07-21 Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm Method for determining the concentration of tissue glucose
US20040249420A1 (en) 1996-05-14 2004-12-09 Medtronic, Inc. Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias
US5776324A (en) 1996-05-17 1998-07-07 Encelle, Inc. Electrochemical biosensors
US5964261A (en) 1996-05-29 1999-10-12 Baxter International Inc. Implantation assembly
US5735285A (en) 1996-06-04 1998-04-07 Data Critical Corp. Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals
DE19626353A1 (en) 1996-06-18 1998-01-02 Biotronik Mess & Therapieg Signal detector
ES2195151T3 (en) 1996-06-18 2003-12-01 Alza Corp IMPROVEMENT OR SAMPLING DEVICE FOR TRANSDERMAL AGENTS.
EP0923335B1 (en) 1996-07-08 2006-08-23 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
JP2943700B2 (en) 1996-07-10 1999-08-30 日本電気株式会社 Biosensor
US5707502A (en) 1996-07-12 1998-01-13 Chiron Diagnostics Corporation Sensors for measuring analyte concentrations and methods of making same
US6325978B1 (en) 1998-08-04 2001-12-04 Ntc Technology Inc. Oxygen monitoring and apparatus
US5758643A (en) 1996-07-29 1998-06-02 Via Medical Corporation Method and apparatus for monitoring blood chemistry
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US5804048A (en) 1996-08-15 1998-09-08 Via Medical Corporation Electrode assembly for assaying glucose
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US5836887A (en) 1996-09-19 1998-11-17 Colin Corporation Physical information monitor system having means for determining reference range for abnormality determination, based on moving average of previously obtained values
US5980728A (en) 1996-09-24 1999-11-09 Rosemont Analytical Inc. Diagnostic method and apparatus for solid electrolyte gas analyzer
US5932175A (en) 1996-09-25 1999-08-03 Via Medical Corporation Sensor apparatus for use in measuring a parameter of a fluid sample
US6168568B1 (en) 1996-10-04 2001-01-02 Karmel Medical Acoustic Technologies Ltd. Phonopneumograph system
DE19642453C2 (en) 1996-10-15 1998-07-23 Bosch Gmbh Robert Arrangement for gas sensor electrodes
US5720295A (en) 1996-10-15 1998-02-24 Pacesetter, Inc. Pacemaker with improved detection of atrial fibrillation
US5990422A (en) 1996-10-18 1999-11-23 Shinko Denshi Company Limited Apparatus for measuring weight and length of article
US6001068A (en) 1996-10-22 1999-12-14 Terumo Kabushiki Kaisha Guide wire having tubular connector with helical slits
ES2401046T3 (en) 1996-10-30 2013-04-16 F.Hoffmann-La Roche Ag Synchronized analyte test system
DK0944731T3 (en) 1996-11-14 2006-05-22 Radiometer Medical Aps enzyme Sensor
DE69722451T2 (en) 1996-11-22 2004-05-19 Therakos, Inc. DEVICE FOR PUMPING A FLUID WITH A CONSTANT FLOW RATE
AU5461298A (en) 1996-12-04 1998-06-29 Enact Health Management Systems System for downloading and reporting medical information
US6071249A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US5810770A (en) 1996-12-13 1998-09-22 Stryker Corporation Fluid management pump system for surgical procedures
US5811487A (en) 1996-12-16 1998-09-22 Dow Corning Corporation Thickening silicones with elastomeric silicone polyethers
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US5836989A (en) 1996-12-26 1998-11-17 Medtronic, Inc. Method and apparatus for controlling an implanted medical device in a time-dependent manner
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US5947911A (en) 1997-01-09 1999-09-07 Via Medical Corporation Method and apparatus for reducing purge volume in a blood chemistry monitoring system
NZ337222A (en) 1997-01-17 2000-10-27 Niagara Pump Corp Linear peristaltic pump
EP0958499B1 (en) 1997-01-17 2002-08-07 Metracor Technologies Inc Method for calibrating sensors used in diagnostic testing
US6122351A (en) 1997-01-21 2000-09-19 Med Graph, Inc. Method and system aiding medical diagnosis and treatment
SE9700182D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Implantable heart stimulator
SE9700181D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Ischemia detector and heart stimulator provided with such an ischemia detector
US5928155A (en) 1997-01-24 1999-07-27 Cardiox Corporation Cardiac output measurement with metabolizable analyte containing fluid
US6293925B1 (en) 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
US6093172A (en) 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
US5851197A (en) 1997-02-05 1998-12-22 Minimed Inc. Injector for a subcutaneous infusion set
ATE227844T1 (en) 1997-02-06 2002-11-15 Therasense Inc SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION
US6891317B2 (en) 2001-05-22 2005-05-10 Sri International Rolled electroactive polymers
SE9700427D0 (en) 1997-02-07 1997-02-07 Pacesetter Ab Ischemia detector
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
EP1011426A1 (en) 1997-02-26 2000-06-28 Diasense, Inc. Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose
US6208894B1 (en) 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6159147A (en) 1997-02-28 2000-12-12 Qrs Diagnostics, Llc Personal computer card for collection of real-time biological data
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US6862465B2 (en) 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
GB9704737D0 (en) 1997-03-07 1997-04-23 Optel Instr Limited Biological measurement system
US5891047A (en) 1997-03-14 1999-04-06 Cambridge Heart, Inc. Detecting abnormal activation of heart
US5792065A (en) 1997-03-18 1998-08-11 Marquette Medical Systems, Inc. Method and apparatus for determining T-wave marker points during QT dispersion analysis
FR2760962B1 (en) 1997-03-20 1999-05-14 Sillonville Francis Klefstad REMOTE MEDICAL ASSISTANCE AND SURVEILLANCE SYSTEM
ES2208876T3 (en) 1997-03-21 2004-06-16 Nellcor Puritan Bennett Incorporated PROCEDURE AND APPARATUS FOR AVERAGE ADAPTIVE DATA SIGNS.
SE9701122D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Medical implant
SE9701121D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Implantable heart stimulator
US6270455B1 (en) 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US6186765B1 (en) 1997-03-31 2001-02-13 Toshiba Kikai Kabushiki Kaisha Apparatus for forming a molded multilayer product
KR100397227B1 (en) 1997-04-04 2003-09-13 유니버시티 오브 써던 캘리포니아 Electroplating article, method and apparatus for electrochemical fabrication
US5942979A (en) 1997-04-07 1999-08-24 Luppino; Richard On guard vehicle safety warning system
US5961451A (en) 1997-04-07 1999-10-05 Motorola, Inc. Noninvasive apparatus having a retaining member to retain a removable biosensor
US6059946A (en) 1997-04-14 2000-05-09 Matsushita Electric Industrial Co., Ltd. Biosensor
US5944661A (en) 1997-04-16 1999-08-31 Giner, Inc. Potential and diffusion controlled solid electrolyte sensor for continuous measurement of very low levels of transdermal alcohol
AT404992B (en) 1997-04-17 1999-04-26 Avl List Gmbh SENSOR FOR DETERMINING AN ENZYME SUBSTRATE
US5911219A (en) 1997-04-18 1999-06-15 Aylsworth; Alonzo C. Therapeutic gas flow meter and monitor
US5928189A (en) 1997-04-22 1999-07-27 Phillips; Robert E. Activity responsive therapeutic delivery system
US5935224A (en) 1997-04-24 1999-08-10 Microsoft Corporation Method and apparatus for adaptively coupling an external peripheral device to either a universal serial bus port on a computer or hub or a game port on a computer
DE19717790A1 (en) 1997-04-26 1998-10-29 Convergenza Ag Device with a therapeutic catheter
US6115634A (en) 1997-04-30 2000-09-05 Medtronic, Inc. Implantable medical device and method of manufacture
US5779665A (en) 1997-05-08 1998-07-14 Minimed Inc. Transdermal introducer assembly
US5807312A (en) 1997-05-23 1998-09-15 Dzwonkiewicz; Mark R. Bolus pump apparatus
TW357517B (en) 1997-05-29 1999-05-01 Koji Akai Monitoring system
SE9702118D0 (en) 1997-06-04 1997-06-04 Siemens Elema Ab Blood Analysis System
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6093167A (en) 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
JP2002505008A (en) 1997-06-16 2002-02-12 エラン コーポレーション ピーエルシー Methods for calibrating and testing sensors for in vivo measurement of analytes and devices for use in such methods
US6013711A (en) 1997-06-18 2000-01-11 Ck Witco Corporation Hydrophilic polysiloxane compositions
US5938636A (en) 1997-06-20 1999-08-17 The Bd Of Regents Of The University Of California Autoinfuser for resuscitation and method of infusion fluid injection
US5928182A (en) 1997-07-02 1999-07-27 Johnson & Johnson Professional, Inc. Pediatric programmable hydrocephalus valve
US6090087A (en) 1997-07-04 2000-07-18 Tsukada Medical Research Co., Ltd. Simplified, automatic opening and closing type urination device
SE9702739D0 (en) 1997-07-17 1997-07-17 Siemens Elema Ab Method for rinsing and calibrating sensors included in a body fluid analysis system
US5861019A (en) 1997-07-25 1999-01-19 Medtronic Inc. Implantable medical device microstrip telemetry antenna
US5823802A (en) 1997-07-30 1998-10-20 General Motors Corporation Electrical connector with combination seal and contact member
US5871514A (en) 1997-08-01 1999-02-16 Medtronic, Inc. Attachment apparatus for an implantable medical device employing ultrasonic energy
CN1124773C (en) 1997-08-05 2003-10-15 斯特里克斯有限公司 Sensor devices and analytical methods using them
US6171276B1 (en) 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
GB2328023A (en) 1997-08-08 1999-02-10 Univ Manchester pH sensing devices
ES2227880T3 (en) 1997-08-09 2005-04-01 Roche Diagnostics Gmbh ANALYSIS DEVICE FOR PERFORMING LIVE ANALYSIS IN A PATIENT'S BODY.
US5904666A (en) 1997-08-18 1999-05-18 L.Vad Technology, Inc. Method and apparatus for measuring flow rate and controlling delivered volume of fluid through a valve aperture
GB9717906D0 (en) 1997-08-23 1997-10-29 Univ Manchester Sensor Devices And Analytical Methods
US6402703B1 (en) 1997-08-28 2002-06-11 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6731976B2 (en) 1997-09-03 2004-05-04 Medtronic, Inc. Device and method to measure and communicate body parameters
US6764581B1 (en) 1997-09-05 2004-07-20 Abbott Laboratories Electrode with thin working layer
US6071391A (en) 1997-09-12 2000-06-06 Nok Corporation Enzyme electrode structure
US5999848A (en) 1997-09-12 1999-12-07 Alfred E. Mann Foundation Daisy chainable sensors and stimulators for implantation in living tissue
US6259937B1 (en) 1997-09-12 2001-07-10 Alfred E. Mann Foundation Implantable substrate sensor
US5917346A (en) 1997-09-12 1999-06-29 Alfred E. Mann Foundation Low power current to frequency converter circuit for use in implantable sensors
JP4357738B2 (en) 1997-09-12 2009-11-04 アポテック エール エ デ− エス.アー. TRAIN, a cysteine-rich receptor
US6183444B1 (en) 1998-05-16 2001-02-06 Microheart, Inc. Drug delivery module
US6117290A (en) 1997-09-26 2000-09-12 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US6007775A (en) 1997-09-26 1999-12-28 University Of Washington Multiple analyte diffusion based chemical sensor
WO1999017095A1 (en) 1997-09-30 1999-04-08 M-Biotech, Inc. Biosensor
US5904671A (en) 1997-10-03 1999-05-18 Navot; Nir Tampon wetness detection system
US7115884B1 (en) 1997-10-06 2006-10-03 Trustees Of Tufts College Self-encoding fiber optic sensor
US5879828A (en) 1997-10-10 1999-03-09 Minnesota Mining And Manufacturing Company Membrane electrode assembly
US6033366A (en) 1997-10-14 2000-03-07 Data Sciences International, Inc. Pressure measurement device
US6585763B1 (en) 1997-10-14 2003-07-01 Vascusense, Inc. Implantable therapeutic device and method
US6409674B1 (en) 1998-09-24 2002-06-25 Data Sciences International, Inc. Implantable sensor with wireless communication
US6736957B1 (en) 1997-10-16 2004-05-18 Abbott Laboratories Biosensor electrode mediators for regeneration of cofactors and process for using
EP0910023A2 (en) 1997-10-17 1999-04-21 Siemens Aktiengesellschaft Method and device for the neuronal modelling of a dynamic system with non-linear stochastic behavior
US6104280A (en) 1997-10-20 2000-08-15 Micron Technology, Inc. Method of manufacturing and testing an electronic device, and an electronic device
US6119028A (en) 1997-10-20 2000-09-12 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces
US6081736A (en) 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
US6088608A (en) 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
BR9812969A (en) 1997-10-23 2000-08-08 Morten Mernoe Infusion pumping system and infusion pump unit
FI107080B (en) 1997-10-27 2001-05-31 Nokia Mobile Phones Ltd measuring device
US6032667A (en) 1997-10-30 2000-03-07 Instrumentarium Corporation Variable orifice pulse valve
ES2281143T3 (en) 1997-11-12 2007-09-16 Lightouch Medical, Inc. METHOD FOR THE NON-INVASIVE MEASUREMENT OF AN ANALYTE.
JPH11153575A (en) 1997-11-20 1999-06-08 Mitsubishi Electric Corp Carbon deoxide detector
US6117643A (en) 1997-11-25 2000-09-12 Ut Battelle, Llc Bioluminescent bioreporter integrated circuit
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US7494816B2 (en) 1997-12-22 2009-02-24 Roche Diagnostic Operations, Inc. System and method for determining a temperature during analyte measurement
US7407811B2 (en) 1997-12-22 2008-08-05 Roche Diagnostics Operations, Inc. System and method for analyte measurement using AC excitation
US7390667B2 (en) 1997-12-22 2008-06-24 Roche Diagnostics Operations, Inc. System and method for analyte measurement using AC phase angle measurements
US6073031A (en) 1997-12-24 2000-06-06 Nortel Networks Corporation Desktop docking station for use with a wireless telephone handset
US6893552B1 (en) 1997-12-29 2005-05-17 Arrowhead Center, Inc. Microsensors for glucose and insulin monitoring
JP3518303B2 (en) 1998-01-06 2004-04-12 日産自動車株式会社 Vehicle pitch angle calculation device
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US6306347B1 (en) 1998-01-21 2001-10-23 Bayer Corporation Optical sensor and method of operation
WO1999038551A1 (en) 1998-02-02 1999-08-05 Medtronic, Inc. Implantable drug infusion device having a safety valve
US7070577B1 (en) 1998-02-02 2006-07-04 Medtronic, Inc Drive circuit having improved energy efficiency for implantable beneficial agent infusion or delivery device
US6191860B1 (en) 1998-02-06 2001-02-20 Orsense Ltd. Optical shutter, spectrometer and method for spectral analysis
US7004924B1 (en) 1998-02-11 2006-02-28 Nxstage Medical, Inc. Methods, systems, and kits for the extracorporeal processing of blood
US6027479A (en) 1998-02-27 2000-02-22 Via Medical Corporation Medical apparatus incorporating pressurized supply of storage liquid
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6013113A (en) 1998-03-06 2000-01-11 Wilson Greatbatch Ltd. Slotted insulator for unsealed electrode edges in electrochemical cells
EP1059882B1 (en) 1998-03-06 2007-10-17 SPECTRX, Inc. Integrated tissue poration, fluid harvesting and analysis device
US6159186A (en) 1998-03-13 2000-12-12 Wft Projects (Proprietary) Limited Infusion delivery system
CA2265119C (en) 1998-03-13 2002-12-03 Cygnus, Inc. Biosensor, iontophoretic sampling system, and methods of use thereof
US6024699A (en) 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US5928130A (en) 1998-03-16 1999-07-27 Schmidt; Bruno Apparatus and method for implanting radioactive seeds in tissue
US6299583B1 (en) 1998-03-17 2001-10-09 Cardiox Corporation Monitoring total circulating blood volume and cardiac output
US5904708A (en) 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US6197181B1 (en) 1998-03-20 2001-03-06 Semitool, Inc. Apparatus and method for electrolytically depositing a metal on a microelectronic workpiece
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
JP3104672B2 (en) 1998-03-31 2000-10-30 日本電気株式会社 Current detection type sensor element and method of manufacturing the same
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
US6074775A (en) 1998-04-02 2000-06-13 The Procter & Gamble Company Battery having a built-in controller
US6340428B1 (en) 1998-04-02 2002-01-22 Matsushita Electric Industrial Co., Inc. Device and method for determining the concentration of a substrate
US6537318B1 (en) 1998-04-06 2003-03-25 Konjac Technologies, Llc Use of glucomannan hydrocolloid as filler material in prostheses
US6721582B2 (en) 1999-04-06 2004-04-13 Argose, Inc. Non-invasive tissue glucose level monitoring
JPH11296598A (en) 1998-04-07 1999-10-29 Seizaburo Arita System and method for predicting blood-sugar level and record medium where same method is recorded
US6241863B1 (en) 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
GB2337122B (en) 1998-05-08 2002-11-13 Medisense Inc Test strip
ATE245937T1 (en) 1998-05-13 2003-08-15 Cygnus Therapeutic Systems MONITORING PHYSIOLOGICAL ANALYTES
PT1077636E (en) 1998-05-13 2004-06-30 Cygnus Therapeutic Systems SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION
WO1999058973A1 (en) 1998-05-13 1999-11-18 Cygnus, Inc. Method and device for predicting physiological values
US6129757A (en) 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
US6526298B1 (en) 1998-05-18 2003-02-25 Abbott Laboratories Method for the non-invasive determination of analytes in a selected volume of tissue
US7043287B1 (en) 1998-05-18 2006-05-09 Abbott Laboratories Method for modulating light penetration depth in tissue and diagnostic applications using same
US6121611A (en) 1998-05-20 2000-09-19 Molecular Imaging Corporation Force sensing probe for scanning probe microscopy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US5995208A (en) 1998-05-28 1999-11-30 Abbott Laboratories Intravascular oximetry catheter
US7540875B2 (en) 1998-06-01 2009-06-02 Avatar Design & Development, Inc. Surgical cutting tool with automatically retractable blade assembly
US6702972B1 (en) 1998-06-09 2004-03-09 Diametrics Medical Limited Method of making a kink-resistant catheter
US7344499B1 (en) 1998-06-10 2008-03-18 Georgia Tech Research Corporation Microneedle device for extraction and sensing of bodily fluids
US6234985B1 (en) 1998-06-11 2001-05-22 Cprx Llc Device and method for performing cardiopulmonary resuscitation
US6022366A (en) 1998-06-11 2000-02-08 Stat Medical Devices Inc. Lancet having adjustable penetration depth
US6231320B1 (en) 1998-06-12 2001-05-15 Abbott Laboratories Drug infusion pumping cassette latching mechanism
US6187062B1 (en) 1998-06-16 2001-02-13 Alcatel Current collection through thermally sprayed tabs at the ends of a spirally wound electrochemical cell
US6294281B1 (en) 1998-06-17 2001-09-25 Therasense, Inc. Biological fuel cell and method
US6077299A (en) 1998-06-22 2000-06-20 Eyetronic, Llc Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma
US6290839B1 (en) 1998-06-23 2001-09-18 Clinical Micro Sensors, Inc. Systems for electrophoretic transport and detection of analytes
US6495023B1 (en) 1998-07-09 2002-12-17 Michigan State University Electrochemical methods for generation of a biological proton motive force and pyridine nucleotide cofactor regeneration
US6066088A (en) 1998-07-13 2000-05-23 Phillip Davis Inventions, Inc. Intraurethral magnetic valve
US6223283B1 (en) 1998-07-17 2001-04-24 Compaq Computer Corporation Method and apparatus for identifying display monitor functionality and compatibility
GB2339912B (en) 1998-07-20 2002-06-05 Univ Bristol Apparatus and method for measuring the moisture level within enamel dentine or tooth tissue
US6115622A (en) 1998-08-06 2000-09-05 Medtronic, Inc. Ambulatory recorder having enhanced sampling technique
AU5394099A (en) 1998-08-07 2000-02-28 Infinite Biomedical Technologies, Incorporated Implantable myocardial ischemia detection, indication and action technology
EP1104254A2 (en) 1998-08-13 2001-06-06 Whitland Research Limited Optical device
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
JP2000060826A (en) 1998-08-19 2000-02-29 Omron Corp Noninvasive vital component measuring instrument
US6107083A (en) 1998-08-21 2000-08-22 Bayer Corporation Optical oxidative enzyme-based sensors
TW495608B (en) 1998-08-26 2002-07-21 Sensors For Med & Science Inc Optical-based sensing devices
JP3267936B2 (en) 1998-08-26 2002-03-25 松下電器産業株式会社 Biosensor
US6233080B1 (en) 1998-08-26 2001-05-15 Ciena Corporation Crosstalk-free signal source for dense wavelength division multiplexed systems
US6087182A (en) 1998-08-27 2000-07-11 Abbott Laboratories Reagentless analysis of biological samples
US6403349B1 (en) 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
DE19841173A1 (en) 1998-09-09 2000-03-16 Meier Bernd Horst Method to transfer and measure gas or liquid volumes, e.g. volatile anaesthetics; involves using alternately rotating pistons to separate liquid volume in vessel formed as rotation body.
US6325788B1 (en) 1998-09-16 2001-12-04 Mckay Douglas William Treatment of wound or joint for relief of pain and promotion of healing
US6740518B1 (en) 1998-09-17 2004-05-25 Clinical Micro Sensors, Inc. Signal detection techniques for the detection of analytes
US6254586B1 (en) 1998-09-25 2001-07-03 Minimed Inc. Method and kit for supplying a fluid to a subcutaneous placement site
US5951521A (en) 1998-09-25 1999-09-14 Minimed Inc. Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
CA2346055C (en) 1998-09-30 2004-06-29 Cygnus, Inc. Method and device for predicting physiological values
US6180416B1 (en) 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6402689B1 (en) 1998-09-30 2002-06-11 Sicel Technologies, Inc. Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
US6201980B1 (en) 1998-10-05 2001-03-13 The Regents Of The University Of California Implantable medical sensor system
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
ATE514372T1 (en) 1998-10-08 2011-07-15 Medtronic Minimed Inc LICENSE PLATE MONITORING SYSTEM WITH REMOTE MEASUREMENT
US6494879B2 (en) 1998-10-15 2002-12-17 Scimed Life Systems, Inc. Treating urinary retention
ATE241705T1 (en) 1998-10-23 2003-06-15 Pierre Beuret HEAT TREATMENT SYSTEM FOR A BATCH OF METALLIC WORKPIECES
US6016448A (en) 1998-10-27 2000-01-18 Medtronic, Inc. Multilevel ERI for implantable medical devices
US6248093B1 (en) 1998-10-29 2001-06-19 Minimed Inc. Compact pump drive system
US6817990B2 (en) 1998-10-29 2004-11-16 Medtronic Minimed, Inc. Fluid reservoir piston
US6156013A (en) 1998-11-04 2000-12-05 Mahurkar; Sakharam D. Safety syringe
US6602469B1 (en) 1998-11-09 2003-08-05 Lifestream Technologies, Inc. Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system
US6164921A (en) 1998-11-09 2000-12-26 Moubayed; Ahmad Maher Curvilinear peristaltic pump having insertable tubing assembly
US6597946B2 (en) 1998-11-09 2003-07-22 Transpharma Ltd. Electronic card for transdermal drug delivery and analyte extraction
US6478771B1 (en) 1998-11-13 2002-11-12 Elan Pharma International Limited Drug delivery systems and methods
DE69924749T2 (en) 1998-11-20 2006-04-27 The University Of Connecticut, Farmington Generically integrated implantable potentiostat remote sensing device for electrochemical probes
US6615061B1 (en) 1998-11-23 2003-09-02 Abbott Laboratories Optical sensor having a selectable sampling distance for determination of analytes
JP2002531884A (en) 1998-11-30 2002-09-24 ノボ ノルディスク アクティーゼルスカブ Method and system for assisting a user in self-treatment involving multiple actions
US6773671B1 (en) 1998-11-30 2004-08-10 Abbott Laboratories Multichemistry measuring device and test strips
JP4749549B2 (en) 1998-11-30 2011-08-17 アボット・ラボラトリーズ Analytical testing instrument with improved calibration and communication process
US6161095A (en) 1998-12-16 2000-12-12 Health Hero Network, Inc. Treatment regimen compliance and efficacy with feedback
CA2352571C (en) 1998-12-02 2007-02-27 Gary S. Sayler In vivo biosensor apparatus and method of use
US6201993B1 (en) 1998-12-09 2001-03-13 Medtronic, Inc. Medical device telemetry receiver having improved noise discrimination
US6128519A (en) 1998-12-16 2000-10-03 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US6329929B1 (en) 1998-12-21 2001-12-11 Medtronic Inc. Telemetry system with phase-locking noise suppressing receiver
US7405149B1 (en) 1998-12-21 2008-07-29 Megica Corporation Post passivation method for semiconductor chip or wafer
WO2000038570A1 (en) 1998-12-31 2000-07-06 Ball Semiconductor, Inc. Miniature implanted orthopedic sensors
US6684090B2 (en) 1999-01-07 2004-01-27 Masimo Corporation Pulse oximetry data confidence indicator
US6169155B1 (en) 1999-01-14 2001-01-02 Dow Corning Corporation Silicone gel composition and silicone gel produced therefrom
US7436511B2 (en) 1999-01-22 2008-10-14 Sensys Medical, Inc. Analyte filter method and apparatus
IT1307750B1 (en) 1999-02-04 2001-11-19 Saicom S R L PH REACTIVE AMPEROMETRIC BIOSENSOR
US6475372B1 (en) 2000-02-02 2002-11-05 Lifescan, Inc. Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US6231560B1 (en) 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
AU3363000A (en) 1999-02-12 2000-08-29 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6112116A (en) 1999-02-22 2000-08-29 Cathco, Inc. Implantable responsive system for sensing and treating acute myocardial infarction
FR2790041B1 (en) 1999-02-23 2002-01-18 Fresenius Vial METHOD FOR CONTROLLING A PUMPING DEVICE COMPRISING A PUMP PROVIDED WITH A FLEXIBLE TUBE AND DEVICE FOR IMPLEMENTING THE METHOD
US6197040B1 (en) 1999-02-23 2001-03-06 Lifescan, Inc. Lancing device having a releasable connector
US6045567A (en) 1999-02-23 2000-04-04 Lifescan Inc. Lancing device causing reduced pain
US6360888B1 (en) 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
ATE552771T1 (en) 1999-02-25 2012-04-15 Medtronic Minimed Inc TEST PLUG AND CABLE FOR GLUCOSE MONITORING DEVICE
US6424847B1 (en) 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US6416651B1 (en) 1999-02-26 2002-07-09 Honeywell Measurex Multi-electrode composition measuring device and method
US7168597B1 (en) 1999-03-12 2007-01-30 Smithkline Beecham Corporation Aerosol metering valve
US6312388B1 (en) 1999-03-12 2001-11-06 Cardiac Pacemakers, Inc. Method and system for verifying the integrity of normal sinus rhythm templates
US6272379B1 (en) 1999-03-17 2001-08-07 Cathco, Inc. Implantable electronic system with acute myocardial infarction detection and patient warning capabilities
US6230059B1 (en) 1999-03-17 2001-05-08 Medtronic, Inc. Implantable monitor
US6400992B1 (en) 1999-03-18 2002-06-04 Medtronic, Inc. Co-extruded, multi-lumen medical lead
US6106494A (en) 1999-03-19 2000-08-22 Stryker Corporation Self-contained fluid management pump system for surgical procedures
US6099511A (en) 1999-03-19 2000-08-08 Merit Medical Systems, Inc. Manifold with check valve positioned within manifold body
US6115628A (en) 1999-03-29 2000-09-05 Medtronic, Inc. Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals
US6128526A (en) 1999-03-29 2000-10-03 Medtronic, Inc. Method for ischemia detection and apparatus for using same
GB9907815D0 (en) 1999-04-06 1999-06-02 Univ Cambridge Tech Implantable sensor
US6285897B1 (en) 1999-04-07 2001-09-04 Endonetics, Inc. Remote physiological monitoring system
WO2000059373A1 (en) 1999-04-07 2000-10-12 Spectrx, Inc. Assay device for measuring characteristics of a fluid on a continual basis
US6585876B2 (en) 1999-04-08 2003-07-01 Applied Materials Inc. Flow diffuser to be used in electro-chemical plating system and method
US6189536B1 (en) 1999-04-15 2001-02-20 Medtronic Inc. Method for protecting implantable devices
US6223083B1 (en) 1999-04-16 2001-04-24 Medtronic, Inc. Receiver employing digital filtering for use with an implantable medical device
US6200265B1 (en) 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
JP2002542498A (en) 1999-04-22 2002-12-10 シグナス, インコーポレイテッド Methods and devices for removing interfering species
US6108577A (en) 1999-04-26 2000-08-22 Cardiac Pacemakers, Inc. Method and apparatus for detecting changes in electrocardiogram signals
SE9901511D0 (en) 1999-04-27 1999-04-27 Siemens Elema Ab Check valve for anesthetic device
US6254061B1 (en) 1999-04-30 2001-07-03 Scimed Life Systems, Inc. Medical suction valve
US6471675B1 (en) 1999-04-30 2002-10-29 Medtronic, Inc. Passive flow control devices for implantable pumps
US6669663B1 (en) 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
AU4798500A (en) 1999-04-30 2000-11-17 University Of Southern California Implantable microbolus infusion pump
US6475750B1 (en) 1999-05-11 2002-11-05 M-Biotech, Inc. Glucose biosensor
US6465066B1 (en) 1999-05-11 2002-10-15 The Coca-Cola Company Packaged potable liquid and packaging for potable liquid
US6300002B1 (en) 1999-05-13 2001-10-09 Moltech Power Systems, Inc. Notched electrode and method of making same
US6165406A (en) 1999-05-27 2000-12-26 Nanotek Instruments, Inc. 3-D color model making apparatus and process
US6359444B1 (en) 1999-05-28 2002-03-19 University Of Kentucky Research Foundation Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing
US6546268B1 (en) 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
EP1106681A4 (en) 1999-06-10 2005-03-23 Matsushita Electric Ind Co Ltd Electrochemical device for moving particles covered with protein
JP2000356275A (en) 1999-06-15 2000-12-26 Seiko Instruments Inc Variable pressure valve
US6684904B2 (en) 1999-06-15 2004-02-03 Seiko Instruments Inc. Variable pressure valve apparatus
WO2000078210A1 (en) 1999-06-17 2000-12-28 Minimed Inc. Characteristic monitor system for use with analyte sensor
GB2351153B (en) 1999-06-18 2003-03-26 Abbott Lab Electrochemical sensor for analysis of liquid samples
AU5747100A (en) 1999-06-18 2001-01-09 Therasense, Inc. Mass transport limited in vivo analyte sensor
US6423035B1 (en) 1999-06-18 2002-07-23 Animas Corporation Infusion pump with a sealed drive mechanism and improved method of occlusion detection
US7247138B2 (en) 1999-07-01 2007-07-24 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6368274B1 (en) 1999-07-01 2002-04-09 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6175753B1 (en) 1999-07-02 2001-01-16 Baltimore Biomedical, Inc. Methods and mechanisms for quick-placement electroencephalogram (EEG) electrodes
US6413393B1 (en) 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
US6514460B1 (en) 1999-07-28 2003-02-04 Abbott Laboratories Luminous glucose monitoring device
US6280432B1 (en) 1999-08-04 2001-08-28 Embol-X, Inc. Clip-on access port and methods of use
US6179806B1 (en) 1999-08-05 2001-01-30 Scimed Life Systems, Inc. Self-occluding catheter
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6673022B1 (en) 1999-08-20 2004-01-06 Innerspace Medical, Inc. Gas column pressure monitoring catheters
US6923763B1 (en) 1999-08-23 2005-08-02 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US6346583B1 (en) 1999-08-25 2002-02-12 General Electric Company Polar solvent compatible polyethersiloxane elastomers
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
DE60031427T2 (en) 1999-08-31 2007-09-20 NIR Diagnostics Inc., Campbellville METHOD FOR CALIBRATING A SPECTROSCOPY DEVICE
US6312469B1 (en) 1999-09-13 2001-11-06 Medtronic Inc. Lamina prosthesis for delivery of medical treatment
US6343225B1 (en) 1999-09-14 2002-01-29 Implanted Biosystems, Inc. Implantable glucose sensor
EP1214596A1 (en) 1999-09-15 2002-06-19 The Regents Of The University Of California Glucose sensing molecules having selected fluorescent properties
AT408182B (en) 1999-09-17 2001-09-25 Schaupp Lukas Dipl Ing Dr Tech DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS
US6579257B1 (en) 1999-09-21 2003-06-17 Medtronic, Inc. Automated occlusion clamp for centrifugal blood pumps
US7063086B2 (en) 1999-09-23 2006-06-20 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
EP1217942A1 (en) 1999-09-24 2002-07-03 Healthetech, Inc. Physiological monitor and associated computation, display and communication unit
US6387324B1 (en) 1999-09-30 2002-05-14 Therox, Inc. Apparatus and method for blood oxygenation
JP2001104470A (en) 1999-10-04 2001-04-17 Seiko Instruments Inc Valve device and valve system using the same
US6464849B1 (en) 1999-10-07 2002-10-15 Pepex Biomedical, L.L.C. Sensor for measuring a bioanalyte such as lactate
US7317938B2 (en) 1999-10-08 2008-01-08 Sensys Medical, Inc. Method of adapting in-vitro models to aid in noninvasive glucose determination
US6478736B1 (en) 1999-10-08 2002-11-12 Healthetech, Inc. Integrated calorie management system
US6249705B1 (en) 1999-10-21 2001-06-19 Pacesetter, Inc. Distributed network system for use with implantable medical devices
US6430437B1 (en) 1999-10-27 2002-08-06 Physiometrix, Inc. Module for acquiring electroencephalograph signals from a patient
US6517508B1 (en) 1999-11-03 2003-02-11 Dsu Medical Corporation Set for blood processing
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US20060091006A1 (en) 1999-11-04 2006-05-04 Yi Wang Analyte sensor with insertion monitor, and methods
US6527729B1 (en) 1999-11-10 2003-03-04 Pacesetter, Inc. Method for monitoring patient using acoustic sensor
SE9904087D0 (en) 1999-11-11 1999-11-11 Pacesetter Ab Recommended replacement time of an implantable medical device
US8268143B2 (en) 1999-11-15 2012-09-18 Abbott Diabetes Care Inc. Oxygen-effect free analyte sensor
DK1230249T3 (en) 1999-11-15 2004-08-30 Therasense Inc Transition metal complexes with bidentate ligand having an imidazole ring
US6925393B1 (en) 1999-11-18 2005-08-02 Roche Diagnostics Gmbh System for the extrapolation of glucose concentration
US6658396B1 (en) 1999-11-29 2003-12-02 Tang Sharon S Neural network drug dosage estimation
US6612984B1 (en) 1999-12-03 2003-09-02 Kerr, Ii Robert A. System and method for collecting and transmitting medical data
US6520997B1 (en) 1999-12-08 2003-02-18 Baxter International Inc. Porous three dimensional structure
JP3852734B2 (en) 1999-12-20 2006-12-06 セイコーインスツル株式会社 Pressure variable valve device and set pressure adjusting device for the valve device
EP2308374B1 (en) 1999-12-22 2012-07-18 Orsense Ltd. A method of optical measurements for determining various parameters of the patient's blood
KR100360774B1 (en) 1999-12-27 2002-11-13 한국전자통신연구원 Enzyme electrode sensor and manufacturing method thereof
US6377852B1 (en) 2000-01-20 2002-04-23 Pacesetter, Inc. Implanatable cardiac stimulation device and method for prolonging atrial refractoriness
WO2001052935A1 (en) 2000-01-21 2001-07-26 Medical Research Group, Inc. Ambulatory medical apparatus and method having telemetry modifiable control software
US7369635B2 (en) 2000-01-21 2008-05-06 Medtronic Minimed, Inc. Rapid discrimination preambles and methods for using the same
DK1248660T3 (en) 2000-01-21 2012-07-23 Medtronic Minimed Inc Microprocessor controlled outpatient medical device with handheld communication device
US6974437B2 (en) 2000-01-21 2005-12-13 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US20020016535A1 (en) 2000-01-28 2002-02-07 Martin W. Blake Subcutaneous glucose measurement device
US6687521B2 (en) 2000-02-03 2004-02-03 Hamamatsu Photonics K.K. Noninvasion biological optical measuring instrument, measured portion holding device, and method for manufacturing the same
EP1130393A3 (en) 2000-02-03 2001-11-28 Nihon Kohden Corporation Gas sensor and gas sensor system
US7003336B2 (en) 2000-02-10 2006-02-21 Medtronic Minimed, Inc. Analyte sensor method of making the same
WO2001058348A2 (en) 2000-02-10 2001-08-16 Minimed Inc. Improved analyte sensor and method of making the same
US6484045B1 (en) 2000-02-10 2002-11-19 Medtronic Minimed, Inc. Analyte sensor and method of making the same
US7890295B2 (en) 2000-02-23 2011-02-15 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
JP4010005B2 (en) 2000-02-29 2007-11-21 ニプロ株式会社 Device for adjusting injection speed of chemical injector
CN1310980A (en) 2000-02-29 2001-09-05 迪亚西斯公司 Method and equipment for treating various kinds of liquid
US6893396B2 (en) 2000-03-01 2005-05-17 I-Medik, Inc. Wireless internet bio-telemetry monitoring system and interface
US6572542B1 (en) 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6551496B1 (en) 2000-03-03 2003-04-22 Ysi Incorporated Microstructured bilateral sensor
US6528318B1 (en) 2000-03-06 2003-03-04 The Johns Hopkins University Scatter controlled emission for optical taggants and chemical sensors
US6733655B1 (en) 2000-03-08 2004-05-11 Oliver W. H. Davies Measurement of substances in liquids
US6498941B1 (en) 2000-03-09 2002-12-24 Advanced Cardiovascular Systems, Inc. Catheter based probe and method of using same for detecting chemical analytes
US6365670B1 (en) 2000-03-10 2002-04-02 Wacker Silicones Corporation Organopolysiloxane gels for use in cosmetics
WO2001069222A2 (en) 2000-03-17 2001-09-20 F. Hoffmann-La Roche Ag Implantable analyte sensor
US6405066B1 (en) 2000-03-17 2002-06-11 The Regents Of The University Of California Implantable analyte sensor
US6612111B1 (en) 2000-03-27 2003-09-02 Lifescan, Inc. Method and device for sampling and analyzing interstitial fluid and whole blood samples
EP1267708A4 (en) 2000-03-29 2006-04-12 Univ Virginia Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US6610012B2 (en) 2000-04-10 2003-08-26 Healthetech, Inc. System and method for remote pregnancy monitoring
US6736783B2 (en) 2000-04-12 2004-05-18 Merck & Co., Inc. Automated blood sampling apparatus
US6440068B1 (en) 2000-04-28 2002-08-27 International Business Machines Corporation Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device
US6544229B1 (en) 2000-05-01 2003-04-08 Baxter International Inc Linearly motile infusion pump
CA2407973C (en) 2000-05-03 2011-06-07 Jen-Jr Gau Biological identification system with integrated sensor chip
US6599281B1 (en) 2000-05-03 2003-07-29 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
IT1314759B1 (en) 2000-05-08 2003-01-03 Menarini Farma Ind INSTRUMENTATION FOR MEASUREMENT AND CONTROL OF THE CONTENT OF GLUCOSIOLACTATE OR OTHER METABOLITES IN BIOLOGICAL FLUIDS
AU2001263022A1 (en) 2000-05-12 2001-11-26 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
DE60137663D1 (en) 2000-05-13 2009-04-02 Alphasense Ltd Electrochemical sensor for the determination of an analyte in the presence of an interfering gas
US7181261B2 (en) 2000-05-15 2007-02-20 Silver James H Implantable, retrievable, thrombus minimizing sensors
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US6885883B2 (en) 2000-05-16 2005-04-26 Cygnus, Inc. Methods for improving performance and reliability of biosensors
US6459917B1 (en) 2000-05-22 2002-10-01 Ashok Gowda Apparatus for access to interstitial fluid, blood, or blood plasma components
WO2001091218A2 (en) 2000-05-22 2001-11-29 Acumentrics Corporation Electrode-supported solid state electrochemical cell
DE10024969A1 (en) 2000-05-22 2001-12-06 Forschungszentrum Juelich Gmbh Procedure for the determination of substrate and product concentrations in a medium
US6887214B1 (en) 2000-09-12 2005-05-03 Chf Solutions, Inc. Blood pump having a disposable blood passage cartridge with integrated pressure sensors
JP3701608B2 (en) 2000-05-23 2005-10-05 ラジオメーター・メディカル・アー・ペー・エス Sensor membrane, method for its preparation, sensor and layered membrane structure for such a sensor
US7395158B2 (en) 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
IL136673A0 (en) 2000-06-11 2001-06-14 Orsense Ltd A method and device for measuring the concentration of glucose or other substance in blood
WO2002100266A1 (en) 2000-06-13 2002-12-19 Edward Henry Mathews A dietary system: 'blood sugar predicting system'
US6991652B2 (en) 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US6565535B2 (en) 2000-06-16 2003-05-20 Nardo Zaias Medical infusion and aspiration system
US6699188B2 (en) 2000-06-22 2004-03-02 Guidance Interactive Technologies Interactive reward devices and methods
US6361503B1 (en) 2000-06-26 2002-03-26 Mediwave Star Technology, Inc. Method and system for evaluating cardiac ischemia
US6400974B1 (en) 2000-06-29 2002-06-04 Sensors For Medicine And Science, Inc. Implanted sensor processing system and method for processing implanted sensor output
US6569521B1 (en) 2000-07-06 2003-05-27 3M Innovative Properties Company Stretch releasing pressure sensitive adhesive tape and articles
US6477392B1 (en) 2000-07-14 2002-11-05 Futrex Inc. Calibration of near infrared quantitative measurement device using optical measurement cross-products
US6444115B1 (en) 2000-07-14 2002-09-03 Lifescan, Inc. Electrochemical method for measuring chemical reaction rates
WO2002005702A2 (en) 2000-07-18 2002-01-24 Healthetech, Inc. Closed loop glycemic index system
US6795068B1 (en) 2000-07-21 2004-09-21 Sony Computer Entertainment Inc. Prop input device and method for mapping an object from a two-dimensional camera image to a three-dimensional space for controlling action in a game program
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
US6685668B1 (en) 2000-07-31 2004-02-03 Abbott Laboratories Closed-loop IV fluid flow control
US6683535B1 (en) 2000-08-09 2004-01-27 Alderon Industries, Llc Water detection system and method
WO2002013886A2 (en) 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
WO2002017210A2 (en) 2000-08-18 2002-02-28 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
CA2408338C (en) 2000-08-18 2009-09-08 Cygnus, Inc. Methods and devices for prediction of hypoglycemic events
WO2002015778A1 (en) 2000-08-18 2002-02-28 Cygnus, Inc. Analyte monitoring device alarm augmentation system
EP1311189A4 (en) 2000-08-21 2005-03-09 Euro Celtique Sa Near infrared blood glucose monitoring system
WO2002018936A2 (en) 2000-08-28 2002-03-07 Cygnus, Inc. Methods of monitoring glucose levels in a subject and uses thereof
US6553241B2 (en) 2000-08-31 2003-04-22 Mallinckrodt Inc. Oximeter sensor with digital memory encoding sensor expiration data
US6600940B1 (en) 2000-08-31 2003-07-29 Mallinckrodt Inc. Oximeter sensor with digital memory
US6572579B1 (en) 2000-09-13 2003-06-03 Image-Guided Neurologics, Inc. Drug delivery and catheter systems, apparatus and processes
US6689413B2 (en) 2000-09-15 2004-02-10 Seagate Technology Llc Using plated surface for recording media without polishing
DE60123086T2 (en) 2000-09-22 2007-06-06 Sorenson Development, Inc., Salt Lake City HOSE PUMP
US6575905B2 (en) 2000-09-22 2003-06-10 Knobbe, Lim & Buckingham Method and apparatus for real-time estimation of physiological parameters
FR2815199B1 (en) 2000-10-10 2003-01-17 Canon Kk CIRCULAR TURBOCODING METHODS OF LARGE MINIMUM DISTANCE, AND SYSTEMS FOR IMPLEMENTING THE SAME
US7077853B2 (en) 2000-10-20 2006-07-18 Ethicon Endo-Surgery, Inc. Method for calculating transducer capacitance to determine transducer temperature
DE60139411D1 (en) 2000-10-26 2009-09-10 Medtronic Inc DEVICE FOR MINIMIZING THE EFFECTS OF A HEART INJURY
US6585675B1 (en) 2000-11-02 2003-07-01 Chf Solutions, Inc. Method and apparatus for blood withdrawal and infusion using a pressure controller
EP1695727B1 (en) 2000-11-09 2008-07-23 Insulet Corporation Transcutaneous delivery means
US6695860B1 (en) 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
WO2002039086A2 (en) 2000-11-13 2002-05-16 Nipro Diabetes Systems Glucose sensor system
US6428123B1 (en) 2000-11-15 2002-08-06 Midwest Quality Gloves, Inc. Product display
US6609071B2 (en) 2000-12-06 2003-08-19 Project Cd System for monitoring and controlling pressure and concentration values in a fluid conduit
KR100742577B1 (en) 2000-12-08 2007-08-02 다이버사코어 엘엘씨 Composite structural framing system
JP2002174610A (en) 2000-12-08 2002-06-21 Nec Corp Biosensor and liquid sample measurement method using biosensor
WO2002047754A1 (en) 2000-12-11 2002-06-20 Christoph Miethke Gmbh & Co. Kg Hydrocephalus valve
DE60045740D1 (en) 2000-12-12 2011-04-28 Sony Deutschland Gmbh Selective chemical sensors based on chained nanoparticle accumulations
ES2382367T3 (en) 2000-12-13 2012-06-07 Panasonic Corporation Quantification procedure of a substrate
US6712796B2 (en) 2000-12-15 2004-03-30 Kirk Buhler High hysteresis valve
US6520937B2 (en) 2000-12-18 2003-02-18 Scimed Life Systems, Inc. Fluid injection device
US7052483B2 (en) 2000-12-19 2006-05-30 Animas Corporation Transcutaneous inserter for low-profile infusion sets
WO2005032400A2 (en) 2003-10-06 2005-04-14 Nicast Ltd. Method and apparatus for coating medical implants
US6742635B2 (en) 2000-12-20 2004-06-01 Jr286 Inc. Sports bag including an attached mat
IL156245A0 (en) 2000-12-22 2004-01-04 Dca Design Int Ltd Drive mechanism for an injection device
US6490479B2 (en) 2000-12-28 2002-12-03 Ge Medical Systems Information Technologies, Inc. Atrial fibrillation detection method and apparatus
US6642015B2 (en) 2000-12-29 2003-11-04 Minimed Inc. Hydrophilic polymeric material for coating biosensors
WO2002053193A2 (en) 2001-01-02 2002-07-11 The Charles Stark Draper Laboratory, Inc. Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US20030034305A1 (en) 2001-01-05 2003-02-20 Gambro, Inc. Purified water supply system for high demand devices and applications
US6666821B2 (en) 2001-01-08 2003-12-23 Medtronic, Inc. Sensor system
US6970529B2 (en) 2001-01-16 2005-11-29 International Business Machines Corporation Unified digital architecture
US7078582B2 (en) 2001-01-17 2006-07-18 3M Innovative Properties Company Stretch removable adhesive articles and methods
US20040197846A1 (en) 2001-01-18 2004-10-07 Linda Hockersmith Determination of glucose sensitivity and a method to manipulate blood glucose concentration
US6968743B2 (en) 2001-01-22 2005-11-29 Integrated Sensing Systems, Inc. Implantable sensing device for physiologic parameter measurement
MXPA03006421A (en) 2001-01-22 2004-12-02 Hoffmann La Roche Lancet device having capillary action.
US6547839B2 (en) 2001-01-23 2003-04-15 Skc Co., Ltd. Method of making an electrochemical cell by the application of polysiloxane onto at least one of the cell components
US6510329B2 (en) 2001-01-24 2003-01-21 Datex-Ohmeda, Inc. Detection of sensor off conditions in a pulse oximeter
US6520477B2 (en) 2001-02-01 2003-02-18 William Trimmer Micro pump
KR20030031894A (en) 2001-02-05 2003-04-23 글루코센스 인코퍼레이티드 Methods of determining concentration of glucose in blood
US7014610B2 (en) 2001-02-09 2006-03-21 Medtronic, Inc. Echogenic devices and methods of making and using such devices
US6486661B2 (en) 2001-02-12 2002-11-26 Delphi Technologies, Inc. Sensor bias drift compensation
US7268562B2 (en) 2001-02-15 2007-09-11 Integral Technologies, Inc. Low cost detectible pipe and electric fencing manufactured from conductive loaded resin-based materials
US6721587B2 (en) 2001-02-15 2004-04-13 Regents Of The University Of California Membrane and electrode structure for implantable sensor
US6749587B2 (en) 2001-02-22 2004-06-15 Insulet Corporation Modular infusion device and method
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6620151B2 (en) 2001-03-01 2003-09-16 Advanced Neuromodulation Systems, Inc. Non-constant pressure infusion pump
US7315767B2 (en) 2001-03-06 2008-01-01 Solianis Holding Ag Impedance spectroscopy based systems and methods
EP1384193A2 (en) 2001-03-14 2004-01-28 Baxter International Inc. Internet based therapy management system
US6968294B2 (en) 2001-03-15 2005-11-22 Koninklijke Philips Electronics N.V. Automatic system for monitoring person requiring care and his/her caretaker
US6702249B2 (en) 2001-03-19 2004-03-09 Seiko Instruments Inc. Pressure-variable valve device and set-pressure adjusting device for the valve device
FR2822383B1 (en) 2001-03-23 2004-12-17 Perouse Lab PROSTHESIS FOR PLASTIC RECONSTRUCTION WITH IMPROVED HYDROPHILICITY PROPERTIES, AND METHOD FOR OBTAINING SAME
US6576102B1 (en) 2001-03-23 2003-06-10 Virotek, L.L.C. Electrochemical sensor and method thereof
US6622045B2 (en) 2001-03-29 2003-09-16 Pacesetter, Inc. System and method for remote programming of implantable cardiac stimulation devices
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
US7288085B2 (en) 2001-04-10 2007-10-30 Medtronic, Inc. Permanent magnet solenoid pump for an implantable therapeutic substance delivery device
US6454710B1 (en) 2001-04-11 2002-09-24 Motorola, Inc. Devices and methods for monitoring an analyte
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US7167734B2 (en) 2001-04-13 2007-01-23 Abbott Laboratories Method for optical measurements of tissue to determine disease state or concentration of an analyte
US6698269B2 (en) 2001-04-27 2004-03-02 Oceana Sensor Technologies, Inc. Transducer in-situ testing apparatus and method
WO2002090948A1 (en) 2001-05-03 2002-11-14 Delta Dansk Elektronik, Lys & Akustik Apparatus and sensing devices for measuring fluorescence lifetimes of fluorescence sensors
US7135342B2 (en) 2001-05-04 2006-11-14 Sensors For Medicine And Science, Inc. Electro-optical sensing device with reference channel
US6723086B2 (en) 2001-05-07 2004-04-20 Logiq Wireless Solutions, Inc. Remote controlled transdermal medication delivery device
US6613379B2 (en) 2001-05-08 2003-09-02 Isense Corp. Implantable analyte sensor
US7395214B2 (en) 2001-05-11 2008-07-01 Craig P Shillingburg Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient
US6676816B2 (en) 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
US6932894B2 (en) 2001-05-15 2005-08-23 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US6945965B2 (en) 2001-05-16 2005-09-20 Howard Anthony Whiting Remote controlled urinary leg/bed bag drain valve
US20020177763A1 (en) 2001-05-22 2002-11-28 Burns David W. Integrated lancets and methods
IL143374A0 (en) 2001-05-24 2002-04-21 Transscan Medical Ltd Anomaly detection based on signal variations
US6549796B2 (en) 2001-05-25 2003-04-15 Lifescan, Inc. Monitoring analyte concentration using minimally invasive devices
US20040023253A1 (en) 2001-06-11 2004-02-05 Sandeep Kunwar Device structure for closely spaced electrodes
US6793632B2 (en) 2001-06-12 2004-09-21 Lifescan, Inc. Percutaneous biological fluid constituent sampling and measurement devices and methods
US6501976B1 (en) 2001-06-12 2002-12-31 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7179226B2 (en) 2001-06-21 2007-02-20 Animas Corporation System and method for managing diabetes
EP2319400B1 (en) 2001-06-22 2012-08-22 Nellcor Puritan Bennett Ireland Wavelet-based analysis of pulse oximetry signals
WO2003000127A2 (en) 2001-06-22 2003-01-03 Cygnus, Inc. Method for improving the performance of an analyte monitoring system
US6802827B2 (en) 2001-06-26 2004-10-12 Stig O. Andersson Hypodermic implant device
GB0115793D0 (en) 2001-06-28 2001-08-22 Univ Cranfield A novel mediator for electrochemical detection
US7044911B2 (en) 2001-06-29 2006-05-16 Philometron, Inc. Gateway platform for biological monitoring and delivery of therapeutic compounds
US6697658B2 (en) 2001-07-02 2004-02-24 Masimo Corporation Low power pulse oximeter
US6569309B2 (en) 2001-07-05 2003-05-27 Asahi Kasei Kabushiki Kaisha Fuel cell type reactor and method for producing a chemical compound by using the same
US7150737B2 (en) 2001-07-13 2006-12-19 Sci/Med Life Systems, Inc. Methods and apparatuses for navigating the subarachnoid space
US20030208113A1 (en) 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6754516B2 (en) 2001-07-19 2004-06-22 Nellcor Puritan Bennett Incorporated Nuisance alarm reductions in a physiological monitor
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US6767441B1 (en) 2001-07-31 2004-07-27 Nova Biomedical Corporation Biosensor with peroxidase enzyme
US20040260478A1 (en) 2001-08-03 2004-12-23 Schwamm Lee H. System, process and diagnostic arrangement establishing and monitoring medication doses for patients
US7481759B2 (en) 2001-08-03 2009-01-27 Cardiac Pacemakers, Inc. Systems and methods for treatment of coronary artery disease
US6788965B2 (en) 2001-08-03 2004-09-07 Sensys Medical, Inc. Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes
US20040162678A1 (en) 2001-08-13 2004-08-19 Donald Hetzel Method of screening for disorders of glucose metabolism
EP1428013A4 (en) 2001-08-14 2007-10-31 Purdue Research Foundation Measuring a substance in a biological sample
WO2003015629A1 (en) 2001-08-20 2003-02-27 Inverness Medical Limited Wireless diabetes management devices and methods for using the same
DE60238202D1 (en) 2001-08-22 2010-12-16 Instrumentation Lab Co METHOD AND DEVICE FOR CALIBRATING SENSORS
US7096064B2 (en) 2001-08-28 2006-08-22 Medtronic, Inc. Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
US7166208B2 (en) 2004-03-03 2007-01-23 Stephen Eliot Zweig Apoenzyme reactivation electrochemical detection method and assay
US6770067B2 (en) 2001-09-07 2004-08-03 Medtronic Minimed, Inc. Infusion device and driving mechanism for same
US7025760B2 (en) 2001-09-07 2006-04-11 Medtronic Minimed, Inc. Method and system for non-vascular sensor implantation
US6595756B2 (en) 2001-09-07 2003-07-22 Medtronic Minimed, Inc. Electronic control system and process for electromagnetic pump
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US8152789B2 (en) 2001-10-23 2012-04-10 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6997921B2 (en) 2001-09-07 2006-02-14 Medtronic Minimed, Inc. Infusion device and driving mechanism for same
CN1282870C (en) 2001-09-11 2006-11-01 爱科来株式会社 Measuring instrument, installation body, and density measurer
US6650915B2 (en) 2001-09-13 2003-11-18 Fovioptics, Inc. Non-invasive measurement of blood analytes using photodynamics
JP2003084101A (en) 2001-09-17 2003-03-19 Dainippon Printing Co Ltd Resin composition for optical device, optical device and projection screen
US7052591B2 (en) 2001-09-21 2006-05-30 Therasense, Inc. Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking
US7425877B2 (en) 2001-09-21 2008-09-16 Ultrasource, Inc. Lange coupler system and method
US6830562B2 (en) 2001-09-27 2004-12-14 Unomedical A/S Injector device for placing a subcutaneous infusion set
JP2003108679A (en) 2001-09-28 2003-04-11 Toshiba Corp Home treatment patient supporting system and method
US6802957B2 (en) 2001-09-28 2004-10-12 Marine Biological Laboratory Self-referencing enzyme-based microsensor and method of use
US7258681B2 (en) 2001-10-04 2007-08-21 Scimed Life Systems, Inc. Angiographic fluid control system
CN1232818C (en) 2001-10-10 2005-12-21 生命扫描有限公司 Electrochemical cell
US6731985B2 (en) 2001-10-16 2004-05-04 Pacesetter, Inc. Implantable cardiac stimulation system and method for automatic capture verification calibration
US7854230B2 (en) 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US6809507B2 (en) 2001-10-23 2004-10-26 Medtronic Minimed, Inc. Implantable sensor electrodes and electronic circuitry
DE60128012T2 (en) 2001-10-24 2008-01-10 J & J Chemical Co. Ltd. METHOD AND DEVICE FOR PREPARING HYDRAZODIC ACETIC ACID AMID USING UREA AS AN OUTPUT MATERIAL
US7097775B2 (en) 2001-10-26 2006-08-29 Second Sight Medical Products, Inc. Coated microfluidic delivery system
US7061593B2 (en) 2001-11-08 2006-06-13 Optiscan Biomedical Corp. Device and method for in vitro determination of analyte concentrations within body fluids
US6989891B2 (en) 2001-11-08 2006-01-24 Optiscan Biomedical Corporation Device and method for in vitro determination of analyte concentrations within body fluids
US6755785B2 (en) 2001-11-20 2004-06-29 Matsushita Electric Industrial Co., Ltd. Ultrasonic image generating apparatus and ultrasonic image generating method
US20040030294A1 (en) 2001-11-28 2004-02-12 Mahurkar Sakharam D. Retractable needle single use safety syringe
US20050101841A9 (en) 2001-12-04 2005-05-12 Kimberly-Clark Worldwide, Inc. Healthcare networks with biosensors
KR100407822B1 (en) 2001-12-04 2003-12-01 한국전자통신연구원 Electrochemical immune-sensor, and kit and method for detecting biochemical analyte using the same
US6679865B2 (en) 2001-12-07 2004-01-20 Nedrip Ltd. Fluid flow meter for gravity fed intravenous fluid delivery systems
US20030113573A1 (en) 2001-12-19 2003-06-19 Pepin John Graeme Thick film composition yielding magnetic properties
US7204823B2 (en) 2001-12-19 2007-04-17 Medtronic Minimed, Inc. Medication delivery system and monitor
US6952604B2 (en) 2001-12-21 2005-10-04 Becton, Dickinson And Company Minimally-invasive system and method for monitoring analyte levels
DE10163972B4 (en) 2001-12-22 2005-10-27 Roche Diagnostics Gmbh Method and device for determining a light transport parameter and an analyte in a biological matrix
US20080255438A1 (en) 2001-12-27 2008-10-16 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7018336B2 (en) 2001-12-27 2006-03-28 Medtronic Minimed, Inc. Implantable sensor flush sleeve
US7399277B2 (en) 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7022072B2 (en) 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US20050027182A1 (en) 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US6985870B2 (en) 2002-01-11 2006-01-10 Baxter International Inc. Medication delivery system
US20080125751A1 (en) 2002-01-14 2008-05-29 Edwards Lifesciences Corporation Temperature compensation for enzyme electrodes
US6980852B2 (en) 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
CA2474359A1 (en) 2002-01-29 2003-08-07 Sicel Technologies, Inc. Implantable sensor housing and fabrication methods
US20030143746A1 (en) 2002-01-31 2003-07-31 Sage Burton H. Self-calibrating body anayte monitoring system
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
FR2836047B1 (en) 2002-02-21 2004-04-02 Henri Mehier FACILITY FOR DELIVERING CALORIES IN ALL OR PART OF A HUMAN OR ANIMAL CELLULAR FABRIC
DK2298370T3 (en) 2002-02-21 2014-01-27 Design Mentor Inc fluid pump
DE10208575C1 (en) 2002-02-21 2003-08-14 Hartmann Paul Ag Blood analyzer device comprises needles, test media, analyzer and display, and has carrier turned with respect to main body, to position needle and test media
US7311690B2 (en) 2002-02-25 2007-12-25 Novashunt Ag Implantable fluid management system for the removal of excess fluid
ES2428965T3 (en) 2002-02-25 2013-11-12 Sequana Medical Ag Bladder bypass for excess fluid drainage
AU2003213638A1 (en) 2002-02-26 2003-09-09 Sterling Medivations, Inc. Insertion device for an insertion set and method of using the same
US20030212379A1 (en) 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US7068610B2 (en) 2002-02-26 2006-06-27 Unruh Lincoln J System and method for reliable communications over multiple packet RF networks
US6692457B2 (en) 2002-03-01 2004-02-17 Insulet Corporation Flow condition sensor assembly for patient infusion device
US6998247B2 (en) 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US7179654B2 (en) 2002-03-18 2007-02-20 Agilent Technologies, Inc. Biochemical assay with programmable array detection
US6936006B2 (en) 2002-03-22 2005-08-30 Novo Nordisk, A/S Atraumatic insertion of a subcutaneous device
CA2480550C (en) 2002-03-22 2011-07-12 Cygnus, Inc. Improving performance of an analyte monitoring device
WO2003091701A2 (en) 2002-03-29 2003-11-06 Board Of Regents Of The University Of Texas System Implantable biosensor from stratified nanostructured membranes
GB2388898B (en) 2002-04-02 2005-10-05 Inverness Medical Ltd Integrated sample testing meter
US20030225437A1 (en) 2002-04-04 2003-12-04 Ferguson Patrick J. Device for retaining material
US7027848B2 (en) 2002-04-04 2006-04-11 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
CA2481501A1 (en) 2002-04-05 2003-10-23 Eyelab Group, Llc Monitoring blood substances using self-sampled tears
AU2003221808A1 (en) 2002-04-05 2003-10-27 Powerzyme, Inc. Analyte sensor
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7410468B2 (en) 2002-04-19 2008-08-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7198606B2 (en) 2002-04-19 2007-04-03 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US7153265B2 (en) 2002-04-22 2006-12-26 Medtronic Minimed, Inc. Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance
US20070227907A1 (en) 2006-04-04 2007-10-04 Rajiv Shah Methods and materials for controlling the electrochemistry of analyte sensors
US6960192B1 (en) 2002-04-23 2005-11-01 Insulet Corporation Transcutaneous fluid delivery system
EP1498067A1 (en) 2002-04-25 2005-01-19 Matsushita Electric Industrial Co., Ltd. Dosage determination supporting device, injector, and health management supporting system
US6743635B2 (en) 2002-04-25 2004-06-01 Home Diagnostics, Inc. System and methods for blood glucose sensing
US7343188B2 (en) 2002-05-09 2008-03-11 Lifescan, Inc. Devices and methods for accessing and analyzing physiological fluid
US7060192B2 (en) 2002-05-09 2006-06-13 Lifescan, Inc. Methods of fabricating physiological sample collection devices
US6801041B2 (en) 2002-05-14 2004-10-05 Abbott Laboratories Sensor having electrode for determining the rate of flow of a fluid
SE524166C2 (en) 2002-05-17 2004-07-06 Hemapure Ab Sensor unit and method for detecting a blood related parameter and system comprising such sensor unit
US20060258761A1 (en) 2002-05-22 2006-11-16 Robert Boock Silicone based membranes for use in implantable glucose sensors
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
AU2003240018A1 (en) 2002-05-31 2003-12-19 Dow Corning Toray Silicone Co., Ltd. Cartridge for moisture-curable sealant
EP1514096B1 (en) 2002-06-03 2011-02-02 Arizona Board Of Regents Acting for Northern Arizona University Hybrid microcantilever sensors
US7018361B2 (en) 2002-06-14 2006-03-28 Baxter International Inc. Infusion pump
US7288368B2 (en) 2002-06-17 2007-10-30 Stephen Eliot Zweig Membrane receptor reagent and assay
AU2003279777A1 (en) 2002-06-28 2004-01-19 November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin Electrochemical detection method and device
US6858020B2 (en) 2002-07-08 2005-02-22 Ideal Instrument, Inc. Vaccinator device
US7316662B2 (en) 2002-07-09 2008-01-08 Gambro Lundia Ab Infusion device for medical use
US6865407B2 (en) 2002-07-11 2005-03-08 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US20040010207A1 (en) 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
AU2003302720B9 (en) 2002-07-19 2008-08-21 Smiths Detection-Pasadena, Inc. Non-specific sensor array detectors
US7171312B2 (en) 2002-07-19 2007-01-30 Smiths Detection, Inc. Chemical and biological agent sensor array detectors
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
US8512276B2 (en) 2002-07-24 2013-08-20 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US20040068230A1 (en) 2002-07-24 2004-04-08 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US7223253B2 (en) 2002-07-29 2007-05-29 Gore Enterprise Holdings, Inc. Blood aspiration system and methods of use
US6892093B2 (en) 2002-08-01 2005-05-10 Ge Medical Systems Information Technologies Inc. Method and apparatus for real time display of filtered electrocardiogram data
EP1534121B1 (en) 2002-08-13 2014-01-22 University Of Virginia Patent Foundation Method, system, and computer program product for the processing of self-monitoring blood glucose(smbg)data to enhance diabetic self-management
DE60234138D1 (en) 2002-09-04 2009-12-03 Solianis Holding Ag METHOD AND APPARATUS FOR GLUCOSE MEASUREMENT
US7610352B2 (en) 2002-09-09 2009-10-27 Meca Communications, Inc. Sharing skins
US7404796B2 (en) 2004-03-01 2008-07-29 Becton Dickinson And Company System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
US6912413B2 (en) 2002-09-13 2005-06-28 Ge Healthcare Finland Oy Pulse oximeter
AU2003274980A1 (en) 2002-09-17 2004-04-08 U.S. Government As Represented By The Secretary Of The Army Needle with fiberoptic capability
US7070591B2 (en) 2002-09-17 2006-07-04 Transoma Medical, Inc. Vascular access port with physiological sensor
US7150741B2 (en) 2002-09-20 2006-12-19 Advanced Neuromodulation Systems, Inc. Programmable dose control module
US6880564B2 (en) 2002-09-20 2005-04-19 Advanced Neuromodulation Systems, Inc. Dosage control apparatus
US7312040B2 (en) 2002-09-20 2007-12-25 Agilent Technologies, Inc. Microcapsule biosensors and methods of using the same
US8303511B2 (en) 2002-09-26 2012-11-06 Pacesetter, Inc. Implantable pressure transducer system optimized for reduced thrombosis effect
DE10245416B4 (en) 2002-09-28 2006-03-16 Pulsion Medical Systems Ag Catheter system with special fasteners
US7192405B2 (en) 2002-09-30 2007-03-20 Becton, Dickinson And Company Integrated lancet and bodily fluid sensor
US7207968B1 (en) 2002-10-07 2007-04-24 Harcinske John C Drinking dispenser for bedridden patients
US7303875B1 (en) 2002-10-10 2007-12-04 Nanosys, Inc. Nano-chem-FET based biosensors
KR101226540B1 (en) 2002-10-11 2013-01-25 벡톤 디킨슨 앤드 컴퍼니 System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US20040074785A1 (en) 2002-10-18 2004-04-22 Holker James D. Analyte sensors and methods for making them
US20050272989A1 (en) 2004-06-04 2005-12-08 Medtronic Minimed, Inc. Analyte sensors and methods for making and using them
US7029443B2 (en) 2002-10-21 2006-04-18 Pacesetter, Inc. System and method for monitoring blood glucose levels using an implantable medical device
US20040108226A1 (en) 2002-10-28 2004-06-10 Constantin Polychronakos Continuous glucose quantification device and method
US6737158B1 (en) 2002-10-30 2004-05-18 Gore Enterprise Holdings, Inc. Porous polymeric membrane toughened composites
US7248912B2 (en) 2002-10-31 2007-07-24 The Regents Of The University Of California Tissue implantable sensors for measurement of blood solutes
US7087017B2 (en) 2002-10-31 2006-08-08 Medtronic, Inc. Atraumatic sensor lead assemblies
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US7572237B2 (en) 2002-11-06 2009-08-11 Abbott Diabetes Care Inc. Automatic biological analyte testing meter with integrated lancing device and methods of use
US6931328B2 (en) 2002-11-08 2005-08-16 Optiscan Biomedical Corp. Analyte detection system with software download capabilities
US7228160B2 (en) 2002-11-13 2007-06-05 Sorenson Medical, Inc. System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors
US7062385B2 (en) 2002-11-25 2006-06-13 Tufts University Intelligent electro-optical nucleic acid-based sensor array and method for detecting volatile compounds in ambient air
US6918982B2 (en) 2002-12-09 2005-07-19 International Business Machines Corporation System and method of transfer printing an organic semiconductor
WO2004052190A1 (en) 2002-12-10 2004-06-24 Koninklijke Philips Electronics N.V. A wearable device for bioelectrical interaction with motion artifact correction means
US7052472B1 (en) 2002-12-18 2006-05-30 Dsp Diabetes Sentry Products, Inc. Systems and methods for detecting symptoms of hypoglycemia
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
US7229288B2 (en) 2002-12-20 2007-06-12 Medtronic Minimed, Inc. Method, system, and program for using a virtual environment to provide information on using a product
US7255690B2 (en) 2002-12-26 2007-08-14 Medtronic Minimed, Inc. Infusion device having piston operated driving mechanism and positive pressure reservoir
US6932584B2 (en) 2002-12-26 2005-08-23 Medtronic Minimed, Inc. Infusion device and driving mechanism and process for same with actuator for multiple infusion uses
US20040127818A1 (en) 2002-12-27 2004-07-01 Roe Steven N. Precision depth control lancing tip
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US20040133131A1 (en) 2003-01-03 2004-07-08 Kuhn David L. In vivo ruminant health sensor
US7396330B2 (en) 2003-01-07 2008-07-08 Triage Data Networks Wireless, internet-based medical-diagnostic system
US7207947B2 (en) 2003-01-10 2007-04-24 Pacesetter, Inc. System and method for detecting circadian states using an implantable medical device
US7228162B2 (en) 2003-01-13 2007-06-05 Isense Corporation Analyte sensor
US7120483B2 (en) 2003-01-13 2006-10-10 Isense Corporation Methods for analyte sensing and measurement
US6902544B2 (en) 2003-01-22 2005-06-07 Codman & Shurtleff, Inc. Troubleshooting accelerator system for implantable drug delivery pumps
US20060235314A1 (en) 2003-01-31 2006-10-19 Michele Migliuolo Medical and surgical devices with an integrated sensor
US20040172307A1 (en) 2003-02-06 2004-09-02 Gruber Martin A. Electronic medical record method
WO2004084820A2 (en) 2003-03-19 2004-10-07 Harry Hebblewhite Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
US8003374B2 (en) 2003-03-25 2011-08-23 The Regents Of The University Of California Reagentless, reusable, bioelectronic detectors
US6965791B1 (en) 2003-03-26 2005-11-15 Sorenson Medical, Inc. Implantable biosensor system, apparatus and method
US7070580B2 (en) 2003-04-01 2006-07-04 Unomedical A/S Infusion device and an adhesive sheet material and a release liner
CN1767872B (en) 2003-04-02 2010-12-08 神经技术无限责任公司 Implantable nerve signal sensing and stimulation device for treating foot drop and other neurological disorders
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US7048727B1 (en) 2003-04-18 2006-05-23 Gerald Moss Continuous feeding and decompressing device and method
CA2520880A1 (en) 2003-04-18 2004-11-04 Insulet Corporation User interface for infusion pump remote controller and method of using the same
DE502004009803D1 (en) 2003-04-22 2009-09-10 Invento Ag Traction sheave for lifts and their production process
US6797877B1 (en) 2003-04-28 2004-09-28 Jonn Maneely Company Electrical metallic tube, coupling, and connector apparatus and method
US7103412B1 (en) 2003-05-02 2006-09-05 Pacesetter, Inc. Implantable cardiac stimulation device and method for detecting asymptomatic diabetes
US7266400B2 (en) 2003-05-06 2007-09-04 Orsense Ltd. Glucose level control method and system
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US7253680B2 (en) 2003-05-21 2007-08-07 World Energy Labs (2), Inc. Amplifier system with current-mode servo feedback
WO2004106891A2 (en) 2003-05-22 2004-12-09 University Of Hawaii Ultrasensitive biochemical sensor
DE10325699B3 (en) 2003-06-06 2005-02-10 Roche Diagnostics Gmbh System for analyzing a sample to be tested and using such a system
US20050016276A1 (en) 2003-06-06 2005-01-27 Palo Alto Sensor Technology Innovation Frequency encoding of resonant mass sensors
US7258673B2 (en) 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US20040254433A1 (en) 2003-06-12 2004-12-16 Bandis Steven D. Sensor introducer system, apparatus and method
US7146202B2 (en) 2003-06-16 2006-12-05 Isense Corporation Compound material analyte sensor
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US7142911B2 (en) 2003-06-26 2006-11-28 Pacesetter, Inc. Method and apparatus for monitoring drug effects on cardiac electrical signals using an implantable cardiac stimulation device
US7510564B2 (en) 2003-06-27 2009-03-31 Abbott Diabetes Care Inc. Lancing device
EP1646312A1 (en) 2003-07-09 2006-04-19 Glucon Inc. Wearable glucometer
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
WO2005010518A1 (en) 2003-07-23 2005-02-03 Dexcom, Inc. Rolled electrode array and its method for manufacture
US20050176136A1 (en) 2003-11-19 2005-08-11 Dexcom, Inc. Afinity domain for analyte sensor
US7460898B2 (en) 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1652088B1 (en) 2003-07-25 2017-09-13 Philips Intellectual Property & Standards GmbH Method and device for monitoring a system
US7366556B2 (en) 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7424318B2 (en) 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7467003B2 (en) 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1649260A4 (en) 2003-07-25 2010-07-07 Dexcom Inc Electrode systems for electrochemical sensors
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
WO2005019795A2 (en) 2003-07-25 2005-03-03 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
WO2007120442A2 (en) 2003-07-25 2007-10-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20050056552A1 (en) 2003-07-25 2005-03-17 Simpson Peter C. Increasing bias for oxygen production in an electrode system
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US8626257B2 (en) * 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8285354B2 (en) 2003-08-01 2012-10-09 Dexcom, Inc. System and methods for processing analyte sensor data
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20070208245A1 (en) 2003-08-01 2007-09-06 Brauker James H Transcutaneous analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US6931327B2 (en) 2003-08-01 2005-08-16 Dexcom, Inc. System and methods for processing analyte sensor data
US20190357827A1 (en) * 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8160669B2 (en) * 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US7211074B2 (en) 2003-08-12 2007-05-01 Sherwood Services Ag Valved catheter
US7529574B2 (en) 2003-08-14 2009-05-05 Isense Corporation Method of constructing a biosensor
US6954662B2 (en) 2003-08-19 2005-10-11 A.D. Integrity Applications, Ltd. Method of monitoring glucose level
BRPI0413213A (en) 2003-08-21 2006-10-03 Agamatrix Inc method and apparatus for determining the presence of a selected analyte in a sample arranged in an electrochemical cell, method for determining the effective separation distance between a first electrode and a second electrode in an electrochemical cell, and method for determining an effective electrode transport property. a species in a liquid sample disposed between a first electrode and a second electrode in an electrochemical cell
US20070066873A1 (en) 2003-08-22 2007-03-22 Apurv Kamath Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7214190B1 (en) 2003-09-09 2007-05-08 Kitchener Clark Wilson Apparatus and method for noninvasive monitoring of analytes in body fluids
US7630747B2 (en) 2003-09-09 2009-12-08 Keimar, Inc. Apparatus for ascertaining blood characteristics and probe for use therewith
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7361155B2 (en) 2003-09-16 2008-04-22 Therafuse, Inc. Compensating liquid delivery system and method
US7433727B2 (en) 2003-09-24 2008-10-07 Legacy Good Samaritan Hospital And Medical Center Implantable biosensor
PL1677668T3 (en) 2003-10-13 2010-12-31 Novo Nordisk As Apparatus and method for determining a physiological condition
US20050090607A1 (en) 2003-10-28 2005-04-28 Dexcom, Inc. Silicone composition for biocompatible membrane
US6928380B2 (en) 2003-10-30 2005-08-09 International Business Machines Corporation Thermal measurements of electronic devices during operation
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
CA2544424A1 (en) 2003-10-31 2005-05-19 Lifescan Scotland Limited Electrochemical test strip for reducing the effect of direct interference current
US20090012376A1 (en) 2003-11-03 2009-01-08 Children's Medical Center Corporation Continuous Analyte Monitor and Method of Using Same
US7417729B2 (en) 2003-11-07 2008-08-26 Cardinal Health 303, Inc. Fluid verification system and method for infusions
US7100628B1 (en) 2003-11-18 2006-09-05 Creare Inc. Electromechanically-assisted regulator control assembly
US9247900B2 (en) * 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US6850859B1 (en) 2003-12-03 2005-02-01 Watlow Electric Manufacturing Company Sensor drift compensation by lot
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8364230B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425416B2 (en) 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425417B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US20080200788A1 (en) 2006-10-04 2008-08-21 Dexcorn, Inc. Analyte sensor
ATE480761T1 (en) 2003-12-05 2010-09-15 Dexcom Inc CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR
US20100185071A1 (en) 2003-12-05 2010-07-22 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20080197024A1 (en) 2003-12-05 2008-08-21 Dexcom, Inc. Analyte sensor
ATE474219T1 (en) 2003-12-08 2010-07-15 Dexcom Inc SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYT SENSORS
WO2005057175A2 (en) 2003-12-09 2005-06-23 Dexcom, Inc. Signal processing for continuous analyte sensor
DE60315691D1 (en) 2003-12-22 2007-09-27 Sgs Thomson Microelectronics Method of producing sensors with barriers of photoresist material
US7076300B1 (en) 2003-12-24 2006-07-11 Pacesetter, Inc. Implantable cardiac stimulation device and method that discriminates between and treats atrial tachycardia and atrial fibrillation
US8147426B2 (en) 2003-12-31 2012-04-03 Nipro Diagnostics, Inc. Integrated diagnostic test system
US20050182451A1 (en) 2004-01-12 2005-08-18 Adam Griffin Implantable device with improved radio frequency capabilities
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
WO2005068973A1 (en) 2004-01-13 2005-07-28 Glucon Inc. Photoacoustic sensor
US20070027284A1 (en) 2004-01-13 2007-02-01 Kuang-Hwa Wei Covalently bonded polyhedral oligomeric silsesquioxane/polyimide nanocomposites and process for synthesizing the same
EP1711101A1 (en) 2004-01-15 2006-10-18 Glucon Inc. Wearable glucometer
US7290985B2 (en) 2004-01-15 2007-11-06 Lord Corporation Rotary wing aircraft rod end and method of making a helicopter vehicle rod end with a precocked orientation
US7776559B2 (en) 2004-01-22 2010-08-17 Hewlett-Packard Development Company, L.P. Disposable blood test device
WO2005070482A1 (en) 2004-01-26 2005-08-04 Novo Nordisk A/S Impulse chamber for jet delivery device
US7580812B2 (en) 2004-01-28 2009-08-25 Honeywell International Inc. Trending system and method using window filtering
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
WO2005079257A2 (en) 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
CA2496646A1 (en) 2004-02-12 2005-08-12 Flowtec Medical Inc. Fluid monitoring device
US7894870B1 (en) 2004-02-13 2011-02-22 Glysens, Incorporated Hermetic implantable sensor
CA2556331A1 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
CA2556592C (en) 2004-02-26 2014-01-28 Lars Gustaf Liljeryd Metabolic monitoring, a method and apparatus for indicating a health-related condition of a subject
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
CN101124472A (en) 2004-03-17 2008-02-13 夏威夷大学 Sensor constructs and detection methods
JP5051767B2 (en) 2004-03-22 2012-10-17 ボディーメディア インコーポレイテッド Device for monitoring human condition parameters
JP2007535974A (en) 2004-03-26 2007-12-13 ノボ・ノルデイスク・エー/エス Display device for related data of diabetic patients
US6971274B2 (en) 2004-04-02 2005-12-06 Sierra Instruments, Inc. Immersible thermal mass flow meter
WO2005106017A2 (en) 2004-04-21 2005-11-10 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
US20050245799A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US7280879B2 (en) 2004-05-20 2007-10-09 Sap Ag Interfaces from external systems to time dependent process parameters in integrated process and product engineering
US7241266B2 (en) 2004-05-20 2007-07-10 Digital Angel Corporation Transducer for embedded bio-sensor using body energy as a power source
US7964146B2 (en) 2004-05-30 2011-06-21 Agamatrix, Inc. Measuring device and methods for use therewith
US7118667B2 (en) 2004-06-02 2006-10-10 Jin Po Lee Biosensors having improved sample application and uses thereof
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
GB0412670D0 (en) 2004-06-07 2004-07-07 Univ Surrey An electrode device process for making an electrode device and a method of ele trochemical detection using an electrode device
US7623988B2 (en) 2004-06-23 2009-11-24 Cybiocare Inc. Method and apparatus for the monitoring of clinical states
US7233822B2 (en) 2004-06-29 2007-06-19 Medtronic, Inc. Combination of electrogram and intra-cardiac pressure to discriminate between fibrillation and tachycardia
US20060015020A1 (en) 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US7313425B2 (en) 2004-07-08 2007-12-25 Orsense Ltd. Device and method for non-invasive optical measurements
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US20060020192A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US20080242961A1 (en) 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US8962165B2 (en) 2006-05-02 2015-02-24 The Penn State Research Foundation Materials and configurations for scalable microbial fuel cells
DK1774324T3 (en) 2004-07-16 2013-05-27 Sensocure As ELECTROCHEMICAL SENSOR FOR IN-VIVO OR EX-VIVO MEASUREMENTS OF CARBON Dioxide PART PRESSURE OF LIVE TIVES
US20060017575A1 (en) 2004-07-20 2006-01-26 Medtronic, Inc. Alert system and method for an implantable medical device
US20060100588A1 (en) 2004-07-23 2006-05-11 Lennart Brunnberg Needle handling device
US7344500B2 (en) 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US8313433B2 (en) 2004-08-06 2012-11-20 Medtronic Minimed, Inc. Medical data management system and process
US20060042353A1 (en) 2004-08-25 2006-03-02 Brent Marquis Analyte quantitation using semiconducting metal oxide gas sensors
US7291107B2 (en) 2004-08-26 2007-11-06 Roche Diagnostics Operations, Inc. Insulin bolus recommendation system
JP2008511373A (en) 2004-09-03 2008-04-17 ノボ・ノルデイスク・エー/エス Method for calibrating a system for measuring the concentration of a body substance and apparatus for carrying out the method
US7468033B2 (en) 2004-09-08 2008-12-23 Medtronic Minimed, Inc. Blood contacting sensor
US7387811B2 (en) 2004-09-21 2008-06-17 Superpower, Inc. Method for manufacturing high temperature superconducting conductors using chemical vapor deposition (CVD)
US20070191716A1 (en) 2004-09-29 2007-08-16 Daniel Goldberger Blood monitoring system
US20060229531A1 (en) 2005-02-01 2006-10-12 Daniel Goldberger Blood monitoring system
US7608042B2 (en) 2004-09-29 2009-10-27 Intellidx, Inc. Blood monitoring system
US8224414B2 (en) 2004-10-28 2012-07-17 Echo Therapeutics, Inc. System and method for analyte sampling and analysis with hydrogel
US7384532B2 (en) 2004-11-16 2008-06-10 Lacks Enterprises, Inc. Platable coating and plating process
CN102512186B (en) 2004-11-16 2015-07-15 拜耳医疗保健公司 Modeling of pharmaceutical propagation and response of patients to medication injection
JPWO2006070827A1 (en) 2004-12-28 2008-06-12 新世代株式会社 Health care support system and recording medium
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US20090082693A1 (en) 2004-12-29 2009-03-26 Therasense, Inc. Method and apparatus for providing temperature sensor module in a data communication system
US20070027381A1 (en) 2005-07-29 2007-02-01 Therasense, Inc. Inserter and methods of use
US20060155212A1 (en) 2005-01-10 2006-07-13 Madonia James R Self flushing luer activated blood sampling devices
US20060166629A1 (en) 2005-01-24 2006-07-27 Therasense, Inc. Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems
US7502644B2 (en) 2005-01-25 2009-03-10 Pacesetter, Inc. System and method for distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device
US20060173260A1 (en) 2005-01-31 2006-08-03 Gmms Ltd System, device and method for diabetes treatment and monitoring
US7547281B2 (en) 2005-02-01 2009-06-16 Medtronic Minimed, Inc. Algorithm sensor augmented bolus estimator for semi-closed loop infusion system
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US7499002B2 (en) 2005-02-08 2009-03-03 International Business Machines Corporation Retractable string interface for stationary and portable devices
AU2006212007A1 (en) 2005-02-11 2006-08-17 The University Court Of The University Of Glasgow Sensing device, apparatus and system, and method for operating the same
US7364562B2 (en) 2005-10-06 2008-04-29 Optiscan Biomedical Corp. Anti-clotting apparatus and methods for fluid handling system
US20060189926A1 (en) 2005-02-14 2006-08-24 Hall W D Apparatus and methods for analyzing body fluid samples
US7907985B2 (en) 2005-02-14 2011-03-15 Optiscan Biomedical Corporation Fluid handling cassette with a fluid control interface and sample separator
KR100638727B1 (en) 2005-02-28 2006-10-30 삼성전기주식회사 Concurrent transceiver for zigbee and bluetooth
AU2006218595A1 (en) 2005-03-02 2006-09-08 Spacelabs Medical Trending display of patient wellness
US8133178B2 (en) * 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
KR100659498B1 (en) 2005-03-10 2006-12-20 애니젠 주식회사 Potassium channel opener having benzofuroindole skeleton
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US20070071681A1 (en) 2005-03-15 2007-03-29 Entelos, Inc. Apparatus and method for computer modeling type 1 diabetes
EP1863559A4 (en) 2005-03-21 2008-07-30 Abbott Diabetes Care Inc Method and system for providing integrated medication infusion and analyte monitoring system
GB0505763D0 (en) 2005-03-22 2005-04-27 Enigma Diagnostics Ltd Polymorphism detection method
WO2006105146A2 (en) 2005-03-29 2006-10-05 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US7889069B2 (en) 2005-04-01 2011-02-15 Codman & Shurtleff, Inc. Wireless patient monitoring system
US20090054753A1 (en) 2007-08-21 2009-02-26 Mark Ries Robinson Variable Sampling Interval for Blood Analyte Determinations
WO2006110193A2 (en) 2005-04-08 2006-10-19 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US7645374B2 (en) 2005-04-15 2010-01-12 Agamatrix, Inc. Method for determination of analyte concentrations and related apparatus
US7344626B2 (en) 2005-04-15 2008-03-18 Agamatrix, Inc. Method and apparatus for detection of abnormal traces during electrochemical analyte detection
US8060174B2 (en) 2005-04-15 2011-11-15 Dexcom, Inc. Analyte sensing biointerface
US7517439B2 (en) 2005-04-15 2009-04-14 Agamatrix, Inc. Error detection in analyte measurements based on measurement of system resistance
US7964089B2 (en) 2005-04-15 2011-06-21 Agamatrix, Inc. Analyte determination method and analyte meter
US7547382B2 (en) 2005-04-15 2009-06-16 Agamatrix, Inc. Determination of partial fill in electrochemical strips
US7372277B2 (en) 2005-04-15 2008-05-13 Agamatrix, Inc. Method and apparatus for providing stable voltage to analytical system
US7713392B2 (en) 2005-04-15 2010-05-11 Agamatrix, Inc. Test strip coding and quality measurement
US7308292B2 (en) 2005-04-15 2007-12-11 Sensors For Medicine And Science, Inc. Optical-based sensing devices
US7590443B2 (en) 2005-04-27 2009-09-15 Pacesetter, Inc System and method for detecting hypoglycemia based on a paced depolarization integral using an implantable medical device
US7904158B2 (en) 2005-04-28 2011-03-08 Medtronic, Inc. Measurement of coronary sinus parameters to optimize left ventricular performance
US20060247985A1 (en) 2005-04-29 2006-11-02 Therasense, Inc. Method and system for monitoring consumable item usage and providing replenishment thereof
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7890285B2 (en) 2005-04-29 2011-02-15 Agilent Technologies, Inc. Scalable integrated tool for compliance testing
US7749445B2 (en) 2005-05-02 2010-07-06 Bioscale, Inc. Method and apparatus for analyzing bioprocess fluids
US7905868B2 (en) 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US20060253085A1 (en) 2005-05-06 2006-11-09 Medtronic Minimed, Inc. Dual insertion set
US20060264783A1 (en) 2005-05-09 2006-11-23 Holmes Elizabeth A Systems and methods for monitoring pharmacological parameters
CA2612714C (en) 2005-05-13 2013-09-24 Trustees Of Boston University Fully automated control system for type 1 diabetes
US20060263839A1 (en) 2005-05-17 2006-11-23 Isense Corporation Combined drug delivery and analyte sensor apparatus
US7541935B2 (en) 2005-05-19 2009-06-02 Proacticare Llc System and methods for monitoring caregiver performance
JP2008542764A (en) 2005-06-02 2008-11-27 アイセンス コーポレーション Filtering and use of multiple data points in analyte sensors
US20060272652A1 (en) 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
US20070033074A1 (en) 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system
US20060276771A1 (en) 2005-06-06 2006-12-07 Galley Paul J System and method providing for user intervention in a diabetes control arrangement
DK2260759T3 (en) 2005-06-17 2015-08-17 Hoffmann La Roche Feel and conditioning device and method for monitoring a connection, in particular glucose, in body tissue
US20070129618A1 (en) 2005-06-20 2007-06-07 Daniel Goldberger Blood parameter testing system
WO2007002580A2 (en) 2005-06-23 2007-01-04 Bioveris Corporation Diagnostic as say system with multi -well reagent container
WO2007002579A2 (en) 2005-06-23 2007-01-04 Bioveris Corporation Assay cartridges and methods for point of care instruments
US7334594B2 (en) 2005-06-29 2008-02-26 Codman & Shurtleff, Inc. Apparatus and method for adjusting a locking mechanism of a shunt valve
EP1741384B1 (en) 2005-07-08 2009-11-11 Draeger Medical Systems, Inc. A system for adjusting power employed by a medical device
US7359723B2 (en) 2005-08-02 2008-04-15 Qualcomm Incorporated Systems, devices and methods for providing a reward based upon use of a mobile communications device
CA2620586A1 (en) 2005-08-31 2007-03-08 Boris P. Kovatchev Improving the accuracy of continuous glucose sensors
ES2575660T3 (en) 2005-09-09 2016-06-30 F. Hoffmann-La Roche Ag System, tools, devices and program for diabetic care
US8298389B2 (en) 2005-09-12 2012-10-30 Abbott Diabetes Care Inc. In vitro analyte sensor, and methods
US7713240B2 (en) 2005-09-13 2010-05-11 Medtronic Minimed, Inc. Modular external infusion device
US7162290B1 (en) 2005-09-16 2007-01-09 Palco Labs, Inc. Method and apparatus for blood glucose testing from a reversible infusion line
US7725148B2 (en) 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US9072476B2 (en) 2005-09-23 2015-07-07 Medtronic Minimed, Inc. Flexible sensor apparatus
US7846311B2 (en) 2005-09-27 2010-12-07 Abbott Diabetes Care Inc. In vitro analyte sensor and methods of use
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7468125B2 (en) 2005-10-17 2008-12-23 Lifescan, Inc. System and method of processing a current sample for calculating a glucose concentration
US20070095661A1 (en) 2005-10-31 2007-05-03 Yi Wang Method of making, and, analyte sensor
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
EP3064236B1 (en) 2005-11-08 2020-02-05 Bigfoot Biomedical, Inc. Method and system for manual and autonomous control of an infusion pump
US20070173706A1 (en) 2005-11-11 2007-07-26 Isense Corporation Method and apparatus for insertion of a sensor
EP1785085A1 (en) 2005-11-12 2007-05-16 Roche Diagnostics GmbH Implantable electrode system, method and device for measuring the concentration of an analyte in a human or animal body
EP1954190A4 (en) 2005-11-15 2010-10-13 Luminous Medical Inc Blood analyte determinations
US7918975B2 (en) 2005-11-17 2011-04-05 Abbott Diabetes Care Inc. Analytical sensors for biological fluid
US7704226B2 (en) 2005-11-17 2010-04-27 Medtronic Minimed, Inc. External infusion device with programmable capabilities to time-shift basal insulin and method of using the same
US20070118030A1 (en) 2005-11-22 2007-05-24 Isense Corporation Method and apparatus for analyte data telemetry
WO2007062173A1 (en) 2005-11-22 2007-05-31 Vocollect Healthcare Systems, Inc. Advanced diabetes management system (adms)
US7963917B2 (en) 2005-12-05 2011-06-21 Echo Therapeutics, Inc. System and method for continuous non-invasive glucose monitoring
US7941200B2 (en) 2005-12-08 2011-05-10 Roche Diagnostics Operations, Inc. System and method for determining drug administration information
US20070135699A1 (en) 2005-12-12 2007-06-14 Isense Corporation Biosensor with antimicrobial agent
US20070179436A1 (en) 2005-12-21 2007-08-02 Braig James R Analyte detection system with periodic sample draw and laboratory-grade analyzer
US7759408B2 (en) 2005-12-21 2010-07-20 Bausch & Lomb Incorporated Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups
US8515518B2 (en) 2005-12-28 2013-08-20 Abbott Diabetes Care Inc. Analyte monitoring
CA2636034A1 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care Inc. Medical device insertion
US8160670B2 (en) 2005-12-28 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
US20070169533A1 (en) 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Methods and systems for detecting the hydration of sensors
US7774038B2 (en) 2005-12-30 2010-08-10 Medtronic Minimed, Inc. Real-time self-calibrating sensor system and method
US20070173712A1 (en) 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Method of and system for stabilization of sensors
US8114269B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
EP2004796B1 (en) 2006-01-18 2015-04-08 DexCom, Inc. Membranes for an analyte sensor
US20070179349A1 (en) 2006-01-19 2007-08-02 Hoyme Kenneth P System and method for providing goal-oriented patient management based upon comparative population data analysis
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US7367942B2 (en) 2006-02-02 2008-05-06 Palco Labs, Inc. Method and apparatus for testing blood glucose in a reversible infusion line
KR101142993B1 (en) 2006-02-20 2012-05-08 삼성전자주식회사 Display device and testing method of sensing unit thereof
EP3649925A1 (en) 2006-02-22 2020-05-13 DexCom, Inc. Analyte sensor
US20070219441A1 (en) 2006-02-27 2007-09-20 Patrick Carlin Catheter with integral biosensor
EP1989537B1 (en) 2006-02-27 2017-02-22 Edwards Lifesciences Corporation Method and apparatus for using flex circuit technology to create a reference electrode channel
WO2007100588A1 (en) 2006-02-27 2007-09-07 Edwards Lifesciences Corporation Hydrogel for an intravenous amperometric biosensor
US8065796B2 (en) 2006-02-27 2011-11-29 Edwards Lifesciences Corporation Method and apparatus for using flex circuit technology to create an electrode
US20070202562A1 (en) 2006-02-27 2007-08-30 Curry Kenneth M Flux limiting membrane for intravenous amperometric biosensor
US7811430B2 (en) 2006-02-28 2010-10-12 Abbott Diabetes Care Inc. Biosensors and methods of making
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US20100049021A1 (en) 2006-03-28 2010-02-25 Jina Arvind N Devices, systems, methods and tools for continuous analyte monitoring
US7887682B2 (en) 2006-03-29 2011-02-15 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US20140066736A1 (en) 2006-03-31 2014-03-06 Abbott Diabetes Care Inc. Analyte Sensor Calibration Management
US20090171178A1 (en) 2006-03-31 2009-07-02 Abbott Diabetes Care, Inc. Method and System for Powering an Electronic Device
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US20070233013A1 (en) 2006-03-31 2007-10-04 Schoenberg Stephen J Covers for tissue engaging members
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8478406B2 (en) 2006-04-24 2013-07-02 Medtronic, Inc. Apparatus and methods of delivering an enhanced refractory period stimulation therapy
US8380300B2 (en) 2006-04-28 2013-02-19 Medtronic, Inc. Efficacy visualization
US8092385B2 (en) 2006-05-23 2012-01-10 Intellidx, Inc. Fluid access interface
US20090054749A1 (en) 2006-05-31 2009-02-26 Abbott Diabetes Care, Inc. Method and System for Providing Data Transmission in a Data Management System
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
JP5390378B2 (en) 2006-06-13 2014-01-15 ケアフュージョン 303、インコーポレイテッド System and method for optimizing the control of PCA and PCEA systems
US20080177149A1 (en) 2006-06-16 2008-07-24 Stefan Weinert System and method for collecting patient information from which diabetes therapy may be determined
US20070299617A1 (en) 2006-06-27 2007-12-27 Willis John P Biofouling self-compensating biosensor
US20080004601A1 (en) 2006-06-28 2008-01-03 Abbott Diabetes Care, Inc. Analyte Monitoring and Therapy Management System and Methods Therefor
GB0612834D0 (en) 2006-06-28 2006-08-09 Glysure Ltd Sensor calibration
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
WO2008053368A2 (en) 2006-07-07 2008-05-08 Medingo Ltd. Fluid delivery device and methods of its operation
EP2037798B1 (en) 2006-07-10 2012-10-31 Accenture Global Services Limited Mobile personal services platform for providing feedback
US7908334B2 (en) 2006-07-21 2011-03-15 Cardiac Pacemakers, Inc. System and method for addressing implantable devices
EP2054476B9 (en) 2006-07-25 2012-03-14 Glumetrics, Inc. Flourescent dyes for use in glucose sensing
US7866026B1 (en) 2006-08-01 2011-01-11 Abbott Diabetes Care Inc. Method for making calibration-adjusted sensors
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
WO2009008892A1 (en) 2006-08-15 2009-01-15 Optiscan Biomedical Corporation Accurate and timely body fluid analysis
US9056165B2 (en) 2006-09-06 2015-06-16 Medtronic Minimed, Inc. Intelligent therapy recommendation algorithm and method of using the same
CA2701006C (en) 2006-09-27 2016-07-12 University Of Connecticut Implantable biosensor and methods of use thereof
US20080081000A1 (en) 2006-09-29 2008-04-03 Macleod John Integrity testing of vials for test sensors
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
CA2664528A1 (en) 2006-10-04 2008-04-10 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8449464B2 (en) 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
US8562528B2 (en) 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US8478377B2 (en) 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US8275438B2 (en) 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8255026B1 (en) 2006-10-12 2012-08-28 Masimo Corporation, Inc. Patient monitor capable of monitoring the quality of attached probes and accessories
US7943034B2 (en) 2006-10-19 2011-05-17 Agamatrix, Inc. Method and apparatus for providing a stable voltage to an analytical system
JP5244116B2 (en) * 2006-10-24 2013-07-24 バイエル・ヘルスケア・エルエルシー Transient decay current measurement method
AU2007308804A1 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care, Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US7822557B2 (en) 2006-10-31 2010-10-26 Abbott Diabetes Care Inc. Analyte sensors and methods
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
EP1922986A1 (en) * 2006-11-15 2008-05-21 Roche Diagnostics GmbH Device for in vivo measurement of glucose
US20130324823A1 (en) 2006-11-20 2013-12-05 Modz Oy Measurement device, system and method
BRPI0719107A2 (en) 2006-11-21 2013-12-03 Baxter Int REMOTE MONITORING AND / OR HANDLING THERAPY MANAGEMENT SYSTEM AND METHOD
US8202491B2 (en) 2006-11-21 2012-06-19 Bioscale, Inc. Apparatus for analyte processing
US20080139910A1 (en) 2006-12-06 2008-06-12 Metronic Minimed, Inc. Analyte sensor and method of using the same
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
US20080154513A1 (en) 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
US7802467B2 (en) 2006-12-22 2010-09-28 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US20080161666A1 (en) 2006-12-29 2008-07-03 Abbott Diabetes Care, Inc. Analyte devices and methods
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US20080168676A1 (en) 2007-01-17 2008-07-17 Getinge Sourcing Llc Axially-compact dryer, particularly adapted for use with a tunnel washer
US7734323B2 (en) 2007-01-24 2010-06-08 Smiths Medical Asd, Inc. Correction factor testing using frequent blood glucose input
US10154804B2 (en) 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
WO2008098011A1 (en) 2007-02-06 2008-08-14 Glumetrics, Inc. Method for polymerizing a monomer solution within a cavity to generate a smooth polymer surface
DK2989975T3 (en) 2007-02-06 2018-09-24 Medtronic Minimed Inc OPTICAL SYSTEMS AND PROCEDURES FOR RATIOMETRIC MEASUREMENT OF BLOOD GLUCOSE CONCENTRATION
US7751863B2 (en) 2007-02-06 2010-07-06 Glumetrics, Inc. Optical determination of ph and glucose
US8738107B2 (en) 2007-05-10 2014-05-27 Medtronic Minimed, Inc. Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement
US8088097B2 (en) 2007-11-21 2012-01-03 Glumetrics, Inc. Use of an equilibrium intravascular sensor to achieve tight glycemic control
US9597019B2 (en) 2007-02-09 2017-03-21 Lifescan, Inc. Method of ensuring date and time on a test meter is accurate
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8226293B2 (en) 2007-02-22 2012-07-24 Medical Solutions, Inc. Method and apparatus for measurement and control of temperature for infused liquids
US20080234943A1 (en) 2007-03-20 2008-09-25 Pinaki Ray Computer program for diabetes management
JP2008253482A (en) 2007-04-04 2008-10-23 Matsushita Electric Ind Co Ltd Non-invasive biological information measuring apparatus
US20080249385A1 (en) 2007-04-04 2008-10-09 Luong Ngoc Phan Isolated intravenous analyte monitoring system
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683930A1 (en) 2007-04-14 2008-10-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2009096992A1 (en) 2007-04-14 2009-08-06 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
CN101715555A (en) 2007-04-27 2010-05-26 艾伯特糖尿病护理公司 Test strip identification using conductive patterns
JP5706686B2 (en) 2007-05-01 2015-04-22 メドトロニック ミニメド インコーポレイテッド Pyridinium boronic acid quencher, method for producing the same, and glucose sensor
US20080278332A1 (en) 2007-05-08 2008-11-13 Abbott Diabetes Care, Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
WO2008141243A2 (en) 2007-05-10 2008-11-20 Glumetrics, Inc. Device and methods for calibrating analyte sensors
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20080312845A1 (en) 2007-05-14 2008-12-18 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) * 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20200037874A1 (en) * 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20080300572A1 (en) 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US20080306472A1 (en) 2007-06-05 2008-12-11 Bwt Property, Inc. Laser apparatus with integrated footswitch control
WO2008154312A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
CA2689459A1 (en) 2007-06-11 2009-01-08 Cesaroni Technology Incorporated Body temperature controlling system
EP2166929B1 (en) 2007-06-15 2012-12-19 F. Hoffmann-La Roche AG Visualization of a parameter which is measured on the human body
EP3533387A3 (en) 2007-06-21 2019-11-13 Abbott Diabetes Care, Inc. Health management devices and methods
US9754078B2 (en) 2007-06-21 2017-09-05 Immersion Corporation Haptic health feedback monitoring
CA2690870C (en) 2007-06-21 2017-07-11 Abbott Diabetes Care Inc. Health monitor
EP2562664B1 (en) 2007-06-27 2020-11-25 Roche Diabetes Care GmbH System for determining an insulin delivery and communicating a dose in automated pancreas software
EP2170159B8 (en) 2007-06-29 2016-09-21 Roche Diabetes Care GmbH Combination communication device and medical device for communicating wirelessly with a remote medical device
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
JP5675350B2 (en) 2007-07-11 2015-02-25 メドトロニック ミニメド インコーポレイテッド Polyviologen compound, method for synthesizing the compound, glucose sensor, and composition for measuring glucose
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20090036760A1 (en) 2007-07-31 2009-02-05 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
EP2181160B1 (en) 2007-08-06 2016-05-11 Medtronic Minimed, Inc. Hpts-mono cys-ma polymerizable fluorescent dyes for use in analyte sensors
US7731658B2 (en) 2007-08-16 2010-06-08 Cardiac Pacemakers, Inc. Glycemic control monitoring using implantable medical device
US9968742B2 (en) 2007-08-29 2018-05-15 Medtronic Minimed, Inc. Combined sensor and infusion set using separated sites
US20090063402A1 (en) 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US20090143725A1 (en) 2007-08-31 2009-06-04 Abbott Diabetes Care, Inc. Method of Optimizing Efficacy of Therapeutic Agent
US20090062645A1 (en) 2007-09-03 2009-03-05 Jens Fehre Method for diagnosis and treatment of prostate cancer
US8868161B2 (en) 2007-09-13 2014-10-21 Jonathan Thierman Detection and display of measured subsurface data onto a surface
US20090085768A1 (en) 2007-10-02 2009-04-02 Medtronic Minimed, Inc. Glucose sensor transceiver
US7731659B2 (en) 2007-10-18 2010-06-08 Lifescan Scotland Limited Method for predicting a user's future glycemic state
US7695434B2 (en) 2007-10-19 2010-04-13 Lifescan Scotland, Ltd. Medical device for predicting a user's future glycemic state
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US20090112626A1 (en) 2007-10-30 2009-04-30 Cary Talbot Remote wireless monitoring, processing, and communication of patient data
US7783442B2 (en) 2007-10-31 2010-08-24 Medtronic Minimed, Inc. System and methods for calibrating physiological characteristic sensors
JP5000765B2 (en) 2007-12-13 2012-08-15 カーディアック ペースメイカーズ, インコーポレイテッド Battery consumption detection system and battery consumption detection method in an embedded device
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US20090164190A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Physiological condition simulation device and method
US20090163855A1 (en) 2007-12-24 2009-06-25 Medtronic Minimed, Inc. Infusion system with adaptive user interface
US20090241028A1 (en) 2008-01-23 2009-09-24 Michael Iskedjian Computer system for administering quality of life questionnaires
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
US7856613B1 (en) 2008-01-30 2010-12-21 Cadence Design Systems, Inc. Method for self-aligned doubled patterning lithography
US20100145174A1 (en) 2008-02-12 2010-06-10 Alferness Clifton A System And Method For Providing A Personalized Tool For Estimating Glycated Hemoglobin
CA2715624A1 (en) 2008-02-20 2009-08-27 Dexcom, Inc. Continuous medicament sensor system for in vivo use
EP2252196A4 (en) 2008-02-21 2013-05-15 Dexcom Inc Systems and methods for processing, transmitting and displaying sensor data
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US20090242399A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US20090247855A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) * 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP2982383B1 (en) 2008-04-10 2019-05-15 Abbott Diabetes Care, Inc. Method for sterilizing an analyte sensor
WO2009129186A2 (en) 2008-04-17 2009-10-22 Glumetrics, Inc. Sensor for percutaneous intravascular deployment without an indwelling cannula
US7783342B2 (en) 2008-04-21 2010-08-24 International Business Machines Corporation System and method for inferring disease similarity by shape matching of ECG time series
US7938797B2 (en) 2008-05-05 2011-05-10 Asante Solutions, Inc. Infusion pump system
US20090294277A1 (en) 2008-05-30 2009-12-03 Abbott Diabetes Care, Inc. Method and system for producing thin film biosensors
US20100025238A1 (en) 2008-07-31 2010-02-04 Medtronic Minimed, Inc. Analyte sensor apparatuses having improved electrode configurations and methods for making and using them
US9161714B2 (en) 2008-08-21 2015-10-20 Palo Alto Research Center Incorporated Specificity of analyte detection in etalons
WO2010022387A1 (en) 2008-08-22 2010-02-25 Eastern Virginia Medical School Method and apparatus for chronic disease control
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
WO2010030609A1 (en) 2008-09-09 2010-03-18 Vivomedical, Inc. Sweat collection devices for glucose measurement
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
CN102197304B (en) 2008-11-04 2013-08-28 松下电器产业株式会社 Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
US20100331644A1 (en) 2008-11-07 2010-12-30 Dexcom, Inc. Housing for an intravascular sensor
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9320470B2 (en) 2008-12-31 2016-04-26 Medtronic Minimed, Inc. Method and/or system for sensor artifact filtering
US8974439B2 (en) 2009-01-02 2015-03-10 Asante Solutions, Inc. Infusion pump system and methods
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
CN102308278A (en) 2009-02-04 2012-01-04 雅培糖尿病护理公司 Multi-function analyte test device and methods therefor
DK3912551T3 (en) 2009-02-26 2023-10-30 Abbott Diabetes Care Inc Procedure for calibrating an analyte sensor
US20100213057A1 (en) 2009-02-26 2010-08-26 Benjamin Feldman Self-Powered Analyte Sensor
US9446194B2 (en) 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
EP2413781B1 (en) 2009-03-31 2019-07-24 Abbott Diabetes Care Inc. Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2010121229A1 (en) 2009-04-16 2010-10-21 Abbott Diabetes Care Inc. Analyte sensor calibration management
US20100274515A1 (en) 2009-04-28 2010-10-28 Abbott Diabetes Care Inc. Dynamic Analyte Sensor Calibration Based On Sensor Stability Profile
EP2424426B1 (en) 2009-04-29 2020-01-08 Abbott Diabetes Care, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
EP2425209A4 (en) 2009-04-29 2013-01-09 Abbott Diabetes Care Inc Method and system for providing real time analyte sensor calibration with retrospective backfill
EP2432393A2 (en) 2009-05-22 2012-03-28 Abbott Diabetes Care, Inc. Method and system for reducing false hypoglycemia alarm occurrence
EP2434944B1 (en) 2009-05-29 2014-12-03 Abbott Diabetes Care, Inc. Glucose monitoring system with wireless communications
EP2438527B1 (en) 2009-06-04 2018-05-02 Abbott Diabetes Care, Inc. Method and system for updating a medical device
US8000763B2 (en) 2009-06-30 2011-08-16 Abbott Diabetes Care Inc. Integrated devices having extruded electrode structures and methods of using same
US9351677B2 (en) * 2009-07-02 2016-05-31 Dexcom, Inc. Analyte sensor with increased reference capacity
TW201103018A (en) 2009-07-02 2011-01-16 Quanta Storage Inc Method for controlling focus on label side
EP3970610A3 (en) 2009-07-02 2022-05-18 Dexcom, Inc. Analyte sensors and methods of manufacturing same
US20120165626A1 (en) 2009-07-13 2012-06-28 Irina Finkelshtein V Devices, methods, and kits for determining analyte concentrations
US8663220B2 (en) 2009-07-15 2014-03-04 Ethicon Endo-Surgery, Inc. Ultrasonic surgical instruments
EP3932309A1 (en) 2009-07-23 2022-01-05 Abbott Diabetes Care, Inc. Continuous analyte measurement system
US8494786B2 (en) 2009-07-30 2013-07-23 Covidien Lp Exponential sampling of red and infrared signals
WO2011014851A1 (en) 2009-07-31 2011-02-03 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
RU2012105949A (en) 2009-08-10 2013-09-20 Диабетес Тоолс Сведен АБ DEVICE AND METHOD FOR PROCESSING DATA VALUE SET
WO2011026130A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Inserter device including rotor subassembly
ES2912584T3 (en) 2009-08-31 2022-05-26 Abbott Diabetes Care Inc A glucose monitoring system and method
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
AU2010286917B2 (en) 2009-08-31 2016-03-10 Abbott Diabetes Care Inc. Medical devices and methods
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
WO2011041449A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Sensor inserter having introducer
US20110081726A1 (en) 2009-09-30 2011-04-07 Abbott Diabetes Care Inc. Signal Dropout Detection and/or Processing in Analyte Monitoring Device and Methods
US9357951B2 (en) 2009-09-30 2016-06-07 Dexcom, Inc. Transcutaneous analyte sensor
WO2011044386A1 (en) 2009-10-07 2011-04-14 Abbott Diabetes Care Inc. Sensor inserter assembly having rotatable trigger
WO2011053881A1 (en) 2009-10-30 2011-05-05 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US9949672B2 (en) 2009-12-17 2018-04-24 Ascensia Diabetes Care Holdings Ag Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels
WO2011082451A1 (en) 2010-01-06 2011-07-14 Terence Vardy Apparatus and method for non-invasively locating blood vessels
JP5462776B2 (en) 2010-01-19 2014-04-02 アークレイ株式会社 Measuring apparatus and measuring method
US20110184268A1 (en) 2010-01-22 2011-07-28 Abbott Diabetes Care Inc. Method, Device and System for Providing Analyte Sensor Calibration
US8579879B2 (en) 2010-02-19 2013-11-12 Medtronic Minimed, Inc. Closed-loop glucose control startup
US20110208027A1 (en) 2010-02-23 2011-08-25 Roche Diagnostics Operations, Inc. Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes
CN102548476A (en) 2010-03-24 2012-07-04 雅培糖尿病护理公司 Medical device inserters and processes of inserting and using medical devices
CA2766947A1 (en) 2010-04-16 2011-10-20 Abbott Diabetes Care Inc. Analyte monitoring device and methods
EP2585165B1 (en) * 2010-05-03 2017-06-21 Optiscan Biomedical Corporation Adjustable connector, improved fluid flow and reduced clotting risk
US8543354B2 (en) 2010-06-23 2013-09-24 Medtronic Minimed, Inc. Glucose sensor signal stability analysis
US9215995B2 (en) 2010-06-23 2015-12-22 Medtronic Minimed, Inc. Sensor systems having multiple probes and electrode arrays
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US9336353B2 (en) 2010-06-25 2016-05-10 Dexcom, Inc. Systems and methods for communicating sensor data between communication devices of a glucose monitoring system
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
EP2588858A1 (en) * 2010-06-30 2013-05-08 Edwards Lifesciences Corporation Analyte sensor
EP2621339B1 (en) 2010-09-29 2020-01-15 Dexcom, Inc. Advanced continuous analyte monitoring system
US9241631B2 (en) 2010-10-27 2016-01-26 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode
US8657746B2 (en) 2010-10-28 2014-02-25 Medtronic Minimed, Inc. Glucose sensor signal purity analysis
US20120165640A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Operations, Inc. Structured blood glucose testing performed on handheld diabetes management devices
US20140088392A1 (en) 2011-02-11 2014-03-27 Abbott Diabetes Care Inc. Feedback from Cloud or HCP to Payer or Patient via Meter or Cell Phone
EP3583901A3 (en) 2011-02-28 2020-01-15 Abbott Diabetes Care, Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
DK2685895T3 (en) 2011-03-17 2019-01-21 Univ Newcastle System for self-monitoring and regulation of blood glucose
EP3575796B1 (en) 2011-04-15 2020-11-11 DexCom, Inc. Advanced analyte sensor calibration and error detection
WO2013022775A1 (en) 2011-08-05 2013-02-14 Dexcom, Inc. Systems and methods for detecting glucose level data patterns
US20130060106A1 (en) 2011-09-06 2013-03-07 Medtronic Minimed, Inc. Optical sensing systems and methods
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
EP3662965A1 (en) 2011-12-30 2020-06-10 Abbott Diabetes Care, Inc. Method and apparatus for determining medication dose information
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9227014B2 (en) 2013-02-07 2016-01-05 The Board Of Trustees Of The Laland Stanford Junior University Kalman filter based on-off switch for insulin pump
US10335075B2 (en) * 2013-03-14 2019-07-02 Dexcom, Inc. Advanced calibration for analyte sensors
WO2014152034A1 (en) 2013-03-15 2014-09-25 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
JP2019193536A (en) * 2018-04-27 2019-10-31 株式会社デンソー Wiper control device

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060001538A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20080000779A1 (en) * 2005-12-30 2008-01-03 Medtronic Minimed, Inc. Method and System for Remedying Sensor Malfunctions Detected by Electrochemical Impedance Spectroscopy
US7985330B2 (en) * 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
US20080214910A1 (en) * 2007-03-01 2008-09-04 Buck Harvey B System and method for operating an electrochemical analyte sensor
US20110230741A1 (en) * 2008-12-29 2011-09-22 Medtronic Minimed, Inc. Methods and systems for observing sensor parameters
US20110040163A1 (en) * 2009-08-14 2011-02-17 Bayer Healthcare Llc Electrochemical impedance spectroscopy enabled continuous glucose monitoring sensor systems
US20120097554A1 (en) * 2010-10-18 2012-04-26 Medtronic Minimed, Inc. Analyte sensors comprising electrodes having selected electrochemical and mechanical properties

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11627900B2 (en) 2003-12-05 2023-04-18 Dexcom, Inc. Analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10610141B2 (en) 2011-04-15 2020-04-07 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10835162B2 (en) 2011-04-15 2020-11-17 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10722162B2 (en) 2011-04-15 2020-07-28 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10682084B2 (en) 2011-04-15 2020-06-16 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10624568B2 (en) 2011-04-15 2020-04-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10561354B2 (en) 2011-04-15 2020-02-18 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10987040B2 (en) 2012-03-16 2021-04-27 Dexcom, Inc. Systems and methods for processing analyte sensor data
US10045723B2 (en) 2012-09-28 2018-08-14 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US11179079B2 (en) 2012-09-28 2021-11-23 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US11864891B2 (en) 2012-09-28 2024-01-09 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US9936909B2 (en) 2012-09-28 2018-04-10 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US10413227B2 (en) 2013-03-15 2019-09-17 Dexcom, Inc. Membrane for continuous analyte sensors
US10327687B2 (en) 2015-12-30 2019-06-25 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
US10729364B2 (en) 2015-12-30 2020-08-04 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
US10362975B2 (en) 2015-12-30 2019-07-30 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
WO2017117416A1 (en) * 2015-12-30 2017-07-06 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile
US11262326B2 (en) 2015-12-30 2022-03-01 Dexcom, Inc. Membrane layers for analyte sensors
US11051731B2 (en) 2015-12-30 2021-07-06 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
US11112377B2 (en) 2015-12-30 2021-09-07 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
AU2017240490B2 (en) * 2016-03-30 2019-12-05 Dexcom, Inc. Systems, devices and methods for analyte monitoring system
AU2020201634B2 (en) * 2016-03-30 2021-10-07 Dexcom, Inc. Systems, devices and methods for analyte monitoring system
US11278244B2 (en) 2016-03-30 2022-03-22 Dexcom, Inc. Systems, devices and methods for analyte monitoring system
WO2017172391A1 (en) * 2016-03-30 2017-10-05 Dexcom, Inc. Systems, devices and methods for analyte monitoring system
US10172564B2 (en) 2016-11-24 2019-01-08 Olympus Corporation Apparatus, computer-readable medium, and method for detecting biological data of target patient from attachable sensor attached to target patient
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
WO2019213428A2 (en) 2018-05-03 2019-11-07 Dexcom, Inc. Automatic analyte sensor calibration and error detection
US11656195B2 (en) 2018-05-03 2023-05-23 Dexcom, Inc. Automatic analyte sensor calibration and error detection
US11714060B2 (en) 2018-05-03 2023-08-01 Dexcom, Inc. Automatic analyte sensor calibration and error detection

Also Published As

Publication number Publication date
US20190261903A1 (en) 2019-08-29
US20200022626A1 (en) 2020-01-23
US20120265036A1 (en) 2012-10-18
EP3575796B1 (en) 2020-11-11
JP6700353B2 (en) 2020-05-27
US20120262298A1 (en) 2012-10-18
US20180008174A1 (en) 2018-01-11
US10722162B2 (en) 2020-07-28
US20210038128A1 (en) 2021-02-11
US10835162B2 (en) 2020-11-17
US20190320948A1 (en) 2019-10-24
US10980461B2 (en) 2021-04-20
US20160157758A1 (en) 2016-06-09
US20230240570A1 (en) 2023-08-03
WO2012142502A3 (en) 2013-01-10
JP2017148583A (en) 2017-08-31
JP6141827B2 (en) 2017-06-07
US20180271415A1 (en) 2018-09-27
US10448873B2 (en) 2019-10-22
JP2020124576A (en) 2020-08-20
US9801575B2 (en) 2017-10-31
DK3575796T3 (en) 2021-01-18
US10327688B2 (en) 2019-06-25
US20210369149A1 (en) 2021-12-02
US20190357817A1 (en) 2019-11-28
EP4324399A2 (en) 2024-02-21
US20210076989A1 (en) 2021-03-18
US20160073941A1 (en) 2016-03-17
JP7013522B2 (en) 2022-01-31
EP2697650B1 (en) 2020-09-30
US20200037936A1 (en) 2020-02-06
US10682084B2 (en) 2020-06-16
US20230309881A1 (en) 2023-10-05
US10624568B2 (en) 2020-04-21
US20120265035A1 (en) 2012-10-18
US20140114153A1 (en) 2014-04-24
EP2697650A4 (en) 2014-12-10
US9149220B2 (en) 2015-10-06
JP6466506B2 (en) 2019-02-06
EP2697650A2 (en) 2014-02-19
EP3825694B1 (en) 2023-10-25
US10610141B2 (en) 2020-04-07
US20210038129A1 (en) 2021-02-11
US20160018246A1 (en) 2016-01-21
JP2023181501A (en) 2023-12-21
US20210000394A1 (en) 2021-01-07
US20120265037A1 (en) 2012-10-18
US20190320949A1 (en) 2019-10-24
US20210068720A1 (en) 2021-03-11
US20200037935A1 (en) 2020-02-06
US20180042530A1 (en) 2018-02-15
US20190336051A1 (en) 2019-11-07
US20160198986A1 (en) 2016-07-14
US10004442B2 (en) 2018-06-26
US20190261902A1 (en) 2019-08-29
EP3825694A1 (en) 2021-05-26
US10561354B2 (en) 2020-02-18
WO2012142502A2 (en) 2012-10-18
US20190380627A1 (en) 2019-12-19
US10555695B2 (en) 2020-02-11
JP2018187479A (en) 2018-11-29
US9848809B2 (en) 2017-12-26
JP2022058646A (en) 2022-04-12
US20190350499A1 (en) 2019-11-21
US20180279928A1 (en) 2018-10-04
US20200037934A1 (en) 2020-02-06
US9808190B2 (en) 2017-11-07
JP2014514093A (en) 2014-06-19
ES2847578T3 (en) 2021-08-03
EP3575796A1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
US10980461B2 (en) Advanced analyte sensor calibration and error detection

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEXCOM, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOHM, SEBASTIAN;RONG, DAITING;SIMPSON, PETER C.;SIGNING DATES FROM 20120427 TO 20120501;REEL/FRAME:033066/0133

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION